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INTRODUCTION 
Preface 
 
Although descriptions of madness and psychotic-like behaviors have existed in many cultures 
since ancient times, neither of these records was of scientific or medical nature. It was 
necessary to wait until the late 19th century and early 20th century to see schizophrenia as an 
illness of neurological origin, when the German psychiatrists Kraepelin and Bleuler began to 
give the first descriptions of this disease. The term “schizophrenia” was originally proposed by 
Eugen Bleuler in 1908 to refer to a group of disorders characterized by serious cognitive, 
emotional and behavioral symptoms (Bleuler, 1911). However, this disease had been 
previously conceptualized by Kraepelin under the name Dementia praecox (see Kraepelin, 
1971 for an English version), in an attempt to differentiate it from the manic-depressive 
insanity (currently known as bipolar disorder), a group of diseases where the psychotic 
symptoms were secondary to the mood changes and with better outcome than dementia 
praecox. Since these initial stages, the knowledge about this devastating brain disorder has 
progressively increased.  
Because of its chronic nature, severity, early onset and psychosocial impairment, 
schizophrenia, and psychoses in general, imply a high human and economic cost when 
compared to other major chronic conditions, such as diabetes or breast cancer (UK National 
Health Service Executive, 1996). Moreover, when compared to some of the most important 
chronic conditions such as Alzheimer disease, asthma, cancer, depression, osteoporosis and 
hypertension, schizophrenia presents the highest prevalence-cost ratio and also one of the 
highest yearly costs per patient, only below Alzheimer disease (Berto et al., 2000). 
Thus, as it can be seen, schizophrenia is an expensive illness which starts just when the 
potential of the individual is at its height (Wong and Van Tol, 2003). For this reason, the 
consequences are especially dramatic, since behavior and personality change, preventing in 
many cases the development of a normal life. Therefore, there are many good reasons to 
study the underlying physiopathological mechanisms of schizophrenia. Particularly, the 
discovery that schizophrenia (as well as other psychiatric conditions) presents an important 
genetic component and a high heritability encouraged researchers to look for the genetic 
factors underlying schizophrenia. However the clinical and genetic complexity of schizophrenia 
makes the road long and difficult. Thus, although many advances have been made in the last 
decades, old questions still remain unresolved and new questions emerge every day.  
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1. Phenomenology and clinical aspects of schizophrenia 
1.1. Diagnostic symptoms 
Schizophrenia symptoms involve several domains (cognitive, emotional or behavioral) and are 
grouped into three main categories: positive or psychotic symptoms, deficit or negative 
symptoms and cognitive impairment. This three–symptom classification, widely accepted by 
clinicians currently, was originally developed by Liddle (1987) as an extension of the Crow’s 
two-syndrome classification in positive and negative symptoms (Crow, 1980), which supposed 
an important step in schizophrenia research.  
Psychotic symptoms are one of the most characteristic features of schizophrenic patients and 
include several clinical manifestations, generally with an episodic pattern, which are not 
present in normal population: hallucinations, delusions and thought disorder. Hallucinations 
consist of false perceptions in a conscious state in the absence of external stimuli which are 
felt as real by the person who suffers from them. In schizophrenia, auditory hallucinations 
(AH), and especially human voices (verbal hallucinations), are the most common form of 
hallucinations. Hallucinations can also be related to the content of the delusions suffered by 
the patient. Delusions or false beliefs are generally paranoid in schizophrenia and include 
delusions of persecution, grandiosity, external control, thoughts inserted or withdrawn from 
one’s head, ideas of reference and mind-reading (Wong and Van Tol, 2003). The content of the 
delusions is directly influenced by the patient’s life and culture (Tateyama et al., 1993; Stompe 
et al., 1999). Thought disorder consists in disorganization of thinking and behavior which 
affects the logical elaboration and development of ideas. Depending on the severity of these 
abnormalities, patients may have important problems to attend their basic needs.  
Negative symptoms refer to the absence or disturbance of certain behaviours such as social 
interaction, motivation, expression of affect, ability to experience pleasure and spontaneous 
speech (Wong and Van Tol, 2003).  
Finally, the cognitive impairment observed in most schizophrenic patients mainly affects 
attention, executive function and memory. The memory organisation deficits can also have 
implications for more general information processing (Kurachi, 2003).  
All these symptoms are part of the diagnostic criteria included in the Diagnostic and Statistical 
Manual of Mental Disorders or DSM, currently in the fourth edition (American Psychiatric 
association, 1994), as well as in the International Classification of Diseases or ICD-10 (World 
Health Organization - WHO, 1992). A summary of the diagnostic criteria for schizophrenia can 
be found at table I1. 
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Table I1. DSM-IV diagnostic criteria for schizophrenia. 
A. Characteristic symptoms: At least two of the following, each present for a significant portion of time during a 
one-month period (or less if successfully treated): 
1. delusions 
2. hallucinations 
3. disorganized speech 
4. grossly disorganized or catatonic behaviour 
5. negative symptoms 
(Note: Only one criterion A is required if delusions are bizarre or hallucinations consist of a voice commenting on 
the patient’s behaviours or thoughts, or at least two voices conversing with each other). 
B. Social/occupational dysfunction: For an important portion of time since the onset of the disturbance, at least 
one major area of functioning (i.e. work, interpersonal relations, self-care) is clearly below the level achieved 
prior to the onset (or when the onset is in childhood or adolescence, failure to achieve the expected level). 
C. Duration: Continuous signs of the disturbance persist for at least 6 months. This period must include at least 1 
month of symptoms (or least if successfully treated) that meet criterion A, and may include other residual 
periods where the signs of the disturbance may be manifested by only negative symptoms or two or more 
symptoms from criterion A in an attenuated form. 
D. Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder and Mood Disorder with Psychotic 
Features have been excluded since (a) no Major Depressive, Manic, Mixed Episodes have occurred together 
with the active-phase symptoms; or (b) if mood symptoms have occurred during active-phase symptoms, 
their total duration has been brief when compared to the duration of the active and residual periods.  
E. Substance/general medical condition exclusion: The disturbance is not caused by the direct physiological 
effects of a substance or a general medical condition. 
F. Relationship to a Pervasive Developmental Disorder: If there is a history of Autistic Disorder or another 
Pervasive Developmental Disorder, the additional diagnosis of schizophrenia is made only if prominent 
delusions or hallucinations are also present for at least one month (or less if successfully treated). 
  
1.2. Controversies in the diagnosis of schizophrenia disorders 
The wide variety of symptoms in the schizophrenic phenotype leads to a great clinical 
heterogeneity, with different patients having different symptoms, to such an extent that two 
schizophrenic patients may not overlap in the clinical manifestation of the disease. This 
situation is the origin of important problems when trying to define and explain schizophrenia 
from a biological point of view. Moreover, it is also important to remind the existence of other 
psychotic disorders included in the schizophrenia spectrum (schizotypal personality disorder, 
schizoaffective disorder and schizophreniform disorder, among others) which share an 
important part of their phenomenology, outcome and treatment response (Siever and Davis, 
2004). Thus, it is difficult to define schizophrenia as a completely differentiated entity. Even 
more, although Kraepelin’s classical division between dementia praecox and manic-depressive 
disorder is still widely used among psychiatrists, many authors doubt about the validity of this 
“artificial” division and defend an overlap between the different diagnosis (see figure I1), as 
well as a single underlying entity for the different psychoses and even for all psychiatric 
disorders (Crow, 1995; Cuesta and Peralta, 2001; Peralta and Cuesta, 2005).  
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1.3. Epidemiological aspects 
Since the famous World Health Organization (WHO) 10-country study (Jablensky et al., 1992), 
the incidence of schizophrenia was considered to be similar across different cultures and 
countries (between 1.6% and 4.2% in all populations). Interestingly, this fact, among others, 
has linked schizophrenia to human evolution (Brüne, 2004). However, more recent revisions of 
this finding doubt this homogeneity, since it has been detected a higher incidence of 
schizophrenia disorders in males, urban areas (Sundquist et al., 2004) and immigrant 
population (Cantor-Graae and Selten, 2005; Fearon et al., 2006), among others. Moreover, 
symptoms usually develop earlier in males (in their late teens or early twenties) than in 
females (in the twenties and thirties) (Riecher-Rossler and Hafner, 2000). Furthermore, other 
environmental conditions have also been described to increase the risk for schizophrenia. 
Among them, some of the best studied are: maternal infections, prenatal malnutrition, 
maternal depression, hypoxia and neural damage, among others (Jablensky, 2003).  Figure I2 
shows the relative risks for some of the factors commented above. Although there are no clear 
signs to state or deny that these are causal factors of schizophrenia, these variations support 
the development of vulnerability x stress interaction models.  
 
 
 
 
 
Figure I1. Graphic view of the 
overlap between some 
common psychiatric disorders 
(Anxiety disorders, 
Depression, Bipolar Disorder 
and Schizophrenia). It has 
been suggested that the 
vulnerabilities to these 
disorders have common 
elements and, as a result, 
some symptoms (in white) are 
shared by different clinical 
conditions, while others are 
unique. Furthermore, this 
common vulnerability can also 
arise from the extreme ends 
of dimensions of personality, 
such as mood, anxiety, volition 
and cognition. (Adapted from 
Burmeister et al., 2008) 
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1.4. What neuropathological findings can tell us about schizophrenia: from 
brain structure to neurotransmitters. 
Despite the wide variety of neuropathological findings related to the schizophrenia-spectrum 
psychoses in the last century, neither of these discoveries can be used as a diagnostic criterion 
for schizophrenia. First of all, the degree of overlap between patients and controls is too high 
to ensure a reliable diagnosis. Moreover, the great majority of symptoms is not specific for 
psychosis and can be also found in other neurological patients, thus restricting their utility in 
the clinical practice. Finally, we cannot forget that many of these findings, although replicated, 
are only partial and appear in a variable percentage of patients. And, unfortunately, many of 
these findings are discrete and have not even been replicated. However, all what we know 
about the neurobiology of schizophrenia can be the first step to understand in greater detail 
its physiopathological mechanisms. 
 
1.4.1. Global macroscopic and histological abnormalities 
Despite both the negative and unreplicated findings, there are some facts which can be 
reliably associated with the schizophrenic condition. Among them, the most important are the 
following (obtained from an interesting revision work from Tandon and colleagues (2008), who 
collected the most important evidences discovered so far): 
- Whole brain volume is reduced in patients when compared to healthy subjects 
(Harrison et al., 2003). Moreover, lateral and third ventricles are enlarged in 
approximately 20-30% of schizophrenic patients prior to the first psychotic episode 
(Elkis et al., 1995; Harrison et al., 2003). However, there is no correlation between 
ventricular size and cortical loss (Ward et al., 1996). These findings are in coherence 
with post-mortem studies (reviewed in Wong and Van Tol, 2003). 
Figure I2: Environmental risk factors for schizophrenia. The relative risk of each factor is indicated.  
Abbreviations: CNS, central nervous system. 
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- Structural brain abnormalities are found at illness onset, thus discarding the possibility 
that these abnormalities are a consequence of the progression of the disease or the 
neuroleptic medication. 
- Absence of gliosis (Iritani, 2007), which is a sign of neurodegeneration. This evidence is 
an argument for a neurodevelopmental rather than neurodegenerative origin for 
schizophrenia. 
- Reductions in neuropil (Selemon and Goldman-Rakic, 1999), which corresponds to 
those elements which are not the neural soma, as well as an altered localization of 
neuronal elements.  
1.4.2. Neurophysiological abnormalities  
Different neurophysiological alterations have also been found in schizophrenic patients 
(Tandon et al., 2008): 
- Abnormalities in the latencies and/or amplitudes of several event-related potentials, 
including P-50 and P-300 and the mismatch negativity (MMN). 
- Eye-movement alterations in patients and, in a milder degree, in their healthy 
relatives.  
- Affectation of the sleep structure, including shortening of the REM (rapid eye 
movement) sleep latency. 
1.4.3. Abnormalities in the neurotransmitter systems  
Studies about the mechanisms of action of antipsychotic drugs revealed that dopamine (DA) 
appeared to have a prominent role in the development of psychotic symptoms, since these 
drugs blocked the dopaminergic receptors. Moreover, amphetamine and cocaine, which 
interfere with the reuptake of DA, can also induce psychosis. These observations led to the 
development of the “dopamine hypothesis of schizophrenia” (Seeman, 1987), which has 
suffered different reformulations, in an attempt to adapt it to the new findings. The current 
hypothesis (Weinberger, 1987) defends the existence of a DA excess in the meso-limbic tracts, 
as a consequence of the hyperstimulation of D2 receptors. This DA hyperactivity would trigger 
the positive symptoms. Moreover, the lack of DA in the prefrontal cortex caused by the 
hypostimulation of D1 receptors would explain the negative and cognitive symptoms. 
However, the study of glutamate, which is the primary excitatory neurotransmitter in the 
brain (Wong and Van Tol, 2003), led to the formulation of the “glutamate hypothesis of 
schizophrenia”. This new approach considers the existence of a glutamatergic misbalance, 
especially in frontal regions, which would ultimately cause the dopaminergic alterations 
described above. This new view is supported by several evidences; the most replicated are that 
dopamine antagonists such as phenylcyclidine (PCP) and ketamine can induce psychotic 
symptoms (Halberstadt, 1995; Lahti et al., 1995).  
The serotonergic system cannot be excluded from the schizophrenia research since alterations 
in this system have been found in schizophrenic patients, although these abnormalities are 
milder than those observed in the DA system. The interest on the relationship between the 
serotonergic system and schizophrenia arouse out of observations about the effects of certain 
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drugs targeting the serotonin (5-HT) system. For example, there are important structural 
similarities between 5-HT and the lysergic acid diethylamide (LSD), one of the psychoactive 
drugs which mimics the action of serotonin, primarily at 2A receptors (Aghajanian and Marek, 
2000; Geyer and Vollenweider, 2008). Moreover, it is also well known that the atypical 
antipsychotic drugs (Harrison, 1999; East et al., 2002) have an effect on both serotonergic and 
dopaminergic receptors and there is also a partial effect of the selective serotonin re-uptake 
inhibitors (SSRIs) on the treatment of negative symptoms in schizophrenia (Silver, 2003). The 
effects of atypical antipsychotics led to another reformulation of the dopaminergic hypothesis 
as an imbalance between both neurotransmitter systems (Reveley and Deakin, 2000).  
 
1.4.4. Neuroimaging findings 
With the arrival of brain imaging techniques three decades ago, new possibilities appeared to 
observe in vivo which brain features are linked to the schizophrenic condition, and to 
understand the underlying processes of neuropsychiatric disorders. These techniques use a 
wide variety of methods (Gur et al., 2007), like magnetic resonance (MR), which allows the 
study of a) structural neuroanatomy through structural resonance imaging (sMRI), b) 
neurochemistry and metabolite levels by means of magnetic resonance spectroscopy (MRS) 
and c) the activation pattern of brain areas using functional MRI (fMRI). Moreover, there are 
other functional methods such us positron emission tomography (PET) and single-photon 
computed emission tomography (SPECT).  
With regard to Structural magnetic resonance imaging, the more replicated evidences can be 
grouped into three categories: 
- The reduction of whole brain volume and enlarged ventricles observed in schizophrenic 
patients by different techniques when compared to controls has also been confirmed by 
sMRI (Lawrie and Abukmeil, 1998; Shenton et al., 2001; Steen et al., 2006). This reduction is 
of about 3%. Interestingly, the decreased cortical volumes and enlarged ventricular spaces 
have been also found in relatives of schizophrenic patients (Cannon et al., 1998; Lawrie et 
al., 1999) suggesting a genetic vulnerability to the disease. 
- There are also regional gray matter reductions, which mainly affect the medial and 
superior temporal lobes (see Honea et al., 2005 for a meta-analysis), prefrontal cortex (PFC) 
and thalamus (reviewed in Tandon et al., 2008). Among these areas, the most severely 
affected region is the medial temporal lobe (MTL), specially hippocampus and amygdala 
(Lawrie and Abukmeil, 1998; Honea et al., 2005). It has been also argued a relationship 
between a) positive symptoms and both hippocampus and temporal cortex size and b) 
negative symptoms, cognitive impairment and PFC size (Gur et al., 2007). 
- However, there are also some artifactual findings, such as the enlargements of basal 
ganglia (specially the globus pallidus) due to medication with typical antipsychotics (Gur et 
al., 2007). Likewise, drug abuse can also trigger structural changes and this fact should be 
also taken into account.  
Abnormalities in functional neuroimaging phenotypes have also been found in PET as well as 
fMRI studies using different paradigms and neural tasks. The most consistent evidences are: 
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- Abnormal activation patterns in several brain regions in cognitive and emotional tasks, as 
well as in resting condition. Of special interest is the hypoactivation of the prefrontal 
cortex, which is also associated with the characteristic negative symptoms of schizophrenia 
(Weinberger et al., 1986; Glahn et al., 2005). Moreover, the abnormal activation of 
temporal and parietal areas anatomically connected with PFC has been also detected. With 
regard to the temporal lobe, there is an increased activity in schizophrenic patients, 
according to several PET and SPECT studies (see Zakzanis et al., 2000 for a meta-analysis).  
- Regarding psychotic symptoms, it has been found that hallucinating patients show changes 
in the activation pattern of certain cortical areas with an important role in speech and 
processing of auditory stimuli (Shergill et al., 2000; Woodruff, 2004). 
- Moreover, negative symptoms have been also studied through several face recognition 
tasks. It has been shown that, with these paradigms, there is an abnormal activation of 
amygdala as well as motor and premotor cortical regions. These findings could be related to 
the difficulties of schizophrenic patients in social interactions (reviewed in Wong and Van 
Tol, 2003). 
Finally, MRS studies have detected reductions in N-acetyl aspartate (NAA, a marker for 
neuronal loss and glia integrity) peaks in patients with chronic schizophrenia. These reductions 
encompass several regions, especially temporal cortex (hippocampus) and frontal cortex 
(Steen et al., 2005; Abbott and Bustillo, 2006), and are associated, in those patients, with 
cortical atrophy, cognitive impairment and negative symptoms (Keshavan et al., 2000).  
1.5. Are these findings enough to formulate hypotheses about the origin of 
schizophrenia? 
Researchers now agree on several basic facts which can serve as the start point to understand 
schizophrenia from a biological, neurodevelopmental point of view: schizophrenia is the result 
of an interaction between the biological predisposition (genetic factors) and environmental 
aspects. According to this scenario, the schizophrenic brain can suffer subtle alterations during 
its early development (including neonatal and postnatal processes) due to genetic factors and 
environmental stressors. These alterations may be affecting the cytoarchitecture, neuronal 
connectivity and/or neuronal plasticity. However, the presence of these alterations would not 
guarantee the development of schizophrenia, since certain environmental factors occurring 
later in childhood and adolescence (for example, vital events) would be necessary to trigger 
the first symptoms of schizophrenia. This general hypothesis, although correct in its 
presentation of the facts, is, however, currently poor in content, to such extent that it could be 
applicable to many other complex diseases. As De Lisi recently emphasized (2008), in response 
to a review article from Tandon et al., (2008), only a few evidences can be considered for the 
moment as real facts in schizophrenia research. The main efforts are now focused in achieving 
a deeper understanding of the genetic factors and how they interact with the environment to 
give the final phenotype.  
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2. Genetics bases of schizophrenia 
The hereditary component of psychiatric disorders was already postulated by Emil Kraepelin 
more than a century ago. Currently, psychiatric genetics is one of the most interesting focuses 
in the research of mental disorders. However, a necessary condition of any genetic study is the 
existence of a valid, precise and measurable phenotype. Nevertheless, mental disorders lack 
these phenotypes, since diagnostic is only made through clinical assessment (see table I1 as a 
reminder). Thus, it is necessary to tackle their study with particular methodologies which may 
help to unravel the causative molecular processes of these pathologies. 
2.1. Genetic epidemiology of schizophrenia 
Genetic epidemiology studies, which include familiar, twin and adoption studies, were the first 
approach to the genetics of mental disorders and have been widely used to disentangle the 
relative contributions of both genetic and environmental factors on the liability to these 
diseases. Family studies can determine the familialty of a mental disorder; however, it is 
impossible to verify whether the observed familial aggregation is due to environmental, 
genetic or both causes. For this reason, twin and adoption studies are used to separate the 
genetic component from the shared environmental factors. 
Studies of families have shown that schizophrenia runs in families. First-degree relatives of 
schizophrenic patients have a higher degree (between 2% and 9%) to develop schizophrenia 
than the general population. This risk progressively diminishes in second degree (2%-6%) and 
third degree relatives (2%) (Kendler and Diehl, 1993; Shih et al., 2004).  
Twin studies are based in the comparison among the concordance rate for certain disorder in 
monozygotic (MZ) and dizygotic (DZ) twins. Since MZ twins share all their genetic material, 
concordance is expected to be higher in those siblings. Regarding schizophrenia twin studies, 
MZ twins have a concordance rate around 30-50%, while DZ have a lower concordance rate for 
schizophrenia (approximately 10%) which is similar to non-twin siblings (McGuffin et al., 1984; 
Kendler and Robinette, 1983). This type of approach shows clearly that schizophrenia is 
predominantly a genetic disease, with an heritability around 80%, higher than other complex 
diseases such as breast cancer (5%-60%) and Parkinson disease (13%-30%), although in these 
cases the genetic factors are now better understood (Burmeister et al., 2008). Moreover, the 
fact that the concordance rate in MZ twins is not close to 100% suggests the existence of 
shared environmental elements probably of prenatal and postnatal origin. 
Adoption studies are a valuable tool to distinguish between inherited genetic factors and 
environmental factors. Children of schizophrenic biological parents adopted by unaffected 
parent are less likely to be exposed to environmental risk factors (Wong and Van Tol, 2003).  
According to this hypothesis, several studies have been performed and it has been shown that 
adopted children whose biological mothers suffered from schizophrenia had a higher liability 
to this disorder than those adoptees with biological mothers who were not schizophrenic 
(Heston, 1966; Lowing et al., 1983; Tienari et al., 2003). Furthermore, the adoptive relatives of 
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schizophrenic children had a risk for schizophrenia similar to the overall risk in the general 
population (Kety, 1987). 
In summary, all these studies confirm that schizophrenia presents a complex pattern of high 
heritability which is also influenced and modulated by non-genetic environmental factors. 
Moreover, this disorder (and all mental disorders in general) does not fit a Mendelian classical 
model with a single highly penetrating gene. 
2.2. The search for the schizophrenia genes. First approach: Linkage studies. 
In 1980s and 1990s, polymorphic markers began to be available for genetic analysis, and 
scientists began to collect large family pedigrees, in an attempt to look for the genetic loci 
which were linked to different pathological conditions. A single DNA marker (which can be a 
VNTR [variable number in tandem repeats] or a single nucleotide polymorphism [SNP]) can be 
used to study whether certain allele of this marker cosegregates with the disease within a 
family more than expected by chance. In this case, it is said that the marker shows linkage to 
the clinical phenotype.    
The first linkage studies were performed on monogenic diseases with a classical Mendelian 
transmission with a high success (for examples, see Knowlton et al., 1985; Guilford et al., 
1994). They were based on parametric linkage analysis, which uses the LOD score (Logarithm 
of Likelihood ratio) to evaluate the level of evidence. This approach can use more than one 
marker simultaneously (multipoint analysis). A good standard for LOD score significance is P = 
0.00005 (LOD ≥ 3.6), which would be equivalent to a 5% chance of randomly finding linkage 
(Wong and Van Tol, 2003). 
Unfortunately, the parametric linkage analysis implies certain difficulties when it is moved 
from monogenic to complex, poligenic diseases. Firstly, larger samples and pedigrees are 
needed to detect the low effect genes which are supposed to be implicated in complex 
diseases such as schizophrenia. Moreover, to apply the parametric approach, it is necessary to 
have a precise knowledge of the inheritance model, the gene frequencies and the penetrance 
of each genotype (Strachan and Read, 2004). However, the inheritance model and the genetic 
contribution of each gene on the disease are not normally known in mental disorders because 
of the use of groups of families with probably variable diagnostics and different causative 
genes each of them with variable effect. There are several ways to face up to these difficulties, 
such as the use of families in which the disorder segregates according to a near-mendelian 
model; to test several inheritance models (recessive and dominant, for example); the use of 
affected pedigree members only in a parametric analysis; or the use of a nonparametric 
(model-free) method of linkage analysis. The nonparametric method of linkage analysis 
ignores unaffected people and searches for alleles or chromosomal regions shared by affected 
individuals. This methodology can be used within nuclear families, extended families, or even 
in whole populations (in this latter case they constitute association analyses, which will be 
tackled in the next sections).  
Linkage studies on schizophrenia pedigrees have found several loci although the results are 
enormously controversial, since there are contradictory findings or unreplicated results. 
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Therefore, the evidence of the linkage studies is limited, as acceptable significance levels have 
been achieved in only four studies (Straub et al., 1995; Blouin et al., 1998; Brzustowicz et al., 
2000; Williams et al., 2003), specifically in chromosomic regions 6p22-24, 8p21-22, 1q21-22 
and 10q25.3-q26-3. However, two meta-analyses have been useful to clarify the situation. 
Meta-analyses are useful because they amplify low signals which are general to most works, 
while strong signals from only one study are somehow silenced. Badner and Gershon in 2002 
found three regions which reached genome-wide signification: 8p, 13q y 22q. Moreover, Lewis 
and colleagues performed in 2003 another meta-analysis (Lewis et al., 2003) and, in this case, 
only one region (2p12-22.1) was found to be linked to schizophrenia under the most stringent 
criteria. Curiously, this region had not been found in any single study. Furthermore, under less 
stringent criteria, other regions emerged: 5q, 3p, 11q, 2q, 1q, 22q, 8p, 6p, 20p y 14q. It is likely 
that these regions contain genes implicated in the pathogenesis of schizophrenia. Then, the 
next step will be to find the specific genes which lay behind the positive linkage findings and to 
test its real implication in the pathophysiology of schizophrenia. 
However, in the light of all these controversial linkage findings, it is really difficult to state that 
the chromosomic regions found with this approach really contain common allelic variants 
which increase the liability for schizophrenia. Firstly, it is possible that families in positive 
linkage studies may be segregating uncommon large effect genes. Moreover, each one of the 
positive regions may contain multiple susceptibility genes with a low effect on schizophrenia 
risk, but together can account for an important increase in the risk, detectable by linkage 
analysis (Harrison and Weinberger, 2005). Thus, it is really necessary to apply new techniques 
which can be helpful to unravel all these contradictory messages from the linkage analysis.       
2.3. The use of genetic polymorphisms in association studies as a new 
approach to tackle the genetics of complex disorders. 
It has been more than thirteen years since Neil Risch and Kathleen Merikangas demonstrated 
that when we face up to genetic variants with a small effect on the liability to suffer certain 
complex disease, association studies represent a more powerful tool than linkage analysis 
(Risch and Merikangas, 1996). Since then, association studies in psychiatric genetics (as well as 
in other complex diseases) have replaced linkage analysis as the preferred approach. But how 
can we define an association study? Although there are several types depending on the sample 
of individuals we are handling (unrelated subjects, family trios…) and the response variable we 
want to analyze (case-control phenotype, response to treatment, age at onset…), we can 
briefly say that the basic aim of association analyses is to evaluate if certain allele or genotype 
from a polymorphic variant appears in the affected group in a higher frequency than expected. 
These polymorphisms of interest would be selected because they would be located on those 
genes considered previously as candidate genes, either because they are part of a pathway 
which is known to be related to the disease (biological candidate genes) or because the genes 
are in a linkage peak (positional candidate genes) (Burmeister et al., 2008). Moreover, another 
recent alternative to find associations with a certain disease is to scan polymorphisms across 
the whole genome (Carlson et al., 2004). These studies are called genome-wide or whole-
genome association studies (GWA). Furthermore, polymorphisms can be of different 
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categories, for example, variable number of tandem repeats (VNTRs), insertions-deletions 
(indels) and, more commonly, single nucleotide polymorphisms (SNPs).  
Association studies led to the first discoveries of genetic risk factors for common diseases, such 
as Alzheimer disease (Strittmatter and Roses, 1996), diabetes (Dorman et al., 1990) or 
inflammatory bowel disease (Hugot et al., 2001). Most of these first studies were focused on 
functional variants which were considered as putative causal variants (or candidate 
polymorphisms). This approach to association studies is known as the “direct approach” 
(Risch, 2000). However, the search of all putative causal risk variants can become a difficult 
task in terms of money and time. For this reason, there is an alternative, known as the 
“indirect approach”, in which the association between a set of polymorphisms and certain 
pathology is studied, without considering whether those polymorphisms are really functional 
or not. This approach is based in the intrinsic structure of every genome: every variable 
position in our genome results from a single historical mutation event and each new allele will 
be associated with the other alleles present in the chromosomic region when this new allele 
arose. All those different alleles located in the same chromosome are called a haplotype and 
new haplotypes will emerge by additional mutations or recombination processes between the 
maternal and paternal haplotypes (Pääbo, 2003). Interestingly, the alleles which are present 
on each haplotype are subject to associations between them as a result of coinheritance 
processes. This association of certain alleles in the population is known as linkage 
disequilibrium (LD). It has been seen that, due to the LD relationships, the human genome can 
be divided into haplotype blocks (Gabriel et al., 2002): considerably large regions over which 
there is little evidence for historical recombination and within which only a few common 
haplotypes are observed. Thus, this LD structure can be enormously useful in association 
studies: since all alleles in each block are inherited together, one can choose only a few of 
these polymorphisms to capture all the variability in the region of study. These 
polymorphisms, known as “tag” SNPs, will represent all those other SNPs in high LD with them 
(called proxies) which will not be included in the study (de Bakker et al., 2005). Thus, these 
haplotype-based methods offer a powerful approach to disease gene mapping (figure I3).  
 
 
 
 
 
 
 
 
Figure I3. Selection of 
tagSNPs.  Although the 
number of SNPs in a human 
chromosome (a) is 
considered to be extremely 
high, this variability is 
generally redundant, due to 
the LD relationships 
established among different 
SNPs. The LD pattern of a 
particular chromosomic 
region (b) can be estimated 
and subsequently used to 
select a subset of SNPs (tag 
SNPs, marked in red), which 
are expected to capture all 
the variability in the area. 
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However, this approach would have been unsuccessful without international initiatives such as 
the HapMap Project (The International HapMap Consortium, 2003). The HapMap Project 
meant a qualitative step forward in association studies, since its main objective is “to 
determine the common patterns of DNA sequence variation in the human genome and to 
make this information freely available in the public domain”, in an attempt to accelerate the 
study of complex diseases.  This project arose as a natural continuation of the Human Genome 
Project. When it was officially launched in October 2002, the number of non-redundant SNPs 
in the public SNP map from NCBI (dbSNP) was around 2.8 million (International HapMap 
Consortium, 2005); however, many regions were poorly represented. Currently, through its 
different phases, the project has increased the SNP coverage across the genome and the whole 
number of non-redundant SNPs has increased spectacularly (figure I4). Interestingly, there is 
also information available on some representative populations to ensure that the HapMap 
includes most of the common variation and some of the less common variation in different 
populations.  
 
 
 
 
 
 
 
 
 
With all this information available for the scientific community, the application of several 
association methods on complex diseases seems to be somehow easier.  
2.3.1. Types of association tests.  
2.3.1.1. Association tests for unrelated individuals 
Case-control association test. This approach compares two groups of unrelated individuals 
with similar demographic characteristics (age, sex, ethnic group…) to avoid stratification 
problems: one group of affected individuals (cases) and another group of healthy subjects 
(controls). It is also necessary that all individuals come from the same genetic population, to 
avoid confounding effects due to differential population ancestries, such as admixture and 
population stratification, among others (Langefeld and Fingerlin, 2007). This analysis is based 
on testing the null hypothesis of no differences in the genotypic or allelic distribution between 
cases and controls (Balding, 2006). If the null hypothesis is rejected, then the polymorphism is 
Figure I4. Graphic overview of the 
number of SNPs from dbSNP. The 
HapMap Project has progressively 
increased the number of 
polymorphisms available in the public 
SNP map (dbSNP). Here, the number 
of available SNPs from 2000 to 2005 is 
shown. Years are divided into 
quarters (Q1-Q4). The cumulative 
number of non-redundant SNPs is 
shown as a solid line, while the 
number of validated SNPs is shown as 
a dotted line (validated by 
genotyping) or a dashed line 
(validated through double-hit status). 
Figure taken from International 
HapMap Consortium, 2005. 
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considered to be associated with the disease. There are different ways to test this hypothesis, 
for example, researchers can use approaches which are based on standard contingency table 
tests for independence, such as the Pearson test and the Fisher exact test. Among these two 
possibilities, the Fisher exact test is more appropriate, particularly if the size of some of the 
categories is small. However, it is also computationally more demanding.  
However, the study of complex disorders generally implies the study of genetic polymorphisms 
with an additive effect, which means that the heterozygote risk will be intermediate between 
the two homozygote risks. In this situation, Pearson and Fisher tests are not powerful enough 
to detect additive risks. Nevertheless, other alternatives exist, such as the Cochran-Armitage 
test, which tests the hypothesis of zero slope for a line that fits the three genotypic risk 
estimates best (Balding, 2006). However, under other models different from the additive one, 
the Cochran-Armitage test has a low power to detect association. Thus, other possibility to 
solve the problems outlined above is the regression analysis.  When information about several 
genetic, phenotypic and environmental factors is available, the regression approach can adjust 
for all these factors. Although several regression tools exist, the logistic regression model 
should be employed for binary traits such as disease status (case or control).  
Furthermore, during case-control association analyses it is also interesting to calculate other 
related parameters to evaluate the impact of each genetic factor on the risk. One of these 
measures is the Odds Ratio (OR), which evaluates the association between genetic 
susceptibility and the disease, that is, the OR associated to certain disease would be the 
quotient between the probability of suffering the disease and the probability of not suffering 
the disease, in the presence of certain genetic factor.  
Finally, it should be noted that other categorical variables different from case-control status 
(presence or absence of auditory hallucinations, age at onset…) can be evaluated through all 
the methods described above. 
Quantitative disease traits. Several quantitative traits, such as the scores for different clinical 
scales or cognitive tasks, can also be studied to search for associations with genetic 
polymorphisms. In those cases, simple linear regression can be used to test for an association 
between a genetic marker and a quantitative trait without adjusting for covariates (Langefeld 
and Fingerlin, 2007). Moreover, other phenotypic or genetic factors can be included in the 
model as covariables. 
2.3.1.2. Family-based association analysis 
Family-based association tests use family members as internal controls. For this reason, they 
are more resistant to population stratification (Langefeld and Fingerlin, 2007). Below there is a 
brief description of some of the most popular association tests based on families. 
The transmission-disequilibrium test or TDT (Spielman et al., 1993) is one of the most famous 
family-based tests and it is widely used to study the genetics of complex disorders on families. 
The TDT assumes that, under the null hypothesis, transmission of each allele is equally 
probable (Mendel’s first law). Thus, this test examines how often each allele of each 
heterozygote parent is transmitted to their affected offspring. An overtransmission of one of 
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the alleles to the affected offspring is then interpreted as an association between the 
polymorphism and the disease. However, it is necessary that the genotypes from both parents 
are available to avoid biases due to allele frequencies in the population. Subsequently, new 
related methods such as the sib transmission/disequilibrium test (S-TDT) and Discordant Allele 
Test or DAT (reviewed in Langefeld and Fingerlin, 2007) were developed to overcome this 
problem, because these tests are based in the comparison of allele frequencies between 
affected subjects and their unaffected siblings. 
Finally, when data about some parents and some discordant siblings is available, there are 
other tests which can use all this information. An example of this approach is the pedigree 
disequilibrium test or PDT, which combines data from the TDT and the S-TDT within families. 
Another variant is the Family Based Association Test or FBAT (Laird et al., 2000), which is a 
generalization of the TDT, with the special feature that it can work with missing parental 
genotype data and relatedness among trios. This is especially useful for those diseases with a 
late onset, such as schizophrenia, where the obtaining of DNA samples from both parents can 
be particularly hard.  
2.3.1.3. Haplotype association analysis 
Another interesting strategy, applicable to both family-based and population-based 
association analyses, is to use haplotypes instead of single SNPs in the association test 
(Balding, 2006). This approach considers the block-like structure of the human genome. 
Interestingly, haplotype analysis is more powerful to detect association when several cis-acting 
causal variants are conferring disease risk (Balding, 2006). However, the phase is generally 
unknown and haplotypes must be inferred from the genotypic frequencies through different 
methods and algorithms. One of the most widely-used methods to calculate the haplotype 
frequencies is the Expectation-Maximization (EM) algorithm (see Zhao et al., 2003 for a 
review), which obtains the maximum likelihood estimates of haplotype frequencies in the 
study sample. It is divided in two steps: the Estimation step, which allows the estimation of the 
haplotype pairs of each subject; and the Maximization step, which estimates those haplotype 
frequencies which maximize the probability to obtain the observed genotypes. Subsequently, 
other methods and modified EM algorithms have been also elaborated. 
2.3.2. Results from the association analyses in schizophrenia  
Since the first association studies began, a huge number of publications have emerged and 
many candidate genes and polymorphisms have been evaluated (figure I5). In some cases, the 
results have been promising and have been confirmed through other approaches.  
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There are some good revisions about this theme which can be helpful to show an overall vision 
of what has been done (Harrison and Weinberger, 2005; Norton et al., 2006; Lang et al., 2007; 
Burmeister et al., 2008). According to these revision works, the candidate genes with a 
stronger evidence of association with schizophrenia are the following:  
- Neuregulin 1 (NRG1): Attention was focused on this gene as a result of a study by 
Stefansson et al., (2002), which found linkage with schizophrenia in an Icelandic sample and 
association with several SNPs and a seven-marker core haplotype. Interestingly, the region 
where NRG1 lies (8p12-21) had been also previously related to schizophrenia in several 
linkage studies. Following the original Stefansson’s report, association between NRG1 gene 
and schizophrenia has also been found in other populations from Scotland, China and 
Ireland, among others (Stefansson et al., 2003; Yang et al., 2003; Corvin et al., 2004). 
Moreover, association of the original core haplotype with bipolar disorder has also been 
detected (Green et al., 2005). Thus, despite some negative findings (Iwatta et al., 2004; 
Thiselton et al., 2004), the overall results support the implication of NRG1 in the 
pathogenesis of schizophrenia. However, there are discrepancies with regard to the 
haplotypes and SNPs implicated on each study. NRG1 is expressed in the developing and 
adult human brain and is involved in several neural processes and signaling mechanisms, 
such as neuronal migration, myelination, synaptogenesis and neurotransmission (Harrison 
and Weinberger, 2005). 
- Dystrobrevin binding protein or dysbindin (DTNBP1) is a promising schizophrenia 
candidate gene which maps to chromosome 6p22.3, one of the most consistently replicated 
schizophrenia linkage regions. Straub et al. (2002) reported, through a family-based analysis 
with individuals of Irish origin, that variation in dysbindin was associated with 
schizophrenia. This original finding has been replicated in different studies and samples 
(Numakawa et al., 2004; Funke et al., 2004; Vilella et al., 2008) but not in other studies 
(Morris et al., 2003). However, clear inconsistencies have also appeared, since risk and 
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Figure I5. In the last decade, the number of association studies in schizophrenia, as well as the 
average sample size of each study, has increased spectacularly. (Adapted from Allen et al., 2008) 
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protective haplotypes vary considerably among studies. Nevertheless, dysbindin expression 
is reduced in schizophrenic patients and several cis-acting variants that results in a 
reduction of dysbindin mRNA expression have also been discovered (Harrison and 
Weinberger, 2005), thus supporting the role of this gene in the etiology of schizophrenia.  
- DAOA (G72) and DAAO genes: The DAOA gene (formerly known as G72) was cloned from 
the 13q linkage region and subsequently analyzed for association in a French-Canadian case 
control sample (Chumakov et al., 2002). Interestingly, several SNPs and haplotypes in DAOA 
(and another overlapping gene called G30) were found to be associated with schizophrenia 
in this original study and replicated in other samples (Schumacher et al., 2004; Zou et al., 
2005). In parallel with these results, associations between polymorphisms in the D-amino 
acid oxidase (DAAO) gene (interaction partner of DAOA according to Chumakov et al., 2002) 
have also been found (Chumakov et al., 2002; Schumacher et al., 2004). However, some 
negative findings and the existence of allelic heterogeneity across studies can obscure the 
meaning of these associations. These two genes are involved in the metabolism of D-serine, 
an important element in the glutamatergic pathways (Harrison and Weinberger, 2005; Lang 
et al., 2007). 
- Regulator of G protein signaling (RGS4) gene: This gene, located in a putative linkage area 
at 1q22, encodes a protein, highly expressed in the central nervous system, which 
modulates G-protein mediated signaling via some dopamine, glutamate and muscarinic 
receptors (Harrison and Weinberger, 2005; Lang et al., 2007). It was originally linked to 
schizophrenia susceptibility due to a study by Mirnics et al. (2001), who found a decreased 
RGS4 expression in schizophrenic postmortem brains. Genetic associations between RGS4 
haplotypes and schizophrenia were subsequently found (Chowdari et al., 2002; Williams et 
al., 2004), although the evidence has been generally modest and inconclusive and in some 
cases the results have been negative (Sobell et al., 2005). Further research is needed to 
elucidate the role of RGS4 in the liability to schizophrenia. 
- Cathecol-O-methyl transferase (COMT) gene: its plausability as a schizophrenia candidate 
gene lies on its role in dopamine catabolism and the existence of a functional variant (a 
valine to methionine polymorphism which affects protein activity and stability) that has 
been associated to schizophrenia in several studies (Egan et al., 2001a; Shifman et al., 
2002). Moreover, this gene is located in 22q11, a region that, when hemideleted, produces 
velocardiofacial syndrome (VCFS), a medical condition associated with an increased risk of 
psychosis (Harrison and Weinberger, 2005). However, the results from association analyses 
are variable or even negative (see Glatt et al., 2003 and Munafò et al., 2005 for meta-
analyses). Therefore, it seems that an effect exists, but it is modest. 
- Disrupted-in-schizophrenia 1 (DISC1): St Clair et al. (1990) described a Scottish family in 
which a balanced translocation involving chromosomes 1 and 11 [(1;11) (q42.1;q14.3)] was 
linked to a complex psychopathological inherited pattern, including schizophrenia, 
depression and mania. This fact led to the discovery of the DISC1 gene at 1q42, a region 
previously linked to schizophrenia in some samples (Ekelund et al., 2001; Hwu et al., 2003). 
Different association studies subsequently found association between DISC1 variation and 
schizophrenia and also with bipolar disorder (Hodgkinson et al., 2004; Callicott et al., 2005); 
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however, there are also negative findings. Moreover, in this case, significant haplotypes and 
SNPs also differed among studies although the involvement of this gene in the 
pathophysiological mechanisms of schizophrenia seems very probable. Its role in 
development, plasticity, neurite outgrowth and membrane trafficking of receptors also 
support this hypothesis (Harrison and Weinberger, 2005; Lang et al., 2007).  
Table I2 summarizes the current evidences coming from different approaches supporting the 
role of the genes presented above on the vulnerability to schizophrenia.  
Table I2. Evidences supporting some promising schizophrenia susceptibility genes. 
GENE Locus Linkage to SCZ 
Association to 
SCZ 
Altered 
expression in 
SCZ 
Expression in 
PFC 
Chromosomic 
aberration 
linked to SCZ 
Biological 
plausability 
NRG1 8p12-21 Yes* Multiple studies Yes Yes No Yes 
DAOA 
(G72) 
13q32-34 Inconsistent Multiple studies Not known Inconclusive No Inconclusive 
DAAO 12q24 Inconsistent Some studies Yes Inconclusive No Yes 
RGS4 1q21-22 Yes* Multiple studies Yes Yes No Yes 
COMT 22q11 Yes* Some estudies Yes Yes Yes Yes 
DISC1 1q42 Yes Multiple studies Yes Yes Yes Yes 
DTNBP1 6p22 Yes* Multiple studies Yes Yes No Yes 
*linkage to SCZ supported by meta-analytic approaches. 
Abbreviations: SCZ, schizophrenia; PFC, prefrontal cortex;  
Information obtained from: Harrison and Weinberger, 2005; Sullivan, 2005; Sawamura and Sawa, 2006; Madeira et 
al., 2008. 
 
However, other candidate genes have also been explored as interesting and plausible 
candidate genes, although the evidences are currently less clear than for the genes presented 
above. Among them, we should highlight a) genes related to the dopaminergic hypothesis, 
such as the dopamine receptors (DRD2 and DRD3), the dopamine and adenosine 3',5'-
monophosphate (cAMP)-regulated phosphoprotein of 32 kD (DARPP-32) and the Brain-derived 
neurotrophic factor (BDNF) (Lang et al., 2007); b) more genes linked to the glutamatergic 
hypothesis of schizophrenia, including the metabotropic glutamate receptor 3 (GRM3), among 
others (Harrison and Weinberger, 2005; Norton et al., 2006); c) genes involved in the response 
to antipsychotic medication, such as the serotonin receptor 2A (HTR2A gene) (Norton and 
Owen, 2005); and finally, d) other genes involved in the Phosphatidylinositide 3-kinase (PI3K) 
pathway (Lang et al., 2007), which is known to have a role in neuronal growth and migration, 
axonal sprouting and cell survival. This group of genes includes Reelin (RELN), BDNF, AKT1 (the 
most important downstream target of PI3K) and other well-known genes such as dysbindin 
and NRG1.  
In summary, many genes have been associated to schizophrenia disorders; however, the 
results remain somehow inconsistent and controversial, even for the most replicated genes, 
due to the existence of negative findings, as well as differences among the positive studies, 
where the lack of consistent replication of the same markers and haplotypes is a normal issue. 
One extreme example of this situation is the dysbindin gene, where every one of the five 
major haplotypes in this gene has been reported to be associated with schizophrenia in at least 
one study (Mutsuddi et al., 2006). For all the reasons exposed above, genome-wide 
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association (GWA) studies appeared very recently in the scientific panorama of schizophrenia 
as a powerful alternative based in high-throughput genotyping chips elaborated with the 
information given by the HapMap project. Until now, several GWA studies have been 
performed (table I3).  
Table I3. Genome-wide association studies in schizophrenia. 
Study Design Population 
Number of 
SNPs 
Sample size 
(SCZ/C) 
Significant results 
(genes or regions)
a
 
Mah et al., 2006 Case-control USA 25494 320/325 Yes (PLXNA2) 
Lencz et al., 2007 Case-control USA 439511 178/144 Yes (CSF2RA, IL3RA) 
Sullivan et al., 2008 Case-control USA 492900 738/733 No 
O'Donovan et al., 2008 Case-control Mixed 362532 7308/12834 
Yes (ZNF804A, 
11p14.1, 16p13.12) 
Kirov et al., 2008 Family-based Bulgaria 433680 574/1753 Yes (CCDC60, RBP1
b
) 
Shifman et al., 2008a Case-control Israel 510552 660/2771 Yes (RELN
b
) 
a Only the regions with the strongest associations are indicated.  
b These genes had been previously considered as candidate genes for SCZ. 
Abbreviations: SNP, Single Nucleotide Polymorphism; SCZ, schizophrenics; C, controls. 
 
 
Unfortunately, despite some significant findings, the associated genes are different on each 
study and neither of the most important candidate genes previously found in the “classical” 
association studies has been replicated with the GWA approach. The situation is also quite 
similar with regard to GWA bipolar disorder studies (Burmeister et al., 2008). Moreover, other 
very recent large scale studies and meta-analyses in schizophrenia could not replicate (Sanders 
et al., 2008) or replicated partially (Allen et al., 2008) some of the original findings in 
association studies of schizophrenia. Thus, at this point, scientists are divided on their opinions 
about the utility of the association studies to find schizophrenia susceptibility genes. The next 
section will evaluate some of the problems which may explain the inefficacy of the association 
approach. 
2.3.3. Inconsistencies and limitations in association studies.  
Several reasons can be invoked to explain the inconsistencies and difficulties derived from 
both case-control and family-based association analysis in the study of the genetics of 
schizophrenia. Firstly, there is evident heterogeneity at a genetic level. The most striking 
heterogeneity is found between different studies of the same candidate gene, where positive 
and negative associations coexist in the literature. This fact could be due to differences in the 
sample ascertainment or the existence of different risk factors depending on the origin of the 
sample. However, the heterogeneity can be also clearly observed across positive studies, since 
there is a lack of strict replication, that is, the risk alleles and haplotypes vary across studies. 
By contrast, association studies of other complex diseases, such as Type 1 and Type 2 diabetes 
mellitus or age-related macular degeneration, have produced consistent and strictly replicated 
findings (Sullivan, 2005). Perhaps schizophrenia has a high genetic heterogeneity, in contrast 
with these other pathologies. However, it is also plausible that many of the positive findings 
are actually false positives (type I error), due to the use of stratified samples of different 
genetic origin which could seriously distort the results. Moreover, false negatives (type II 
error) can also account for a considerable part of the inconsistencies, in coherence with the 
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widely accepted hypothesis of genetic risk variants with a very small effect. A high level of 
genetic heterogeneity (with many rare risk variants) would also favor the increase of type II 
errors. However, this type II error could be avoided with larger samples.  
Moreover, epigenetic mechanisms should be also considered, since they may regulate the 
expression of several genes in the central nervous system (Petronis, 2004; Tsankova et al., 
2007). As a result, epigenetic processes may regulate complex behaviors without changes in 
the DNA sequence. Furthermore, changes in the epigenetic pattern can partially account for 
the existence of abnormalities in psychiatric disorders, such as depression or schizophrenia 
(Petronis, 2004). 
Nevertheless, the genetic heterogeneity is not the only confounding element in psychiatric 
genetics, since the high clinical complexity of schizophrenia (with the existence of many 
symptoms which can vary among patients or during the course of the illness) also makes the 
comparisons among studies extremely difficult. Finally, risk environmental factors cannot be 
forgotten and undervalued but, unfortunately, the majority of schizophrenia association 
studies do not consider them in the analyses. These environmental factors can modulate the 
risk for schizophrenia independently or by means of interactions among different 
environmental factors, but also through gene x environment interactions (Caspi and Moffitt, 
2006). Several recent studies have begun to show the importance of epistatic processes to 
properly understand the pathophysiology of schizophrenia and other mental disorders (Caspi 
et al., 2003, 2005).    
Thus, it is necessary to tackle alternative strategies to resolve the inconsistencies of the 
association approach. 
 
3. Returning to the symptom: the alternative phenotypes in 
psychiatric genetics. 
As we have seen, the phenotypic complexity of schizophrenia together with the probable lack 
of biological validity of the current nosology of mental disorders are limiting factors in 
understanding the genetic basis of schizophrenia. Therefore, new strategies should be defined. 
A critical issue in clinical psychiatry is that, despite the advances in neuropsychiatry in the last 
decades, the symptom is still poorly understood. Thus, to focus on the symptom instead of a 
syndromic phenotype appears to be a valid approach. As a result, during the last decade many 
researchers have begun to focus on other study phenotypes in an attempt to approach 
psychiatry to biology (table I4).  
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Table I4. Some alternative phenotypes used in schizophrenia genetic studies. 
Phenotype Examples Advantages Disadvantages 
Broad phenotype 
- Unique psychosis 
- Unique Mental 
Disorder 
- Identification of common risk factors 
- Reconsideration of the nosology 
Phenotypic differences 
cannot be explained 
Extreme phenotypes 
- VCFS 
- Chronic hallucinators 
- Catatonic psychosis 
Consistent results in other complex 
disorders 
It only explains a small 
fraction of the patients 
Clinical subtypes 
- Positive symptoms 
- Disorganized SCZ 
Closer to the traditional 
psychopathology 
Doubtful biological validity 
Dimensions of 
personality 
- Schizotypy 
- Schizotaxia 
Continuum with normal personality Doubtful biological validity 
Neurophysiological 
alterations 
- P50 and P300  
- Eye movement 
- Closer to genotype 
- Biological validity 
- Study through animal models 
Not specific for 
schizophrenia 
Neuroimaging 
phenotypes 
- Hypofrontality 
- Brain size 
Closer to the genotype 
Not specific for 
schizophrenia 
Hallucinations - Auditory hallucinations  
- High specificity 
-Close to the clinical diagnosis 
- Studied through neuroimaging 
Episodic nature 
Cognitive impairment 
- Working memory 
- Attention  
- Continuum with normal cognition 
- Studied through neuroimaging 
- Knowledge about its physiology 
Not specific for 
schizophrenia 
Abbreviations: SCZ, schizophrenia; VCFS, velocardiofacial syndrome. 
 
  
Among the different phenotypes which could be chosen, one of the most widespread 
approaches is the deconstruction of schizophrenia in simpler elements to increase power and 
simplify the genetics. At this point, several interrelated concepts (usually treated as 
synonyms), such as alternative phenotype, intermediate phenotype or endophenotype, arise. 
All of them are based on the same principle: since genes do not encode for psychopathology, 
we have to deal with the study of other phenotypes which are closer to the biological 
processes underlying psychiatric diseases. The reason to use these phenotypes would lie in the 
belief that these entities involve fewer genes than the whole disorder (Gottesman and Gould, 
2003).     
The concept of endophenotype was formulated more than thirty years ago by Gottesman and 
Shields (1973); however, its popularity only grew in the last decade as a result of the 
difficulties to find the underlying genetic causes of psychiatric disorders. It was originally 
defined as an internal trait which is presumably causally closer to the gene than the pathology 
as a whole and can be detected through biochemical or microscopic tests (figure I6). 
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Figure I6. The relationship between genes, endophenotypes and liability to 
schizophrenia. Genetic factors have an effect on a wide variety of endophenotypes, which 
can be considered intermediate elements among the genes and the liability to 
schizophrenia, which is the result of dynamic interplay between genetic, environmental 
and epigenetic factors during lifetime.   
(Figure extracted from Gottesman and Gould, 2003). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although there is some controversy about which phenotypes are meaningful, the following are 
some necessary criteria (Gottesman and Gould, 2003; Prathikanti and Weinberger, 2005; 
Bearden and Freimer, 2006): 
- The endophenotype co-segregates with the illness in the population. 
- It is heritable and detectable in family members of individuals with disorders associated 
with that phenotype at a higher rate than in the general population. 
- It should be associated with the causes rather than consequences of the disorder.  
- They should have good reliability, validity and good psychometric properties. 
- It should be distributed continuously (or even normally) in the general population. 
- It must be stable over time and can be present even when the disease is not active (state 
independent). 
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According to these criteria several clinical measures have been found to be useful in 
schizophrenia research. These include several cognitive deficits related to executive function 
and attention, electroencephalogram (EEG)-evoked potential abnormalities and eye 
movement disfunctions, among others (Prathikanti and Weinberger, 2005; Flint and Munafò, 
2007).  
In contrast with the endophenotype concept, but at the same time closely related to it, we 
consider that the alternative phenotype particularly refers to those clinical symptoms which 
can be used as selection criteria instead of the traditional DSM or ICD criteria. These 
phenotypes are useful for several reasons. Firstly, they allow a more precise selection of 
patients for molecular genetic studies and facilitate the collection of more homogeneous 
patient samples. Secondly, an alternative phenotype should represent a simpler 
pathopshysiological pathway, which can be studied by different approaches with probably 
more chances of success than the schizophrenia phenotype as a whole.  
Neuroimaging phenotypes also need a special mention since they can be excellent 
endophenotypes which are really closer to the genotype than a behavioral phenotype. 
Moreover, they can also be useful tools to investigate other alternative phenotypes or 
endophenotypes such as cognitive dysfunction or auditory hallucinations.  
For the present study, two alternative phenotypes have been chosen: auditory hallucinations 
and cognitive impairment. 
3.1. Auditory hallucinations in psychoses. 
Hallucinations have been defined as sensorial experiences in a conscious state in the absence 
of an external sensorial stimulus with characteristics of a real perception, since they are vivid, 
substantial, and located in external objective space (David, 2004; Sanjuán, 2006). Several 
studies have shown that hallucinations are phenomenologically heterogeneous events as they 
can be of different sensorial nature: visual, auditory (verbal or musical), olfactory, gustatory, 
tactile, kinesthetic, hypnagogic (at sleep onset), hypnopompic (during awakening) or even 
multimodal. Moreover, hallucinations also present phenomenological variations across clinical 
populations and may be clearly influenced by the person’s mood, emotional experiences 
suffered in the past and cultural beliefs (Aleman and Larøi, 2008). Interestingly, hallucinations 
can be present even in healthy individuals with no psychiatric or neurological disorders and it 
has been hypothesized that there is a continuum between the perception of normal 
population and the perception of psychiatric patients; consequently, hallucinations should be 
viewed as a dimensional phenomenon rather than a categorical event.  
Auditory hallucinations (AH) are the most common type of hallucinations in psychotic 
patients, with prevalence between 50% and 70% in schizophrenic patients (Slade and Bentall, 
1988; Andreasen and Flaum, 1991). Although they may involve simple sounds, AH in psychosis 
generally consist of a voice or voices (verbal hallucinations or “phonemes”) speaking about 
the subject’s thoughts aloud, commenting the individual’s behavior or giving instructions or 
commands (Aleman and Larøi, 2008). Interestingly, voices can be located inside or outside the 
head and this location can change over time. Content is also variable and, despite patients 
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usually describe AH as negative, they can also be perceived as positive or even pleasurable 
(Sanjuán et al., 2004a; Aleman and Larøi, 2008).  
However, the dimensional nature of auditory hallucinations is also a critical issue. 
Traditionally, different dimensions of AH have been considered (Oulis et al., 1995; Nayani and 
David, 1996; Stephane et al., 2003): a) physical dimension (which includes aspects such as 
intensity, localization and complexity of voices); b) emotional influence; c) insight (which refers 
to the belief about the origin of voices) and d) grade of control of AH. Among them, we 
consider that the emotional component has been particularly undervalued. Emotional factors 
may have a significant role in the hallucinatory experience of hearing voices. Firstly, certain 
states of high emotionality have been described as preceding psychosis (Freeman and Garety, 
2003) and it has been also described an increase in anxiety prior to the onset of hallucinations. 
Secondly, auditory hallucinations in psychotic patients generally involve a highly emotional 
content (Nayani and David, 1996; Smith et al., 2006), which seems to be correlated with the 
general emotional state (presence of depression, lower self-steem). Finally, the emotional 
response triggered by AH (which includes depression and anxiety states) may have important 
consequences in the development of the psychotic outbreaks. It has been also suggested that 
AH would be associated with auditory affective processing deficits (Rossell and Boundy, 2005).  
In conclusion, the multidimensional characteristics of AH must be evaluated through 
appropriate assessment strategies, which include specific hallucination scales such as the 
Psychotic Symptom Rating Scale (PSYRATS), the Launay-Slade Hallucination scale (LSHS), the 
Beliefs About Voices Questionnaire (BAVQ) and the Verbal Hallucinations Questionnaire 
(reviewed in Aleman and Larøi, 2008).    
To better understand the underlying processes controlling the hallucinatory experience, it is 
important to investigate which differential processes are taking place in the brain when a 
subject is suffering from AH. With this purpose, many neuroimaging studies have been 
performed, although these approaches generally do not take into account the dimensional 
nature of auditory hallucinations. With regard to structural studies, the best replicated finding 
is a reduction of gray matter (GM) volumes of the temporal lobe, especially the left superior 
temporal gyrus (STG), which is negatively correlated with the severity of hallucinations 
(reviewed in Aleman and Larøi, 2008). Interestingly, this region includes the primary auditory 
cortex. Moreover, volume reductions in other areas have been also reported in some studies. 
These areas include the dorsolateral prefrontal cortex (DLPFC), cerebellum and left inferior 
supramarginal gyrus (involved in speech perception). Moreover, connectivity studies through 
resonance diffusion tensor imaging (Hubl et al., 2004) have found alterations in hallucinatory 
patients compared to controls in different white matter tracts located predominantly in left 
areas. Regarding functional neuroimaging studies, hallucination-related activity has been 
found in those areas related to the normal processing of auditory stimuli (Silbersweig et al., 
1995; Woodruff, 2004; Aleman and Larøi, 2008), such as those left regions involved in prosodic 
aspects of language, the emotional response and verbal monitoring. Some of the most 
replicated areas are the left superior temporal cortex, Broca’s area, thalamus, basal ganglia 
and anterior cingulate cortex.  In summary, the neuroimaging findings support the existence of 
a distributed network of cortical and subcortical areas involved in the whole hallucinatory 
experience. Of remarkable interest is the use of functional neuroimaging to study particular 
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dimensions of auditory hallucinations, such as the emotional response to voices. Regarding 
this issue, our group has developed an auditory-emotional fMRI paradigm (further explained 
in the Materials and Methods section) to evaluate the impact of emotional words on brain 
activation in hallucinatory patients and healthy subjects. In this study (Sanjuán et al., 2007), 
patients showed stronger activation of prefrontal areas, temporal cortex, insula, cingulate and 
amygdala. The latter finding is coherent with the hypothesis that hyperactivation of the 
amygdala may be related to the affective components of positive symptoms of schizophrenia 
(Aleman and Kahn, 2005).  
In the light of all these results, we consider auditory hallucinations to be a valid and useful 
alternative phenotype in psychiatric genetics for the following reasons: 
- AH are the most frequent and characteristic feature of psychotic patients. 
- AH can be easily identified and measured through different methodologies (clinical scales, 
neuroimaging protocols…). 
- Despite the existence of AH in other types of patients, the phenomenon of “hearing voices” 
has very particular features in psychotic patients (table I5).  
- Its importance for the clinical diagnostic and prognostic is high. 
Table I5. Clinical features of auditory hallucinations in psychotic patients. 
Form of hallucinations Voices in second or third person speaking to the patient or talking 
between them about the patient. 
Physical features Variable frequency. Normal volume and variable location (inside or 
outside the patient’s head).  
Content of hallucinations Generally negative content. Sometimes perceived as neutral or positive. 
Triggering factors Stress, drug abuse, poor response to medication. 
Emotional response Very high, normally with anxiety, irritation or anger. Some patients feel 
them as pleasurable. 
Insight  Low level of insight: delusional explanations of hallucinations. 
Information extracted from González et al., 2003a. 
 
Our hypothesis is that auditory hallucinations in psychotic patients are consequence of 
disturbances in specific neurobiological circuits related to the different dimensions of AH. The 
integrity of those circuits would be also mediated by genetic factors. The idea of genetic 
factors implicated in AH is not new. A classical study from Rosenthal and Quinn (1977) showed 
a unique case of monozygous quadruplets concordant for auditory hallucinations and 
schizophrenia. The authors concluded that a genetic predisposition to AH should be 
considered. However, until now, only a few studies have been focused on the molecular 
genetics of hallucinations, and most of them have been performed in neurological patients. 
Table I6 shows a summary of those studies.  
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Table I6. Molecular genetic studies of auditory hallucinations. 
Study Disease 
Type of 
hallucinations 
Gene Polymorphism Sample size 
Malhotra et al., 1998 SCZ Auditory SLC6A4 (5-HT transporter) 5-HTTLPR 50 p 
Wei & Hemmings, 1999 SCZ Auditory CCK-AR (CCK receptor) 779C/T 210 p 
Tachikawa et al., 2001 SCZ Auditory CCK-AR (CCK receptor) -81A/G 87 p/100 c 
Sanjuán et al., 2004b SCZ Auditory CCK-AR (CCK receptor) 779C/T 105 p 
Sanjuán et al., 2006a SCZ Auditory FOXP2 rs2396753 186 p 
Holmes et al., 1998 Alzheimer Auditory/Visual 
HTR2A/HTR2C  
(5-HT receptors) 
T102C/Cys23Ser 211 p 
Goetz et al., 2001 Parkinson Visual DRD3 (dopamine receptor) Ser9Gly 88 p 
Wang et al., 2003a Parkinson Visual CCK (cholecystokinin) -45C/T 160 p 
Limosin et al., 2004 Alcoholism Visual  DAT (dopamine transporter) VNTR 
64 alcoholic 
women 
Fujii et al., 1999 Parkinson Undetermined
a
 CCK (cholecystokinin) -45C/T 116 p 
Okubo et al., 2002 Alcoholism Undetermined
a
 CCK-AR (CCK receptor) -85C/G 201 p/98 c 
Chang et al., 2004 Alzheimer Undetermined
a
 ApoE (Apolipoprotein E) ε4 allele 135 p 
Goldman et al., 2004 Parkinson Undetermined
a
 CCK (cholecystokinin) -45C/T 86 p 
Note: CCK is a neuropeptide whose function is directly related to the DA system. 
a No information about the modality of hallucination is provided by the authors. 
Abbreviations: SCZ, schizophrenia; 5-HT, serotonin; p, patients; c, controls. 
 
 
Therefore, a deeper study on the genetic basis of auditory hallucinations is still necessary. We 
also consider that auditory hallucinations could be a good environment to study the emotional 
dysfunction suffered by schizophrenic patients.  
 
3.2. Cognitive dysfunction in schizophrenia. 
Cognitive impairment has been traditionally described as one of the most severe symptoms of 
schizophrenia, which accounts for much of the psychosocial disability found in these patients 
(Breier et al., 1991; Green, 1996; Lewis, 2004). Both global and specific cognitive deficits in 
schizophrenic patients can be found in the literature. These deficits also have a high 
prevalence in adult patients. In an exhaustive meta-analysis, Heinrichs and Zakzanis (1998) 
reported that 61%-78% of schizophrenic patients scored below the normal median on all 
cognitive tests, while the largest effects were found in verbal memory, some measures of the 
intelligence quotient (IQ), as well as attention and word fluency. With regard to children and 
adolescents with schizophrenia, cognitive functions are also clearly compromised, with a low 
full-scale IQ and reduced ability for information processing, as well as deficits in attention and 
several types of memory, including working memory and episodic memory.  
As a result of all these observations, some logical questions arise: are these cognitive deficits a 
consequence of the psychotic state, and if so, does the cognitive dysfunction worsen together 
with the progression of the illness? Several studies support the hypothesis that cognitive 
alterations are not dependent on positive symptoms of schizophrenia and are relatively 
stable as the illness progresses (Bedwell et al., 1999; Elvevåg and Goldberg, 2000). Moreover, 
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some cognitive deficits, especially related to attention and working memory, can be also found 
prior to the onset of the disease (Davidson et al., 1999; Cannon et al., 2002a; Lewis, 2004)  
Working memory seems to be one of the key elements to understand the cognitive 
dysfunction in schizophrenia, since many studies have reported an abnormal functioning of 
this system in schizophrenic patients (Goldberg et al., 1987; Goldman-Rakic, 1994; Silver et al., 
2003). Working memory can be defined as a limited capacity system which maintains, stores 
and works with relevant information, through complex processes involving thinking, language 
and goal-directed behavior (Baddeley, 2003). Working memory is in fact extremely complex, 
since the current hypotheses suggest that it really involves many systems related to attention, 
storage of peripheral information and executive function (Baddeley, 2003; Tan et al., 2007). 
This memory system is also necessary for a wide range of cognitive abilities, such as reasoning, 
learning and comprehension.  
Currently, there is a great interest in studying the cognitive impairment of schizophrenic 
patients in depth. This interest has been partially motivated by the fact that, unless cognitive 
deficits in schizophrenic patients are potentially treatable, the current antipsychotic drugs 
used to treat the positive symptoms of schizophrenia have been found to be useless with 
regard to cognitive symptoms and, as a result, there is an intense search of drugs which can 
relieve some of the cognitive alterations suffered by those patients. Therefore, a deep study of 
the neurobiology of cognitive processing in schizophrenia is necessary to achieve this goal. 
Table I7 shows some cognitive and neuroanatomic traits frequently studied in psychiatry. 
Table I7. Cognitive and neuroanatomic measures studied in schizophrenia research. 
MEASURE COGNITIVE DOMAIN 
Neurocognitive tasks 
California Verbal Learning Test Verbal memory 
Logical memory Verbal memory 
Visual reproduction Visual memory 
Wisconsin Card Sorting Test Executive function 
N Back task Working memory 
Trailmaking Test, A and B Attention and executive function 
Digit symbol Processing speed 
Spatial span Working memory and attention (visual) 
Digit span Working memory and attention (verbal) 
Perceptual span Sustained attention and visual search 
Verbal fluency Language 
Neuroanatomic measures 
Gray matter density 
 
White matter volume 
 
Hippocampus size 
 
Frontal lobe volume 
 
Prefrontal activity
a
 Working memory, attention 
Hippocampal activity
a
 Working memory, episodic memory 
a While performing an specific neurocognitive task that engages this brain region. 
Information extracted from Bearden and Freimer, 2006. 
 
Interestingly, cognitive abilities can be considered as some of the most valid and useful 
endophenotypes for schizophrenia genetics research. Several reasons support this idea: 
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Figure I7. “Inverted-U” 
response as a result of 
the progressive increase 
in memory load. Working 
memory performance, 
measured through PFC 
fMRI signal, progressively 
increases and then 
declines when capacity is 
reached in a pattern that 
has been denominated 
“capacity-constrained 
response”. Abbreviations: 
PFC, prefrontal cortex. 
- Cognitive abilities (memory, processing speed, attention, overall IQ…) seem to be highly 
heritable in humans. Evidences from twin studies corroborate this hypothesis in healthy 
subjects (McClearn et al., 1997; Devlin et al., 1997) and schizophrenic patients (Cannon et 
al., 2000; Toulopoulou et al., 2007). Moreover, several cognitive abnormalities related to 
schizophrenia have been found in healthy siblings of affected individuals with a higher 
prevalence than in normal population, thus implying a higher relative risk for those siblings 
(Keefe et al., 1997; Kremen et al., 1994; Cannon et al., 2000; Egan et al., 2001b). 
Particularly, several family (Park et al., 1995; Conklin et al., 2000) and twin (Goldberg et al., 
1988; Cannon et al., 2000) studies also support the heritability of working memory deficits 
in schizophrenia.  
- Functional neuroimaging techniques can be considered a powerful tool which allows the 
correlations of the poor performance in cognitive tests with alterations in certain neural 
systems. There are many evidences that the prefrontal cortex (PFC), and especially the 
DLPFC, is involved in human working memory (see Tan et al., 2007 for a review). Many 
studies have also found a prefrontal cortical physiological dysfunction in schizophrenic 
subjects compared to controls. These abnormalities have been also found in healthy 
relatives and twins of schizophrenic patients, as well as in subjects with an At Risk Mental 
State (ARMS) (Fusar-Poli et al., 2007). What these functional findings mainly show is a 
reduced blood oxygenation level-dependent (BOLD) activation in the PFC of schizophrenic 
patients (Callicott et al., 1998; Carter et al., 1998; Stevens et al., 1998; Barch et al., 2001; 
Perlstein et al., 2001). Moreover, in those studies using the N-Back task (which is known to 
activate storage and executive processes related to working memory), schizophrenic 
subjects exhibit a decrease in performance accuracy and reaction time, which normally 
correlates with a decrease in prefrontal activation. This pattern is also specific to 
schizophrenia when compared to other psychiatric disorders (reviewed in Tan et al., 2007). 
Thus, these findings suggest that abilities on working memory tasks in schizophrenia may 
reflect differences in capacity limitation between patients and controls. Capacity limitation 
refers to a decrease in the performance as the memory load increases. Thus, the activity of 
prefrontal regions would adjust to a nonlinear “inverted-U” shaped physiological response 
(Callicott et al., 1999). A representation of this activation pattern can be found in figure I7.  
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- Structural neuroimaging can also supply valuable information with regard to cognition in 
schizophrenic patients. It is well established that there is a clear relationship between 
intelligence and regional brain volumes (Toga and Thompson, 2005). Moreover, gray matter 
density and brain morphology are highly heritable traits (Bartley et al., 1997; Cannon et al., 
2002a; Thomson et al., 2001) and neocortical gray matter volumes are also heritable and 
correlate with several cognitive domains (Thomson et al., 2001). Furthermore, several 
volume deficits seem to be related to genetic liability to schizophrenia (Cannon et al., 1998; 
Cannon et al., 2002b; Goldman et al., 2008; Honea et al., 2008).  
As a result of the previous findings related to cognition and risk for schizophrenia, imaging 
genetics appears to be one of the most powerful strategies to study the underlying 
mechanisms of cognitive dysfunction affecting schizophrenic subjects. Although behavioral and 
cognitive tasks can give valuable information per se, these phenotypes are undoubtedly less 
sensitive to detect the effect of a risk allele of small effect, since they are specially away from 
genotype (Meyer-Lindenberg and Weinberger, 2006; Roffman et al., 2006). By contrast, 
neuroimaging captures biological processes which are closer to the genotype. Thus, imaging 
phenotypes are expected to be more directly predicted by the genotype than a pure 
behavioral or clinical phenotype. In conclusion, the combination of both cognitive tasks and 
neuroimaging tools are becoming essential elements to elucidate the genetic mechanisms of 
cognitive dysfunction in schizophrenia.  
Some examples of imaging genetics applied to the study of cognitive deficits in schizophrenia 
will be briefly described now. One of the most studied genes is COMT, because of its clear 
relationship to the dopaminergic hypothesis of schizophrenia. Several studies have been 
performed to elucidate how the functional Val158Met polymorphism influences on working 
memory phenotypes (reviewed in Meyer-Lindenberg et al., 2006; Roffman et al., 2006; and 
Tan et al., 2007). COMT genotypes were found to account for approximately 3-4% of the 
variance in performance of tasks involving prefrontal cortex (such as the Wisconsin Card 
Sorting test or WCST), with a poorer performance for the Val-allele carriers when compared to 
the Met-allele carriers (Egan et al., 2001a; Nolan et al., 2004; de Frias et al., 2006). This effect 
has been found even in healthy subjects. Subsequently, an effect of COMT variation has been 
seen in fMRI studies, since Val-allele carriers present a higher N-Back prefrontal activation than 
Met-allele carriers, suggesting that those subjects with the Val-allele are less efficient (Egan et 
al., 2001a; Meyer-Lindenberg et al., 2006). Likewise, these effects increased as memory load 
increases, adjusting to an inverted-U response (Mattay et al., 2003).    
Furthermore, other genes apart from COMT have also been reported to influence cognition 
and risk for schizophrenia (Roffman et al., 2006; Tan et al., 2007). Some examples are the 
GRM3 gene, which encodes the metabotropic glutamate receptor 3; the DAOA (G72) gene; 
and the Ser-allele of the polymorphism Ser704Cys from DISC1. 
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4. Schizophrenia candidate genes selected for this study. 
In the present study, several issues have been taken into account to select many different 
candidate genes. Basically, the selection has been focused on several interrelated aspects of 
schizophrenia: auditory hallucinations, cognitive dysfunction and emotional response.  
Firstly, we are especially interested in those genes which could have a role in the vulnerability 
to auditory hallucinations and/or cognitive dysfunction in schizophrenia, which are the two 
alternative phenotypes we have decided to focus. However, another aspect of schizophrenia, 
the emotional response, has been considered of special interest, given its implication for the 
prognosis and outcomes of the pathological manifestations of schizophrenia. Particularly, the 
emotional response to auditory hallucinations is a critical but unappreciated aspect in the 
pathophysiology of AH.       
On the basis of these criteria, nine genes have been included in this study. Some of them 
belong to systems which have been traditionally related to schizophrenia, while others 
represent new approaches to tackle the study of the genetics of schizophrenic processes.     
4.1. Serotonergic system genes. 
Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter (figure I8a) 
diversely present in plants and animals (Jonnakuty and Gragnoli, 2008). In mammals, it is 
mainly synthesized in the serotonergic neurons of the central nervous system (Fuller and 
Wong, 1990) and the enterochromaffin cells of the gastrointestinal tract (Furness and Costa, 
1982). 5-HT synthesis requires the presence of the essential amino acid L-tryptophan, which is 
hydroxylated to 5-hydroxy-L-tryptophan (5-HTP) via the enzyme tryptophan hydroxylase 
(figure I8b). This first step constitutes the rate-limiting step in the synthesis of serotonin 
(Jonnakuty and Gragnoli, 2008).  
 
 
 
 
 
 
 
 
 
 
a b 
Figure I8. a. Chemical 
structure of serotonin. b. 
5-HT synthesis and model 
of a 5-HT synapse.  
Abbreviations: 5HTP, 5-
hydroxy-L-tryptophan; 
5HT, serotonin; MAO, 
monoamine oxidase; SERT, 
serotonin transporter. 
Figures from Nichols and 
Nichols, 2008. 
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In mammalian species, serotonin has an important role in the central and peripheral nervous 
system. However, only a small fraction of total body serotonin is produced in the central 
nervous system (CNS), particularly in specialized groups of cell bodies known as the raphe 
nuclei, located in the brainstem reticular formation (Maurer-Spurej et al., 2004). From the 
brainstem, serotonergic neurons project to virtually every part of the CNS (cortex, amygdala, 
hippocampus, cingulated gyrus, cerebellum…). Serotonin is produced within axon terminals 
and stored in secretory granules until it is released in response to an action potential from 
serotonergic neurons into a synapse and then diffuses across the synapse to activate 
postsynaptic 5-HT receptors (figure I8b). Here, the action of serotonin is terminated by 
reuptake via a specific transporter (SERT) located in the membrane of presynaptic terminals. 
Once again in the presynaptic neuron, it is metabolized by the monoamine oxidase (MAO) 
enzyme to 5-hydroxyindole acetic acid (5-HIAA).  
As a result of its widespread projection pattern, serotonin plays a key role in the regulation of 
several behavioral, physiological, and cognitive behaviors (Jacobs and Azmitia, 1992), 
including motor function, memory, cognition and emotionality, as well as many endocrine 
functions (temperature regulation, sleep, food intake, sexual activity…). However, serotonin, 
like other monoamine neurotransmitters, also plays an initial role in regulating brain 
development and can also set its own terminal density, a phenomenon known as 
autoregulation of development (Whitaker-Azmitia, 2001).  
The ubiquitous expression of serotonin receptors throughout the brain (Baumgarten and 
Grozdanovic, 1997) explains its multifunctional role in all the physiological systems explained 
above. The serotonin receptor family is larger than any other family of G-protein coupled 
(GPCR) neurotransmitter receptors: 13 receptors with seven transmembrane domains, which 
transduce signals through coupling to guanine nucleotide-binding regulatory proteins. In 
addition, there is one ligand-gated ion channel, the 5-HT3 receptor (Cravchik and Goldman, 
2000; Hoyer et al., 2002). Serotonin receptors are classified according to their structure, 
transduction signal, and pharmacology (Côté et al., 2004). The earlier discovered 5-HT1, 5-HT2, 
5-HT3, and 5-HT4 receptors have been studied extensively and their functional properties are 
the best understood of all the serotonin receptors. By contrast, 5-HT5, 5-HT6, and 5-HT7 
receptors have been cloned within the last decade and their physiology is poorly understood 
(Cravchik and Goldman, 2000; Jonnakuty and Gragnoli, 2008). 
Serotonin has long been implicated in the pathophysiology of psychiatric disorders such as 
depression, anxiety, aggressive behavior, obsessive–compulsive disorder (OCD), eating 
disorders and drug abuse (Giacalone et al., 1968; Mehlman et al., 1994; Bellivier et al., 1998a; 
Bellivier et al., 1998b; Lucki, 1998; Mann et al., 2001). The serotonin system is one of the main 
targets for pharmacologic treatment of several psychiatric disorders and hallucinogens such as 
LSD and psilocybin inhibit the peripheral actions of 5-HT. This led to the hypothesis that brain 
5-HT activity might be altered in psychiatric disorders. This hypothesis was strengthened by 
the introduction of tryciclic antidepressants and MAO inhibitors for the treatment of major 
depression and the finding that those drugs affect 5-HT and noradrenaline metabolism 
(Glowinsky and Axelrod, 1964). Moreover, selective serotonin reuptake inhibitors (SSRIs), 
which target the serotonin transporter, are used in the treatment of depression, OCD and 
panic disorder (Nutt et al., 1999). 5HT2 receptors have also attracted interest as potential 
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Figure I9. Structure of the 
serotonin transporter. In color, 
different aminoacid changes 
described in the literature are 
indicated. Abbreviation: TM, 
transmembrane. 
Figure extracted from Murphy et 
al., 2008. 
pharmacologic targets for the treatment of schizophrenia, mainly due to the fact that some 
atypical antipsychotics show high 5HT2 to D2 receptors affinity ratio, relative to typical 
antipsychotic drugs (Meltzer et al., 1989). 5-HT2A receptor also mediates the effects of several 
hallucinogens. Abnormalities in the serotonin system have also been found in schizophrenia. 
In several cortical regions of postmortem schizophrenic brains, there have been reports on 
increased density of 5-HT1A receptors (see Bantick et al., 2001, for a review). This finding has 
been confirmed by PET studies (Tauscher et al., 2002). Moreover, reduced densities of 5-HT2A 
receptors (for review, see Dean, 2003) have been found in cortical regions of postmortem 
schizophrenic brains. Several abnormalities in serotonergic binding sites have been 
demonstrated in suicide victims such as reduced levels of 5-HT transporters and increased 
levels of 5-HT1A receptors (Arango et al., 1995) in the ventrolateral prefrontal cortex, and 
increased 5-HT2A receptor binding in the PFC (Arango et al., 1997). Finally, Hernandez and 
Sokolov (1997) found an approximately four-fold increase of serotonin transporter mRNA in 
Brodmann area 9 and a two-fold decrease in Brodmann areas 21 and 22 in a group of 
schizophrenic patients compared to controls.             
Now, we will focus in the three serotonergic system genes which have been studied in this 
doctoral thesis work: the serotonin transporter gene (SLC6A4), the tryptophan hydroxylase 2 
gene (TPH2) and the serotonin receptor 2A gene (HTR2A). 
4.1.1.  The serotonin transporter gene.  
The serotonin transporter (SERT) is a protein of 630 aminoacids which is predicted to contain 
twelve hydrophobic transmembrane (TM) domains (figure I9). This solute carrier is part of the 
genic family of Na+- and Cl-- dependent neurotransmitter sodium:symporters (NSS) for 
monoamines, which also includes other cotransporters such as the dopamine transporter 
(DAT) and the norepinephrine transporter (NET). Its mechanism of action depends on the 
existence of a Na+-K+ gradient, and it is based on conformational changes as a result of the 
simultaneous binding of serotonin, Na+ and Cl- (Murphy et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
The human serotonin transporter gene (official name: SLC6A4; other names: 5-HTT or SERT) 
maps to chromosome 17q11.2, where it spans approximately 38 kb (figure I10). It is composed 
of 16 exons, including several alternative non-coding exons (1A, 1B and 1C), which, together 
with several alternative promoters and polyadenilation signals, have an important role in the 
regulation of gene expression (Lesch et al., 1994; Bradley and Blakely, 1997; Ozsarac et al., 
2002). In addition to several regulatory domains which control selective expression in 
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Figure I10. Genomic structure of the serotonin transporter gene (SLC6A4). Exons are indicated in 
Roman numerals. Untranslated regions are shown in white. A polymorphism in the promoter region 
gives rise to two alleles with different level of expression. 
serotoninergic neurons, transcriptional activity of SLC6A4 gene is mainly modulated by a 
polymorphic repetitive element in the 5’ regulatory region (5-HTT- Linked Polymorphic Region 
or 5-HTTLPR) located approximately 1.4 kb upstream of the transcription start site (figure I10). 
It consists of a deletion in a GC-rich region of repetitive elements, which mainly originates two 
alleles: a short allele (S) with fourteen repeat elements and a long allele (L) with sixteen repeat 
elements (Heils et al., 1996). However, alleles with up to twenty repeats can be also found in a 
low frequency. Comparison of different mammalian species confirmed the presence of the 5-
HTTLPR in platyrrhini and catarrhini (hominoids, cercopithecoids) but not in prosimian 
primates and other mammals (Lesch et al., 1997). As a result, it has been speculated that the 
5-HTTLPR region originated from a progenitor viral DNA or transposable element which may 
have been introduced into the genome around 40 million years ago (Lesch and Mössner, 
1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, 5-HTTLPR regulates the transcriptional activity of the SLC6A4 gene and also 
affects protein expression and function. The S allele has been associated with lower SLC6A4 
expression and function when compared to the L allele (figure I10). This fact has been 
confirmed by several approaches, such as analysis of the promoter region in cell cultures, 
postmortem analysis of mRNA levels in the raphe complex of human brain, platelet serotonin 
uptake, responsivity of the serotonergic system to pharmacologic challenge tests with SSRIs 
and mood changes related to tryptophan depletion (Lesch et al., 1996; Little et al., 1998; 
Greenberg et al., 1999; Mortensen et al., 1999; Eichhammer et al., 2003).  
   
Moreover, two recently discovered SNPs (rs25531 and rs25532), located inside the 5-HTTLPR 
region, have been also reported to modulate the transcriptional activity of SLC6A4 (Hu et al., 
2006; Wendland et al., 2006, 2008). Of special interest is SNP rs25531, a relatively frequent 
A/G substitution immediately upstream of 5-HTTLPR that changes the consensus sequence for 
the activator protein 2 transcription factor (Kraft et al., 2005). The combination of this SNP 
with the 5-HTTLPR variation generates four main alleles in the promoter region: the LA allele 
with high activity, and the LG, SA and SG alleles, which result in lower transcriptional levels and 
less serotonergic activity (Kraft et al., 2005; Hu et al., 2006; Gallinat et al., 2007).   
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Additional variants at the SLC6A4 locus have been also described. Among them, one of the 
most frequently studied is a 17-bp variable number of tandem repeats (VNTR) located in intron 
2 (known as STin2), which seems to act as an enhancer during embryonic development 
(MacKenzie and Quinn, 1999). STin2 has two common alleles of 10 and 12 repeats. However, 
rare alleles of 7 and 9 repeats have been also found (Lesch et al., 1994). Although the 
evidences are less than for the 5-HTTLPR variation, it has been reported that STin2 variation 
also affects SLC6A4 expression (Hranilovic et al., 2004). Other polymorphisms at the SLC6A4 
gene which have been previously studied include several common SNPs (Battersby et al., 1999; 
Kim et al., 2002; McCauley et al., 2004) as well as rare functional SNP variants located in the 
coding region that change the structure or function of the serotonin transporter (reviewed in 
Murphy et al., 2008).  
The existence of several functional variants at the SLC6A4 locus, as well as the unique and 
limiting role of the serotonin transporter in serotonin uptake, has focused the attention on this 
gene since the last decade. Great efforts have been made to know the role of the serotonin 
transporter genetic variation in several behavioral traits and psychiatric conditions. As a result, 
a large number of studies have related this gene to several neuropsychiatric disorders, 
especially anxiety-spectrum and mood disorders, such as bipolar disorder (Cho et al., 2005), 
obsessive-compulsive disorder (Bengel et al., 1999), suicidal behavior (Li and He, 2007), major 
depression (Kraft et al., 2005; Levinson, 2006) and high neuroticism (Lesch et al., 1996). These 
findings come from different approaches, including studies in humans, non-human primates 
and mice.  
With regard to human studies, there is a large body of evidence about the implication of the 
short, low-expressing allele of 5-HTTLPR in affective disorders. Lesch et al. first reported in 
1996 an association of the short allele with anxiety related-traits (neuroticism, anxiety and 
harm avoidance) in a large sib-pair sample. Subsequently, many other single studies (Mazzanti 
et al., 1998; Willeit et al., 2003; Jacob et al., 2004, among others) and meta-analyses 
(Anguelova et al., 2003) replicated this original finding. Moreover, other studies have found a 
relationship between the S allele of 5-HTTLPR and other related behavioral traits, such as 
shyness (Battaglia et al., 2005), aggressiveness (Beitchman et al., 2006) and suicidal behavior 
(Courtet et al., 2004). It is also worth mentioning the work from Caspi and colleagues (2003), 
who found that the short allele of 5-HTTLPR predisposed individuals to depression in response 
to life events. Since then, these promising results have been replicated (Eley et al., 2004; 
Kaufman et al., 2004; Grabe et al., 2005; Kendler et al., 2005; Cervilla et al., 2007). Studies with 
primate models also support this hypothesis (Bennett et al., 2002; Champoux et al., 2002). 
Furthermore, several fMRI studies have shown that the S allele of 5-HTTLPR produces an 
increased amygdala response to fearful stimuli in healthy subjects (Hariri et al., 2002, 2005). 
Furthermore, higher amygdala activation associated with the s allele was found in psychiatric 
patients (Furmark et al., 2004; Domschke et al., 2006) as well as in phobic-prone healthy 
subjects (Bertolino et al., 2005). 
With regard to mice studies, the results from investigations with mice having one or no copies 
of the serotonin transporter gene (Slc6a4 +/- and -/-, respectively) suggest that variation at 
SLC6A4 gene can impact on the vulnerability to complex psychiatric and behavioral disorders, 
such as polysubstance abuse, REM sleep disorders and anxiety disorders, among others 
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(reviewed in Holmes et al., 2003; Murphy et al., 2008). An extraordinarily parallelism in several 
behavioral and neuroendocrine traits has been found between Slc6a4 +/- mice and human 
subjects with anxiety-spectrum disorders (reviewed in Holmes et al., 2003), thus supporting 
the role of serotonin transporter in emotionality. In conclusion, with regard to anxiety-related 
disorders, the use of Slc6a4 +/- mice is very useful, since they resemble the S/S genotype from 
5-HTTLPR. 
However, the relationship between the genetic variation of SLC6A4 gene and schizophrenia-
spectrum disorders is still a matter of debate. Some studies have reported alterations related 
to the serotonin transporter in schizophrenic patients, such as reduced 5-HT reuptake sites in 
distinct brain areas of schizophrenics detected in postmortem radioligand binding studies 
(Joyce et al., 1993; Naylor et al., 1996) or a significant increase of 5-HTT mRNA in the frontal 
and temporal cortex of schizophrenic subjects (Hernandez and Sokolov, 1997). However, 
association studies with SLC6A4 polymorphisms (mainly 5-HTTLPR and STin2) have given 
inconsistent results. Table I8 is a summary from the SchizophreniaGene database 
(http://www.schizophreniaforum.org/res/sczgene/default.asp), which stores information 
about all the association studies of schizophrenia. As it can be seen, the results are mainly 
negative. However, recent meta-analyses have found evidences of association between the 
serotonin transporter STin2 polymorphism and schizophrenia, but not with 5-HTTLPR (Fan and 
Sklar, 2005; Allen et al., 2008; Shi et al., 2008).  
Table I8. Summary of the association studies between the SLC6A4 gene and risk for schizophrenia 
performed until now. 
ETHNIC GROUP 
NUMBER OF 
STUDIES 
CONTROL SAMPLE SIZE
a
 SCZ SAMPLE SIZE
a
 RESULTS 
Case-control studies 
Caucasian 16 
236 
(ranging from 62 to 587) 
170 
(ranging from 39 to 684) 
1 positive 
2 trend 
13 negative 
Asian 8 
186 
(ranging from 103 to 362) 
181 
(ranging from 90 to 338) 
2 positive 
6 negative 
Other/mixed 1 15 12 Negative 
Family-based studies 
Caucasian 3 
236 
(ranging from 206 to 266) 
121 
(ranging from 103 to 139) 
2 positive 
1 negative 
a, the mean value and the range are indicated. 
Abbreviation: SCZ, schizophrenia. 
Information obtained from the SCZgene database (Allen et al., 2008). 
 
 
With regard to auditory hallucinations in schizophrenic patients, there is only one study from 
Malhotra et al. (1998), who reported an association between a higher intensity of 
hallucinations and the L/L genotype from the 5-HTTLPR polymorphism. Lesch (1998) 
hypothesized that the L/L individuals (with high levels of serotonin uptake and reduced 
synaptic 5-HT concentration) may be suffering a hypersensitivity of those serotonin 
subsystems which are activated by hallucinogenic stimuli.  
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Figure I11. Tridimensional 
model of a 5-HT2A receptor 
inside a lipidic membrane.   
A serotonin molecule docked 
to the binding domain is also 
shown. 
Abbreviation: TM, 
transmembrane. 
Figure extracted from Nichols 
and Nichols, 2008. 
For all the premises presented above, we consider that the genetic variation of serotonin 
transporter could have a role in the vulnerability to schizophrenia and the emotional 
alterations suffered by schizophrenic patients.   
4.1.2.  HTR2A gene.  
The 5-HT2A receptor belongs to the GPCR-type serotonin receptor family, which are also 
classified as “type A” rhodopsin-like receptors (Nichols and Nichols, 2008), all of them 
presenting highly conserved motifs within the seven transmembrane (TM) regions (figure I11), 
a strong evidence for an evolutionary relationship.  
 
 
 
 
 
 
 
 
5HT2A receptors are especially abundant in human cortical regions, particularly in frontal and 
temporal areas, and less abundant in basal ganglia (Pazos and Palacios, 1985; Pazos et al., 
1985). By contrast, they are rare at the thalamus (Wong et al., 1987). This localization of 5-HT2A 
receptors in the CNS is consistent with those neuroanatomical structures believed to be 
involved in the pathophysiology of schizophrenia. Higher resolution localization studies 
allowed locating the 5-HT2A receptors to the heads and necks of dendritic spines (Jakab and 
Goldman-Rakic, 1998; Miner et al., 2003).  
The serotonin receptor 5HT2A is encoded by the HTR2A gene, which is located in the long arm 
of chromosome 13 (13q14-q21). The HTR2A locus (figure I12) spans over 20 kb and consists of 
three exons separated by two introns (Chen et al., 1992). The predicted 471 amino acid 
sequence of the human protein shares a high level of similarity with the mouse and rat 5HT2 
receptors (Chen et al., 1992).  
 
 
 
 
 
 
 
 
Several polymorphisms along the HTR2A sequence have been described in the literature. The 
most important are the following: 
Figure I12. Genomic structure of the HTR2A gene. It has a simple structure with three exons. The 
untranslated regions are indicated in white. 
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- A thymidine to cytosine (T→C) silent polymorphism (known as T102C or rs6313) within the 
first exon of the gene which does not alter the predicted amino acid sequence of the 
receptor. This polymorphism has been the focus of most research. Remarkably, in human 
postmortem studies, the expression of 5HT2A receptors in temporal cortex has been found 
to be about 20% less for the C allele than for the T allele (Polesskaya and Sokolov, 2002). 
- An adenine to guanine (A→G) polymorphism at position -1438 in the putative promoter 
region (named -1438A/G or rs6311) of the HTR2A locus. This polymorphism is in perfect 
linkage disequilibrium with T102C. 
- A histidine to tyrosine amino acid substitution at position 452 (known as his452tyr or 
rs6314), which seems to affect the agonist-induced desensitization process (Nichols and 
Nichols, 2008) as well as calcium mobilization (Cravchik and Goldman, 2000).  
These three variants, as well as other polymorphisms of the HTR2A gene have been associated 
with many different psychiatric conditions, such as schizophrenia (Williams et al., 1996; 
Inayama et al., 1996; Lohmueller et al., 2003), mood disorders (Enoch et al., 1999), suicidal 
behavior (Li et al., 2006), impulsivity (Nomura and Nomura, 2006), obsessive-compulsive 
disorder (Enoch et al., 1998; Walitza et al., 2002), eating disorders (Nishiguchi et al., 2001), 
alcohol dependence (Nakamura et al., 1999) and late-onset Alzheimer disease (Holmes et al., 
1998). There is an especial interest in understanding the potential role of the genetic variation 
at HTR2A locus in the pathogenesis of schizophrenia. Many evidences indicate that this gene 
may be really important. As it has been previously described, 5-HT2A agonists (including LSD, 
psilocin and mescaline) possess potent hallucinogenic properties in humans that are highly 
correlated with their receptor affinities (Glennon et al., 1984); moreover, the 5-HT2A receptor 
has a high affinity for the atypical antipsychotic drugs such as clozapine, risperidone, and 
olanzapine and it is thought to have a role in the therapeutic activity of these drugs (Worrel et 
al., 2000). 
Until now, several association studies on the genetics of schizophrenia involving HTR2A 
polymorphisms have been performed. Moreover, several alternative phenotypes have been 
also studied, including a formal diagnosis (Williams et al., 1996), earlier onset and poorer 
outcome (Joober et al., 1999) and susceptibility to tardive dyskinesia (Segman et al., 2001). 
However, the results still remain controversial, because of the high number of negative 
findings (table I9). Unfortunately, this uncertainty is also present when meta-analytic 
approaches are used: although three meta-analyses (Williams et al., 1997; Lohmueller et al., 
2003; Abdolmaleky et al., 2004) found an association of the 102C allele with schizophrenia, 
this finding could not be confirmed by another recent meta-analysis (Li et al., 2006). By 
contrast, the most promising results come from studies which evaluate the response to 
antipsychotic drugs, especially clozapine, depending on HTR2A genotype (Arranz et al., 1995, 
1998; Ellingrod et al., 2003; Anttila et al., 2007). Data suggest that 102C, Tyr452 and -1438G 
alleles are associated with a poor antipsychotic response, since these variants are more 
frequent in patients who do not respond to the clozapine medication (known as non-
responders). However, a proportion of studies focused on the response to clozapine have still 
produced contrary results (Nimgaonkar et al., 1996; Lin et al., 1999).  
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Table I9. Summary of the association studies between the HTR2A gene and risk for schizophrenia 
performed so far. 
ETHNIC 
GROUP 
NUMBER OF 
STUDIES 
CONTROL SAMPLE SIZE
a
 SCZ SAMPLE SIZE
a
 RESULTS 
Case-control studies 
Caucasian 28
b
 
241  
(ranging from 57 to 2002) 
225  
(ranging from 37 to 1870) 
22 positive 
3 trend  
16 negative 
Asian 15 
146  
(ranging from 55 to 523) 
158  
(ranging from 31 to 471) 
2 positive 
13 negative 
Other/mixed 6 
224  
(ranging from 37 to 936) 
161  
(ranging from 47 to 536) 
2 positive 
4 negative  
Family-based studies 
Caucasian 6 
236  
(ranging from 104 to 548) 
272  
(ranging from 63 to 919) 
1 positive 
5 negative 
Asian 2 224 
146  
(ranging from 112 to 179) 
All negative 
Other/mixed 2 
346  
(ranging from 104 to 709) 
249  
(ranging from 52 to 651) 
All negative 
a the mean value and the range are indicated. 
b some studies have analyzed more than one sample. 
Abbreviation: SCZ, schizophrenia; N/A, not applicable. 
Information obtained from the SCZgene database (Allen et al., 2008). 
 
 
The relationship between the HTR2A gene and both emotionality and affective disorders is 
another interesting issue. The serotonergic system has been considered to be involved in the 
neurophysiology of emotionality; thus, the serotonin receptor 5HT2A appears to be an 
interesting candidate gene for mood disorders, such as bipolar disorder, major depression 
(including response to antidepressants), anxiety-spectrum disorders and many others. 
However, the situation is similar to schizophrenia studies, with a mix of negative and positive 
results which is difficult to be interpreted (Golimbet et al., 2002; Anguelova et al., 2003; 
McMahon et al., 2006). However, other study (Weisstaub et al., 2006) demonstrated that 
global disruption of 5-HT2A receptor signaling in mice reduces inhibition in conflict anxiety 
paradigms without affecting fear-conditioned and depression-related behaviors. 
In conclusion, despite the uncertainties, we consider that HTR2A could be involved in the 
pathogenesis of both auditory hallucinations and emotional disturbances in schizophrenic 
patients. 
4.1.3.  TPH2 gene.  
Tryptophan hydroxylase (TPH) is the key regulator of serotonin biosynthesis. Utilizing BH4 and 
O2 as co-substrates and Fe
2+ as a cofactor, TPH hydroxylates tryptophan to 5-
hydroxytryptophan (Carkaci-Salli et al., 2006). Finally, decarboxylation of 5-hydroxytryptophan 
by amino acid decarboxylase generates serotonin (figure I13).  TPH belongs to a superfamily of 
aromatic amino acid hydroxylases that include phenylalanine and tyrosine hydroxylase 
(Fitzpatrick, 1999). There are two tryptophan hydroxylase (TPH) isoforms, TPH1 and TPH2, 
which act as rate-limiting enzymes in serotonin synthesis (Walther and Bader 2003; McKinney 
et al., 2005). The gene for the brain-specific isoform of tryptophan hydroxylase was 
discovered 6 years ago and designated TPH2 (Walther and Bader, 2003). The TPH2 isoform is 
exclusively expressed in the brain in a circadian rhythm and is responsible for the neuronal 5-
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HT synthesis. The human TPH2 gene spans approximately 100 kb, consists of 11 exons and 
maps on chromosome 12q21.1 (figure I14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TPH2 enzyme is highly homologous to TPH1 (>70% identity in amino acid sequence), and both 
have a particular high sequence identity within the COOH-terminal catalytic domain (Walther 
and Bader, 2003). TPH2 is also highly conserved between mammalian species. However, the 
brain isoform is more soluble and has different kinetic properties than TPH1 (McKinney et al., 
2005).  
Post-mortem studies confirmed the presence of TPH2 mRNA in the human frontal cortex, 
hippocampus, amygdala, hypothalamus, and thalamus but not in peripheral organs (Zill et al., 
2004a). The two initial studies revealing the existence of TPH2 (Walther and Bader 2003; Côté 
et al., 2003) concluded that the expression of the two isoforms is mutually exclusive, 
designating TPH1 as the peripheral form and TPH2 as the neuronal subtype. However, this is 
still a matter of debate, as several subsequent studies have also reported a detectable TPH1 
expression in raphe neurons of the rat (Patel et al., 2004; Malek et al., 2005), the mouse 
(Gundlah et al., 2005) and humans (Zill et al., 2007). By contrast, Gutknecht et al. (2008) have 
not found significant TPH1 expression in the human and murine raphe.  
a 
b 
Tryptophan 5-hydroxytryptophan Serotonin (5-HT) 
Regulatory 
domain 
Catalytic 
domain 
Tetramerization 
domain 
Figure I13. a Tryptophan 
hydroxylase catalyzes the  first 
(rate-limiting) step in serotonin 
biosynthesis. The final step in 
serotonin biosynthesis is 
catalyzed by the aromatic amino 
acid decarboxylase (AAADC). b 
Tridimensional structure of 
TPH2. The three functional 
domains are indicated.  
Figure adapted from Carkazi-
Salli et al., 2006.  
Figure I14. Genomic structure of the TPH2 gene. It has 11 exons. The untranslated regions of exons 1 
and 11 are indicated in white. 
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The identification of TPH2 genetic variants with a functional effect on enzymatic activity could 
be an interesting approach to study the neurobiology of emotional behaviors, as well as the 
vulnerability to phsychiatric disorders with emotional alterations, such as depression, anxiety, 
suicidality and even schizophrenia. According to this idea, several variants have been analyzed 
up to now. One of the polymorphisms which has received more attention is T−703G 
(rs4570625), due to its functional implications that we will review later.  
Until now, variation of TPH2 has been implicated in several affective disorders. The first SNP 
and haplotype analyses of the TPH2 locus revealed evidence for association of TPH2 variants 
with depression (Zill et al., 2004b; Zhang et al., 2005) as well as bipolar I and II disorders 
(Harvey et al., 2004). Zhou et al., (2005) reported a haplotype-based association with major 
depression, anxiety disorders, and suicidal behavior in different ethnic populations. 
Interestingly, this haplotype was predictive of lower 5-HIAA concentrations in cerebrospinal 
fluid. Moreover, investigation in postmortem brain samples of bipolar and schizophrenic 
patients revealed higher concentrations of TPH2 mRNA in the bipolar group in comparison 
with controls (De Luca et al., 2005a). Measurement of TPH2 mRNA in the brainstem of 
depressed patients who had committed suicide also demonstrated greater expression in the 
dorsal and median raphe nuclei when compared to control subjects (Bach-Mizrachi et al., 
2006). Furthermore, Cichon et al. (2008) found association between bipolar disorder (BPD) 
and several SNPs located in a haplotype block covering the 5’ regulatory region of the gene, as 
well as a rare, non-synonymous SNP, (Pro206Ser) which affects thermal stability and solubility 
of the enzyme. Lin and colleagues also reported in 2007 (Lin et al., 2007) a significant 
association of a TPH2 haplotype and BPD. They also showed that allelic alteration of 
polymorphisms in the promoter region and exon 2 of TPH2 caused a remarkable loss of 
functionality in promoter and enzyme activities. Finally, Haghighi and colleagues (Haghighi et 
al., 2008) identified a novel TPH2 short isoform with a truncated catalytic domain. An 
exploratory study revealed association between a novel SNP located in exon 6 of this short 
isoform and major depression or suicide. 
Evidences that TPH2 variation may play a role in cognition comes from studies that have 
implicated TPH2 variants in the etiology of disorders which affect executive control, such as 
attention-deficit hyperactivity disorder (ADHD) and obsessive–compulsive disorder (OCD). 
Several studies have reported transmission disequilibrium of TPH2 promoter variants in 
children and adolescents with ADHD, as well as a preferential transmission of a haplotype 
linked to the transcriptional control region of TPH2 in early onset OCD (Walitza et al., 2005; 
Mössner et al., 2006). Subsequently, Strobel and colleagues (2007) measured the impact of 
THP2 variation on behavioral measures in a cognitive control task in healthy subjects. They 
found that individuals lacking the rare TPH2 T allele from rs4570625 were not faster than T 
allele carriers, but committed fewer errors and were less variable in responding. They also 
suggested that genetic variants associated with higher negative emotionality may have 
beneficial effects on some cognitive functions. More recently, Baehne and colleagues (2008) 
studied the effect on prefrontal brain function of two TPH2 SNPs (including SNP rs4570625) in 
large samples of adult ADHD patients and healthy controls while performing a continuous 
performance test (CPT) during recording of an ongoing electroencephalogram (EEG). 
Interestingly, ADHD risk alleles of both polymorphisms affected prefrontal function during 
response inhibition in both healthy controls and ADHD patients. 
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Furthermore, there have been also associations with personality traits: Gutknecht and 
colleagues (Gutknecht et al., 2007) also reported an overrepresentation of T allele carriers of 
the functional polymorphism in the upstream regulatory region of TPH2 (SNP G-703T, 
rs4570625) in both patient groups from clusters B and C from personality disorders. Reuter et 
al., (2007) also showed that the T/T genotype from the same SNP was associated with the 
temperament trait harm avoidance. 
With regard to schizophrenia, apart from the first work from De Luca et al., (2005a), who could 
not find differences in mRNA expression of TPH2 in schizophrenic patients, the remaining 
studies which have analyzed the relationship between schizophrenia (and suicidal behavior in 
SCZ patients) have been negative (De Luca et al., 2005b, 2006; Higashi et al., 2007).   
Finally, functional magnetic resonance imaging (fMRI) was employed to provide evidence that 
acute tryptophan depletion, which results in a transient reduction of brain 5-HT, as well as SNP 
G-703T (rs4570625), appear to bias the responsiveness of the amygdala, a structure with an 
important role in the modulation of emotionality (Brown et al., 2005; Canli et al., 2005a). 
Finally, Herrman and colleagues (2007) also found, through the measurement of event-related 
potentials (ERPs) during a passive emotional picture perception task, that both the 5-HTTLPR 
and the TPH2 SNP rs4570625 genotypes modulate the sensory encoding of affective stimuli 
during early steps of visual processing and revealed additive effects of these 2 genes in the 
serotonergic control of emotion regulation.  
Thus, it can be hypothesized that TPH2 variation can have a role in the emotional processing of 
auditory hallucinations in schizophrenic patients. 
 
4.2. NOS1 gene. 
Nitric oxide (NO) is a pleiotropic messenger molecule functionally linked to glutamatergic 
transmission (Garthwaite, 2008). Entry of Ca2+ through a NMDA channel binds to calmodulin 
and stimulates NO synthesis (Baba et al., 2004). NO can also form covalent linkages with many 
targets, including guanylate cyclase (GC) (Dawson and Snyder, 1994), which synthesizes cyclic 
guanosine monophosphate (cGMP) in response to NO. NO and cGMP have various reversible 
excitatory or inhibitory effects on neuronal excitability and synaptic transmission (Garthwaite, 
2008). 
NO has been implicated in a wide range of neural functions. In the vertebrate CNS, NO 
appears to have roles as a gaseous messenger/neurotransmitter influencing local blood flow, 
learning and memory, neurodevelopment, feeding, sleeping, reproductive behavior, and 
sensory and motor function (Garthwaite, 2008). Depending on the circuit, NO may be 
produced pre- or postsynaptically and it has been suggested that it could provide a 
simultaneous signal to both pre- and postsynaptic elements, with importance in coordinating 
responses on the two sides of the synapse. Like other receptors, NO receptors are 
heterodimers with two known isoforms that, although widespread, have a differing cellular 
distribution in the brain and also at the subcellular level (Gibb and Garthwaite, 2001; Mergia et 
al., 2003).  
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NO is synthesized by nitric oxide synthase (NOS). NOS enzymes represent a family of 
cytochrome P450-like flavohemeproteins that catalyze the oxidation of L-arginine to form L-
citrulline and NO (Bredt et al., 1991; Stuehr and Ikedo-Saito, 1992). Two main isoforms with 
distinct functional and structural features exist (Bredt et al., 1991; Garthwaite, 2008): neuronal 
(nNOS or NOS-I) and endothelial (eNOS or NOS-II). A third, inducible, type (iNOS) is rarely 
present normally but can be expressed in numerous cell types (prototypically in macrophages, 
mainly in microglia in the CNS) in response to immunological challenge. The three isoforms 
have distinct functional and structural features. 
NOS-I is the main source of NO in excitable tissue and can be found in up to 1% of all neurons 
(Snyder and Ferris, 2000). In addition to regulation by Ca2+⁄calmodulin, NOS-I has several 
putative sites for phosphorylation (Garthwaite, 2008). CaMKII, a kinase found at synapses 
together with NMDA receptors and NOS-I, was found to phosphorylate the enzyme and inhibit 
NO formation by 50%, probably by affecting Ca2+⁄calmodulin binding (Hayashi et al., 1999; 
Komeima et al., 2000). The protein kinase Akt (novel candidate gene for schizophrenia) can 
also phosphorylate NOS-I (Rameau et al., 2007). Recent evidence indicates that NOS-I can also 
bind to the serotonin transporter in the plasma membrane in such a way that serotonin 
uptake couples to NO formation (Chanrion et al., 2007). Thus, the regulation of NOS-I activity 
in neurons is really complex. 
The human gene encoding NOS-I (NOS1) is an extremely complex gene located at 
chromosome 12q24.3 (Hall et al., 1994; Zhang et al., 2004). It is structured in two regions 
(figure I15a): a 110 kb region containing 28 protein-coding exons (named 2 to 29) and another 
130 kb region, called the “variable region”, which includes at least 12 distinct first non-coding 
exons (designated as exon 1a to 1l). Transcription of those alternative first exons is driven by at 
least 6 alternative promoters resulting in a tissue-specific expression pattern (Bros et al., 
2006). The promoter region of exon 1f is mainly expressed in the basal ganglia, but also the 
hippocampus and cortex. Remarkably, this exon contains a highly polymorphic dinucleotide 
repeat, termed NOS1 Ex1f-VNTR, with 180 – 210 CA units, 33 bp downstream of the TATA box 
(Reif et al., 2006). The most common alleles are 182, 184, 192, 200, 202 and 204 repeats 
(figure I15b). Although NOS1 exon 1f is highly conserved across different species, the promoter 
repeat element appears to be exclusive to humans. To facilitate genetic studies the 
polymorphism is generally dichotomized in short (180-196 repeats) and long (198-210 repeats) 
alleles. Together with MAO-uVNTR and 5HTTLPR, NOS1 ex1f-VNTR is a type of promoter VNTR 
with effects on gene expression. Reif and colleagues (personal communication) demonstrated 
that the short variant is associated with decreased transcriptional activity of the NOS1 exon 1f 
promoter and alterations in the neuronal transcriptome of human postmortem brains, 
including altered expression of RGS4 and GRIN1, which had been previously linked to 
psychiatric disorders. Apart from NOS1 Ex1F-VNTR, other polymorphisms have been described 
and analyzed in the literature. 
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NOS-I has been linked to several behavioral traits and severe psychiatric and neurologic 
pathologies. With regard to dimensional behavioral traits, it has been linked to murine 
behavior by numerous pharmacological studies. Likewise, knockdown of the Nos1 gene in mice 
results in behavioral changes, such as learning deficits, decreased anxiety, impulsivity and 
increased aggressiveness (Nelson et al., 1995). Very recently, Reif and colleagues (personal 
communication) studied a high cohort of 3500 adult subjects and showed that the NOS1 Ex1f-
VNTR is associated with impulsivity-related traits, such as hyperactive and aggressive 
behaviors. Furthermore, carriers of the NOS1 Ex1f-VNTR short alleles appear to have an 
increased risk to develop Alzheimer’s disease, with evidence for NOS1 x ApoE4 interaction 
(Galimberti et al., 2008). 
With regard to psychiatric disorders, evidence is accumulating that NO may be affected in the 
pathophysiology of schizophrenia. Altered populations or distribution of NOS-containing 
neurons in schizophrenia have been reported in frontal (Akbarian et al., 1993a; Baba et al., 
2004) and temporal (Akbarian et al., 1993b) cortex, hypothalamus (Bernstein et al., 1998), 
cerebellum (Karson et al., 1996) and striatum (Lauer et al., 2005). Moreover, alterations of the 
NO system in plasma and platelets of schizophrenics have been also found (Das et al., 1995). 
Remarkably, NOS-I is involved in several signaling cascades likely involved in the pathogenesis 
of schizophrenia. First, NO can function as the second messenger of the NMDA receptors. 
Second, the adaptor protein of NOS-I to the NMDA receptor, CAPON, has been shown to be 
associated with schizophrenia (Brzustowicz et al., 2004; Zheng et al., 2005). Moreover, the 
nitrinergic system is also tightly linked to DA and 5-HT neurotransmission: NO can inhibit 
monoamine transporters by nitrosylation, which results in increased synaptic availability of 
monoamine neurotransmitters (Kiss and Vizi, 2001). However, there are conflicting data with 
regard to the direct NO effects on these transporters: it has been shown that the NO donor 
compound SNAP increases SERT function (Kilic et al., 2003). Moreover, NOS-I knockout mice 
feature clear alterations in serotonergic function, with an impaired 5-HT turnover, 
Figure I15. a Genomic structure of the 
human NOS1 gene. b Allelic distribution of 
the Ex1f- VNTR in 1088 chromosomes,  
Alleles are arranged from the shortest (B, 
180 repeats) to the longest (Q, 196 repeats).  
Figure b extracted from Reif et al., 2006. 
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desensitization of 5-HT receptors and decreased expression of the serotonin transporter in the 
brain stem neurons (Chiavegatto et al., 2001).  
Association studies also support the role of the NOS1 gene in schizophrenia and other 
psychiatric disorders. The first studies studying single NOS1 markers found associations with 
bipolar disorder and schizophrenia (Detera-Wadleigh et al., 1999; Morissette et al., 1999; 
Bailer et al., 2000, 2002; Shinkai et al., 2002) although some negative results exist (Liou et al., 
2003). However, other studies failed to detect association with bipolar disorder (Buttenschon 
et al., 2004) or major depression (Yu et al., 2003). More recently, Fallin et al. (2005) performed 
a genotypic screen of 64 genes on families of Ashkenazi Jewish descent origin with bipolar 
disorder I or schizophrenia and found that NOS1 showed evidence of association with both 
disorders. Reif and colleagues (2006) found association of Ex1f VNTR and a mini-haplotype 
with schizophrenia and reported that promoter polymorphisms impacted on prefrontal 
functioning. Moreover, two other recent studies (Tang et al., 2008; O’Donovan et al., 2008) 
have also reported an association between NOS1 polymorphisms and schizophrenia.   
Therefore, NO appears to be a promising candidate to be involved in the pathophysiology of 
schizophrenia, and its interaction with the serotonergic system could also implicate both 
systems in the manifestation of several behavioral traits. 
4.3. STMN1 gene. 
Stathmin (Sobel, 1991), also known as Oncoprotein 18 (Hailat et al., 1990), is a member of a 
protein family that regulates the dynamics of  microtubule (MT) polymerization/ 
depolymerization during different phases of the cell cycle (Belmont and Mitchison, 1996; 
Gavet et al., 1998) in a phosphorylation-dependent manner: this ubiquitous cytosolic protein 
interacts with tubulin heterodimers and prevents them from forming microtubules by 
stablishing a T2S complex of one stathmin (S) and two tubulin (T) α/β heterodimers (Jourdain 
et al., 1997) (figure I16). After phosphorylation of specific serine residues by cell surface 
receptor kinase cascades and cycle-dependent kinases (Gavet et al., 1998; Cassimeris, 2002), 
stathmin releases tubulin, allowing MT formation. Stathmin has also been suggested to act as 
an intracellular relay for extracellular signals (Sobel, 1991) and many proteins, apart from 
tubulin, have been identified as target/partners for stathmin (Li and Cohen, 1996; Maucuer et 
al., 1995; Maucuer et al., 1997).  
 
 
 
 
 
 
 
Figure I16.  Model for the 
role of stathmin in the 
regulation of microtubule 
formation: when stathmin 
sequesters unpolymerized 
tubulin heterodimers,  MT 
formation rate decreases. 
Moreover, stathmin can also 
promote MT 
depolymerization by inducing 
a conformational change in 
the MT structure.   
Figure from Rubin and Atweh, 
2004. 
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In humans, the stathmin gene (known as STMN1) is a small gene that maps to chromosome 1 
(1p36.1-p35). Alternatively spliced transcript variants varying in the 5’ UTR region but encoding 
the same protein of 149 aminoacids have been identified (figure I17). Stathmin protein is 
highly conserved among vertebrates (Koppel et al., 1990). The protein structure of stathmin 
could be divided into two domains, an N-terminally located phosphorylation-regulatory 
domain and a C-terminally located microtubule-interacting coiled-coil domain (Mori and Morii, 
2002; Ozon et al., 2002).  
 
 
 
 
 
 
 
 
 
Stathmin has a key role in different cellular processes. First, a huge number of studies support 
the relationship between stathmin expression and/or phosphorylation and regulation of 
cellular proliferation. Stathmin was first identified as a 17-kDa cytosolic protein that is rapidly 
phosphorylated when leukemic cells are induced to differentiate and cease to proliferate. 
Similar observations were also made in carcinoma cell lines and in other solid tumors like 
breast and ovarian cancer (reviewed in Rubin and Atweh, 2004). Moreover, in rodent and 
humans, stathmin was reported to be highly expressed in tissues with a high proliferation rate 
such as testis and hematopoietic cells. Stathmin is critically important not only for the 
formation of the mitotic spindle when cells enter mitosis but also for the morphological 
changes associated with cytokinesis and the entry into a new cell cycle (Rubin and Atweh, 
2004). When cells enter mitosis, stathmin is switched off by phosphorylation, allowing 
microtubules to assemble into a mitotic spindle. Subsequently, the reactivation of stathmin in 
the later stages of mitosis allows the disassembly of the mitotic spindle and the exit from 
mitosis. Moreover, several findings support a role for the downregulation of stathmin 
expression in the physiological regulation of endomitosis and polyploidzation. 
However, in addition to their well known role in mitosis, interphasic microtubules are essential 
for many other cellular processes such as intracellular transport, cell motility, cell polarity, and 
maintenance of cell shape. Cell migration is an important example. It is a complex cellular 
behavior which involves coordinated changes in the cytoskeleton and the controlled formation 
and dispersal of adhesion sites (Giampietro et al., 2005). As a result, stathmin expression 
appears to be crucial in migrating cells. Stathmin was found to be expressed at high levels in 
migrating cells of the rat olfactory system (Camoletto et al., 1997; Giampietro et al., 2005). Jin 
Figure I17. Genomic structure and alternative splicing of the stathmin gene (STMN1). This gene 
presents 5 exons (untranslated regions are shown in white). Although three variants differing at its 5’ 
UTR region have been described, all of them encode the same 149-aminoacid protein. 
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et al. (2004) have also shown that decreased stathmin levels in these cells inhibit their 
mobilization from the subventricular zone (SVZ) of rat brain. The relationship between 
stathmin levels and migration is also supported by studies with epithelial cells (Niethammer et 
al., 2004), as well as studies on tumoral cell lines in which stathmin levels correlate with an 
invasive phenotype (Walter-Yohrling et al., 2003).  
Stathmin functions in the development, maturation, and functional regulation of the CNS 
(Curmi et al., 1999) have a special interest for the present study. Stathmin is highly expressed 
during embryogenesis and progressively declines during the development of the nervous 
system (Koppel et al., 1990; Amat et al., 1991; Pellier-Monnin et al., 2001). Interestingly, the 
high expression of stathmin in postmitotic neurons suggests that stathmin may have a distinct 
function in neurons that is not related to proliferation. Moreover, the expression pattern in 
germinal areas of the adult CNS with neurogenic and gliogenic potential (olfactory epithelium, 
dentate gyrus of the hippocampus and SVZ of the rat brain) (Amat et al., 1991) clearly suggests 
the idea that this protein is involved in processes of differentiation (Camoletto et al., 1997). 
The level of stathmin expression was also shown to be highly increased during neurite 
outgrowth and synapse formation, supporting a role for stathmin in neuronal differentiation 
(Di Paolo et al., 1997). Moreover, an abnormal stathmin expression has been detected in 
pathological conditions. Stathmin gene expression is severely affected in the brains of patients 
with Alzheimer disease (Jin et al., 1996). It is also of interest to note that stathmin is 
downregulated in the brains from patients with Down syndrome (Cheon et al., 2001). Liu et al., 
(2005) also reported the increased expression of stathmin in the brains of patients with 
multiple sclerosis.  
An intriguing finding is that, despite the wide variety of functions which had been attributed to 
stathmin, the inactivation of this gene in mouse did not produce any apparent major 
phenotype (Schubart et al., 1996), probably due to the redundant functions of some of the 
stathmin family proteins. However, several recent reports from Dr. Shumyatsky’s lab have 
revealed that in the normal adult brain of the mouse, stathmin is highly expressed in the 
lateral nucleus (LA) of the amygdala as well as in the thalamic and cortical structures that send 
information to the LA about the conditioned (learned fear) and unconditioned stimuli (innate 
fear) (Shumyatsky et al., 2005). Coherently, the inactivation of stathmin affects long-term 
potentiation (LTP) in the cortico-amygdala and thalamo-amygdala pathways, although synaptic 
transmission and NMDA-receptor function is normal. Moreover, as expected, inactivation of 
stathmin gene in mouse has a marked impact on those behaviors dependant on neural 
circuitry of fear and threat assessment of the environment: knockout mice exhibit decreased 
memory in amygdala-dependent fear conditioning and fail to recognize danger in innately 
aversive environments (Shumyatsky et al., 2005). Moreover, this deficiency in fear processing 
also leads to improper threat assessment, which consequently affects innate maternal care 
and adult social interactions. Stathmin-/- females are a clear example: they lack motivation 
for retrieving pups and are unable to choose a safe location for nest-building (Martel et al., 
2008). Remarkably, stathmin-/- females have an enhancement in social interactions (Martel 
et al., 2008). In conclusion, stathmin is a necessary element for the induction of LTP in afferent 
inputs to the amygdala and is essential in regulating both innate and learned fear, which has 
consequences in related behaviors such as innate maternal care and social interactions. 
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These latest results open new possibilities for the study of stathmin function in the CNS and 
places stathmin as an interesting candidate to be involved in psychiatric disorders where 
threat assessment and social interactions are affected. Emotional dysfunctions and 
schizophrenia are good examples of this type of disorders. 
4.4. ASPM gene. 
From an evolutionary point of view, the high increment of cognitive abilities during Homo 
sapiens evolution may have favoured the appearance of certain pathologies which are 
associated to cognitive alterations, such as schizophrenia (Crow, 1997; Horrobin, 1998). This 
idea generates an evolutionary-genetic paradox which could also explain how the frequency 
of such a deteriorating mental disease is maintained across time in all human populations. 
According to this hypothesis, those genes which have been subject to an accelerated evolution 
in the human lineage may have been involved in the development of certain human features, 
including those of cognitive nature, as well as other features, such as speech. As a 
consequence of this important role in human evolution, such genes could also be implicated in 
the emergence of psychiatric diseases, such as schizophrenia. One gene included in this study, 
ASPM, is directly related to neurodevelopment and suffered positive selection in the human 
lineage. For these reason, it has been considered as an interesting candidate gene for 
schizophrenia.  
ASPM (abnormal spindle-like microcephaly-associated) gene (formerly known as MCPH5) is 
known to play an important role in cortical development. The first evidence in this direction 
was the finding that protein-truncating mutations in this gene were implicated in autosomal 
recessive primary microcephaly (MCPH), a condition in which the head circumference is less 
than three standard deviations (SDs) below the age-related mean (Ross and Frias, 1977). 
Although the whole brain is affected by this reduction, the cerebral cortex seems to be the 
most severely affected region in these patients. The ASPM gene is the locus which explains the 
highest number of microcephaly cases (Bond et al., 2002). It is predicted that all ASPM 
mutations detected in MCPH patients truncate the protein, because of the presence of a 
premature stop codon, or because of the alteration of a splicing site. 
ASPM gene spans 62 kb in 1q31 (Bond et al., 2002).  It has a 10434 bp open reading frame 
(ORF), which includes 28 exons and codes for a protein of 3477 amino acid (figure I18a). 
However, two predominant mRNAs have been observed in humans as well as in mouse: the 
complete mRNA of 10434 bp and a smaller transcript of 5.6 kb (1892 amino acids), called 
variant 1, which lacks exon 18.  
The full-length ASPM protein is predicted to contain the following domains (figure I18b) 
(Kouprina et al., 2005): a) an amino terminal microtubuline-binding domain, which seems to be 
member of the novel family of ASH domains (Ponting, 2006), also present in other proteins 
related to cillia, flagela, centrosome or Golgi complex; b) a tandem of two calponin-homology 
(CH) domains, which are generally implicated in actin binding; c) a particularly large domain of 
81 isoleucine-glutamine (IQ) motifs, which are normally related to calmodulin interaction; and 
finally, d) a carboxi-terminal region. The CH and IQ domains are normally found in motor 
proteins, such as non-conventional myosins: when calmodulin binds to the IQ repeats, a 
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conformational change in the myosin is induced, regulating actin union to CH domain (Bähler 
and Rhoads, 2002).  
 
 
 
 
 
 
 
 
 
According to the investigations from Kouprina and colleagues (2005), the different IQ repeats 
have a variable length in humans. However, the central region (repeats 4-54) conforms a high 
order repeat (HOR) structure, with a highly regular pattern which comprises units of 1 long 
repeat (27 amino acids) + 2 short repeats (23 amino acids). Moreover, certain amino acids of 
this HOR are conserved among short repeats, whereas others are conserved among the long 
repeats. This conservation pattern can be observed in primates and rodents. These findings 
indicate that the HOR structure may have an important function, for example, during the 
interactions between ASPM and polymeric proteins such as actin and calmodulin.  
Expression studies (Bond et al., 2002) have shown that the murine aspm protein is highly 
expressed in the cerebral cortical ventricular areas, the proliferative region of the lateral and 
medial ganglionic eminence and the ventricular zone of the dorsal diencephalon. In coherence 
with these results, human ASPM is also expressed in the developing brain and in other tissues 
during development, but not in the adult brain (Kouprina et al., 2005). Furthermore, ASPM 
protein can be detected in other proliferating tissues, including developing tissues as well as 
cancers. Interestingly, ASPM expression has been detected in spindles during mitosis, in 
coherence with a previous work with the homologue Drosophila asp protein, where it was also 
described that asp mutant cells suffered metaphase arrest (González et al., 1990). These 
evidences point out the possibility that this gene plays an important role in cell division. 
Indeed, ASPM seems to be crucial in the control of the cleavage plane orientation that allows 
symmetric, proliferative divisions of embryonic neuroepithelial (NE) cells during mouse brain 
development (Fish et al., 2006). As a result, it has been hypothesized that ASPM may control 
the proliferative symmetry of progenitors that appears to be pivotal for the expansion of 
cerebral cortex. Thus, the lack of ASPM could reduce the ability of neural stem cells to produce 
neurons and would also explain the reduction of brain volume observed in microcephalic 
patients. However, given that ASPM is also expressed in many other tissues, it is possible that 
ASPM codifies for different products, one that is necessary in brain and another necessary for 
the mitosis of other cells. According to this idea, Ponting (2006) suggested the possibility that 
Figure I18. a, Genomic structure of ASPM. It contains 28 exons in a 10434 bp ORF. b, Domains of 
ASPM protein. As it can be seen, the IQ domain is mainly coded by exon 18 in humans. 
Abbreviations: ASH, ASPM SPD-2 Hydin; IQ, isoleucine-glutamine. 
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ASPM protein may have a ciliary function, since it contains an amino-terminal domain also 
present in other proteins, related to cillia. As we know, ASPM is associated to the centrosome 
and, although the centrosome has a key role in the regulation of cell divisions, it is also 
necessary for the basal bodies in the cilia. So, the possibility that ASPM has a role in other 
functions related to cilia, such as spermatogenesis, cannot be ruled out. Another conciliatory 
hypothesis would be that ASPM takes part in the cilia-mediated neuronal migration, rather 
than in neurogenesis (Ponting, 2006). 
One of the most interesting features of ASPM gene are the evidences which support the 
existence of accelerated evolution, presumably by positive selection, particularly at the IQ 
domain, in the primate lineage leading to Homo sapiens (figure I19), especially in the 6 million 
year of hominid evolution, where ASPM accumulated one advantageous amino acid change 
every 350000 years (Zhang, 2003; Evans et al., 2004; Kouprina et al., 2004). A recent report 
from Ali and Meier (2008) also demonstrated that accelerated evolution of ASPM at 16 amino 
acid sites occurred in nine primate lineages with major changes in cerebral cortex size. 
Interestingly, this positive selection seems to be still ongoing in humans: Mekel-Bobrov and 
colleagues reported in 2005 the existence of a highly polymorphic variant (rs41310827 or 
A44871G, being the A allele the ancestral one) which arose in humans approximately 5800 
years ago and increased its frequency by positive selection. An interesting fact which supports 
the existence of positive selection around this ASPM region is the existence of an extended LD 
in the region around A44871G (Mekel-Bobrov et al., 2005).  
These interesting findings suggest that ASPM gene could have had an outstanding role in the 
progressive increasing of the relative brain size in the course of primate evolution. Along 
with this idea, it is plausible to think that ASPM could be implicated in the evolution of 
cognition, as there is a strong correlation between brain size and mental abilities (Vernon et 
al., 2000; Rushton and Ankney, 2007). Thus, it is also likely that ASPM could have also been 
related to psychiatric diseases which include cognitive symptoms, such as schizophrenia. 
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Figure I19. a, Phylogenetic tree of ASPM in the primate lineage. The branches leading to humans are 
indicated in bold red. The Ka/Ks ratios of each segment are also indicated. As it can be seen, the 
evolutionary rate of the lineage leading to humans is significantly higher. b, Ka/Ks in some mammalian 
taxa. The highest values are observed in the lineage leading to humans. Abbreviations: Ka, 
nonsynonymous changes per nonsynonymous site; Ks, synonymous changes per synonymous site. 
Adapted from Evans et al., 2004. 
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Moreover, it has been recently argued that ASPM accelerated evolution could be related to 
pressures on ciliary function, rather than pressures on neurogenesis (Ponting, 2006). This fits 
with the idea that ASPM may have a role in sperm flagellar function (in fact, it is expressed in 
male germ cells) and it has been seen that proteins involved in male reproductive function 
have evolved adaptively.    
However, despite the signs of positive selection and the firm evidences which relate ASPM 
mutations to a reduction in brain size, the relationship between ASPM and human cognition 
still remains unclear. None of the prior studies which have tried to relate this gene with global 
brain size or cranial volume (Woods et al., 2006; Rushton et al., 2007; Timpson et al., 2007; 
Dobson-Stone et al., 2007; Wang et al., 2008) has obtained significant results. Furthermore, no 
relationship has been found between ASPM and intelligence or other related parameters, such 
as mental ability (Mekel-Bobrov et al., 2007; Rushton et al., 2007). However, these negative 
findings are not surprising, as some considerations should be taken into account. On one hand, 
we can presume that the effect of each individual gene on variables such as global brain size or 
intelligence may be small, as these variables are extraordinarily complex and multifactorial 
(Toga and Thompson, 2005). Moreover, until now, all these prior studies have only focused on 
one polymorphism of ASPM commented above, A44871G, but not in other variations along its 
sequence.  
Therefore, a deeper study of ASPM variation is necessary to know the real role of this gene on 
brain evolution, neurodevelopment and vulnerability to schizophrenia and its cognitive 
deficits.  
4.5. Other schizophrenia candidate genes. 
The three last genes which had been considered for this PhD work were selected as a result of 
a previous exploratory study performed in the University of Würzburg under the supervision of 
Dr. Lesch (unpublished results). This study consisted in the search for rare copy number 
variations (CNVs) associating with ADHD in a sample of patients and control subjects. As a 
result, the region harboring the smallest isoform of the PDE4D gene (PDE4D6), as well as the 
region encoding PLEKHB1 and RAB6A genes, appeared to be affected in ADHD patients. Since 
ADHD and schizophrenia share a common phenomenology, these results can be also 
considered to be of interest for schizophrenia research. Thus, these three genes were finally 
considered as schizophrenia candidate genes for this study.  
4.5.1.  PDE4D gene.  
The intracellular cyclic adenosine monophosphate (cAMP) plays important roles as a second 
messenger molecule. It plays an important role in learning and memory formation (Dudai, 
1986), through its role in long-term potentiation and synaptic plasticity, among others 
(Morimoto and Koshland, 1991). An important regulation point for cAMP is the degradation of 
cAMP, a process mediated by phosphodiesterases (PDEs). These enzymes are distributed 
throughout the body and take part in a wide variety of roles in different organs, including the 
brain. PDEs are classified into 11 different families, named PDE1 to PDE11, which differ in 
molecular weight, charge, affinity for substrates and inhibitors, subcellular localization and 
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tissue distribution (Beavo, 1995; Soderling and Beavo, 2000). PDE heterogeneity is achieved 
through a large number of genes, which also suffer alternative splicing. 
Four cAMP-specific, rolipram-inhibited phosphodiesterases (PDE4s) have been identified in 
mammals (Conti et al., 2003); they are encoded by four different genes (PDE4A, B, C and D) 
which are homologs of dunce, a gene required for learning and memory in Drosophila (Byers et 
al., 1981; Zhong and Wu, 1991). The four variants have specificity for cAMP as a substrate, a 
low enzyme-substrate affinity and Ca2+-insensitivity. They interact with various scaffolding 
proteins through their unique amino-terminal sequence, the ultra conserved region 2 (UCR2) 
domain and the catalytic region (Wang et al., 2003b). These unique N-terminal sequences of 
PDE4 isoforms may serve to direct the proteins to specific signaling pathways (Wang et al., 
2003b).  
At least PDE4A, PDE4B, and PDE4D are expressed in the brain (Engels et al., 1995; Iwahashi et 
al., 1996). The distribution of these 3 subtypes occurs in nonoverlapping areas, suggesting that 
each of these enzymes may have different roles (Cherry and Davis, 1999). PDE4D gene maps 
on chromosome 5q11.2-5q12.1. It contains at least 27 exons (figure I20) over approximately 
1.5 Mb overlapping with another gene (PART1) (Gretarsdottir et al., 2003). It encodes at least 
nine protein isoforms and has at least seven promoters. All isoforms identified so far have an 
identical C-terminal catalytic domain but differ at the N-terminal regulatory domain. Miró et al. 
(2002) found that the different splice variants showed a distinct distribution pattern. The most 
relevant differences were in hippocampus, medial habenula, basal ganglia, and area postrema.  
Of special interest is PDE4D6; it is a supershort splicing variant that can only be detected in the 
brain, representing the most specifically expressed among the isoforms (Wang et al., 2003b). 
The determinant for membrane insertion, localized in the helix-2 of the unique N-terminal 
region, is lacking in PDE4D6 and its intracellular localization remains to be determined.  
 
 
 
 
 
 
 
 
Interestingly, the PDE4 family, and particularly the PDE4D protein, appear to be particularly 
important in neuropsychopharmacology since they are inhibited pharmacologically by the 
neuroactive drug rolipram (Henkel-Tigges and Davis, 1990). The inhibition by rolipram and 
related drugs produces a characteristic symptomatology in rats (hypothermia, hypoactivity, 
forepaw shaking, grooming, and head twitches) and can be related to high levels of cAMP. 
Moreover, PDE4D expression is increased in mouse cerebral cortex by the repeated treatment 
Figure I20. PDE4D exonic structure. The PDE4D gene encodes for at least 9 isoforms, which share 
the last nine exons (exons 7 to 14). However, the first exon used on each case (named 1D1 to 1D9) 
is different. Moreover, exons 2-5 are only common to long isoforms (PDE4D3, D4, D5, D7, D8 and 
D9). Isoform PDE4D6 also lacks exon 6 and part of the UCR2 region, and it is the shortest isoform. 
UCR1 and UCR2 regions are highly conserved among different species.   
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with desipramine, fluoxetine and rolipram and in the hippocampus by fluoxetine and rolipram 
(Shifman et al., 2008b). In addition, rolipram and related drugs also produce antidepressant-
like effects in behavioral models (Wachtel and Schneider, 1986; Zhang et al., 2002) and can 
alleviate the symptoms of patients with major depression (Horowski and Sastre-y-Hernandez, 
1985; Fleischhacker et al., 1992). Finally, several regions in the human brain where PDE4D and 
other PDE4s are abundant could be possible sites in which mood-elevating effects of rolipram 
may be mediated (Cherry and Davis, 1999). All these findings suggest that the PDE4D subtype 
is an essential mediator of the antidepressant effects of rolipram and suggest a potential role 
for PDE4s in human behavior. 
The implication of the PDE4D gene in depression and mood has been also evaluated through 
association analyses. Shifman et al. (2008b) performed the first genome wide association 
analysis for extreme scores of the personality trait neuroticism and found one significant SNP, 
rs702543, located in an intron of PDE4D gene, which was predicted to affect a putative cAMP 
response element (CRE). Subsequently, Heck and colleagues (2008) found nominal associations 
for 38 SNPs with Neuroticism and Harm Avoidance in healthy subjects. In addition, another 
intronic SNP was associated with some Harm Avoidance items in a group of patients with 
major depression. The case–control association analysis also revealed significant differences 
for two other polymorphisms. However, SNP rs702543 was not found to be associated with 
any response variable. To summarize, these observations indicate that the PDE4D gene is likely 
to be involved in susceptibility to neuroticism and associated psychiatric disorders (major 
depression and anxiety). 
Sun et al. (2004) also found that chronic lithium treatment at a therapeutically relevant 
concentration decreased the expression of PDE4D in lymphoblasts from bipolar patients, all 
excellent responders to lithium prophylaxis. Interestingly, PDE4D was not regulated by lithium 
in healthy control subjects. Since lithium has multiple effects on cAMP signaling, it can be 
speculated that PDE4D is particularly relevant for the mechanism of action of lithium. 
Another aspect which could be influenced and regulated by PDE4D is memory formation. 
Numerous studies have shown memory-enhancing effects of PDEs inhibitors, presumably via 
increasing intracellular cAMP levels, when performing different memory tasks (reviewed in 
Blokland et al., 2006). In particular, it has been hypothesized and demonstrated that selective 
inhibition of the PDE4 protein has procognitive properties (reviewed in Blokland et al., 2006). 
Moreover, rolipram can also facilitate LTP in the hippocampus (Barad et al., 1998; Navakkode 
et al., 2004) in addition to improving cognitive performance in several murine models (Barad 
et al., 1998; Rutten et al., 2006). PDE4 inhibitors have also been shown to reverse memory 
impairments in genetic mouse models of human disorders, including Rubinstein–Taybi 
syndrome and Alzheimer disease. Finally, PDE4D -⁄- mice present significant impairments in 
associative learning using a conditioned fear paradigm as well as alterations in synaptic 
plasticity, which may be explained by adaptive responses occurring throughout development 
(Rutten et al., 2008). 
The involvement of PDE4D in both memory and emotionality places this gene as an interesting 
candidate for schizophrenia. According to this idea, Benes and colleagues (2004) developed a 
‘partial’ rodent model for schizophrenia to characterize the regulation of hippocampal genes in 
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response to amygdalar activation. Remarkably, they found that PDE4D expression was 
increased after the activation of the basolateral amygdala (BLA). They hypothesize that the 
synthesis and breakdown of cAMP could potentially have attained a steady-state condition. 
More recently, Murdoch and colleagues (2007) reported that the full length isoform of DISC1 
can bind different members of the PDE4 family, including an isoform from PDE4D (PDE4D3). 
Moreover, an elevation of intracellular cAMP levels resulted in the release of PDE4D3 isoform 
from DISC1. This is an encouraging finding, since DISC1 is one of the most promising 
schizophrenia candidate genes. 
Curiously, PDE4D gene has also been related to stroke through several association studies. 
However, there are still doubts about the real implication of this locus on the vulnerability to 
stroke (for a revision, see Worrall and Mychaleckyj, 2006). 
4.5.2.  PLEKHB1 and RAB6A genes.  
The last genes which had been included in this study are PLEKHB1 and RAB6A. Both are 
adjacent genes located in chromosome 11 that appear in opposite orientations, thus their 
regulatory upstream regions probably overlap. However, both genes perform apparently 
unrelated functions.  
4.5.2.1. PLEKHB1 gene 
PHR1, recently named with the official name of PLEKHB1, is an integral membrane protein that 
contains a pleckstrin homology (PH) domain. PLEKHB1 is highly expressed in mature 
photoreceptor cells, cochlear and vestibular hair cells, and olfactory receptor neurons (Xu et 
al., 1999; Xu et al., 2004). In the retina, it can be found in the outer segments of the 
photoreceptors. PLEKHB1 is also expressed in many other cells with a possible involvement in 
sensory function, such as peripheral retinal ganglion cells, cochlear interdental cells, and 
neurons of the circumventricular organ (Xu et al., 2004). However, mice lacking PLEKHB1 do 
not have apparent sensory deficits (Xu et al., 2004).  
As commented above, the protein encoded by the PLEKHB1 gene contains an N-terminal 
pleckstrin homology domain (Krappa et al., 1999; Xu et al., 1999). PH domains are 100- to 120-
amino acid modules characterized for their ability to bind to phosphoinositides (Lemmon et al., 
2002). PH domains are multifunctional motifs found in numerous and different proteins, many 
of which are involved in signal transduction pathways. All PH domains have a common tertiary 
structure (Ferguson et al., 2000; Lemmon et al., 2002). The amino-terminal sequence 
comprises seven antiparallel β-strands, with the first four and the last three arranged in two β-
sheets and forming a β-sandwich structure. By contrast, the carboxi-terminal region of the PH 
domain is structured as a folded α-helix that “closes off” the wider end of the β-sandwich 
(Shaw, 1996; Ferguson et al., 2000). In PLEKHB1, the PH domain comprises approximately half 
of the entire protein. However, unlike the great majority of PH domains, the one of PLEKHB1 
lacks most of the eight conserved residues which coordinate binding to phosphoinositides (Xu 
et al., 1999). In fact, using in vitro binding assays, Xu and colleagues (2004) showed that the PH 
domain of PLEKHB1 does not bind any of several inositol phosphates (IP), but it does exhibit 
specific binding to transducin βγ subunits, that suggests that PLEKHB1 might play a role in 
modifying signal transduction in the photoreceptors and probably in other cells. Moreover, 
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Etournay and colleagues (2005) showed that PLEKHB1 protein interacts with the myosin 1c and 
myosin VIIa tails, and is able to dimerise. The interaction with these myosin proteins suggests 
that, as both myosins have been implicated in the mechanotransduction slow adaptation 
process occurring in the hair cells, PLEKHB1 protein could also be involved in this process.  
 The human PLEKHB1 gene maps at chromosome 11 (11q13.5-q14.1). It spans around 28 kb 
and has 9 exons (figure I21). The use of two promoters and alternative splicing of exon 7 leads 
to four different PLEKHB1 transcripts (Krappa et al., 1999; Xu et al., 1999), encoding isoforms 
of 243, 224, 208, and 189 amino acids, each one with an exposed pleckstrin homology domain 
at their N terminus and a transmembrane domain at their C terminus. Moreover, each isoform 
has different tissue or cell type-specificity. Both variants 1 and 2 result from the use of the 
more upstream promoter, which is photoreceptor-specific and has at least three Crx-like 
elements (Xu et al., 1999), recognized by Crx, a photoreceptor-specific transcription factor 
(Chen et al., 1997). These two isoforms contain a 19- amino acid amino-terminal sequence 
(NT19), which is absent from variants 3 and 4. In addition, variants 1 and 3 contain a region of 
36 amino acids encoded by exon 7 that cannot be found in variants 2 and 4. To summarize, the 
PLEKHB1 proteic sequence can be subdivided in six different regions: NT19 sequence (only in 
variants 1 and 2), PH domain, a sequence corresponding to exon 7 (only in variants 1 and 3), a 
juxtamembrane domain (JMD), a transmembrane domain, and a short six amino acid carboxi-
terminal peptide. All four transcripts are expressed in retina with transcripts 1 and 2 
predominating. In brain, only transcripts 3 and 4 are expressed with transcript 4 
predominating (Xu et al., 1999). 
 
 
 
 
 
 
 
4.5.2.2. RAB6A gene 
Rab proteins are small GTPases that are key regulators of intracellular membrane traffic 
through constant cycling between a membrane-associated GTP-bound active state and 
cytosolic GDP-bound inactive state (Wanschers et al., 2008). The Rab family is huge and 60 
proteins, including isoforms, are known (Stenmark and Olkkonen, 2001). Rab proteins exert 
their function by binding to a several effector proteins and taking part in different membrane 
trafficking events, such as fission, tethering, fusion of membranes, and transport along the 
actin or microtubule cytoskeleton (reviewed in Jordens et al., 2005). With regard to the 
transport process, the small GTPase Rab6 is a key regulator in the retrograde transfer from 
endosomes via the Golgi to the endoplasmic reticulum (ER). It interacts with kinesins, such as 
Rabkinesin-6 (Echard et al., 1998) or with the dynein/dynactin complex (Short et al., 2002; 
Wanschers et al., 2007).  
Figure I21. Genomic structure of PLEHKB1. This gene has 9 exons and encodes for 4 different 
isoforms. Alternative exons are indicated in green and untranslated regions are shown in white. The 
variety of isoforms is achieved through the use of two different promoters (a photoreceptor-
specific promoter located 5’ upstream of exon 1/2, and an internal promoter located 5’ upstream of 
exon Pre3), as well as the alternative splicing of exon 7. 
Abbreviations: Pr, photoreceptor-specific promoter; Pi, internal promoter.   
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Figure I22. Exonic structure of the RAB6A gene. This gene has 9 exons. Alternative exons are 
indicated in green and untranslated regions appear in white. Alternative splicing of exons 4 and 5 
gives rise to two different isoforms: Rab6A’ and Rab6A. 
Three different isoforms of the Rab6 protein have been identified until now: Rab6A (Goud et 
al., 1990), encoded by the RAB6A gene; Rab6A’, generated by alternative splicing of a 
duplicated exon within the RAB6A gene (Echard et al., 2000); and Rab6B, a brain specific 
isoform (Opdam et al., 2000) encoded by the RAB6B gene.  
The RAB6A gene (figure I22) maps at chromosome 11q13.3 and has 9 exons, including two 
exons (4 and 5) resulting from a duplication, which are separated by a small 66 bp intron 
(Echard et al., 2000). This exon duplication has occurred late during evolution as most 
organisms, including Drosophila, express only one copy of Rab6. Both Rab6A and Rab6A’ 
isoforms have 208 amino acids, which give rise to proteins with the following domains: a 
GTP/Mg2+ binding domain; a putative guanine nucleotide exchange factor (GEF) interaction 
site; a putative guanine nucleotide dissociation inhibitor (GDI) interaction site; and two regions 
known as Switch1 and Switch2, which undergo conformational changes upon GTP-binding. 
Rab6A and Rab6A’ only differ in three amino acids due to substitutions in regions flanking the 
GTP-binding domain (Echard et al., 2000).  
 
 
 
 
 
Both Rab6A and Rab6A′ are ubiquitously expressed (Echard et al., 2000). Until recently, both 
Rab6A and Rab6A’ were thought to play a role in a Golgi to ER retrograde transport (White et 
al., 1999; Young et al., 2005) with an additional function for Rab6A’ in specific endosome to 
Golgi transport (Mallard et al., 2002). However, recent studies showed that Rab6A is 
dispensable for Golgi to ER transport and that Rab6A’ is the isoform that regulates the entire 
pathway from late endosomes to ER (Del Nery et al., 2006). Furthermore, Rab6A’ has also 
been implicated in the transition from metaphase to anaphase during mitosis (Del Nery et al., 
2006; Miserey-Lenkei et al., 2006). Very recently, Wanschers et al. (2008) showed for the first 
time and interaction of the Rab6 proteins with a member of the cytoplasmic dynein complex 
(DYNLRB1, one of the light chains of this complex) and co-localisation at the Golgi. Cytoplasmic 
dynein is the main motor protein complex for the retrograde transfer from endosomes via the 
Golgi to the ER. 
As it can be shown, the relationship between schizophrenia and these two genes is not very 
clear, however, it cannot be discarded since both are novel genes which are expressed in the 
brain and which seem to be somehow affected in a neuropsychiatric disorder such as ADHD. 
In summary, with the genetic analysis of these nine genes, this work has the main purpose to 
go further in the molecular bases of schizophrenia and its most characteristic symptoms. 
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This study is part of a multidisciplinary research project whose main objective is to further 
study the genetic bases of schizophrenia and its most important symptoms. According to this 
general framework, the general hypothesis and objectives of the present study are the 
following. 
 
GENERAL WORKING HYPOTHESIS 
 Variations in the genes previously presented modulate the vulnerability to schizophrenia or 
some of its most characteristic features, particularly auditory hallucinations, cognitive 
impairment, neuroanatomical alterations, as well as the emotional dysfunction linked to 
the pathological conditions described before.    
 
GENERAL OBJECTIVES 
 Analysis of several polymorphisms from the different candidate genes through case-control 
association analyses. For this purpose, different samples of schizophrenic patients and 
healthy controls will be included. This will allow the comparison among different clinical 
subtypes and populations of patients. 
 Search of associations between single alleles or haplotypes and different quantitative 
variables and disease traits, including a) scores on general and hallucination schizophrenia 
scales, and b) performance on several cognitive tasks. 
 Evaluation of the effect of several selected polymorphisms on certain magnetic resonance 
imaging (MRI) phenotypes which are known to be affected in schizophrenic patients. 
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MATERIALS AND METHODS 
1. Writing Guidelines 
Genes are designated by their official symbol and name according to the HUGO Gene 
Nomenclature Committee (http://www.genenames.org/), which provides and approves names 
for human genes to avoid confusions when searching for information about genes. 
With regard to the single nucleotide polymorphisms (SNPs), the rs number from the NCBI 
dbSNP database is preferred against other existing names. If the rs number is not available, 
then the most common name in the existing literature is used. Other polymorphic variants 
(VNTRs, indels) are also identified with the most common name in the previous literature.        
Alleles from SNPs are designated with reference to the nucleotide located in the coding strand 
of the studied gene. However, there is an exception to this rule: if a genomic region with 
several genes and different coding strands is studied as a whole, then the alleles will be named 
with reference to the base located in the plus strand, according to the reference assembly 
from the NCBI dbSNP database.  
All chemical and biochemical compounds are designated according to the recommendations 
from the IUPAC (“International Union of Pure and Applied Chemistry”) and the IUBMB 
(“International Union of Biochemistry and Molecular Biology”), which can be consulted in 
http://www.chem.qmul.ac.uk/iupac/. 
 
 
2. Clinical samples 
Three different groups of patients and controls coming from three different countries (Spain, 
Germany and United States of America) have been used for this study.   
General demographic information about both patients and controls can be found in table M2, 
whereas table M3 shows the most relevant clinical features of the three samples of patients. 
Patients were evaluated for one or more of the following scales:  
o BPRS (Brief psychiatric rating scale) from Overall and Gorham, 1962: It was originally 
developed as a tool to evaluate psychopathological characteristics and to measure 
treatment response in clinical psychopharmacology research. It allows the evaluation 
of 18 (originally 16) different psychiatric symptoms, which can be evaluated from 1 
(not present) to 7 (extremely severe). The 18 items which can be assessed are: somatic 
concern, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, 
tension, mannerisms and posturing, grandiosity, depressive mood, hostility, 
suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual 
thought content, blunted affect, excitation and disorientation and confusion.        
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o Psychiatric Assessment scale or KGV Symptom scale (Krawiecka et al., 1977; Spanish 
version by Pérez-Fuster et al., 1989): It is a 14-item scale to assess the patient’s general 
mental state in chronic psychotic patients.  Its main purpose is to provide a summary 
of the different symptoms suffered by these patients. It has 14 sub-scales which can be 
scored from 0 (absence of symptom) to 4 (severe manifestation of symptom). The 14 
items are: anxiety, depression, suicidal thoughts and behaviors, elevated mood, 
hallucinations, delusions, flattened affect, incongruous affect, overactivity, 
psychomotor retardation, abnormal speech, poverty of speech, abnormal movements 
and accuracy of assessment. 
o PANSS (Positive and negative syndrome scale) from Kay et al., 1987 (Spanish version 
from Peralta and Cuesta, 1994): It is an exhaustive measurement which provides 
information about 30 different items, which can be grouped in three wide domains: 
Positive symptoms, Negative Symptoms and Cognitive or General Psychopathology. 
Moreover, it evaluates the schizophrenic syndrome from two different points of view: 
on the one hand, a dimensional perspective, which studies the severity of negative, 
positive and general symptoms; on the other hand, a categorical perspective, which 
classifies the disorder as negative, positive or mixed, depending of the scores for each 
domain. Table M1 shows a scheme of the items evaluated by PANSS.  
 
More detailed information about the three samples of individuals included in this study can be 
also found below (tables M2 and M3).  
 
 
Positive (p)  Cognitive or general psychopathology (g) 
P1. Delusions  G1. Somatic concern 
P2. Conceptual disorganization  G2. Anxiety 
P3. Hallucinatory behavior  G3. Guilt feelings 
P4. Excitement  G4. Tension 
P5. Grandiosity  G5. Mannerism and posturing 
P6. Suspiciousness / persecution  G6. Depression 
P7. Hostility  G7. Motor retardation 
 G8. Uncooperativeness 
Negative (n)  G9. Unusual thought content 
N1. Blunted affect G10. Disorientation 
N2. Emotional withdrawal G11. Poor attention 
N3. Poor rapport G12. Lack of judgment and insight 
N4. Passive / apathetic social withdrawal  G13. Disturbing of volition 
N5. Difficulty in abstract thinking  G14. Poor impulse control 
N6. Lack of spontaneity/flow of conversation  G15. Preoccupation 
N7. Stereotyped thinking G16. Active social avoidance 
 
 
SCORES 
1. Absent    
2. Minimal  
3. Mild    
4. Moderate 
5. Moderate severe 
6. Severe 
7. Extreme 
  
Table M1. List of items evaluated in PANSS scale. 
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2.1. Spanish sample 
For this study, 328 unrelated psychiatric patients were included. They came from the 
Psychiatric In-patient and Out-patient Units of the Mental Health Service number 4 of the 
Clinical Hospital (University of Valencia, Spain). Age ranged from 18 to 77 years old. The 
retrospective clinical data collected from each patient were compared with the information 
provided from previous clinical reports and family members. All patients met DSM-IV criteria 
for different psychoses, mainly schizophrenia (76.25%). These diagnoses were confirmed for 
every patient by a consensus meeting with the treating psychiatrist and one of the 
psychiatrists of our research group. Patients also had a minimum one-year evolution of the 
illness and were on antipsychotic treatment at evaluation time. Exclusion criteria for this study 
included incoherence of speech and/or the incapacity for basic comprehension of the 
questions. 
Symptom severity was assessed in some patients through BPRS, KGV and PANSS scales (136, 
295 and 135 individuals, respectively). Furthermore, other scales were used to evaluate some 
specific symptoms: 
o Auditory hallucinations were assessed in 314 patients using the Psychotic Symptom 
Rating Scale (PSYRATS) for auditory hallucinations (Haddock et al., 1999; Spanish 
version by González et al., 2003b) This standardized scale rates 11 parameters of AH 
on a five-point scale (0-4): frequency, duration, location, loudness, beliefs about the 
origin of voices, amount of negative content, degree of negative content, amount of 
distress, intensity of distress, disruption to life and controllability of voices.  
o Delusions were also evaluated in a subsample of 166 individuals through the Psychotic 
Symptom Rating Scale (PSYRATS) for delusions (Haddock et al., 1999).  It is a six-item 
scale which assesses dimensions of delusions. The items are also rated on a five-point 
ordinal scale and are the following: amount of preoccupation, duration of 
preoccupation, conviction, amount of distress, intensity of distress and disruption. 
348 healthy unrelated subjects with no history or familiar background of mental disorders 
were also selected for the analysis. The selection of control individuals with similar 
demographic characteristics to the psychotic group (Caucasian ethnic group, similar age…) was 
considered to be an important requisite to avoid sample stratification. These control subjects 
were between 18 and 91 years old and were also of Spanish origin. Drug abuse was also 
considered among the exclusion criteria. 
All subjects gave their written informed consent to participate in this study, which was 
approved by the Ethical Committee of the Medicine Faculty, University of Valencia. 
2.2. German sample 
This sample was managed at the Department of Psychiatry and Psychotherapy, University of 
Würzburg. A total of 336 unrelated patients (mean age was 41.63 years old) took part in the 
study. They were hospitalized at the Department of Psychiatry at least once. Diagnoses were 
made by an extensive, semi structured interview performed by an experienced psychiatrist. 
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Clinical data obtained from the interview was contrasted with the information obtained from 
family members and previous clinical assessments. In short, 247 patients met ICD-10 criteria 
for chronic schizophrenia, while 89 individuals suffered from bipolar disorder (table M3). 
Symptom severity was assessed in some individuals through BPRS. Patients did not show other 
disorders (neurological disorders, epilepsy, mental retardation…) which could be the 
underlying cause of the psychiatric disorder. Substance-induced psychosis and affective 
disorders were also considered as exclusion criteria.  
540 control subjects were also included in the study. They were healthy blood donors from the 
same catchment area as the patient group (Lower Franconia, Bavaria). To avoid ethnic 
stratification, they were also from Caucasian origin. Although these individuals were not 
assessed for psychiatric disorders, all of them were free of medication and the aim of the study 
was explained to them, so it is unlikely that the subjects from the control group are suffering 
from severe psychiatric disorders.  
Only those patients and controls who gave their written informed consent were accepted for 
the study, which was approved by the Ethics Committee of the University of Würzburg.  
2.3. North-American sample 
All subjects were recruited for the Clinical Brain Disorders Branch (CBDB) “Sibling Study”, a 
study of neurobiological abnormalities associated to genetic risk for schizophrenia. This study 
was developed at the National Institute of Mental Health (Bethesda, MD, USA). All study 
procedures were also approved by the Institutional Review Board of the National Institute of 
Mental Health. 
In summary, the sample included 498 patients who fulfilled the DSM-IV criteria for 
schizophrenia-spectrum disorders (all of them suffered from schizophrenia or schizoaffective 
disorder), 427 unaffected siblings, 612 parents and 483 unrelated healthy controls. All 
participants were between 18 and 60 years of age, had a premorbid IQ above 70 and were able 
to give a written informed consent. Significant medical problems, history of head trauma and 
alcohol or drug abuse within the last 6 months were considered as exclusion criteria. In order 
to avoid ethnic stratification, only Caucasian subjects of European ancestry were included in 
this study. Patients were also evaluated through PANSS (see table M3). 
Cognitive measures were obtained for some subgroups. Control subjects and schizophrenic 
patients performed an extensive battery of neuropsychological tests previously found to be 
abnormal in healthy siblings of patients with schizophrenia (Elvevag and Goldberg 2000; Egan 
et al., 2001b). The test battery included the Weschler Adult Intelligence Scale, revised edition 
(WAIS-R) as a measure of general intelligence; selected subtests of the Wechsler Memory 
Scale, revised version (WMS-R), to assess episodic memory; Trail Making Test Parts A and B, to 
measure psychomotor speed and also as an oculomotor scanning; Verbal and Category Fluency 
tests; a measure of attention (Gordon's Continuous Performance Task  or CPT); two measures 
of working memory:  N-Back (Zero-back, One-back, Two-back, and Three-back conditions) and 
the Wisconsin Card Sorting Test (WCST); the California Verbal Learning Test (CVLT), which tests 
episodic memory; and finally, the Judgment of Line Orientation Test  as a measure of 
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visuospatial ability. To avoid the increase of type I error related to multiple testing, effect of 
genotype was examined only in seven measures derived from these cognitive tests: Verbal 
Memory, Working Memory-N back, Visual Memory, IQ-Processing Speed-Fluency, Executive 
Function-WCST, Attention and Digit Span (Genderson et al., 2007).  
3. Genomic DNA extraction methods 
Genomic DNA from the Spanish individuals described above was obtained from different 
methods and cellular types: 
 DNA extraction from blood leukocytes: blood was the preferable source of genomic 
DNA, since the amount of DNA which can be obtained from blood cells is generally 
higher than the DNA obtained from other tissues.  
 DNA extraction from saliva: Although DNA extraction from blood samples is more 
desirable and preferable because of its higher yield, sometimes it was necessary to use 
other types of cellular tissues, such as buccal epithelial cells, which can be obtained 
from saliva with a less invasive method than blood extraction. 
3.1. DNA extraction from peripheral blood leukocytes 
Three different methods were used.  
3.1.1. Phenol-chloroform DNA extraction method (Sambrook and Russell, 2001) 
This methodology is mainly based on the use of an organic solvent (phenol-chloroform 
solution). After destroying the leukocytes’ cellular and nuclear membranes with the use of 
detergents (nonidet and SDS) and proteinase K, proteins can be separated from nucleic acids 
since they are captured by the organic solvents, while nucleic acids remain in the aqueous 
phase. After phenolisation, it is also necessary to wash the DNA phase with chloroform-
isoamilic solution to eliminate phenol residues which can remain in the aqueous DNA phase. 
Finally, DNA is precipitated with absolute ethanol in the presence of NaCl. 
 REAGENTS AND SOLUTIONS 
 Saline solution (0.9% NaCl): 
 NaCl    9 g 
 Distilled water   1 L 
 Erythrocytes lysis solution:  
 Tris 2M pH 7.5    5 mL  
 MgCl2 1M   2.5 mL 
 Distilled water    up to 500 mL  
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 Nonidet P-40 0.1%: 
  Nonidet™ P-40   1 mL  
(FLUKA, catalog no. 21-3277 )  
 Distilled water   999 mL 
 Solution A: 
 NaCl 5M   1 mL 
 EDTA 0.25M pH 8  5 mL 
  SDS 10%   2.5 mL 
 Distilled water   up to 50 mL  
 Proteinase K (Sigma-Aldrich, catalog no. P2308)  10 mg/mL 
  Phenol-chloroform-isoamilic solution 25:24:1 
 Chloroform-isoamilic solution 24:1  
 NaCl 5M 
 Cold absolute ethanol 
 70% Ethanol solution  
 TE buffer pH 7.5: 
 Tris-HCl 10mM pH 7.5  5 mL 
 EDTA 1mM pH 8  1 mL 
 Distilled water             up to 500 mL 
PROCEDURE 
a) Obtaining of blood cells 
 Mix peripheral blood (from 10 to 20 mL, collected in tubes with EDTA-K3 as a 
coagulant) with saline solution, up to a final volume of 15-50 mL. 
 Centrifuge for 20 minutes at 4oC and 3000 rpm. 
 Aspirate and discard the supernatant. The process can be stopped at this point 
and the pellet, which corresponds to the cellular layer, can be frozen at -20oC. 
b) Lysis of erythrocytes 
 Add the sterile erythrocytes lysis solution to the pellet obtained in the previous 
step, up to a final volume of 50 mL. Shake carefully by inversion to 
homogenize the mix. 
 Leave at 4oC for 30 minutes, shaking by inversion from time to time. 
 Centrifuge for 15 minutes at 4oC and 3000 rpm. 
 Discard and decant the supernatant.  
 To dry the pellet, leave the tube in an inverted position on a filter paper sheet 
for some minutes. 
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COMMENT: if the pellet is still red (a sign of the presence of undesirable blood cells), this 
process can be repeated again by adjusting volumes and lysis times. The final pellet must be 
whitish or slightly pink. 
c) Lysis of leukocytes 
 Add 15 mL of Nonidet P-40 0.1% to the pellet. Mix gently. 
 Centrifuge for 20 minutes at 4oC and 3500 rpm. During the centrifugation time, 
prepare the solution A, which must be fresh. 
 Discard the supernatant and break up the pellet vortexing it. 
 Add 10 mL of solution A and vortex the tube until it is completely 
homogenized. 
 Add 200 µL of proteinase K. 
 Incubate at 56oC overnight.  
d) DNA purification 
 Add an equal volume (v/v) of the phenol-chloroform-isoamilic solution. Shake 
vigorously. 
 Centrifuge for 10 minutes at 4oC and 3000 rpm. 
 Discard the lower phase by aspiration with a pasteur pipette and transfer the 
upper DNA phase to a new tube.  
 Repeat the three previous steps. 
 Add an equal volume of the chloroform-isoamilic solution to remove any trace 
of phenol and shake vigorously.  
 Centrifuge for 10 minutes at 4oC and 3000 rpm. 
 Transfer the upper phase to a new tube. 
 Repeat the three previous steps. 
e) DNA precipitation and wash 
 Add NaCl 5M (400 µL per 5 mL of solution) and shake vigorously. 
 Precipitate the DNA with two volumes of absolute ethanol. 
 Homogenize by gentle inversion until the DNA precipitate appears. The 
precipitate will look as a white fibrous medusa. 
 Catch the DNA precipitate and wash it by immersion in 70% ethanol.  
 Let the medusa dry and transfer it with a sterile microbiology loop (or 
something similar) to a Nunc CryoTube™ which contains 1mL of TE buffer pH 
7.5. 
3.1.2. DNA extraction by saline precipitation  
The saline precipitation method was selected to substitute the phenol-chloroform method, 
since it avoids the use of organic solvents, such as phenol, which are highly contaminant and 
toxic. It is based on the use of a moderated concentration of a monovalent cation such as Na+, 
followed by the addition of absolute cold ethanol to obtain the precipitation of DNA. Since the 
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first three steps (obtaining of blood cells, erythrocytes lysis and leukocytes lysis) are common 
to the phenol-chloroform extraction method, we will focus on the DNA purification step. 
d) DNA purification 
 Add 1mL of saturated NaCl 5M per 3 mL of the resulting solution from step c). 
 Shake vigorously for 2 minutes. 
 Centrifuge for 15 minutes at room temperature and 13000 rpm. 
 Transfer the supernatant to a fresh tube and repeat the two previous steps. 
 Add one volume of cold absolute ethanol. Homogenize by gentle inversion 
until the DNA precipitate appears. 
 Catch the DNA precipitate and wash it by immersion in 70% ethanol. 
 Redisolve the DNA medusa in 1mL of TE buffer pH 7.5. 
3.1.3. DNA extraction by Puregene Blood Kit  
The Gentra® Puregene® Blood kit (Qiagen®, catalog no. 158389) allows the extraction of high 
quality DNA from whole blood with a high yield and without the use of organic solvents. Cells 
are lysed with an anionic detergent in the presence of a DNA stabilizer, which reduces the 
activity of DNases. Proteins and other contaminants are removed by salt precipitation and 
finally DNA is precipitated with alcohol and redisolved in a buffered solution. Thus, this 
method fulfills the best features of the two previous methods and for this reason it was 
considered to be the best alternative to DNA extraction from blood cells. 
The protocol used in this study presents some variations with respect to the original 
manufacturer’s protocol.  
REAGENTS AND SOLUTIONS 
 PBS solution 1X pH 7.4 (prepared at the laboratory): 
 NaCl   8 g 
 KCl   0.2 g 
 KH2PO4   0.24 g 
 Na2HPO4  1.44 g 
 Distilled water  up to 1 L 
 Erythrocytes lysis solution (prepared at the laboratory):  
 NH4Cl    7.007 g 
 NH4CO3   0.071 g 
 Distilled water   up to 1 L  
 Cell Lysis Solution (from the commercial kit) 
 Protein Precipitation Solution (from the commercial kit) 
 100% Isopropanol  
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 70% Ethanol  
 DNA Hydration Solution (from the commercial kit) 
PROCEDURE 
a) Obtaining of leukocytes 
 Centrifuge 10 mL of whole peripheral blood (collected in EDTA-K3 tubes) for 15 
minutes at 2500 rpm and room temperature (rt). 
 Aspirate and discard the upper liquid layer (which corresponds to the plasma). 
 Add up to 10 mL of PBS solution to the buffy coat, which contains the red and 
white cells, and mix by inversion. 
 Centrifuge for 15 minutes at 2500 rpm and rt. 
 Discard the supernatant and repeat the two previous steps, to ensure the 
complete wash of the buffy coat. 
 Aspirate the white layer which contains the leukocytes with a transfer or 
pasteur pipette. Transfer these cells to a fresh 10 mL tube. 
 Add 7 mL of the erythrocytes lysis solution and mix by inversion. 
 Incubate 20 minutes at room temperature, mixing by inversion from time to 
time. This step will lyse those red blood cells which were transferred together 
with the white blood cells.  
 Centrifuge for 15 minutes at 2500 rpm and rt to pellet the leukocytes.   
 Carefully discard the supernatant and wash the borders of the pellet with 1 mL 
of erythrocytes lysis solution. 
 Resuspend the pellet in 1-2 mL of erythrocytes lysis solution and add more lysis 
solution up to a volume of 10 mL. 
 Centrifuge for 15 minutes at 2500 rpm and rt to pellet the leukocytes.   
 Discard the supernatant and wash the borders of the pellet again with 
erythrocytes lysis solution. 
 Drain the tube by inverting on a clean piece of absorbent paper, taking care 
that the pellet remains in the tube. 
 At this point, it is possible to store the leukocytes for a later DNA extraction. In 
this case, resuspend the pellet in 0.9 mL of PBS solution, transfer it to a 
cryotube and store at -80oC for an optimal cell conservation. For a prompt 
DNA extraction, then resuspend the leukocytes pellet with 0.4 mL of PBS, 
transfer it to a fresh 13 mL tube and add 10 mL of Cell Lysis Solution.  
 Incubate the tube at room temperature for at least 7 days (however, samples 
are stable in Cell Lysis Solution for at least 2 years at rt).     
b) Protein precipitation 
 Add 3.33 mL of Protein Precipitation Solution and vortex the tube vigorously 
for 15 seconds to homogenize the sample.   
 Incubate on ice for 30 minutes. 
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 Centrifuge for 20 minutes at 4000 rpm and rt. The precipitated proteins should 
form a tight, dark brown pellet. 
c) DNA precipitation 
 Aspirate the supernatant (which contains the DNA) with a transfer pipette and 
transfer it to a tube with 5 mL of cold 100% Isopropanol. 
 Mix gently by inversion until the DNA is visible as threads or a clump. 
 Centrifuge for 6 minutes at 4000 rpm. The DNA will be visible as a small white 
pellet. 
 Carefully discard the supernatant and drain the tube by inverting on a clean 
piece of absorbent paper.  
 Add 10 mL of cold 70% ethanol and invert several times to wash the DNA 
pellet. 
 Centrifuge for 8 minutes at 4000 rpm.  
 Carefully discard the supernatant and drain the tube again on a piece of 
absorbent paper for 30-40 minutes at room temperature to dry the DNA 
pellet. 
d) DNA hydration 
 Add 600 uL of DNA Hydration Solution to the tube which contains the DNA 
pellet. 
 Incubate at room temperature for 3-4 days with gentle shaking. This step is 
necessary to completely rehydrate the DNA. 
 Store the DNA sample in a cryotube at -80oC.  
3.2. DNA extraction from saliva samples 
Two different methods were used.   
3.2.1. DNA extraction from saliva with SSS DNA extraction kit. 
The SSS DNA extraction kit (Real®, catalog no. RBME02) is an easy and scalable method with 
allows the DNA extraction from different sources, including saliva. It is also based on the saline 
precipitation method and the protocol used for this study includes few modifications from the 
original manufacturer’s protocol. 
REAGENTS AND SOLUTIONS 
 Lysis Solution (from the commercial kit) 
 Protein Precipitation Solution (from the commercial kit) 
 RNase 10mg/mL 
 100% Isopropanol  
76 Materials and Methods 
 
 70% Ethanol  
 TE buffer pH 7.5 
 
PROCEDURE 
a) Saliva collection 
 Ask the subject to rinse mouth with cold water just before collecting saliva. It is 
also desirable not to eat, drink or brush teeth before collection. 
 Ask the subject to deliver saliva in a sterile tube, up to a minimum volume of 1-
2 mL.  
 Take the saliva tube and prepare 800 µL aliquots.  
 Store the samples at -20oC (or 4oC for a prompt extraction). 
b) Cellular lysis 
 Centrifuge for 90 seconds at 13000 rpm. 
 Discard the supernatant with a pipette, leaving a residual volume of 10-20 µL. 
 Vortex the tube to resuspend the pellet and to optimize the cellular lysis in the 
following step. 
 Add 800 µL of Lysis Solution and mix with the pipette to lyse the buccal cells.       
 Incubate at 37oC for 5 minutes. 
 Add 20 µL of RNase solution and mix by inversion at least 25 times to ensure 
the complete homogenization of the sample. 
 Incubate at 37oC for 45 minutes. 
c) Protein precipitation 
 Let the sample to temper at rt. 
 Add 480 µL of Protein Precipitation Solution and vortex it vigorously for 30 
seconds. 
 Centrifuge for 4 minutes at 14000 rpm. A dark brown precipitate (which 
contains the protein fragments) will appear.  
d) DNA precipitation 
 Transfer the supernatant (which contains the DNA) to a fresh tube containing 
800 µL of Isopropanol. 
 Mix by inversion at least 50 times. 
 Centrifuge for 2 minutes at 14000 rpm. The DNA precipitate appears as a small 
white medusa. 
 Discard the supernatant and drain the tube briefly by inverting on a clean 
sheet of absorbent paper.  
 Add 800 µL of 70% Ethanol solution to wash the DNA. 
 Centrifuge for 1 minute at 14000 rpm.  
 Carefully discard the supernatant without disturbing the DNA pellet. 
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 Centrifuge again for 1 minute at 14000 rpm to fully eliminate the residual 
ethanol. 
 Dry the tube by inverting it on a clean sheet of absorbent paper for 15 
minutes.  
e) DNA hydration 
 Add between 70 and 100 µL of TE buffer to the tube which contains the DNA 
pellet. Resuspend the DNA with a pipette. 
 Incubate at rt overnight with gentle shaking. This step will ensure the complete 
rehydration of the DNA. 
 Transfer the DNA sample to a cryotube and store at -80oC. 
3.2.2. DNA extraction from saliva with Oragene. 
The Oragene™ DNA self-collection kit (DNA Genotek Inc., catalog no. OG-250) is based on the 
use of an innovative recollection tube (the Oragene vial, see figure M1) containing a stabilizer 
which preserves saliva samples for long term storage at room temperature without DNA 
degradation. For this reason, this methodology (also based on the saline precipitation method) 
is clearly superior to other DNA extraction methods from saliva, such as the SSS DNA 
extraction kit, and allows the obtaining of high DNA yields, which are comparable to the yields 
when using whole blood. Moreover, the purity and quality of the DNA is also very high and 
similar or even better than DNA from blood. 
 
 
 
 
 
 
 
 
REAGENTS AND SOLUTIONS 
 Oragene vial (from the commercial kit) 
 Oragene Purifier (from the commercial kit) 
 95% Ethanol 
 TE buffer pH 7.5 
Figure M1. Oragene™ vial used to collect saliva for DNA 
extraction. 
  
DNA stabilizer 
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PROCEDURE 
a) Saliva collection and stabilization 
 Ask the subject to deliver saliva in the Oragene vial. Once the vial is capped, 
the DNA-preserving fluid is mixed with saliva. Saliva is now stable for long-
term storage at room temperature. 
 Incubate the saliva sample in the Oragene vial at 50oC in a water bath 
overnight.  
b) Cell lysis and protein precipitation 
 Transfer 500 µL of the saliva sample to a fresh tube (the remaining sample can 
be stored at room temperature for further use). 
 Add 20 µL of the Oragene Purifier and mix gently by inversion. With the 
Purifier, all impurities (including proteins) will precipitate. 
 Incubate on ice for 10 minutes.  
 Centrifuge for 3 minutes at 13000 rpm at room temperature. 
c) DNA precipitation 
 Carefully transfer the supernatant with the DNA to a fresh tube and discard the 
pellet. 
 Add 500 µL of 95% ethanol and mix gently by inversion at least 5 times or until 
the DNA medusa appears. 
 Let the solution stand for 10 minutes at room temperature to ensure the full 
precipitation of DNA.  
 Centrifuge for 1 minute at 13000 rpm at room temperature. 
 Discard the supernatant and centrifuge again to remove the residual ethanol. 
d) DNA hydration 
 Once all of the ethanol has been completely eliminated, dissolve the DNA 
pellet in 100 µL of TE buffer. Vigorous vortexing is also useful. 
 Incubate at room temperature overnight to dissolve the DNA. 
 Store the sample at -80oC. 
3.3. DNA quantification 
DNA samples were quantified by absorbance. Two different spectrophotometers, a 
BioPhotometer from Eppendorf and a NanoDrop® ND-1000 were used. The Nanodrop was 
especially useful in those cases when the DNA yield was very low (for example, for DNA 
samples from saliva), as this spectrophotometer allows measurements of small volumes (1 µL) 
without any dilution of the sample. 
The absorbances at the following wavelengths were measured: 
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 A260: It measures amounts of DNA. To ensure an accurate measurement of DNA 
concentration with the Biophotomether, this value should fall between 0.1 and 1, thus it 
is necessary to prepare a 1:20 dilution of the original sample. With regard to the 
Nanodrop, its high sensitivity allows to make the measurement directly on the original 
sample.  
It is considered that 1 unit of optic density (DO) at 260 nm corresponds to 50 ng/µL of 
double-stranded DNA. 
 A280: It is a measure of the protein concentration.  
 A320: It measures the light scattering and it also gives an estimation of the background 
turbidity. If the DNA extraction protocol has been followed successfully, this value is 
expected to be low. 
The calculation of concentration and purity was as it follows: 
 DNA concentration in ng/µL = (A260 – A320) x dilution factor x 50 ng/µL (conversion 
factor) 
 DNA purity (measured with the A260-A280 ratio) = (A260 – A320) / (A280 – A320). For a good 
DNA performance, this value should fall between 1.6 and 2.    
4. Genotyping  
4.1. Selection of polymorphisms 
Several polymorphisms located in the 9 candidate genes were selected for this study. Almost 
all the polymorphisms are Single Nucleotide Polymorphisms (SNPs), with the exception of 
some VNTRs (variable number of tandem repeats) which were selected due to their functional 
implications.  
In short, the polymorphism selection process could be divided in two steps: 
 Selection of informative SNPs, known as tag SNPs, to capture all the variability present 
in the regions of interest. This is applicable to all genes except TPH2, HTR2A and NOS1, 
because only a few markers of interest were studied on those genes. 
 Selection of other additional polymorphisms.  
 
Table M4 shows an overview of the Internet resources used to select the genetic markers. 
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Table M4. Internet databases and utilities used for the selection of polymorphisms. 
Name Web page Description 
NCBI-dbSNP http://www.ncbi.nlm.nih.gov/sites/entrez/ 
Database from the National Center for 
Biotechnology Information which contains 
information about millions of 
polymorphisms from Homo sapiens and 
other species. 
Ensembl http://www.ensembl.org/ 
It provides access to all the databases from 
the Ensembl Project, a joint project 
between EMBL - EBI and the Sanger 
Institute. 
UCSC 
Genome 
Browser 
http://genome.ucsc.edu/ 
Group of interrelated databases and utilities 
from the Genome Bioinformatics Group at 
the University of California Santa Cruz. 
HapMap http://www.hapmap.org/ 
International approach to the study of the 
genetic differences and similiarities of 
human beings, with special attention to 
SNPs. 
Pupa Suite http://pupasuite.bioinfo.cipf.es/ 
Online utility which performs a high-
throughput search of SNPs with a potential 
phenotypic effect. 
Polyphen http://genetics.bwh.harvard.edu/pph/ 
Tool which evaluates the possible impact of 
a non synonymous change on the structure 
and function of human proteins. 
 
 
4.1.1. Selection of tag SNPs. 
Although nowadays it is possible to genotype all the SNPs located in a gene of interest, this 
approach is in fact unnecessary, since many SNPs could provide redundant information, 
depending on the linkage disequilibrium (LD) structure of the area. An alternative is to select a 
group of polymorphisms which ensure that we are capturing an acceptable level of variability 
for our study. These polymorphisms are called tag SNPs, since they give indirect information 
about nearby variants (also called proxies) which are in high LD with the selected tags. 
Therefore, the selection of tags is based on the LD pattern between the different 
polymorphisms.  
However, it is also important to consider which source of genotypic data we will use to analyze 
the LD pattern and to select the tags. These genotype data can be provided by the HapMap 
Project, a big collaborative effort whose main objective is to determine the common patterns 
of DNA sequence variation in the human genome and to make this information freely available 
in the public domain (International HapMap Consortium, 2003). Currently (HapMap data 
release #23a, March 2008, on NCBI B36 assembly, dbSNP b126), almost four millions of SNPs 
have been genotyped in four different populations, representing a huge volume of 
information.  
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The procedure followed to select the tags for our studies was the following: 
 Download the genotype data for all the SNPs located in the region of interest. The 
HapMap population used as a reference for tag selection is CEPH (Utah residents with 
ancestry from northern and western Europe). These DNA samples come from the 
Centre d'Etude du Polymorphisme Humain and are also known as CEU. Although it is 
unclear how accurately these samples reflect the patterns of genetic variation in 
European people, we decided to use these individuals as our reference because we 
assume that CEU samples present the highest similarity with the samples analyzed in 
this study. Moreover, we considered a chromosomic region which spans the genomic 
region of our candidate gene plus some kilobases (Kb) downstream and upstream the 
gene.   
 Selection of tag SNPs with the software Tagger, implemented in Haploview program 
version 4.0 (Barrett et al., 2005). Generally, only those SNPs with a minor allele 
frequency (MAF) equal or higher than 0.1 were considered. Moreover, the threshold 
value for the correlation coefficient (r2) was set at 0.8, which means that each tag SNP 
has at least an LD value of 0.8 with respect to its proxies. Finally, we used an 
aggressive multimarker test, where single tags as well as haplotypes of tags are tested 
against other single SNPs. 
4.1.2. Selection of additional polymorphisms. 
Other polymorphisms were also selected attending to the following criteria: 
 Location in the coding region. Non synonymous changes are of special interest given its 
possible effect on the protein’s structure and function. To test the effect of a non 
synonymous SNP, the Polyphen utility was used.  
 Polymorphisms which had been previously associated with schizophrenia or other 
mental or neurological disorders. Examples of this category are SNP rs6311, from 
HTR2A gene, rs4570625 from TPH2 and the VNTR from the NOS1 gene. 
  Polymorphisms with a demonstrated effect on gene function, like 5-HTTLPR and STin2, 
from the serotonin transporter gene. 
 Polymorphisms with a potential phenotypic effect, estimated through the software 
PupaSuite (Conde et al., 2006), an online tool which evaluates the effect of SNPs 
located in conserved regions that the cellular machinery uses for the correct 
processing of genes (intron/exon boundaries, exonic splicing enhancers) as well as 
predicted transcription factor binding sites. As an example, PupaSuite (Conde et al., 
2006) identified that SNP rs1042173 (from the serotonin transporter gene) was 
altering a predicted exonic splicing enhancer.  
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4.1.3. Polymorphisms selected for this study. 
The tables M5 to M12 show all the polymorphisms selected and analyzed in this doctoral 
thesis work. The chromosomic positions are in base pairs (bp) and refer to the NCBI build 
36. Moreover, a figure with the structure of each gene is also included and the position of 
each polymorphism is also indicated with an orange arrow (figures M2 to M9). 
 
 
Table M5. SLC6A4 polymorphisms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rs code (or 
other name) 
Type 
Position  
(dbSNP Build 127) 
MARKER 
ORDER 
DISTANCE 
FROM M1 
ALLELE 
CHANGE 
CEU MAF 
LOCATION/ 
FUNCTION 
rs3813034 SNP 25548930 M1 0 G/T 0.440 (G) 3' near gene 
rs1042173 SNP 25549137 M2 207 T/G 0.433 (G) 3'UTR 
rs140700 SNP 25567515 M3 18585 A/G 0.108 (A) INTRON 5 
rs2228673 SNP 25569357 M4 20427 
C(Asn)/ 
G(Lys) 
NO DATA EXON 4 
rs2020942 SNP 25571040 M5 22110 A/G 0.383 (A) INTRON 2 
STin2  VNTR 25572717-25572518 M6 23787 
9rep 
10rep 
12rep 
NO DATA 
INTRON 2/ 
transcriptional 
enhancer 
rs2020939 SNP 25574858 M7 25928 C/T 0.400 (T) INTRON 1A 
rs2020936 SNP 25574940 M8 26010 T/C 0.200 (C)  INTRON 1A 
rs2066713 SNP 25575791 M9 26861 C/T 0.383 (T) INTRON 1A 
rs4251417 SNP 25575984 M10 27054 A/G 0.117 (A) INTRON 1A 
5-HTTLPR 
(including 
rs25531) 
VNTR + SNP 25588600-25588250 M11 39670 
LA/LG/ 
SA/SG 
NO DATA 
Promoter/ 
regulator of 
expression 
rs12945042 SNP 25596054 M12 47124 G/A 0.300 (A) 5' Upstream 
Figure M2. SLC6A4 gene structure  
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Table M6. HTR2A polymorphisms. 
rs code (or other 
name) 
Type 
Position  
(dbSNP Build 127) 
MARKER 
ORDER 
DISTANCE 
FROM M1 
ALLELE 
CHANGE 
CEU MAF 
LOCATION/ 
FUNCTION 
rs6313 SNP 46367941 M1 0 
T(Ser)/ 
C(Ser) 
0.450 (T) EXON 1 
rs6311 SNP 46369479 M2 1538 G/A 0.450 (A) 
PROMOTER/ 
regulator of 
expression 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table M7. TPH2 polymorphisms.  
rs code (or other 
name) 
Type Position (dbSNP Build 127) 
ALLELE 
CHANGE 
CEU MAF LOCATION/FUNCTION 
rs4570625 SNP 70618190 T/G 0.207 (T) 
5' Upstream/possible 
regulator of TPH2 
expression 
 
 
 
 
 
 
 
 
 
 
Table M8. NOS1 polymorphisms. 
rs code (or other 
name) 
Type Position (dbSNP Build 127) ALLELE CHANGE CEU MAF LOCATION/FUNCTION 
NOS1 Ex1f-VNTR VNTR 116284130-116284026 
from 180 to 210 
CA repeats 
NO DATA 
Exon 1f/regulation of 
gene expression 
 
 
 
 
 
 
 
Figure M4. TPH2 gene structure  
Figure M5. NOS1 gene structure  
Figure M3. HTR2A gene structure  
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Table M9. STMN1 polymorphisms. 
rs code (or other 
name) 
Type 
Position 
(dbSNP Build 127) 
MARKER 
ORDER 
DISTANCE 
FROM M1 
ALLELE 
CHANGE 
CEU MAF 
LOCATION/ 
FUNCTION 
rs12037513 SNP 26097220 M1 0 C/T 0.325 (C ) 3' near gene 
rs182455 SNP 26107570 M2 10350 T/C 0.408 (T) 5' Upstream 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table M10. ASPM polymorphisms. 
rs code (or 
other name) 
Type 
Position 
 (dbSNP Build 127) 
MARKER 
ORDER 
DISTANCE 
FROM M1 
ALLELE 
CHANGE 
CEU MAF 
LOCATION/ 
FUNCTION 
rs6700180 SNP 195331119 M1 0 T/C 0.492 (C) INTRON 19 
rs3762271 SNP 195337065 M2 5946 C(Leu)/A(Ile) 0.43 (A) EXON 18 
rs12138336 SNP 195337144 M3 6025 G(Gln)/C(His) 0.078 (C) EXON 18 
rs41310927 SNP 195337320 M4 6201 A(Ser)/G(Gly) 0.470 (A) EXON 18 
rs964201 SNP 195337524 M5 6405 T(Tyr)/C(His) 0.020 (T) EXON 18 
rs10922163 SNP 195344014 M6 12895 G/A 0.490 (A) INTRON 17 
rs12116571 SNP 195355616 M7 24497 G/A 0.120 (A) INTRON 16 
rs4915337 SNP 195358160 M8 27041 A(Ser)/T(Ser) 0.068 (T) EXON 14 
rs12025066 SNP 195379068 M9 47949 A(Ile)/G(Val) 0.009 (G) EXON 3 
rs6677082 SNP 195379156 M10 48037 T(Ser)/C(Ser) 0.080 (C) EXON 3 
rs9726778 SNP 195383377 M11 52258 C/G NO DATA PROMOTER 
 
 
 
 
 
 
 
 
 
 
 
Figure M7. ASPM  gene structure  
Figure M6. STMN1 gene structure  
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Table M11. PDE4D polymorphisms. 
rs code (or other 
name) 
Type 
Position 
(dbSNP Build 
127) 
MARKER 
ORDER 
DISTANCE 
FROM M1 
ALLELE 
CHANGE 
CEU MAF 
LOCATION/ 
FUNCTION 
rs17291089 SNP 58301362 M1 0 C/A 0.103 (C) 3´near gene 
rs829259 SNP 58303733 M2 2371 A/T 0.45 (A) 3 ´UTR 
rs1058458 SNP 58306373 M3 5011 
C(Arg)/ 
T(Cys) 
0.0 (C) EXON 15 
rs17719378 SNP 58309205 M4 7843 G/A 0.325 (G) INTRON 11 
rs10055954 SNP 58309342 M5 7980 G/C 0.164 (C) INTRON 11 
rs10461656 SNP 58312107 M6 10745 G/A 0.356 (A) INTRON 11 
rs7713345 SNP 58314588 M7 13226 G/C 0.186 (G) INTRON 11 
rs12656462 SNP 58316381 M8 15019 T/A 0.110 (A) INTRON 11 
rs17853590 SNP 58320100 M9 18738 
T(Phe)/ 
C(Ser) 
NO DATA EXON 11 
rs10056492 SNP 58327740 M10 26378 T/C 0.119 (T) INTRON 6 
rs4700316 SNP 58330448 M11 29086 G/C 0.153 (G) INTRON 6 
rs7714708 SNP 58330771 M12 29409 T/C 0.333 (T) INTRON 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table M12. PLEKHB1 and RAB6A polymorphisms. 
GENE 
rs code (or 
other 
name) 
Type 
Position 
(dbSNP Build 
127) 
MARKER 
ORDER 
DISTANCE 
FROM M1 
ALLELE 
CHANGE 
CEU MAF 
LOCATION/ 
FUNCTION 
- rs663303 SNP 73029494 M1 0 C/T 0.208 (T) N/A 
PLEKHB1 rs4944850 SNP 73033744 M2 4250 A/C 0.183 (C) 5´NEAR GENE 
PLEKHB1 rs11538627 SNP 73040539 M3 11045 
A(Glu)/ 
T(Asp) 
NO DATA EXON 4 
PLEKHB1 rs591804 SNP 73040858 M4 11364 A/G 0.367 (G) INTRON 4 
PLEKHB1 rs6592527 SNP 73042016 M5 12522 C/G 0.288 (C) INTRON 5 
PLEKHB1 rs940828 SNP 73043807 M6 14313 G/T 0.267 (G) INTRON 5 
PLEKHB1 rs3741147 SNP 73044399 M7 14905 G/T 0.142 (G) INTRON 5 
 
Figure M8. Genomic structure of the PDE4D small isoform (PDE4D6). Image taken from UCSC genome browser. The 
isoform of interest for this study is indicated by a red arrow. All the selected SNPs are located in the PDE4D6 region. 
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Table M12 (continuation). PLEKHB1 and RAB6A polymorphisms. 
GENE 
rs code (or 
other 
name) 
Type 
Position 
(dbSNP Build 
127) 
MARKER 
ORDER 
DISTANCE 
FROM M1 
ALLELE 
CHANGE 
CEU MAF 
LOCATION/ 
FUNCTION 
- rs12274970 SNP 73055790 M8 26296 C/T 0.258 (C) N/A 
RAB6A rs3182788 SNP 73066620 M9 37126 
T (Thr)/ 
G (Pro) 
NO DATA EXON 8 
RAB6A rs10736793 SNP 73080224 M10 50730 A/C 0.186 (A) INTRON 6 
RAB6A rs3203705 SNP 73107544 M11 78050 
G (Leu)/ 
A (Phe) 
NO DATA 
INTRON 3 
(variant 2)/ 
EXON 4 
(variant 1) 
RAB6A rs11235876 SNP 73108249 M12 78755 A/G 0.450 (A) INTRON 3 
RAB6A rs11235880 SNP 73112944 M13 83450 A/C 0.200 (A) INTRON 2 
RAB6A rs7127066 SNP 73136522 M14 107028 C/G 0.250 (C) INTRON 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2. Genotyping Methods 
Different genotyping methodologies were used to carry out this project. A brief description of 
these techniques can be found here, although they will be explained in detail later. 
a. Agarose gel-based methods: Based on polymerase chain reaction (PCR) amplification and 
genotype discrimination in agarose gels. For some polymorphisms, the genotypes could be 
determined directly by electrophoresis of the PCR products. However, in almost all cases it 
was necessary to digest the products which an appropriate restriction enzyme, which only 
recognizes and cuts one of the alleles. This type of variation is called Restriction Fragment 
Length Polymorphism (RFLP).   
b. Genotyping by capillary electrophoresis: It is especially useful when the resolution of 
agarose electrophoresis is insufficient.   
c. Taqman® SNP genotyping assays: This methodology is based on the use of allele-specific 
fluorescent probes. 
Figure M9. Genomic structure of PLEKHB1-RAB6A region.  
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d. MassArray® genotyping:  It is based on the generation of multiplex PCR and extension 
products with different size and weight depending on the allele and the SNP. These 
products can be then analyzed by MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization 
- Time-Of-Flight) mass spectrometry (MS) to determine the size and subsequently the 
genotype of each individual for every SNP.   
Table M13 shows the methodology used to genotype each SNP. 
 
Table M13. Genotyping methods used for each polymorphism. 
GENE Polymorphism 
Marker 
number 
Genotyping method (sample) 
SLC6A4 
rs3813034 M1 RFLP (1) 
rs1042173 M2 RFLP (1) 
rs140700 M3 MassArray (1) 
rs2228673 M4 RFLP (1) 
rs2020942 M5 RFLP (1) 
STin2 M6 Product size determination in agarose (1) 
rs2020939 M7 MassArray (1) 
rs2020936 M8 RFLP (1) 
rs2066713 M9 RFLP (1) 
rs4251417 M10 MassArray (1) 
5-HTTLPR (+ rs25531) M11 RFLP (1) 
rs12945042 M12 MassArray (1) 
TPH2 rs4570625 - RFLP (1) 
HTR2A all M1-M2 RFLP (1) 
NOS1 VNTR1 - Product size determination in capillary EF (1) 
PLEKHB1-RAB6A all M1-M14 MassArray (1, 2) 
STMN1 
rs12037513 M1 MassArray (1) 
rs182455 M2 RFLP (1) 
PDE4D all M1-M12 MassArray  (1, 2) 
ASPM 
rs6700180 M1 MassArray  (1) 
rs3762271 M2 TaqMan assay (3); RFLP (1) 
rs12138336 M3 TaqMan assay (3); RFLP (1) 
rs41310927 M4 TaqMan assay (3); RFLP (1) 
rs964201 M5 RFLP (3) 
rs10922163 M6 TaqMan assay (3); MassArray™  (1) 
rs12116571 M7 TaqMan assay (3) 
rs4915337 M8 RFLP (1) 
rs12025066 M9 RFLP (1) 
rs6677082 M10 TaqMan assay (3); MassArray  (1) 
rs9726778 M11 RFLP (1) 
1: It indicates that this is the methodology used for the Spanish samples. 
2: It indicates that this methodology was used for the German samples. 
3: it indicates that this methodology was used to genotype the American samples. 
Abbreviation: EF, electrophoresis; RFLP, Restriction Fragment Length Polymorphism. 
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It is important to mention that several research centers with different resources took part in 
the genotyping process: 
 Department of Genetics, University of Valencia, Spain: RFLP genotyping of SLC6A4, HTR2A 
and ASPM genes.  
 Department of Psychiatry and Psychotherapy, University of Würzburg, Germany: during my 
short stay at this center, the genotyping by MassARRAY technology of PLEKHB1, RAB6A and 
PDE4D genes was performed, as well as the genotyping of the NOS1 VNTR and STMN1 and 
TPH2 RFLPs. 
 Clinical Brain Disorders Branch (CBDB), National Institute of Mental Health, USA: during my 
short internship at the CBDB, ASPM genetic variation was genotyped in the CBDB sample 
via Taqman assays. 
 Spanish National Genotyping Centre (CeGen): it provides many services, being the most 
important a high throughput genotyping platform. The SNPs from SLC6A4, ASPM and 
STMN1 genes genotyped through MassArray technology were genotyped at this center, as 
an external service.   
4.2.1. Gel-based genotyping methods. 
4.2.1.1. Design of primer sequences 
Several primer sequences were used to amplify the regions around the polymorphisms 
of interest. Some of them were from the literature, whereas others were designed 
manually according to the following criteria: 
 Oligonucleotide size between 18-22 base pairs (generally 20-21 bp). 
 Balanced content of adenine, guanine, thymine and cytosine. 
 Absence of sequences which could potentially generate secondary structures. 
 When possible, avoid primer sequences beginning and ending in T or A, since this will 
make the primer annealing and extension by the polymerase more difficult. 
 Avoid more than three consecutive G/C or A/T. 
 Absence of other polymorphisms located in the primer sequences. 
 Similar melting temperatures for each pair of reverse and direct primer. 
 The PCR product must have an adequate size according to the genotyping conditions. 
Oligonucleotides were synthesized by TIB MOLBIOL (Berlin, Germany), Metabion 
International (Martinsried, Germany) or Operon Biotechnologies (Cologne, Germany).  
Materials and Methods 89 
 
4.2.1.2. Amplification conditions 
The adjustment of PCR conditions was made with test DNA samples, which were at the 
same concentration than the working dilutions of the DNA samples from our study (25 
ng/µL). Conditions were adjusted depending on the primers’ melting temperatures.  
The standard reaction mix was the following: 
In some cases, to improve PCR efficiency, it was necessary the addition of 5µL of 
Dimethyl Sulfoxide (DMSO) 50% (Sigma, catalog no. D8418) or Glycerol 50% (Sigma, 
catalog no. G5516) to the reaction mix.  
Once the PCR conditions were adjusted, reactions took place in 96-well PCR plates. 
Reactions were made on Eppendorf Mastercycler and MJ Research PTC 200 
thermocyclers. The general amplification program was: 
 
     95oC 5 min 
                              94oC 30 s 
                                                      72oC 1 min    72oC 3 min 
 
                                             Annealing temp 45 s 
 
 
 
Tables M14 to M18 show the primer sequences and amplification conditions (annealing 
temperature, product sizes) as well as the restriction enzymes used in the RFLP analysis 
for all those polymorphisms genotyped through a gel-based methodology. In some 
cases, when applicable, a modification of the standard reaction mix or PCR program is 
indicated. 
 
 
   DNA (25 ng/µL) 1-2 µL 
   Nucleotides (dNTPs) 10 mM (Roche, catalog no. 1969064) 0.5 µL 
   Forward primer (10 pmol/µL) 0.5 µL 
   Reverse primer (10 pmol/µL) 0.5 µL 
   PCR Buffer 10X (with Mg2+ 25mM) 2.5 µL 
   Polymerase Netzyme™ 1U/µL (NEED, catalog no. NE-002) 0.5 µL 
   dH2O up to 25 µL 
30 cycles 
Initial DNA 
denaturation 
DNA 
denaturation 
Primer 
annealing 
Extension 
Final 
extension 
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Table M14. Genotyping conditions for SLC6A4 polymorphisms (gel-based technology).  
Marker Primer sequences 5' → 3' Temp PCR cond. 
PCR 
product 
(bp) 
Restriction 
enzyme 
Alleles sizes 
after 
digestion 
rs3813034 
TGCTGGAATCTACTAGAACCTTC 
TCCAATAATAACCTCCATACACA 
(Melke et al., 2003) 
58 °C Standard 244 Tru1I 
G: 244 
T: 192+52 
rs1042173 
CATGGTAGACTGTGACACAGC 
CTCACAAGCTTGCATGGACAC 
61 °C Standard 377 AcsI/Xap I 
T: 377 
G: 262+115 
rs2228673* 
GGCCTGGAGTCCTTGGAATGG 
GTTGCCAGTGTTCCAGGAGCT 
58 °C Standard 295 SacI 
C: 295 
G: 278 + 17 
rs2020942 
ATCTCCTGCTCCAGAGGACTC 
TGGTGTCTCCTGGATCTTGTG 
60 °C Standard 366 HpaII 
A: 366 
G: 209+157 
STin2 
GTCAGTATCACAGGCTGCGAG 
TGTTCCTAGTCTTACGCCAGTG 
(Wendland et al., 2006) 
65.5 °C 
-35 cycles 
-Final 
extension 7 
min 
2.9: 250 
2.10: 267 
2.12:300 
- - 
rs2020936 
ACCACTGACTACCAAGTTCAG 
CACCAGGCAATGTCAGTCAC 
59 °C Standard 503 Eco31I 
T: 503 
C: 242+261 
rs2066713 
CTCCTGAGAACACACGTTGCC 
CACAGGTGTGAGACACCATGC 
59.5 °C 
-DMSO 
-35 cycles 
365 BfmI 
C: 61+304 
T:61+147+157 
5-HTTLPR 
(including 
rs25531) 
TCCTCCGCTTTGGCGCCTCTTCC 
TGGGGGTTGCAGGGGAGATCCTG 
(Wendland et al., 2006) 
61 °C  
- glicerol 
-Annealing 1 
min  
-Initial denat. 
15 min 
-Final 
extension 10 
min 
-35 cycles 
L: 512 
S: 469 
HpaII (for 
rs25531) 
LA: 512 
LG: 402+110 
SA:469 
SG: 402+67 
* One of the primers used to amplify the region around rs2228673 includes a mutation site which introduces a 
recognition site for SacI in one of the alleles. This site is indicated in bold. 
Abbreviations: Temp, annealing temperature; denat, denaturation; bp, base pairs; 
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Table M15. Genotyping conditions for TPH2 polymorphism.  
Marker Primer sequences 5' → 3' Temp PCR cond. 
PCR 
product 
(bp) 
Restriction 
enzyme 
Alleles sizes 
after 
digestion 
rs4570625* 
TTTCCATGATTTCCAGTAGAGAG 
AAGCTTTTTCTGACTTGACAAAT 
55 °C -40 cycles 309 ApoI/XapI 
T: 309 
G: 285 + 24 
* One of the primers used to amplify the region around rs2228673 includes a mutation site which introduces a 
recognition site for ApoI and XapI in one of the alleles. This site is indicated in bold. 
Abbreviations: Temp, annealing temperature; bp, base pairs. 
 
 
Table M16. Genotyping conditions for HTR2A polymorphisms.  
Marker Primer sequences 5' → 3' Temp PCR cond. 
PCR 
product 
(bp) 
Restriction 
enzyme 
Alleles sizes 
after digestion 
rs6313 
TCTGCTACAAGTTCTGGCTT 
CTGCAGCTTTTTCTCTAGGG 
54 °C 
-Annealing 1 
min 
-35 cycles 
342 MspI/HpaII 
T: 342 
C: 125 + 217 
rs6311 
AAGCTGCAAGGTAGCAACAGC 
AACCAACTTATTTCCTACCAC 
56 °C Standard 469 MspI/HpaII 
A: 471 
G: 243 + 226 
Abbreviations: Temp, annealing temperature; bp, base pairs. 
 
 
Table M17. Genotyping conditions for STMN1 polymorphism.  
Marker Primer sequences 5' → 3' Temp PCR cond. 
PCR product 
(bp) 
Restriction 
enzyme 
Alleles sizes 
after 
digestion 
rs182455 
CCCTCTCAGTCCTCAAGCAG 
CCCCCACATTTTCTTTCTCC 
60 °C -32 cycles 200 SacI 
T: 200 
C: 168 + 32 
Abbreviations: Temp, annealing temperature; bp, base pairs. 
 
 
Table M18. Genotyping conditions for ASPM polymorphisms.  
Marker Primer sequences 5' → 3' Temp PCR cond. 
PCR 
product 
(bp) 
Restriction 
enzyme 
Alleles sizes 
after digestion 
rs3762271 
TCAGACAATGGCATTCTGCTG 
TAACTGCTTGGGTACGCA 
58 °C Standard 426 DdeI 
A: 426 
C: 357+69 
rs12138336 
TCAGACAATGGCATTCTGCTG 
TAACTGCTTGGGTACGCA 
58 °C Standard 426 HinfI 
C: 426 
G: 278+148 
rs41310927 
GAAGAGTATGCATTCCTCTGC 
ACCTGCCTGAACACAAGTCTC 
59 °C Standard 622 BshNI 
A: 622 
G: 473 149 
rs964201 
GAAGAGTATGCATTCCTCTGC 
ACCTGCCTGAACACAAGTCTC 
59 °C Standard 622 
Csp6I/ 
Rsa I 
C: 143+479 
T:143+126+353 
rs4915337 
TTACAGTGTCTTTCTCAGACG 
TCTAGGAGCTCTTTGTATAGC 
55 °C Standard 318 Alw26I 
A: 318 
T: 182+136 
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Table M18 (continuation). Genotyping conditions for ASPM polymorphisms.  
Marker Primer sequences 5' → 3' Temp PCR cond. 
PCR 
product 
(bp) 
Restriction 
enzyme 
Alleles sizes 
after digestion 
rs12025066 
TACCTACTCATCTCTTCATGC 
CATGTTTGCTGAGATGTACAC 
55 °C Standard 498 
Csp6I/ 
Rsa I 
A: 498 
G:48+156+294 
rs9726778 
ATGACCTGTATTCCTCATCTG 
GGACTCAGTACATTTACATGC 
55 °C Standard 624 MspA1I 
C:624 
G:136+488 
Abbreviations: Temp, annealing temperature; bp, base pairs. 
 
 
4.2.1.3. Verification of the PCR 
Electrophoreses on agarose gels were performed to verify the existence and size of each 
PCR product. The concentration of agarose gels varied between 1% and 4% depending 
on the product’s size. For the VNTR STin2, from the serotonin transporter gene, 
genotypes could be determined directly by electrophoresis of the PCR products in a 4% 
agarose gel.  
The protocol of electrophoresis in agarose gels is the following: 
 Solutions and additives:  
Agarose (Roche, catalog no. 1685678) 
TBE buffer solution 1x: 
Tris    89 mM   
Boric Acid   89mM   
EDTA   2mM   
Ethidium bromide solution 10 mg/mL (Sigma, catalog no. E-8751) 
Gel loading solution 6x: 
Bromophenol blue  0.05% 
Xylene cyanol blue  0.05% 
EDTA 0.5M pH 8  100 mM 
Glycerol   50% 
DNA molecular weight marker XIV (Roche, catalog no. 1721933) 
DNA molecular weight marker XIII (Roche, catalog no. 1721925) 
Lambda DNA/HindIII Marker 2 (Fermentas, catalog no. SM0101) 
 Procedure: The necessary amount of agarose is dissolved in TBE 1x by boiling the 
solution twice in a microwave oven. Afterwards, the solution is cooled down to 
55oC and then the ethidium bromide is added up to a final concentration of 
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0.5µg/mL. After homogenizing the solution, it is poured into a casting tray, which 
also contains a comb necessary to form the wells in the gel. Generally after one 
hour the gel has solidified and can be placed in a horizontal tank which contains 
TBE 1x (with ethidium bromide 0.5µg/mL) as the electrophoresis buffer.   
The gel loading solution is added to the DNA samples, which are then loaded on the 
gel wells and run together with an appropriate molecular weight marker. 
Electrophoreses are performed at 90-100 V and a variable running time. Finally, 
DNA fragments can be visualized in a UV transilluminator at 312 nm.  
4.2.1.4. RFLP genotyping 
The PCR-RFLP genotyping technique is based on the idea that SNPs can modify the 
target sequence for restriction endonucleases. Thus, this fact can be used to 
discriminate between the different alleles of a SNP through the use of an appropriate 
restriction enzyme. Figure M10 shows an overview of the entire process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure M10. The RFLP-based genotyping process. a. Description of the basis of RFLP-based genotyping 
technique. If one of the alleles changes the recognition sequence for a restriction endonuclease, this 
restriction enzyme will not be able to cleave the DNA fragment. b. The genotyping process step by step.  
Abbreviations: RE, restriction endonuclease. M, molecular weight marker; 1, allele 1; 2, allele 2. 
1. Amplification 
of the target 
region by PCR 
 
2. Incubation with 
the appropriate 
restriction enzyme 
 
3. Separation of 
fragments by agarose 
gel electrophoresis 
 
DNA is not cut by the 
restriction enzyme 
 Cleavage of DNA by the 
restriction enzyme 
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Moreover, if the polymorphic change is not altering the recognition sequence for any 
commercial restriction endonuclease, it is possible to create a mutagenic primer which 
creates a restriction site for one of the alleles. This approach was used for SNPs 
rs2228673 and rs4570625, as it is indicated in tables M15 and M16.  
The online utility Webcutter 2.0 (http://rna.lundberg.gu.se/cutter2/) was used to check 
all the restriction enzymes affected by the polymorphic site. This program identifies all 
the restriction enzymes in a given sequence and it also indicates the length of the 
restriction fragments, thus it is especially useful to decide the most suitable enzyme in 
each case. Restriction endonucleases used in this study can be found in table M19. 
 
Table M19. List of the restriction endonucleases used for the RFLP genotyping. 
Name 
Manufacturer/Cat. 
number 
Recognition sequence Buffer 
Digestion 
temperature 
AcsI NEB/no longer available 
5'...R↓AATTY…3' 
3'...YTTAA↑R…5' 
--- 50 °C 
Alw26I Fermentas/ER0031 
5'...GTCTC(N)1↓…3' 
3'...CAGAG(N)5↑…5' 
Tango™ 37 °C 
ApoI NEB/R0566L 
5'…R↓AATTY...3' 
3'…YTTAA↑R...5' 
NEBuffer 3 
(+ BSA*) 
50 °C 
BfmI Fermentas/ER1162 
5'...C↓TRYAG…3' 
3'...GAYRT↑C…5' 
Tango™ 37 °C 
BshNI Fermentas/ER1001 
5'...G↓GYRCC…3' 
3'...CCRYG↑G…5' 
O 37 °C 
Csp6I Fermentas/ER0211 
5'...G↓T A C...3' 
3'...C A T↑G...5' 
B 37 °C 
DdeI NEB/R0175L 
5’…C↓TNAG…3’ 
3’…GANT↑C…5’ 
NEBuffer 3 37 °C 
Eco31I Fermentas/ER0291 
5'…GGTCTC(N)1↓…3' 
3'…CCAGAG(N)5↑…5' 
G 37 °C 
HinfI Fermentas/ER0801 
5'…G↓ANTC…3' 
3'…CTNA↑G…5' 
R 37 °C 
HpaII Fermentas/ER0511 
5'…C↓CGG…3' 
3'…GGC↑C…5' 
Tango™ 37 °C 
MspA1I NEB/R0577L 
5'…CMG↓CKG…3' 
3'…GKC↑GMC…5' 
NEBuffer 4 
(+ BSA*) 
37 °C 
MspI Fermentas/ER0541 
5'…C↓CGG…3' 
3'…GGC↑C…5' 
Tango™ 37 °C 
RsaI Fermentas/ER1121 
5'...GT↓AC...3' 
3'...CA↑TG...5' 
Tango™ 37 °C 
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Table M19 (continuation). List of the restriction endonucleases used for the RFLP genotyping. 
Name 
Manufacturer/Cat. 
number 
Recognition sequence Buffer 
Digestion 
temperature 
SacI NEB/R0156S 
5'...GAGCT↓C...3' 
3'...C↑TCGAG...5' 
NEBuffer 1 
(+ BSA*) 
37 °C 
Tru1I Fermentas/ER0982 
5'...T↓TAA...3' 
3'...AAT↑T...5' 
R 65 °C 
XapI Fermentas/ER1382 
5'…R↓AATTY...3' 
3'…YTTAA↑R...5' 
Tango™ 37 °C 
*Some NEB restriction enzymes required the separate addition of Bovine Serum Albumin (BSA) to prevent adhesion 
of the enzyme to the reaction tubes and pipette tips and to stabilize some proteins during incubation. Its use will 
guarantee the complete digestion of products.    
 
The general digestion mix was: 
PCR assay       10-16 µL 
Digestion buffer 10x   2 µL 
Restriction enzyme    5 U 
dH2O  up to 20 µL 
 
Digestion assays were incubated at the manufacturer’s recommended temperature in a 
water bath overnight. Exceptionally, for digestions at 65oC performed at 96-well plates, 
assays were incubated on a thermal cycler at a constant temperature of 65oC for 8 
hours, since the adhesive foils used to close the plates are not very resistant to wet heat. 
After incubation, samples were loaded into a gel of variable agarose percentage 
depending on the size of DNA fragments. Electrophoreses were run at a constant 
voltage (100-150 V, depending on the tank’s length) and time enough to ensure the 
separation of digested DNA fragments. Digestion conditions for each SNP can be 
consulted at tables M14 to M19.  
4.2.1.5. Purification of PCR products 
During the adjustment of genotyping conditions, each PCR product was sequenced to a) 
verify that the target region was really amplified and b) to check that the genotype 
resulting from RFLP genotyping was correct.  
For this purpose, first it was necessary to purify PCR products to eliminate all the 
nucleotides, salts and remaining primers which could interfere with the sequencing 
reaction.      
Two different methods were used: 
 JETQUICK PCR Product Purification Spin Kit (Genomed, Catalog no. 410250): With 
this kit, the PCR products are extracted using micro spin cups. The binding matrix is a 
surface modified silica membrane which binds DNA but not nucleotides or 
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oligonucleotides. The DNA is then eluted from the membrane in sterile distilled 
water. 
Solutions (from the commercial kit):  
Solution H1 (binding solution): it contains guanidine hydrochloride and 
isopropanol. 
Solution H2 (washing solution): it contains ethanol, NaCl, EDTA and Tris/HCl.  
Procedure:  
1. Add 400 µL of solution H1 to a 20 µL PCR assay and mix thoroughly. 
2. Place a JETQUICK spin column inside a 2 mL receiver tube (also included with the 
kit). Load the mixture from step 1 into the prepared spin column.  
3. Centrifuge at 14000 rpm for 1 min and discard the flowthrough. 
4. Reinsert the spin column into the empty receiver tube and add 500 µL of solution 
H2.  
5. Centrifuge at 14000 rpm for 1 minute, discard the flowthrough and place again 
the column into the same receiver tube. 
6. Centrifuge again at 14000 rpm for 1 minute. 
7. Place the spin column into a fresh 1.5 mL tube and add 50 µL of sterile water 
directly onto the center of the column matrix. 
8. Centrifuge at 14000 rpm for 2 minutes.  
 DNA precipitation with ammonium acetate: With this method, the PCR products are 
precipitated with ammonium acetate 4M. This method is recommended when 
primer concentrations in the PCR reaction are below 10 pmol.  
Solutions:  
Ammonium acetate 4M 
100% ethanol 
70% ethanol 
Sterile water 
Procedure:  
1. Mix 15 µL-20 µL of PCR assay with one volume (15 µL) of ammonium acetate and 
6 volumes (90 µL) of absolute ethanol. Mix thoroughly. 
2. Centrifuge for 15 minutes at 13000 rpm at rt. Discard the supernatant. 
3. Add 400 µL of 70% ethanol solution and mix well with a vortex mixer. 
4. Centrifuge for 5 minutes at 13000 rpm and room temperature. Discard the 
supernatant. 
5. Dry the DNA pellet at 37oC for approximately 5 minutes. 
6. Resupend the pellet in 20 µL of sterile water. 
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4.2.1.6. Purification of DNA from agarose gel bands 
Sometimes the purification from PCR products is not useful because of the presence of 
unspecific products (seen as additional undesired bands in an agarose gel). Therefore, in 
these cases, the best option is to purify the DNA directly from the band of interest and 
use this extracted DNA for the sequencing reaction.  The GFX™ PCR DNA and Gel Band 
Purification Kit (GE Healthcare, Catalog no. 27-9602-01) was used for this purpose. It is 
based on the use of a chaotropic agent which denatures protein, dissolves agarose and 
facilitates the binding of double-stranded DNA to a glass fiber matrix. Then, the DNA can 
be eluted with sterile water. 
Solutions:  
 Capture buffer: it contains acetate and chaotrope. 
 Wash buffer: tris EDTA pH 8.0, 80% ethanol. 
 Sterile water. 
Procedure:  
1. Weigh an empty 1.5 mL microcentrifuge tube to the nearest 10 mg and record 
the weight.  
2. Using a scalpel, cut the agarose fragment containing the DNA band of interest. It 
is very important to cut as close to the band as possible.  
3. Transfer the agarose fragment to the tube weighted in step 1. Weigh again the 
tube to determine the weight of the agarose slice. 
4. For each 10 mg of agarose, add 10 µL of capture buffer to the agarose fragment. 
Close the tube and mix by vortexing thoroughly.  
5. Incubate at 60oC until the agarose is fully dissolved. During the incubation, place 
a GFX column in a collection tube.  
6. Once the agarose is fully dissolved, centrifuge briefly to collect the sample at the 
bottom of the tube. 
7. Transfer the sample to the GFX column and incubate at room temperature for 1 
minute. 
8. Centrifuge at 13000 rpm for 30 seconds. 
9. Discard the flow-through in the collection tube and place again the GFX column 
back inside the collection tube. 
10. Add 500 µL of wash buffer and centrifuge at 13000 rpm for 30 seconds twice. 
11. Transfer the GFX column to a new 1.5 mL microcentrifuge tube and add from 10 
to 50 µL of elution buffer directly to the center of the column matrix. 
12. Incubate at room temperature for 1 minute and centrifuge at 13000 rpm for one 
minute to recover the DNA.      
4.2.1.7. DNA Sequencing 
The BigDye® terminator v3.1 Cycle sequencing kit (Applied Biosystems, catalog no. 
4336911) was used for the sequencing reactions of the purified DNA fragments. This kit 
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is based on the dideoxynucleotide termination method (Sanger et al., 1977). It contains 
a ready-to-use reaction mix which includes all the components we need for the reaction 
excepting the primer: dNTPs, polymerase, reaction buffer and the four terminator 
dideoxynucleotides labeled with four different fluorochromes. At the end of the 
sequencing reaction, we will have a mix of fragments of different size, each of them 
ending in a fluorescent nucleotide. 
The following reaction mix was used: 
 
Reactions were made on Eppendorf Mastercycler and MJ Research PTC 200 
thermocyclers. The general amplification program was: 
 
                96oC 5 min        96oC 30 s                      
                                                                                                  60oC 4 min     
                                                 50oC 15 s 
 
                   4oC ∞ 
 
 
 
Reaction products were purified and separated by capillary electrophoresis in a 48-
capillary sequencer (Applied Biosystems 3730 DNA Analyzer) at the Sequencing Service 
from the University of Valencia. The sequences obtained from the Sequencing Service 
were analyzed with the Sequencher software v.4.0.5 (Gene Codes Corporation). With 
this program, it is possible to check the quality of chromatograms and also to edit those 
base calls which have been wrongly assigned by the sequencer. Moreover, it is also 
possible to verify the identity of the sequences by aligning them with the reference 
sequence in the NCBI database. Finally, we also checked that the genotype for each 
polymorphism in study agreed with the genotype assigned by RFLP methodology (see 
figure M11).  
 
 
   DNA template (purified PCR product) 50 ng (between 1 and 7 µL) 
   Forward or reverse primer (10 pmol/µL) 1 µL 
   BigDye®  2 µL 
   dH2O up to 10 µL 
Initial DNA 
denaturation 
DNA 
denaturation 
Primer 
annealing Extension Maintenance 
36 cycles 
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4.2.2. Genotyping by product size determination in capillary electrophoresis. 
Genotypes for Ex1f-VNTR polymorphism from the NOS1 gene were determined by PCR 
amplification and product size determination by capillary electrophoresis in a DNA sequencer. 
For this purpose, the forward primer was labeled with cy-5 fluorescent dye (TIB MolBiol, 
Berlin), enabling detection of the resulting PCR product. The reaction mix included: 
DNA (25 ng/µL) 50 ng 
dNTPs 200 µM 
Forward primer (TGCGTGGCGACTACATTCAGC) 50 nM 
Reverse primer (GGAGACGTCGCAACCCTCAT) 50 nM 
PCR Buffer 10X (with Mg2+ 15mM) 5 µL 
Taq polymerase 0.4 U 
dH2O up to 50 µL 
Figure M11. Verification, by means of DNA sequencing, of the RFLP genotyping conditions 
for a particular SNP (in this example, SNP rs1042173 from the serotonin transporter gene). 
a, Alignment of the sequencing chromatograms corresponding to individuals A, B, C and D; b, 
Genotyping of individuals A, B, C and D by means of RFLPs; allele T is not cut by the restriction 
enzyme AcsI, while allele G is cut into two fragments.  
As expected, the genotype assigned for subjects A, B, C and D was the same with the two 
approaches. Particularly, subject A was homozygote T/T, while the remaining individuals were 
heterozygotes T/G. Heterozygotes can be distinguished in the chromatogram by the presence 
of two superimposed peaks (red, T; black, G)  in the position corresponding to the SNP of 
interest (nucleotide marked in black).   
Abbreviations: M, molecular weight marker.    
b a 
A 
B 
C 
D 
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The amplification program was the following: 
 
      96oC 5 min       96oC 20 s 
                                                                                    72oC 30 s        72oC 3 min 
 
                                                58oC 20 s 
 
 
 
 
Electrophoretic separation of the PCR products was performed using a CEQ8000 DNA-
sequencer from Beckman-Coulter. The use of an external standard allows size determination 
of the PCR products. Moreover, internal standards containing previously sequenced DNA 
fragments of known alleles were also used. NOS1 Ex1f-VNTR genotyping was accomplished by 
comparing the allele sizes of each sample with the sizes of these known alleles from the STR 
markers D2S2186, D3S1314, D4S2950 and D22S420.  
 
4.2.3. Taqman SNP genotyping assays. 
4.2.3.1. Basis of the methodology  
ASPM polymorphisms were genotyped in the American samples through the Taqman® 
SNP genotyping technology. Taqman® SNP genotyping assays from Applied Biosystems 
(ABI) provide an efficient and optimized method to genotype SNPs. Each assay allows 
the genotyping of one particular SNP and contains the following components in a single 
tube: 
 Two primers used to amplify the sequence of interest.  
 Two Taqman® probes, each one specific for one allele. Each probe contains: 
- A reporter dye linked to the 5’ end (VIC for allele 1 and FAM™ for allele 2). 
- A minor groove binder (MGB): this modification allows designing shorter 
probes, since it increases the melting temperature (Tm) without increasing the 
probe length. As a result, the difference in Tm between matched and 
mismatched probes is higher, which produces a better allelic discrimination. 
- A nonfluorescent quencher (NFQ) at the 3’ end of the probe. If the probe is 
intact, the presence of the NFQ suppresses the reporter fluorescence by 
Förster-type energy transfer. 
During the PCR reaction (see figure M12), each probe binds specifically to its 
complementary sequence in the genomic DNA, between the forward and reverse 
primers. When the DNA polymerase arrives to the position where the probe is 
hybridized to the target, the polymerase cleaves the probe with its exonuclease activity, 
which results in the separation of the quencher and the dye and a production of 
33 cycles 
Initial DNA 
denaturation 
DNA 
denaturation 
Primer 
annealing Extension 
Final 
extension 
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Figure M12. Scheme of the TaqMan® SNP genotyping methodology. In situations a and c, the VIC and 
FAM™ probes match and hybridize perfectly with allele 1 and allele 2, respectively, while in situations b 
and d there is a mismatch between the probe and the genomic sequence. Only when there is a perfect 
match, the polymerase cleaves the probes, which are hybridized to the target. The cleavage separates the 
fluorescent reporter dye from the quencher dye, resulting in a fluorescence emission from the reporter. 
This fluorescence emission is specific for each allele. (Adapted from Livak et al., 1995a) 
fluorescence by the reporter. It is remarkable that only when the probe matches the 
target genomic sequence perfectly, the polymerase will cleave it and the fluorescence 
will increase. Furthermore, the DNA polymerase is more likely to displace a mismatched 
probe without cleaving it, which does not produce a fluorescent signal, giving a high 
specificity to the method.  
 
 
In summary, the presence of a high increase in VIC fluorescence indicates that the 
individual is homozygote for allele 1, while a substantial increase in FAM fluorescence 
will happen if the individual is homozygote for allele 2. Finally, an increase in both 
fluorescence signals indicates that the individual is heterozygote. 
4.2.3.2. PCR reaction 
The following table (M20) shows some features of the Taqman SNP genotyping assays 
used in this study. 
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Table M20. Conditions of the TaqMan® genotyping assays.  
GENE SNP code Assay code number 
Allele detected with 
VIC® dye 
Allele detected with 
FAM™ dye 
ASPM rs6677082 C___2759679_10 T C 
ASPM rs12116571 C___2759692_10 G A 
ASPM rs10922163 C___2759697_10 G A 
ASPM rs41310927 C__27830876_10 G A 
ASPM rs12138336 C__31565480_10 G C 
ASPM rs3762271 C__27478941_10 C A 
 
The following reaction mix was used: 
DNA (predelivered and dried in the bottom of the well) 10 ng 
20x SNP genotyping assay mix 0.06 µL (final concentration: 0.25x) 
2x Taqman Universal PCR Mastermix 
(Applied Biosystems, catalog no. 4304437) 
2.5 µL 
TE buffer 2.44 µL 
Reactions were prepared in ABI Prism™ 384-Well Clear Optical Reaction Plates (Applied 
Biosystems, catalog no. 4309849) and run on ABI GeneAmp® PCR System 9700 thermal 
cyclers. The reaction program (standard for all assays) was: 
 
              95oC 10 min        
                           92oC 15 s 
                                                           60oC 1 min 
 
                                                                                                   4oC ∞ 
 
 
 
4.2.3.3. Plate read 
After PCR amplification, plates were read on an ABI PRISM® 7900HT Sequence 
Detection System (Applied Biosystems) to measure the end-point fluorescence levels for 
each sample in the plate. The software SDS v. 2.1 allowed us to calculate the 
measurements and to make a plot based on the fluorescence levels from each well. A 
template file with all the information regarding the assay (type of plate, dyes…) was also 
created to read the fluorescence for the FAM and VIC dyes from all the plates that were 
genotyped.  
40 cycles 
AmpliTaq 
Gold enzyme 
activation 
DNA 
denaturation 
Primer 
annealing and 
extension 
Maintenance 
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Once the plate was read and the plot was created, genotypes were assigned manually. 
Figure M13 shows how a plot looks after genotype calling. Finally, after genotype 
assignment, data was exported as a text file. 
 
 
4.2.4. SNP Genotyping through MassARRAY® System. 
4.2.4.1. Basis of the methodology  
iPLEX™ genotyping assays, together with the MassARRAY® platform (Sequenom®), were 
used to genotype all the SNPs from PDE4D, PLEKHB1 and RAB6A genes, as well as some 
SNPs from SLC6A4, ASPM and STMN1. The iPLEX assays allow the genotyping of up to 29 
Legend 
• Homozygote for allele 1  
• Heterozygote 
• Homozygote for allele 2 
 Negative control  
x Undetermined sample 
Figure M13. Plot from a plate read for one SNP genotyping assay. x-axis corresponds to VIC dye 
fluorescence, while FAM dye fluorescence levels can be found at y-axis. In this case, although there 
is some dispersion on each cluster, the separation between clusters is good and there are only a few 
samples of undetermined genotype. Moreover, negative controls only present some residual 
fluorescence, as expected.  
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SNPs in the same reaction (Oeth et al., 2005). This method has the following basic steps 
(figure M14): 
 Amplification of the target regions by multiplex PCR. In order to improve the reaction 
performance, PCR primers have a non-templated tag on the 5’ ends, to increase the 
masses of unused primers so they fall outside the mass range of analytical peaks.  
 iPLEX reaction: it is a post-PCR primer extension reaction, with the particularity that 
all reactions are terminated after a single base extension (SBE), because only 
terminator dideoxynucleotides (ddNTPs), but not dNTPs, are added to the reaction 
mix. This extension reaction generates fragments with a specific mass for each allele 
of each SNP. Moreover, the use of mass-modified terminators avoids the overlap 
between different SBE products. 
 SBE products are loaded onto a chip and analyzed through MALDI-TOF mass 
spectroscopy. Finally, masses are converted to genotypes by specific software.    
The next sections will explain in detail all the steps of this genotyping technique. 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
Figure M14. Overview of the MassARRAY™ genotyping technology. The process can be divided into 
three main steps. First, a PCR reaction of the regions which contain the SNPs of interest (a and b). 
Second, an extension process (c and d), which generates allele-specific extension products, each of 
them having a unique molecular mass.  Finally, the masses of the extension products are analyzed by 
MALDI-TOF Mass Spectroscopy and genotypes are automatically assigned.   
Abbreviations: MS, Mass Spectroscopy. 
PCR amplification 
(up to 29 different SNPs) 
Generation of multiple different 
PCR products 
 
Analysis with 
MALDI-TOF MS 
 
Generation of multiple allele- 
specific extension products 
 
Extension reaction (addition of a single 
terminator nucleotide in the polymorphic site) 
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4.2.4.2. Assay design 
The primer design for iPLEX assays is especially sensitive, since these assays require the 
use of multiplex primers with marked mass differences. Therefore, the use of specific 
software is essential. 
A sequence of 200-400 bp around the SNPs of interest was pre-edited through ProxSNP 
and PreXTEND online utilities from the webpage www.realsnp.com (Sequenom). 
ProxSNP is used to search for additional registered SNPs that are within a given 
proximity of the SNP of interest and prevents primers for being designed over those 
locations. By contrast, PreXTEND is used to pre-design PCR primers with respect to the 
whole genome and also re-formats the sequences so that subsequent assay design will 
employ these primers. This program avoids the amplification of undesired regions from 
the genome with each pair of primers.  
Afterwards, Mass-ARRAY Assay design 3.0 software from Sequenom was used to design 
the extend primers for each assay. These primers will ensure that the generated SBE 
products have different masses. 
Finally, the PleXTEND application, also from www.realsnp.com, was used to validate 
multiplexed assay designs with respect to the genome. The purpose of this application is 
also to check for undesired amplification products resulting from random couplings of all 
primers present in a multiplex of assays. 
All oligonucletides were synthesized by Metabion International (Martinsried, Germany). 
Concentrations from extend primers were adjusted to avoid high levels of signal-to-
noise ratio. Thus, the concentration of those oligonucleotides which produced the 
largest SBE products was doubled relative to the remaining assays in the multiplex 
reaction. Table M21 shows the conditions for each iPLEX assay, with the exception of 
the genotyping of ASPM, STMN1 and SLC6A4 SNPs, which were genotyped by CeGen as 
a private service and therefore this information was not provided.  
Table M21. Assay conditions for PDE4D, PLEKHB1 and RAB6A SNPs genotyped through MassArray® platform. 
GENE Marker 
Plex 
no. 
PCR primer sequences 5' → 3' Extension primers 5' → 3' 
Mass of 
extension 
products 
PDE4D rs17291089 1 
ACGTTGGATGCTTAATTGAATATTCTGGG 
ACGTTGGATGGAGTAGGTAACCAAAAATA 
taTGGGATATTGAAAATTATTCAGAT 
C: 8294.5   
A: 8318.5 
PDE4D rs829259 1 
ACGTTGGATGCCAAAACATTCTCATTCCTC 
ACGTTGGATGAGATTCTAGGCACTCTGTGG 
ATTCCTCTCCTCCCTAC  
T: 5263.5   
A: 5319.4 
PDE4D rs1058458 2 
ACGTTGGATGACACTAGCTGCAGTGACTCC 
ACGTTGGATGTTCAACCTGTTCATCAAGGG 
ccGCTGCAGTGACTCCAAGACTCTT  
C: 7825.1   
T: 7905.0 
PDE4D rs17719378 1 
ACGTTGGATGGCTCATGGCAACTCTAGAGG 
ACGTTGGATGCTCTGTAGGTCTCAGCTTTC 
AACTCTAGAGGAGAGGTT 
A: 5858.9   
G: 5874.9 
PDE4D rs10055954 1 
ACGTTGGATGGTACCCTCTTTGAGTACAAAC 
ACGTTGGATGCTGTGAATTACCTACCCTGC 
ctgACAAACAATCCTGTAACACA 
C: 7216.8  
G: 7256.8 
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Table M21 (continuation). Assay conditions for PDE4D, PLEKHB1 and RAB6A SNPs genotyped through 
MassArray®. 
GENE Marker 
Plex 
no. 
PCR primer sequences 5' → 3' Extension primers 5' → 3' 
Mass of 
extension 
products 
PDE4D rs10461656 1 
ACGTTGGATGCAAATGAGCACAATTGATCTA 
ACGTTGGATGTTTTTATTGAGAGGCCATGC 
ATGATGGCTTTGAGTTTGTA 
A: 6464.2   
G: 6480.2 
PDE4D rs7713345 1 
ACGTTGGATGTTCTTTCTCACCAGTTTTCC 
ACGTTGGATGGGGCCGTAGCCAATGATTTG 
ggcATCATATTCCTTCTAAGTCCCT 
G: 7790.1   
C: 7830.1 
PDE4D rs12656462 1 
ACGTTGGATGAAAAAGTATCAAAAGTACAG 
ACGTTGGATGAGGCATCTTTGCTATTAAC 
GTATCAAAAGTACAGAATATAGCA 
A: 7673.1   
T: 7729.0 
PDE4D rs17853590 2 
ACGTTGGATGTGCAGCAATTTTTGCCAGTG 
ACGTTGGATGACTTACTTGTATTGATCAG 
TGTAGATCATCCTGGTGTGT 
C: 6401.2   
T: 6481.1 
PDE4D rs10056492 2 
ACGTTGGATGCTACATTAGGTATTTTGCC 
ACGTTGGATGCATCACACACCAGGGCCTAT 
gatGTATTTTGCCTAATGCTGT 
C: 6993.6   
T: 7073.5 
PDE4D rs4700316 1 
ACGTTGGATGTTGTGTCCATGCTTGGCAGG 
ACGTTGGATGCCTCCTTCTATTGTGGAGAC 
TGCTTGGCAGGCTTTTT 
C: 5445.6   
G: 5485.6 
PDE4D rs7714708 1 
ACGTTGGATGCATACTAACTGGAATCCAT 
ACGTTGGATGGGTAATTAAATACATTCATTGC 
AATCAGTATAAGTAATTTGGCCC 
T: 7317.8   
C: 7333.8 
- rs663303 1 
ACGTTGGATGCTCTTGCTCCAATAATGACC 
ACGTTGGATGGTGACTGAACTTTGTCAAGA 
cctACAGATCATTTCTCAAGAGACG 
T: 7881.2   
C: 7897.2 
PLEKHB1 rs4944850 2 
ACGTTGGATGGGAAATAGTGGACTGGCTC 
ACGTTGGATGTCTCATTATATTATACTCTC 
cCTGGCTCATCAAATTCAAAT 
C: 6636.4   
A: 6676.3 
PLEKHB1 rs11538627 2 
ACGTTGGATGATGGCCTGCTGACTGTGAAC 
ACGTTGGATGACAGGGCATCATCCTTGGTC 
ACTGTGAACCTACGGGA 
A: 5490.6   
T: 5546.5 
PLEKHB1 rs591804 2 
ACGTTGGATGTGCCTCAGGTATCTGGTTCC 
ACGTTGGATGTGCTGCTTTGCATCACCCTC 
CTGGTTCCTGGTCTTTAGC 
A: 6048.0   
G: 6064.0 
PLEKHB1 rs6592527 2 
ACGTTGGATGGTGTGGTGCAGGTATCATTC 
ACGTTGGATGCAGAGAGAGAACAATAACCC 
GTATCATTCCAGCTGCT 
C: 5383.5   
G: 5423.6 
PLEKHB1 rs940828 1 
ACGTTGGATGAGGCCGCTTCATAGAGTCAC 
ACGTTGGATGAGTTCCACCAAAGAGAGGCG 
 gggTCATAGAGTCACAGAGTG 
G: 6782.4   
T: 6806.5 
PLEKHB1 rs3741147 1 
ACGTTGGATGAGAGACTCAAGAGCTCTTTC 
ACGTTGGATGAGAAAGAGGATGCTCCCTGC 
aAGCTCTTTCCAGACCCT 
G: 5641.7   
T: 5665.7 
- rs12274970 1 
ACGTTGGATGTTTTCCTTTGTTACTCCACC 
ACGTTGGATGTCTCCATGTCATCACCAGCC 
TTTGTTACTCCACCATTTCT 
T: 6255.1   
C: 6271.1 
RAB6A rs3182788 1 
ACGTTGGATGCATAAAACTGGAAAAGCCTC 
ACGTTGGATGGAAGATGACATGGGAGATTA 
ccttAAAAGCCTCAGGAGCAA 
G: 6655.4   
T: 6679.4 
RAB6A rs10736793 2 
ACGTTGGATGCTGCACTGATTGTAATAGCC 
ACGTTGGATGATGAGAGCCTTGCTCTCCAG 
TAATAGCCTATTTTTACTTCTCT 
C: 7176.7   
A: 7200.7 
RAB6A rs3203705 1 
ACGTTGGATGCACGGATGTAACTGGGAATG 
ACGTTGGATGCATCTCACAGATCAGGCTTC 
gAACTGGGAATGAGGCTACGGA 
A: 7144.7   
G: 7160.7 
RAB6A rs11235876 1 
ACGTTGGATGCGACTTTATCATGATGCAAG 
ACGTTGGATGCTTTACGTACTATCCATATC 
GATACTTGTTTTCAGGCTT 
G: 6047.0   
A: 6126.9 
RAB6A rs11235880 2 
ACGTTGGATGGTACTTTGATGTTCGAACT 
ACGTTGGATGTATCCCACTGAACACTTCAT 
ATATATTCTCAAGTGAATGTTTTT 
C: 7634.0   
A: 7673.9 
RAB6A rs7127066 1 
ACGTTGGATGTTGTCTGATGTTTTCTCACG 
ACGTTGGATGGCACATCAGTTCTGTGGTAG 
ttcTGTTTTCTCACGATTAGACAGAG 
C: 8198.4   
G: 8238.4 
 Note: all these SNPs were genotyped as a part of the same assay. 
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4.2.4.3. PCR amplification 
With the help of the workstation epMotion 5075 (Eppendorf AG), the following reaction 
mix was prepared for each assay in 384-well PCR microplates (the volumes refer to one 
single reaction): 
DNA (8-25 ng/µL)     1 µL 
dNTPs 25mM (Qiagen, cat. no. 201912)     0.1 µL 
Primer mix (0.5 µM)      1 µL 
HotStar PCR Buffer 10X      0.625 µL 
MgCl2 25mM     0.325 µL 
HotStar Taq DNA polymerase (5U/µL) (Qiagen, cat. no. 203205)    0.1 µL 
dH2O     1.85 µL 
 
Reactions were run on Biometra TGradient thermocyclers with the following standard 
program: 
 
      94oC 15 min    94oC 20 s 
                                                                 72oC 1 min   72oC 3 min 
 
                             56oC 30 s 
                                                                                                                                           15oC ∞ 
                                                                                                                    4oC 5 min 
                                                                                                                                                  
 
 
4.2.4.4. SAP treatment  
Before the iPLEX reaction, it is necessary to dephosphorylate unincorporated dNTPs with 
shrimp alkaline phosphatase (SAP). If this step is omitted, unincorporated dNTPs could 
extend in the primer extension reactions, giving as a result contaminant products which 
could be detected by the mass spectrometer. SAP treatment consists in the addition of 
0.17 µL of 10x SAP buffer, 0.3 µL of SAP enzyme (1U/µL) and 1.53 µL of sterile distilled 
water to each well. Then, the plate is incubated in a thermocycler with the following 
program: 37oC for 20 minutes (dephosphorylation step), 85oC for 5 minutes (SAP 
inactivation) and 4oC forever.  
4.2.4.5. iPLEX reaction  
The iPLEX reaction mix contained: 
 
Initial DNA 
denaturation 
DNA 
denaturation 
Primer 
annealing 
Extension 
Final 
extension Maintenance 
44 cycles 
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iPLEX termination mix*     0.2 µL 
iPLEX Buffer 10X *     0.2 µL 
iPLEX enzyme*       0.1 µL 
dH2O     0.755 µL 
Primer mix**     0.804 µL 
TOTAL VOLUME (for one single reaction)    2 µL 
 * from the iPLEX reaction kit (SEQUENOM, catalog no. 10116). 
** the concentrations of each primer pair vary according to the mass of each SBE product. 
 
The mix was added to each well of the PCR plates and the plates were thermocycled 
with the following 200-cycle program with two cycling loops: 
 
 
                94oC 30 s    94oC 5 s 
                                                                            80oC 5 s    
                   72oC 3 min 
 
                                          52oC 5 s 
                                                                                                                                             
                                                                                                                                   4oC ∞ 
                                                                                                                                                  
 
4.2.4.6. MALDI-TOF MS analysis 
Samples were firstly desalted to optimize MS analysis. For this purpose, samples were 
diluted with 16 µL of water and 6 mg of resin (SEQUENOM, catalog no. 10053) were 
added to each well. Then the 384-well was rotated for 20 minutes to allow the resin to 
trap all interfering ions in the sample. Finally, the plate was centrifuged at 3000 rpm for 
5 minutes to deposit the resin together with the salts at the bottom of each well. 
After resin treatment, a small volume (around 15 nL) of each sample of the PCR plate 
was transferred onto a 384-well SpectroCHIP bioarray (SEQUENOM, catalog no. 00601) 
with the MassARRAY® Nanodispenser S instrument (SEQUENOM AG). Moreover, a 
calibrant solution was also dispensed onto the chip. 
Once the chip was ready to be read, it was placed on the Scout plate of the MALDI-TOF 
mass spectrometer, which was controlled by the MassARRAY Typer Workstation version 
3.4 software, where the position of the chip and the assay definitions had been 
previously set. Spectra were then acquired and automatically sent to the MassARRAY 
Typer software. Genotypes were also automatically assigned by this software. 
4.2.4.7. Post-read quality checking 
Genotype calls and spectra for each assay were subsequently checked with the 
MassARRAY Typer 3.4 software to detect wrong calls and low-quality peaks. Genotype 
data were edited when necessary. 
Initial DNA 
denaturation 
DNA 
denaturation 
Primer 
annealing 
Single base 
extension 
Final   
extension Maintenance 
40 cycles 
5 cycles 
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5. Statistical methods 
Many computer programs have been used for the statistical analysis of the genotypic data. 
Table M22 shows a summary of their uses. 
Table M22. Software used for the statistical analyses. 
 
5.1. Genotyping verification 
All genotype data were checked through different methods to ensure that there were no 
genotyping errors.  
5.1.1. Hardy-Weinberg Equilibrium. 
All polymorphisms were assessed for Hardy-Weinberg Equilibrium (HWE) in both patient and 
control samples by applying a 2 test implemented in Haploview Program version 4 (Barrett et 
al., 2005). 
The deviation from HWE in the control sample could be indicating a genotyping error, since 
control subjects are not suffering from any psychiatric disorder which could be acting as a 
selective pressure, thus explaining the deviation from equilibrium. Therefore, in those cases, 
the best solution is to re-genotype the samples to verify the initial finding. However, although 
a genotyping error is the most plausible explanation for the Hardy-Weinberg disequilibrium, 
other possibilities cannot be ruled out.   
By contrast, when the control sample is in HWE but the patients’ sample is not, this finding 
could suggest a manifestation of the association of genotype with the disease. 
Finally, we cannot forget that the existence of HWE is not a guarantee of absence of 
genotyping errors. 
Program Uses 
Quanto version 1.2.3 Statistical power calculation 
Haploview version 4 
Hardy-Weinberg Equilibrium 
Linkage disequilibrium analysis 
Merlin version  0.10.2 Mendelian inheritance checking 
SNPstats 
http://bioinfo.iconcologia.net/snpstats/start.htm 
Case control association analysis (genotypic frequencies) 
Association analysis of quantitative variables 
Gene-gene interaction analysis 
STATA version 8.2 
Case-control association analysis 
Association analysis of quantitative variables 
FBAT version 2.0.2 Family-based association analysis 
Unphased version 3.0.12 
Association analysis of allelic frequencies 
Case-control haplotype analysis  
Haplostats Case-control haplotype analysis 
PLINK version 1.0.2 Pooled association analysis 
SeqBon Correction for multiple testing 
SPM Neuroimaging analysis 
110 Materials and Methods 
 
5.1.2. Mendelian inheritance errors. 
For the American family samples from CBDB, the presence of Mendelian inconsistencies on 
each pedigree was checked through Merlin software. Those pedigrees with Mendelian 
inheritance errors were discarded before the association analyses, since they are a clear sign of 
genotyping error.  
5.2. Linkage disequilibrium analysis 
The Haploview program version 4.0 (Barrett et al., 2005) was used to estimate,  in both cases 
and controls separately, the statistical values Delta prime (D’) and squared correlation 
coefficient (r2) as measures of pair wise linkage disequilibrium LD. Haplotype block structure 
was determined according to the criteria shown in Gabriel et al (2002). 
5.3. Measurement of the statistical power. 
Prior to any association analysis, it is important and highly recommendable to make a priori 
calculation to know the statistical power of the study. This power varies attending to different 
parameters, such as the sample size, the risk allele frequency, the incidence of the disease and 
the risk (odds ratio) assumed for each polymorphism, among others.  
For this study, QUANTO software version 1.2.3 (Gauderman, 2002; Gauderman and Morrison, 
2006) was used to calculate the statistical power to find associations between genetic 
polymorphisms and the different study variables that include case-control, family-based and 
quantitative trait analyses. For case-control and family-based association studies we assumed 
an odds ratio between 1.3 and 2, while for quantitative traits we considered that the 
proportion of variance explained by each polymorphism could vary between 1% and 20%. We 
also set the incidence of schizophrenia at 1% and the inheritance model as additive. 
5.4. Case-control analyses 
These analyses are based on the comparison of the allelic, genotypic or haplotype frequencies 
between two groups of individuals, generally patients versus healthy subjects, but also 
comparisons between two subsets of patients. The different comparisons performed in this 
study are the following. 
SPANISH SAMPLE 
1. Controls versus all patients. 
2. Controls versus hallucinatory patients. 
3. Controls versus patients with no AH. 
4. Hallucinatory patients vs patients with no AH. 
5. Controls versus schizophrenic patients. 
6. Controls versus schizophrenic patients with AH. 
7. Controls versus patients with chronic AH. 
8. Patients with chronic AH versus patients with 
no AH. 
GERMAN SAMPLE 
1. Controls versus all patients. 
2. Controls versus schizophrenic patients. 
3. Controls versus patients with bipolar 
disorder. 
AMERICAN SAMPLE 
1. Controls versus all patients. 
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It should be noted that the comparisons performed on each sample depended on the nature 
of each patient group and the clinical information available on each case.  
In all cases, statistical significance threshold was set at 0.05.  
5.4.1. Allelic frequencies. 
Allelic differences between patients and control subjects were assessed with a 2 test via 
Unphased program version 3.0.12 (Dudbridge, 2003, 2006).   
5.4.2. Genotypic frequencies. 
Different programs and approaches were used depending on the sample: 
 Spanish and German samples: The web-based application SNPStats (Solé et al., 2006) was 
used to evaluate the existence of differences in the genotypic frequencies between groups. 
This software uses a logistic regression approach for the case-control comparisons and 
calculates the odds ratios (OR) and 95% confidence intervals as a sign of the risk associated 
to each genotype. Different inheritance models (codominant, dominant, recessive, and 
additive) were considered and tested during the analysis. To decide the best inheritance 
model, a score associated to each model based on minimizing the expected entropy (the 
Akaike’s information criterion or AIC) is also calculated. According to this value, the model 
with the less AIC value would be the most probable model.  
Moreover, it should be noted that, when differences in the allelic, genotypic or haplotype 
distribution between sexes were detected, sex was used as a covariable. 
 American sample: we used STATA software for single SNP analysis by using two approaches: 
a Fisher’s exact test (performing a comparison of the three genotypic frequencies) and a 
logistic regression analysis with two different contrasts, where the homozygotes 1/1 (where 
1 refers to the major allele) were compared against the other two genotypes (1/2 or 2/2) 
separately. 
5.4.3. Haplotype analysis. 
Haplotype frequencies were estimated in the German and the Spanish sample through a 
retrospective likelihood algorithm and compared between patients and controls with the 
Unphased package version 3.0.12 (Dudbridge 2003, 2006). Sliding windows of two, three and 
four-marker haplotypes were tested. Moreover, those haplotypes with a frequency below 0.03 
were considered as rare and therefore discarded from the statistical analysis. A 1000-
permutation run was performed in each case to better estimate the significance of the positive 
associations.  
By contrast, the haplotype analysis in the American sample was performed via HAPLOSTATS 
program. This program uses the expectation-maximization algorithm, which is based on the 
determination of those haplotype frequencies which maximize the probability to obtain the 
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observed genotypes. Analysis was made by considering a sliding window of three-marker 
haplotypes.  
5.4.4. Pooled association analysis. 
When genotype data for more than one case or control sample was available, we performed a 
pooled analysis by combining the affected individuals and healthy subjects with a different 
country of origin. Moreover, to ensure certain level of homogeneity between all the affected 
individuals included in the pooled analysis, only those patients diagnosed as schizophrenics 
(according to DSM-IV criteria) were included in the analysis.  
The linkage disequilibrium patterns between SNPs were determined to assess the validity of 
such type of analysis. Moreover, these analyses were only stratified according to the region of 
origin of each individual (Germany vs. Spain; Spain vs. USA) since there were no differences in 
other possible stratification variables, for example ethnicity. 
Particularly, we analyzed pooled data for the following genes, SNPs and samples (see table 
M23). 
 
Table M23. List of the polymorphisms which were analyzed in the pooled analyses. 
Pooled samples Gene 
SNPs included in the pooled 
analysis 
USA + Spain ASPM 
rs6677082 
rs12116571 
rs10922163 
rs41310927 
rs12138336 
rs3762271 
Germany + Spain PLEKHB1-RAB6A 
rs663303 
rs940828 
rs3741147 
rs12274970 
rs3182788 
rs3203705 
rs11235876 
rs7127066 
Germany + Spain PDE4D 
rs17291089 
rs829259 
rs17719378 
rs10055954 
rs10461656 
rs7713345 
rs12656462 
rs4700316 
rs7714708 
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PLINK software version 1.0.2 (Purcell et al., 2007) was used for the analyses of the pooled 
samples. This package is especially designed for GWA studies, although it can work on a small 
scale, as this is case. The selected statistical tests were the Cochran-Mantel-Haenszel (CMH) 
tests, which are valid with a small number of large clusters. These tests are very useful when 
the presence of possible stratifying variables is suspected, since they are based on an 
"average" odds ratio that controls for the potential confounding due to the cluster variable.  
Two variants of the CMH tests were performed: 
 CMH test for 2x2xK stratified tables: it performs the case-control association test but 
controlling the effect of the cluster variable. In our particular case, the cluster variable was 
the country of origin (Spain, Germany or USA). 
 CMH test for IxJxK stratified tables: this test is useful to see if a SNP varies between clusters 
and can be extraordinarily helpful to interpret the results from the CMH test for 2x2xK 
tables and also to understand the results of the different clusters separately.   
5.5. Family-based association analysis. 
This type of analysis was performed with the family American samples. The association study 
was performed on each SNP as well as in haplotypes of SNPs. We used FBAT program to test 
for association of single SNPs or haplotypes (with a sliding window of three-marker 
haplotypes) with schizophrenia. FBAT (acronym for Family-Based Association Tests) compares 
the genotypic distribution observed in the patients to its expected distribution under the null 
hypothesis (“no linkage and no association with the disease”). The expected distribution is 
based on Mendelian segregation.     
The obtained P values are based on a run of at least 500 permutations.  
5.6. Association analysis with disease traits. 
Information about different clinical variables was available for individuals of the following 
samples: 
 Spanish sample: different scales and measures were assessed in some patients and were 
available for its study: BPRS general score, PANSS scores, KGV scale and PSYRATS scales for 
auditory hallucinations and delusions. It should be noted that the scores corresponding to 
the PSYRATS subscale for AH are only available for hallucinatory patients. Moreover, we 
also studied the effect of genetic variation on other dichotomic clinical variable: age at 
onset of the disease. In this case, patients were divided in two categories: patients with 
early-onset psychosis (age at onset of up to 20 years old) and patients with late-onset 
psychosis (when the age at onset is more than 20 years old). The online utility SNPStats 
(Solé et al., 2006) was used to study the likely relationship between genetic polymorphisms 
and all the response variables. The program applies a linear regression analysis to test the 
existence of associations between polymorphisms and quantitative variables, also 
considering different inheritance models (codominant, dominant, recessive, and additive). 
The analysis is summarized by the mean value for each genotype and mean differences 
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with respect to a reference category, as well as the Bayesian Information Criterion (BIC) 
score (similar to the AIC score), a score which indicates the most probable inheritance 
model in the linear regression analyses. By contrast, for the variable “Age of onset”, a 
logistic regression analysis was performed. This approach, similar to the case-control 
analysis, compares the genotypic frequencies in both groups of patients. 
 American sample: scores for seven measures derived from different cognitive tests were 
available in both unrelated controls and schizophrenic patients. These variables are Verbal 
Memory, Working Memory-N back, Visual Memory, IQ-Processing Speed-Fluency, Executive 
Function-WCST, Attention and Digit Span. A linear regression analysis via STATA software 
was used to examine the effect of genotype, both in controls and patients, on the 
performance of the seven cognitive factors. Particularly, two types of comparisons were 
assessed: on one hand, 1/1 genotype (where 1 refers to the major allele) was compared to 
the heterozygote genotype, whereas, on the other hand, the two types of homozygotes 
(1/1 and 2/2) were compared to each other. 
5.7. Correction for multiple testing. 
The Bonferroni sequential test for multiple comparisons (Rice, 1989) was applied to correct all 
the reported P values. We considered that this correction was more appropriate than the 
Bonferroni correction because it has an increased statistical power in detecting a false 
negative result and the rejection criteria are less stringent.  
5.8. Gene-gene interaction analysis. 
Gene-gene interaction analyses were performed when we considered that two polymorphic 
variants from different genes could be interacting with each other and thus modifying the 
effect each single variant has on certain phenotype (e.g. the disease risk or another disease 
trait). PLINK software version 1.0.2 (Purcell et al., 2007) was used for this purpose. This 
program performs either a linear or logistic regression test, depending on whether the 
phenotype is a quantitative (e.g. clinical scales) or a binary trait (for example a case-control 
variable). PLINK makes a model based on the allele dosage for each SNP separately, as well as 
for the SNP epistasis. As a result, the program gives an estimation of the effect of the epistasis 
(an Odds Ratio value for binary traits, a β value for quantitative traits) and an asymptotic p-
value. 
5.9. Correlation with neuroimaging variables. 
We used VBM and fMRI to assess the impact of certain polymorphisms on brain structure and 
function of both normal controls and schizophrenic patients. This study was made with the 
collaboration of the neuroimaging group of the Clinical Brain Disorders Branch at NIMH, as 
well as the neuroimaging group of Dr. Luis Martí Bonmatí from the Departments of Radiology 
of the Dr. Peset University Hospital and Quirón Hospital (Valencia).  
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5.9.1. Structural Magnetic Resonance – Voxel-Based Morphometry (VBM).  
We analyzed how different polymorphisms affected human brain volumes. The effect of 
genotype on total intracranial volume from patients or controls was examined using a multiple 
regression test. Total brain volume, gender and age were used as covariables. Moreover, the 
effect on regional intracranial volumes was also studied. All results were thresholded at p<0.05 
and corrected for multiple comparisons using the false discovery rate criteria (Genovese et al., 
2002). 
The genes analyzed through this approach were: 
 Serotonin transporter gene (SLC6A4): the effect of 5-HTTLPR polymorphism on the gray 
matter (GM) volume of limbic areas was studied in a group of 24 patients and 30 controls 
from the Spanish sample. Both groups where matched by sex (all males), ethnic group (all 
Caucasian), laterality (all right handed) and educational level (all had a secondary school 
qualification) to avoid stratification in the sample. The structural image methodology 
chosen to extract features for genetic analysis was based on a VBM optimized protocol. The 
quantification and processing analysis was performed with Statistical Parametric Mapping 
(SPM5, Wellcome Institute, London, United Kingdom). A region of interest (ROI) around the 
limbic system was defined (figure M15). This region included the cingulate cortex, fornix, 
hippocampus, parahippocampal gyrus and amygdale. ROI masks were overlayed with the 
gray matter maps to define the areas to study. 
Statistical measurements were performed following a non-parametric approach, which 
provides a robust variance estimation method based on permutation test. Statistical non-
Parametric Mapping (SnPM) tool was used to examine the structural associates of genetic 
features. Three separate analyses were designed in order to measure the relationship 
between image and genotype. First, a model to check the effects of the 5-HTTLPR 
polymorphism on the variability of the GM in limbic areas in both the healthy control 
subjects and schizophrenic patients separately was performed. Statistical models were 
estimated by performing an independent voxel by voxel Student-t test with analysis of the 
covariance (ANCOVA). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure M15. 
Region of interest 
(ROI) defined in 
the limbic lobe. 
This region 
includes: 
cingulated gyrus, 
fornix, 
hippocampus, 
parahippocampal 
gyrus and 
amygdala. 
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 ASPM gene: MRI scans for VBM of 169 patients and 153 normal controls from the American 
sample were available. We analyzed how ASPM variation affected regional intracranial 
volumes in the two separated samples. However, in this case, we decided not to use a 
hypothesis-driven region of interest (ROI) approach, given that there are no previous 
studies which can throw light about the brain regions which could be more affected by a 
variation in ASPM gene. Thus, all reported loci for genotype effects show uncorrected P 
values at p<0.001 and are reported with reference to the MNI (Montreal Neurological 
Institute) standard space. Statistical measurements were performed with Statistical 
Parametric Mapping (SPM5, Wellcome Institute, London, United Kingdom). 
5.9.2. Functional Magnetic Resonance Imaging (fMRI).   
 SLC6A4 gene: the working hypothesis was that the 5-HTTLPR polymorphism influenced the 
emotional response of psychotic patients. According to this hypothesis, the main objective 
was to study the differences in the amygdala activation to neutral and emotional words 
depending on the 5-HTTLPR genotype. For this purpose, an emotional-auditory paradigm 
was designed to replicate those words and emotions related to hallucinatory experiences 
(Sanjuán et al., 2007): during the fMRI procedure, two sessions were randomly presented 
to each subject, one session with high emotional content words and the other with neutral 
emotional content words. For each session (see figure M16), the stimuli consisted of four 
blocks of activation interleaved with four blocks of rest. Each activation block was 
composed of 13 Spanish words. fMRI images were obtained by means of BOLD (Bold 
Oxygenation Level Dependent) and data were preprocessed and transformed into a 
standard space (MNI150, Montreal Neurological Institute). A region of interest (ROI) 
including the left and the right amygdala was considered. The statistical analysis was 
performed with SPM2 software, to evaluate the existence of differences in the amygdala 
activation depending on the genotype. Bonferroni correction for multiple testing was also 
applied with a p<0.05 threshold.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure M16. fMRI 
auditory-emotional 
paradigm. The 
upper image shows 
the general 
structure of each 
session, while the 
other two schemes 
represent the 
sequence of each 
session.  
Abbreviations: R, 
rest; A, activation; 
s, seconds.  
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Figure M17. Scheme of the N Back working memory task.  
 ASPM gene: To test the hypothesis that ASPM has an impact on brain function, we used 
fMRI to measure BOLD activation during the N back task, a measure of short-term working 
memory, in 79 normal subjects from the American sample. Subjects performed the task as 
it was previously described (Callicott et al. 1999). Briefly, subjects were scanned while 
performing a simple N back block design (see figure M17) alternating between a two back 
(2B) working memory condition and a no back (0B) control condition. Subjects were 
instructed to recall the stimuli (numbers 1-4 shown randomly) seen “n” previously (two 
prior for the 2B condition and the currently presented digit for 0B).  
 
 
 
 
 
 
 
 
 
 
 
All normal subjects were matched for N back performance and reaction time, handedness, 
age, gender and IQ. Whole brain BOLD fMRI data were collected on a 3-T Signa scanner by 
using GE-EPI-RT pulse sequence (GE Medical Systems). All fMRI data were processed and 
spatially normalized to a MNI standard space and analyzed via SPM2 software as described 
previously. Reported loci for genotype effects on task-related activation exceed 
significance levels at p<0.001 (uncorrected P value).  
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RESULTS  
In this doctoral thesis work, several schizophrenia candidate genes have been studied and many 
different statistical analyses have been performed depending on the gene and the clinical 
information available for each sample. Thus, the Results section has been structured to facilitate 
the access to all data: first, there will be a section which will include the tests for Hardy-
Weinberg Equilibrium (HWE) and Mendelization. Afterwards, the analyses of the linkage 
disequilibrium (LD) patterns for each gene will be presented. Then, the results for the case-
control and family-based analyses will be shown. The fourth section will include the significant 
associations with quantitative variables and disease traits. Following these results, the positive 
findings from the gene-gene interaction analyses will be presented. Finally, the last section will 
show the association analysis with neuroimaging variables (fMRI, sMRI-VBM and MRS). 
It is important to remark that, prior to the analysis, 32 patients and 6 control subjects from the 
Spanish sample were excluded from the study for several reasons: 
 Impossibility to obtain DNA samples (33 individuals).  
 Existence of a relationship with other subjects (2 individuals). 
 Doubts about the ethnicity (3 subjects). 
Moreover, depending on the genotyping technique and the quality of each DNA sample, there 
was a variable number of fails during the genotyping procedure.  
1. Genotyping verification 
The existence of HWE and the absence of Mendelian inconsistencies (when applicable) were 
verified for all samples and polymorphisms. The results can be found below. 
1.1. SLC6A4 gene 
Nine markers located along SLC6A4 gene were included in the study. These markers were 
genotyped in the Spanish sample and subsequently analyzed.  
Table R1 shows information about the minor allele frequencies for both healthy subjects and the 
whole group of psychotic patients, as well as the P values corresponding to the 2 tests 
performed to verify the existence of Hardy-Weinberg Equilibrium (HWE). As it can be seen, one 
SNP (rs2228673, located in exon 4) was found to be monomorphic for allele G in our sample; 
therefore it was excluded of the analyses. Furthermore, one SNP (rs2020936, located in intron 
1A) deviated from HWE in controls. However, the significance is very slight (p = 0.0434) and did 
not resist Bonferroni sequential correction, and therefore we decided not to exclude this 
polymorphism from the analyses. Moreover, the low frequency of the nine repeat allele of STin2 
(0.009 in control subjects) led us to exclude all genotypes including this allele from all the 
analyses and therefore the 10-repeat allele was considered as the minor allele. 
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Table R1. Frequency and HWE data for SLC6A4 polymorphisms. 
Polymorphism 
Marker 
order 
MAF (controls)
a
 
HWE P value 
(controls) 
MAF (patients)
b
 
HWE P value 
(patients) 
rs3813034 M1 0.471 (G) 0.529 0.47 (G) 0.888 
rs1042173 M2 0.474 (G) 0.537 0.48 (G) 1.0 
rs140700 M3 0.083 (A) 1.0 0.05 (A) 1.0 
rs2228673 M4 Monomorphic (G) N/A Monomorphic (G) N/A 
rs2020942 M5 0.328 (A) 0.693 0.365 (A) 0.868 
STin2 M6 0.322 (10rep) 0.694 0.356 (10rep) 0.916 
rs2020939 M7 0.443 (T) 0.545 0.458 (T) 1.0 
rs2020936 M8 0.213 (C) 
0.043  
(0.473 corrected) 
0.167 (C) 0.196 
rs2066713 M9 0.328 (T) 0.693 0.353 (T) 0.426 
rs4251417 M10 0.074 (A) 0.319 0.064 (A) 0.622 
5-HTTLPR 
(including 
rs25531) 
M11 0.006 (SG) 0.259 0.011 (SG) 0.975 
rs12945042 M12 0.279 (A) 0.186 0.279 (A) 0.628 
Significant P values (P < 0.05) are indicated in bold. 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium; N/A, not applicable; rep, repeat. 
 
 
 
1.2. HTR2A gene 
As it is shown in table M6, from the Materials and Methods section, two markers from the 
serotonin receptor 2A gene, rs6313 (located in exon 1) and rs6311 (located in the promoter 
region), were selected for this study. These markers were genotyped in the individuals 
corresponding to the Spanish sample.  
According to the information shown in table R2, both SNPs were found to be in HWE in both 
controls and patients.  
 
 
Table R2. Frequency and HWE data for HTR2A polymorphisms. 
Polymorphism 
Marker 
order 
MAF (controls)
a
 
HWE P value 
(controls) 
MAF (patients)
b
 
HWE P value 
(patients) 
rs6313 M1 0.439 (T) 0.6344 0.435 (T) 1.0 
rs6311 M2 0.449 (A) 0.1114 0.463 (A) 0.1428 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium. 
 
 
 
Results 123 
 
1.3. TPH2 gene 
One marker, SNP rs4570625, located in the 5’ regulatory region and with probable functional 
implications, was genotyped in the Spanish sample and statistically analyzed. 
The minor allele frequencies (MAF) of rs4570625 in both control subjects and psychotic patients, 
as well as the results for the HWE tests can be found in table R3. The polymorphism was in HWE 
in both subsets. 
 
 
Table R3. Frequency and HWE data for the TPH2 polymorphism. 
Polymorphism MAF (controls)
a
 HWE P value (controls) MAF (patients)
b
 HWE P value (patients) 
rs4570625 0.183 (T) 0.5725 0.153 (T) 1.0 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium. 
 
 
1.4. NOS1 gene 
 
A VNTR located in exon 1f of the NOS1 gene, (NOS1 Ex1f-VNTR) was genotyped in all the Spanish 
subjects and then analyzed in order to find associations with psychosis. Table R4 shows 
information about the minor allele frequencies (MAF) of the NOS1 VNTR in control subjects and 
psychotic patients, as well as the results for the HWE test. This polymorphism was in HWE in 
both groups of individuals. 
 
 
Table R4. Frequency and HWE data for the NOS1 VNTR. 
Polymorphism MAF (controls)
a
 HWE P value (controls) MAF (patients)
b
 HWE P value (patients) 
NOS1 Ex1f-VNTR 0.464 (S) 0.4546 0.472 (S) 0.8143 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium; S, Short alleles. 
 
1.5. STMN1 gene 
As it is shown in table M9, from the Materials and Methods section, two tags from the Stathmin 
gene, rs12037513 (located downstream the gene) and rs182455 (located in the putative 5’ 
regulatory region), were selected for the study. These two markers were genotyped in the 
Spanish sample. Table R5 shows information about the minor allele frequencies in both samples 
of cases and controls, as well as the results from the HWE tests. Both SNPs were found to be in 
HWE. 
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Table R5. Frequency and HWE data for STMN1 polymorphisms. 
Polymorphism 
Marker 
order 
MAF (controls)
a
 
HWE P value 
(controls) 
MAF (patients)
b
 
HWE P value 
(patients) 
rs12037513 M1 0.308 (C) 0.8807 0.266 (C) 0.8472 
rs182455 M2 0.447 (T) 0.0751 0.419 (T) 0.5383 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium. 
 
1.6. ASPM gene 
The ASPM gene, located in chromosome 1q, was genotyped in both the Spanish and the 
American samples. Specifically, 10 different polymorphisms were genotyped in the Spanish 
sample, while 6 SNPs were genotyped in the North-American sample. Of those SNPs, five of 
them were genotyped in both samples: rs3762271, rs12138336 and rs41310927, located in exon 
18; rs10922163, located in intron 17; and rs6677082, situated in exon 3. 
Minor allele frequencies for all the polymorphisms, as well as the results from the test to verify 
the existence of HWE can be found at tables R6 (Spanish sample) and R7 (American sample). 
Regarding the Spanish sample (table R6), two SNPs (rs964201 and rs12025066), located in the 
coding region, were found to be monomorphic. Moreover, two other SNPs (rs6700180 and 
rs10922163, located in introns 19 and 17, respectively) were out of HWE in both patients and 
controls. The deviation from HWE in the control group could be indicating a genotyping error. 
However, the significance is low, thus we cannot discard other possibilities. In any case, this 
deviation from HWE should be taken into account in the subsequent association analyses, 
especially the haplotype analyses. Finally, 8 SNPs were included in the association analysis, 
although the results from SNPs which deviated from HWE were considered cautiously. 
 
Table R6. Frequency and HWE data for ASPM SNPs in the Spanish sample. 
Polymorphism 
Marker 
order 
MAF (controls)
a
 
HWE P value 
(controls) 
MAF (patients)
b
 
HWE P value 
(patients) 
rs6700180 M1 0.457 (T) 
0.0211 
(0.168 corrected) 
0.495 (T) 
0.0424 
(0.297 corrected) 
rs3762271 M2 0.429 (A) 0.3633 0.396 (A) 0.6481 
rs12138336 M3 0.067 (C) 0.3643 0.086 (C) 1.0 
rs41310927 M4 0.414 (G) 0.3342 0.396 (G) 0.6481 
rs964201 M5 Monomorphic (C) N/A Monomorphic (C) N/A 
rs10922163 M6 0.447 (G) 
0.0238 
(0.168 corrected) 
0.494 (G) 
0.0308 
(0.246 corrected) 
rs4915337 M7 0.1 (T) 1.0 0.111 (T) 0.521 
rs12025066 M8 Monomorphic (A) N/A Monomorphic (A) N/A 
rs6677082 M9 0.111 (C) 0.4388 0.105 (C) 0.3529 
rs9726778 M10 0.112 (C) 0.7207 0.122 (C) 0.6327 
Significant P values (P < 0.05) are indicated in bold. 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets.  
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium; N/A, not applicable. 
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With regard to the American sample (table R7), all the polymorphisms were in HWE, with the 
only exception of rs12116571, which deviated from HWE in the patients group, but not in the 
control group. Therefore, all the SNPs were included in the association analysis. Moreover, 
thirteen families showed Mendelian inconsistencies for some SNPs (data not shown). Therefore, 
all the unlikely genotypes were discarded for the analysis. 
 
Table R7. Frequency and HWE data for the ASPM SNPs in the North-American sample. 
Polymorphism 
Marker 
order 
MAF (controls)
a
 
HWE P value 
(controls) 
MAF (patients)
b
 
HWE P value 
(patients) 
rs3762271 M1 0.407 (A) 1.00 0.400 (A) 0.6735 
rs12138336 M2 0.076 (C) 1.00 0.082 (C) 0.3389 
rs41310927 M3 0.418 (G) 1.00 0.403 (G) 0.7516 
rs10922163 M4 0.473 (G) 0.6992 0.494 (A) 0.1963 
rs12116571 M5 0.130 (A) 0.2031 0.107 (A) 
0.0006  
(0.0036 corrected) 
rs6677082 M6 0.104 (C) 0.2978 0.080 (C) 0.0942 
Significant P values (P < 0.05) are indicated in bold. 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium; N/A, not applicable. 
 
 
 
 
1.7. PDE4D gene 
 
 
This gene was studied in both the Spanish and the German samples with the genotyping of 
several tags. Particularly, nine markers were genotyped in the Spanish sample, whereas twelve 
SNPs were genotyped in the German sample (the nine genotyped in the Spanish individuals plus 
three additional SNPs).  
The information about minor allele frequencies and tests of Hardy-Weinberg Equilibrium can be 
found below. Table R8 shows the results for the Spanish sample, while table R9 contains the 
information about the German sample.  
In both samples, all markers were found to be in HWE in control subjects and patients. 
Moreover, two of the SNPs genotyped in the German individuals (rs1058458 and rs17853590) 
were monomorphic in this sample for alleles T and C, respectively. 
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Table R8. Frequency and HWE data for PDE4D polymorphisms in the Spanish sample. 
Polymorphism 
Marker 
order 
MAF 
(controls)
a
 
HWE P value 
(controls) 
MAF 
(patients)
b
 
HWE P value 
(patients) 
rs17291089 M1 0.059 (C) 0.4782 0.072 (C) 1.0 
rs829259 M2 0.353(A) 0.2576 0.376 (A) 0.9784 
rs17719378 M3 0.38 (G) 0.8013 0.37 (G) 0.824 
rs10055954 M4 0.149 (C) 0.1702 0.148 (C) 0.4534 
rs10461656 M5 0.296 (A) 0.1109 0.3 (A) 0.983 
rs7713345 M6 0.131(G) 0.328 0.151 (G) 0.465 
rs12656462 M7 0.047 (A) 1.0 0.074 (A) 0.536 
rs4700316 M8 0.208 (G) 0.5724 0.18 (G) 0.9445 
rs7714708 M9 0.347 (T) 0.6822 0.328 (T) 0.9634 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium. 
 
 
Table R9. Frequency and HWE data for PDE4D polymorphisms in the German sample. 
Polymorphism 
Marker 
order 
MAF (controls)
a
 
HWE P value 
(controls) 
MAF (patients)
b
 
HWE P value 
(patients) 
rs17291089 M1 0.065 0.3433 0.07 0.9667 
rs829259 M2 0.404 0.3934 0.406 0.6833 
rs1058458 M3 Monomorphic (T) N/A Monomorphic (T) N/A 
rs17719378 M4 0.351 0.423 0.331 1.0 
rs10055954 M5 0.171 0.7506 0.169 0.7428 
rs10461656 M6 0.337 0.6916 0.329 0.5718 
rs7713345 M7 0.166 0.761 0.159 0.1746 
rs12656462 M8 0.089 0.8259 0.1 1.0 
rs17853590 M9 Monomorphic (C) N/A Monomorphic (C) N/A 
rs10056492 M10 0.131 0.8354 0.106 0.2816 
rs4700316 M11 0.2 0.6543 0.195 0.4819 
rs7714708 M12 0.363 0.3856 0.353 0.0815 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium; N/A, not applicable. 
 
 
Finally, nine markers were analyzed in the Spanish sample, while ten SNPs were studied in the 
German subjects (the same nine SNPs plus an additional one, rs10056492, located in intron 6).   
 
 
1.8. PLEKHB1 and RAB6A genes 
These two genes located in chromosome 11q13.5 were genotyped in both the Spanish and the 
German samples. Particularly, eight SNPs (three from PLEKHB1, four from RAB6A and one 
located in the intergenic region between both genes) were genotyped in the Spanish sample, 
while fourteen SNPs (seven from PLEKHB1, six from RAB6A and another one in the intergenic 
region) were genotyped in the German sample.  
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Table R10 and R11 show the minor allele frequencies and the results from tests of Hardy-
Weinberg Equilibrium for both the Spanish and the German samples. One SNP, rs3182788, 
clearly violated HWE in the Spanish Sample, as well as in the German controls, suggesting the 
existence of a failure during the genotyping process. Several SNPs were also out of HWE only in 
the German affected subset (rs4944850, rs940828, rs11235880 and rs7127066, see table R11). 
Furthermore, the non-synonymous change rs3203705 was monomorphic in both the Spanish 
and the German samples for allele A. The SNP rs11538627, genotyped only in the German 
sample, was also found to be monomorphic for allele A.  
 
 
Table R10. Frequency and HWE data for PLEKHB1 and RAB6A SNPs in the Spanish sample. 
SNP 
Marker 
order 
MAF (controls)
a
 
HWE P value 
(controls) 
MAF (patients)
b
 
HWE P value 
(patients) 
rs663303 M1 0.092 (T) 1.0 0.137 (T) 1.0 
rs940828 M2 0.206 (G) 0.3574 0.216 (G) 0.4121 
rs3741147 M3 0.196 (G) 0.3081 0.154 (G) 1.0 
rs12274970 M4 0.32 (C) 0.1059 0.304 (C) 0.303 
rs3182788 M5 0.474 (T) 3.13E-21 (0.000000) 0.465 (T) 3.94E-11 (0.000000) 
rs3203705 M6 
Monomorphic 
(A) 
N/A Monomorphic (A) N/A 
rs11235876 M7 0.498 (A) 0.3272 0.487 (A) 0.8093 
rs7127066 M8 0.224 (C) 1.0 0.241 (C) 0.9297 
Significant P values (P < 0.05) are indicated in bold and corrected values are indicated in brackets. 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium; N/A, not applicable. 
 
 
Table R11. Frequency and HWE data for PLEKHB1 and RAB6A SNPs in the German sample. 
SNP 
Marker 
order 
MAF (controls)
a
 
HWE P value 
(controls) 
MAF (patients)
b
 
HWE P value 
(patients) 
rs663303 M1 0.127 (T) 0.9732 0.119 (T) 0.1478 
rs4944850 M2 0.154 (C) 0.62 0.14 (C) 0.0263 (0.236)  
rs11538627 M3 Monomorphic (A) N/A Monomorphic (A) N/A 
rs591804 M4 0.325 (G) 0.9475 0.312 (G) 0.8578 
rs6592527 M5 0.218 (C) 0.5046 0.248 (C) 0.1129 
rs940828 M6 0.212 (G) 0.3934 0.234 (G) 0.01 (0.12) 
rs3741147 M7 0.111 (G) 1.0 0.114 (G) 0.7339 
rs12274970 M8 0.235 (C) 0.7606 0.221 (C) 0.4221 
rs3182788 M9 0.341 (T) 8.3E-06  (0.000092) 0.24 (T) 0.0511 
rs10736793 M10 0.171 (A) 0.7925 0.163 (A) 0.3683 
rs3203705 M11 Monomorphic (A) N/A Monomorphic (A) N/A 
rs11235876 M12 0.42 (A) 0.1951 0.434 (A) 0.7516 
rs11235880 M13 0.179 (A) 0.6455 0.194 (A) 0.0147 (0.147) 
rs7127066 M14 0.239 (C) 0.6869 0.255 (C) 0.0104 (0.12) 
Significant P values (P < 0.05) are indicated in bold and corrected values are indicated in brackets. 
a. The minor allele in control subjects is indicated in brackets. 
b. The minor allele in patients is indicated in brackets. 
Abbreviation: MAF, minor allele frequency; HWE, Hardy-Weinberg Equilibrium; N/A, not applicable. 
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The monomorphic SNPs as well as rs3182788 were subsequently excluded from the analysis. 
Finally, this association analysis included 6 SNPs in the Spanish sample and 11 SNPs in the 
German sample. 
 
2. Linkage disequilibrium analysis 
The LD structure for all samples and genes (with the exception of TPH2 and NOS1 genes, 
because only one polymorphism was studied) can be consulted below. 
2.1. SLC6A4 gene 
Table R12 shows the linkage disequilibrium (LD) values observed in the control sample. The r2 
values present a wide range which oscillates between 0.0 and 0.98. A representation of the LD 
pattern which includes these r2 values is also shown in figure R1. According to Gabriel et al. 
criteria (Gabriel et al., 2002), two LD blocks were observed. Polymorphism 5-HTTLPR showed the 
lowest LD values (both r2 and D’) when compared with the rest of the SNPs. 
The patients’ LD structure is not shown since it does not differ significantly from the controls’ LD 
pattern. 
 
Table R12. Linkage disequilibrium values for SLC6A4 polymorphisms in the Spanish controls.  
The values over the diagonal correspond to the r
2
 values, while the D' values can be found below the diagonal.  
 
 
 
 
 
  rs3813034 rs1042173 rs140700 rs2020942 STin2  rs2020939 rs2020936 rs2066713 rs4251417 5-HTTLPR  rs12945042 
rs3813034 - 0.954 0.083 0.308 0.304 0.786 0.167 0.291 0.087 0.082 0.174 
rs1042173 0.982 - 0.085 0.323 0.318 0.823 0.169 0.305 0.086 0.08 0.188 
rs140700 1.0 1.0 - 0.043 0.043 0.078 0.341 0.043 0.0070 0.0 0.141 
rs2020942 0.843 0.858 1.0 - 0.98 0.385 0.122 0.961 0.037 0.118 0.196 
STin2  0.839 0.854 1.0 0.993 - 0.384 0.111 0.966 0.037 0.126 0.205 
rs2020939 0.938 0.965 1.0 1.0 1.0 - 0.206 0.367 0.096 0.133 0.236 
rs2020936 0.832 0.833 1.0 0.962 0.922 0.973 - 0.132 0.021 0.0 0.0050 
rs2066713 0.819 0.834 1.0 0.98 0.986 0.973 1.0 - 0.015 0.13 0.201 
rs4251417 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.621 - 0.086 0.018 
5-HTTLPR 0.316 0.311 0.026 0.472 0.493 0.427 0.027 0.497 1.0 - 0.128 
rs12945042 0.7 0.721 0.776 0.488 0.496 0.845 0.082 0.496 0.754 0.556 - 
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2.2. HTR2A gene 
Table R13 shows the linkage disequilibrium (LD) values observed in the control sample. As it can 
be seen, both SNPs are in almost complete LD and conform a block according to the criteria 
from Gabriel et al., 2002 (see figure R2). The sample of schizophrenic patients does not differ 
from the control one (data not shown). 
 
 
Table R13. Linkage disequilibrium values for HTR2A polymorphisms in the Spanish controls. 
The values over the diagonal correspond to the r
2
 values, while the D' values can be found below the diagonal.  
 
 
 
  rs6313 rs6311 
rs6313 - 0.913 
rs6311 0.975 - 
Figure R1. LD structure of SLC6A4 polymorphisms. Values refer to the Spanish control 
subjects. Functional polymorphisms are shown in green. r
2
 values are represented as 
percentages and colored in grayscale (where the highest values have more intensity).  
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Figure R2. LD structure of 
HTR2A SNPs. Values refer 
to the Spanish control 
subjects. The known 
functional polymorphism 
is shown in green. The r
2
 
value is represented as a 
percentage and colored 
in grayscale (where the 
highest values have more 
intensity). 
 
 
 
 
 
 
 
 
2.3. STMN1 gene 
The LD values (D’ and r2) for both SNPs from the STMN1 gene are shown in table R14 and figure 
R3. Values correspond to the control sample, but the LD pattern observed in patients was 
extremely similar. 
As expected, LD values are low, even for D’ parameter, since these two SNPs were selected as 
tagSNPs. 
 
 
Table R14. Linkage disequilibrium values for STMN1 polymorphisms in the Spanish controls. 
The value over the diagonal correspond to the r
2
 value, while the D' value can be found below the diagonal.  
 
 
 
 
 
 
 
 
 
 
  rs12037513 rs182455 
rs12037513 - 0.081 
rs182455 0.39 - 
Figure R3. LD 
structure of 
STMN1 SNPs. 
Values refer to the 
Spanish control 
subjects. The r
2
 
value is 
represented as a 
percentage and 
colored in 
grayscale (where 
the highest values 
have more 
intensity). 
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2.4. ASPM gene 
The LD structure observed in the Spanish control subjects is shown at table R15 and figure R4. D’ 
values were very high and all the SNPs formed a LD block (figure R10). By contrast, r2 values 
were more variable and ranged between 0.008 (between rs12138336 and rs4915337) and 1.0 
(between rs6700180 and rs10922163). The highest r2 values were concentrated around two 
regions: on the one hand, between rs6700180 (intron 19) and rs10922163 (intron 17); on the 
other hand, between rs4915337 (exon 14) and rs9726778 (promoter). The LD pattern observed 
in patients was also very similar (data not shown). 
 
Table R15. Linkage disequilibrium values for the ASPM polymorphisms in the Spanish controls. 
The values over the diagonal correspond to the r
2
 values, while the D' values can be found below the diagonal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 rs6700180 rs3762271 rs12138336 rs41310927 rs10922163 rs4915337 rs6677082 rs9726778 
rs6700180 - 0.604 0.087 0.577 1.0 0.092 0.104 0.105 
rs3762271 0.991 - 0.054 0.896 0.608 0.083 0.096 0.081 
rs12138336 1.0 1.0 - 0.051 0.094 0.0080 0.01 0.0090 
rs41310927 1.0 0.975 1.0 - 0.581 0.079 0.09 0.076 
rs10922163 1.0 0.991 1.0 1.0 - 0.087 0.101 0.099 
rs4915337 1.0 1.0 1.0 1.0 1.0 - 0.86 0.827 
rs6677082 1.0 1.0 1.0 1.0 1.0 1.0 - 0.922 
rs9726778 1.0 0.926 1.0 0.924 1.0 0.967 0.968 - 
Figure R4. LD structure of ASPM polymorphisms. Non-synonymous 
changes are marked in green. Values refer to the Spanish control 
subjects. r
2
 values are represented as percentages and colored in 
grayscale (where the highest values have more intensity).  
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With respect to the LD structure in the North-American control subjects, it was very similar to 
the structure observed in the Spanish subjects (table R16). All the SNPs conformed a block 
according to Gabriel et al. (2002) criteria (figure R5).  The highest r2 value was found between 
the polymorphisms rs3762271 and rs41310927 (both very close to each other, in exon 18). By 
contrast, the lowest r2 value (0.0090) was found between rs12138336 (exon 18) and rs6677082 
(exon 3). 
 
 
Table R16. Linkage disequilibrium values for ASPM polymorphisms in the American controls. 
The values over the diagonal correspond to the r
2
 values, while the D' values can be found below the diagonal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 rs3762271 rs12138336 rs41310927 rs10922163 rs12116571 rs6677082 
rs3762271 - 0.057 1.000 0.639 0.106 0.074 
rs12138336 1.000 - 0.058 0.092 0.012 0.0090 
rs41310927 1.000 1.000 - 0.644 0.109 0.075 
rs10922163 1.000 1.000 1.000 - 0.164 0.106 
rs12116571 1.000 0.997 1.000 1.000 - 0.017 
rs6677082 0.951 0.998 0.954 1.000 1.000 - 
Figure R5. LD structure of ASPM polymorphisms. 
Non-synonymous changes are marked in green. 
Values refer to the North-American control subjects. 
r
2
 values are represented as percentages and colored 
in grayscale (where the highest values have more 
intensity).  
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2.5. PDE4D gene 
Table R17 and figure R6 show the information about the LD pattern in the healthy subjects from 
Spanish sample. Although D’ values are 1.0 for many pairwise values, r2 values (which are more 
restrictive than D’ values) are generally lower and oscillate between 0.0020 and 0.746. 
Moreover, according to Gabriel et al. (2002) criteria (which are based in D’ values), two blocks 
(one of 8 kb and another of 16 kb) were detected. The LD structure in patients is not shown 
because it is very similar to the structure in the control sample. 
 
 
Table R17. Linkage disequilibrium values for PDE4D polymorphisms in the Spanish controls. 
The values over the diagonal correspond to the r
2
 values, while the D' values can be found below the diagonal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  rs17291089 rs829259 rs17719378 rs10055954 rs10461656 rs7713345 rs12656462 rs4700316 rs7714708 
rs17291089 - 0.106 0.037 0.012 0.031 0.013 0.0020 0.015 0.034 
rs829259 1.0 - 0.357 0.291 0.746 0.308 0.13 0.028 0.344 
rs17719378 1.0 1.0 - 0.104 0.267 0.111 0.047 0.087 0.256 
rs10055954 1.0 1.0 1.0 - 0.39 0.036 0.448 0.301 0.095 
rs10461656 1.0 1.0 1.0 1.0 - 0.414 0.175 0.056 0.505 
rs7713345 1.0 1.0 1.0 1.0 1.0 - 0.016 0.028 0.342 
rs12656462 0.688 1.0 1.0 1.0 1.0 1.0 - 0.012 0.0 
rs4700316 1.0 0.278 0.816 0.613 0.34 0.789 0.18 - 0.435 
rs7714708 1.0 0.641 0.925 0.523 0.752 0.963 0.102 1.0 - 
Figure R6. LD structure of PDE4D polymorphisms. Values refer to 
the Spanish control subjects. r
2
 values are represented as 
percentages and colored in grayscale (where the highest values 
have more intensity).  
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The information about the LD pattern in the German controls is shown in table R18 and figure 
R7. As it can be seen, LD values are similar to those obtained with the Spanish controls.  
 
 
Table R18. Linkage disequilibrium values for PDE4D polymorphisms in the German controls. 
The values over the diagonal correspond to the r
2
 values, while the D' values can be found below the diagonal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 rs17291089 rs829259 rs17719378 rs10055954 rs10461656 rs7713345 rs12656462 rs10056492 rs4700316 rs7714708 
rs17291089 - 0.104 0.038 0.014 0.035 0.014 0.0070 0.0080 0.017 0.04 
rs829259 1.0 - 0.368 0.304 0.749 0.292 0.145 0.029 0.011 0.25 
rs17719378 1.0 1.0 - 0.112 0.275 0.107 0.053 0.06 0.113 0.281 
rs10055954 1.0 1.0 1.0 - 0.407 0.041 0.478 0.169 0.188 0.05 
rs10461656 1.0 1.0 1.0 1.0 - 0.391 0.193 0.044 0.033 0.397 
rs7713345 1.0 1.0 1.0 1.0 1.0 - 0.02 0.018 0.038 0.334 
rs12656462 1.0 1.0 1.0 1.0 1.0 1.0 - 0.013 0.0010 0.01 
rs10056492 0.871 0.362 0.84 0.471 0.387 0.757 1.0 - 0.603 0.257 
rs4700316 1.0 0.172 0.919 0.476 0.26 0.872 0.038 1.0 - 0.438 
rs7714708 1.0 0.547 0.957 0.37 0.666 0.978 0.418 1.0 1.0 - 
Figure R7. LD structure of PDE4D polymorphisms. Values refer to the German 
control subjects. r
2
 values are represented as percentages and colored in grayscale 
(where the highest values have more intensity).  
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2.6. PLEKHB1 and RAB6A genes 
The LD values and the LD structure in the control Spanish group can be found at table R19 and 
figure R8. As it can be seen, LD between these markers is low. D’ values ranged between 0.241 
and 1.0. Moreover, as expected, the r2 values were lower than D’ values and ranged between 
0.001 and 0.436. The highest pairwise LD value was found between markers rs663303 and 
rs940828 (D’ = 1.0; r2 = 0.436), which also constituted a block according to Gabriel et al. (2002) 
criteria (figure R8). The LD structure in patients (data not shown) was found to be highly similar 
to the pattern observed in the control sample. 
 
 
Table R19. Linkage disequilibrium values for PLEKHB1 and RAB6A SNPs in the Spanish controls. 
The values over the diagonal correspond to the r
2
 values, while the D' values can be found below the diagonal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  rs663303 rs940828 rs3741147 rs12274970 rs11235876 rs7127066 
rs663303 - 0.436 0.025 0.013 0.07 0.023 
rs940828 1.0 - 0.0060 0.0010 0.185 0.326 
rs3741147 1.0 0.315 - 0.325 0.236 0.013 
rs12274970 0.241 0.108 0.788 - 0.471 0.105 
rs11235876 0.806 0.832 1.0 1.0 - 0.303 
rs7127066 0.249 0.61 0.449 0.407 1.0 - 
Figure R8. LD structure of PLEKHB1-RAB6A 
polymorphisms. Values refer to the Spanish control 
subjects. The non-synonymous changes are shown in 
green. r
2
 values are represented as percentages and 
colored in grayscale (where the highest values have 
more intensity).  
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Information about the LD pattern in the German controls is shown in table R20 and figure R9. 
On the whole, for those LD values which could be compared to the Spanish sample, there were 
great similarities, with a slight trend to higher values in the German sample. The highest LD 
value was found between the markers rsrs6592527 and rs940828 (r2 = 0.918). Moreover, three 
LD blocks were observed (see figure R9):  block 1: from rs663303 (5’ upstream of PLEKHB1) to 
rs591804 (intron 4 from PLEKHB1); block 2: from rs6592527 to rs940828 (both in intron 5 from 
PLEKHB1 gene); and block 3: from rs10736793 (intron 6 of RAB6A gene) to rs7127066 (intron 1 
of RAB6A gene). 
 
 
Table R20. Linkage disequilibrium values for PLEKHB1 and RAB6A polymorphisms in the German controls. 
The values over the diagonal correspond to the r
2
 values, while the D' values can be found below the diagonal.  
 
 
 
 
 
 
 
 
 
 
 
 rs663303 rs4944850 rs591804 rs6592527 rs940828 rs3741147 rs12274970 rs10736793 rs11235876 rs11235880 rs7127066 
rs663303 - 0.025 0.259 0.459 0.519 0.018 0.124 0.014 0.178 0.183 0.135 
rs4944850 1.0 - 0.385 0.051 0.046 0.462 0.192 0.247 0.045 0.016 0.029 
rs591804 0.956 1.0 - 0.035 0.054 0.147 0.506 0.177 0.29 0.164 0.084 
rs6592527 0.967 1.0 0.248 - 0.918 0.01 0.0090 0.0010 0.371 0.2 0.41 
rs940828 0.979 1.0 0.323 1.0 - 0.0040 0.03 0.0 0.358 0.223 0.465 
rs3741147 1.0 0.801 0.734 0.52 0.354 - 0.231 0.384 0.157 0.0060 0.0090 
rs12274970 0.512 0.561 0.899 0.101 0.184 0.754 - 0.176 0.424 0.27 0.175 
rs10736793 0.145 0.524 0.643 0.115 0.0040 0.778 0.508 - 0.282 0.045 0.063 
rs11235876 0.943 0.421 0.664 0.985 0.98 0.956 1.0 1.0 - 0.289 0.433 
rs11235880 0.542 0.629 0.601 0.505 0.509 0.446 0.61 1.0 0.982 - 0.704 
rs7127066 0.54 0.721 0.364 0.67 0.736 0.473 0.423 1.0 1.0 0.989 - 
Figure R9. LD structure of PLEKHB1-RAB6A polymorphisms. The values 
refer to the German control subjects. The non-synonymous changes are 
shown in green. r
2
 values are represented as percentages and colored in 
grayscale (where the highest values have more intensity).  
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3. Case-control and family-based association analyses 
The allelic, genotypic and haplotypic frequencies of both patients and controls were compared 
in order to detect any association with psychosis or schizophrenia.  
With regard to the case-control analyses, several comparisons were made on each sample 
separately: 
Spanish sample 
1. Controls (N = 342) versus all patients (N=298). 
2. Controls (N = 342) versus hallucinatory patients (N = 220). 
3. Controls (N = 342) versus schizophrenic patients (N = 218). 
4. Controls (N = 342) versus patients with no AH (N = 77). 
5. Hallucinatory patients (N = 220) versus patients with no AH (N = 77). 
6. Controls (N = 342) versus schizophrenic patients with AH (N = 183). 
7. Controls (N = 342) versus patients with chronic AH (n = 81). 
8. Patients with chronic AH (n = 81) versus patients with no AH (N = 77). 
German sample 
1. Controls (N = 540) versus all patients (N=336). 
2. Controls (N = 540) versus schizophrenic patients (N = 247). 
3. Controls (N = 540) versus bipolar patients (N = 89). 
American sample 
1. Controls (N = 483) versus the whole sample of patients (all of them schizophrenics or 
with schizoaffective disorder) (N = 498). 
However, for the case-control haplotype association analysis, only the comparisons marked in 
bold were made, to ensure that sample sizes were large enough to make a reliable estimation of 
haplotype frequencies. 
Moreover, for those genes with genotypic information for more than one sample, an additional 
case-control analysis of the genotypic frequencies with a pooled sample (result of the 
combination of individuals from different country of origin) was also performed.  
Finally, to simplify the information given in this section, only the complete results for the first 
two comparisons will be shown. Only in case there is a significant result for any of the other 
comparisons, then it will be indicated in the text or in a summary table.  
3.1. Estimation of the statistical power 
Prior to the association analysis, the statistical power to detect association was calculated with 
Quanto software. These estimations are summarized in table R21. Particularly, this power 
ranged between 0.08 and 0.99 depending on several factors, such as the sample size, the risk 
associated to each allele and the frequency of this allele. Thus, for those polymorphisms with a 
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low MAF, the statistical power to detect association with the disease is expected to be lower, 
especially if the expected risk is low.  
 
 
Table R21. Estimation of the statistical power associated to the different case-control and family-based 
studies. 
Type of study Sample N Frequency of the risk allele
a
 
Statistical Power 
OR = 1.3 OR = 2 
Case-control Spanish 
298 patients 
 348 controls 
0.01 0.076 0.2834 
0.03 0.1334 0.6839 
0.05 0.1891 0.8743 
0.1 0.3366 0.9919 
0.2 0.4938 0.9997 
0.3 0.5943 0.9998 
0.4 0.6405 0.9999 
0.5 0.6480 0.9999 
Case-control German 
330 patients 
 534 controls 
0.01 0.0872 0.3831 
0.03 0.1614 0.8053 
0.05 0.2328 0.9460 
0.1 0.3889 0.9977 
0.2 0.5959 0.9999 
0.3 0.7008 0.9999 
0.4 0.7455 0.9999 
0.5 0.7509 0.9999 
Case-control American 
498 patients  
483 controls 
0.01 0.09 0.4355 
0.03 0.1832 0.8626 
0.05 0.2681 0.9715 
0.1 0.4489 0.9994 
0.2 0.6729 0.9999 
0.3 0.7768 0.9999 
0.4 0.8189 0.9999 
0.5 0.8245 0.9999 
Family-based American 400 families 
0.01 0.086 0.3718 
0.03 0.1584 0.7914 
0.05 0.2280 0.9390 
0.1 0.3808 0.9971 
0.2 0.5859 0.9999 
0.3 0.6912 0.9999 
0.4 0.7369 0.9999 
0.5 0.7429 0.9999 
a. The risk allele was considered to be the minor allele. 
Abbreviation: OR, Odds Ratio. 
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3.2. SLC6A4 gene 
Prior to the statistical analyses, genotypes of 5-HTTLPR promoter polymorphism were grouped 
according to the level of activity detected in previous reports for each of the four alleles (Kraft et 
al., 2005; Hu et al., 2006). Therefore, three groups of genotypes were considered: “high 
expression genotypes” (LA/LA), “medium expression genotypes” (LA/LG, LA/SA and LA/SG) and “low 
expression genotypes” (LG/LG, LG/SA, LG/SG, SA/SG, SA/SA and SG/SG). With this strategy, genotypic 
groups with very low frequency are avoided and the statistical power is increased. However, for 
the haplotype and allele analysis, the four alleles of 5-HTTLPR were considered separately. 
All the results from the case-control analysis of this gene can be found below.  
3.2.1. Allelic frequencies. 
The results from the comparisons of the allelic frequencies between a) controls and all patients 
and b) controls and hallucinatory patients are shown in tables R22 and R23, respectively. As it 
can be seen, SNPs rs140700 and rs2020936 were found to be associated with psychosis when all 
patients were considered (table R22). Particularly, allele C from rs2020936 and allele A from 
rs140700 were significantly less frequent in the psychotic group. However, only the association 
with rs2020936 remained significant when the subset of hallucinatory patients was compared 
with the controls (table R23). In any case, the associations were in general weak and after 
multiple-testing correction the P values did not remain significant. 
 
 
Table R22. Comparison of the allelic frequencies of SLC6A4 polymorphisms in psychotic patients and 
healthy controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs3813034 
G 0.4715 0.4693 1 
0.006 0.938 (1) 
T 0.5285 0.5307 0.991 (0.796-1.235) 
rs1042173 
G 0.4815 0.4721 1 
0.113 0.737 (1) 
T 0.5185 0.5279 0.963 (0.773-1.2) 
rs140700 
A 0.04833 0.08254 1 
5.45 
0.0196 
(0.2152) G 0.9517 0.9175 1.772(1.09-2.879) 
rs2020942 
A 0.3658 0.3284 1 
1.959 0.162 (1) 
G 0.6342 0.6716 0.848 (0.673-1.068) 
STin2 
12 rep 0.6429 0.6776 1 
1.668 0.197 (1) 
10 rep 0.3571 0.3224 1.168 (0.923-1.478) 
rs2020939 
C 0.5406 0.558 1 
0.359 0.549 (1) 
T 0.4594 0.442 1.073 (0.852-1.35) 
rs2020936 
C 0.1644 0.2141 1 
5.075 
0.0243 
(0.2427) T 0.8356 0.7859 1.384 (1.042-1.838) 
rs2066713 
C 0.646 0.6711 1 
0.892 0.345 (1) 
T 0.354 0.3289 1.118 (0.887-1.409) 
rs4251417 
A 0.06506 0.07166 1 
0.198 0.657 (1) 
G 0.9349 0.9283 1.109 (0.702-1.753) 
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Table R22 (continuation). Comparison of the allelic frequencies of SLC6A4 polymorphisms in psychotic 
patients and healthy controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
5-HTTLPR 
(including 
rs25531) 
LA 0.4505 0.4797 1 
1.104 0.576 (1) 
LG 0.04785 0.05072 1.005 (0.599 - 1.686) 
SA 0.4901 0.4638 1.125 (0.899 - 1.409) 
SG 0.01155 0.005797 2.122 (0.615 - 7.324) 
rs12945042 
G 0.7286 0.719 1 
0.133 0.715 (1) 
A 0.2714 0.281 0.9532 (0.737-1.233) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; rep, repeats. 
 
 
Table R23. Comparison of the allelic frequencies of SLC6A4 polymorphisms in hallucinatory psychotic 
patients and healthy controls from the Spanish sample. 
Polymorphism Allele 
Hallucinatory 
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs3813034 
G 0.4614 0.4693 1 
0.0677 0.795 (1) 
T 0.5386 0.5307 1.032 (0.812 - 1.313) 
rs1042173 
G 0.4727 0.4721 1 
0.00037 0.985 (1) 
T 0.5273 0.5279 0.998 (0.785 - 1.268) 
rs140700 
A 0.05122 0.08254 1 
3.733 
0.0534 
(0.5335) G 0.9488 0.9175 1.667 (0.988 - 2.811) 
rs2020942 
A 0.3795 0.3284 1 
3.076 
0.0795 
(0.5171) G 0.6205 0.6716 0.799 (0.623 - 1.027) 
STin2 
12 rep 0.6297 0.6776 1 
2.651 
0.1035 
(0.828) 10 rep 0.3703 0.3224 1.236 (0.958 - 1.595) 
rs2020939 
C 0.5463 0.558 1 
0.137 0.711 (1) 
T 0.4537 0.442 1.048 (0.817 - 1.345) 
rs2020936 
C 0.1659 0.2141 1 
3.95 
0.0469 
(0.5156) T 0.8341 0.7859 1.369 (1.004 - 1.868) 
rs2066713 
C 0.6364 0.6711 1 
1.431 0.232 (1) 
T 0.3636 0.3289 1.166 (0.907 - 1.499) 
rs4251417 
A 0.05122 0.07166 1 
1.74 0.187 (1) 
G 0.9488 0.9283 1.43 (0.839 - 2.438) 
5-HTTLPR 
(including 
rs25531) 
LA 0.4467 0.4797 1 
2.156 0.340 (1) 
LG 0.04 0.05072 0.847 (0.467 - 1.535) 
SA 0.5022 0.4638 1.163 (0.911 - 1.485) 
SG 0.01111 0.005797 2.059 (0.546 - 7.756) 
rs12945042 
G 0.7293 0.719 1 
0.129 0.719 (1) 
A 0.2707 0.281 0.950 (0.719 - 1.255) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; rep, repeats. 
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With regard to the remaining case-control comparisons, there were some significant 
associations (table R24). However, neither of the significant values resisted the sequential 
Bonferroni correction. Moreover, the validity of the results presented in table R24 is limited 
because of the small number of patients without AH (N = 77) and patients with chronic AH (N = 
81). 
 
 
Table R24. Summary of the significant associations found for the remaining case-control comparisons. 
Comparison Polymorphism P Value
a
 
Patients with AH vs patients without AH rs4251417 0.0245 (0.269) 
Patients with cronic AH vs controls rs2020942 0.0060 (0.066) 
Patients with cronic AH vs controls STin2 0.0072 (0.072) 
Patients with cronic AH vs controls rs2020936 0.0332 (0.299) 
Patients with cronic AH vs controls rs2066713 0.0437 (0.349) 
Patients with cronic AH vs patients without AH rs2020942 0.0285 (0.314) 
Patients with cronic AH vs patients without AH STin2 0.0314 (0.314) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: AH, auditory hallucinations; vs, versus. 
 
 
3.2.2. Genotypic frequencies. 
Tables R25 and R26 show the results from the case-control association analyses. In coherence 
with the comparisons of the allelic frequencies (section 3.2.1), polymorphisms rs140700 and 
rs2020936 appeared to be associated with psychosis when all patients were considered (table 
R25: P = 0.017 and P = 0.0045, respectively) but also when the subsample of patients with AH 
was compared to the genotypic distribution in healthy subjects (table R26: P = 0.047 for 
rs140700 and P = 0.014 for rs2020936). Regarding rs140700, genotypes with the A allele were 
less frequent in the patients group, while, with regard to rs2020936, T/C heterozygotes were 
less frequent than homozygotes T/T in the affected group. Interestingly, after correction for 
multiple testing, the differences in the genotypic distribution of rs2020936 between all patients 
and controls still remained significant (p = 0.0495, see table R25). 
Table R25. Comparison of the genotypic distributions of SLC6A4 polymorphisms in psychotic patients and 
healthy controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P value 
b
 AIC Model 
rs3813034 
T/T-G/T 270 (79%) 230 (77.2%) 1.00 
0.59 (1) 887.9 Recessive 
G/G 72 (21.1%) 68 (22.8%) 1.11 (0.76-1.61) 
rs1042173 
T/T-T/G 268 (78.6%) 228 (76.5%) 1.00 
0.53 (1) 886.5 Recessive 
G/G 73 (21.4%) 70 (23.5%) 1.13 (0.78-1.64) 
rs140700 
G/G 265 (84.1%) 243 (90.3%) 
0.56(0.34-0.91)
a
 
0.017 
(0.17) 
804.3 Additive 
A/G 48 (15.2%) 26 (9.7%) 
A/A 2 (0.6%) 0 (0%) 
rs2020942 
G/G 156 (45.8%) 119 (39.9%) 1.00 
0.14 (1) 884.7 Dominant 
A/G-A/A 185 (54.2%) 179 (60.1%) 1.27 (0.93-1.74) 
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Table R25 (continuation). Comparison of the genotypic distributions of SLC6A4 polymorphisms in 
psychotic patients and healthy controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P value 
b
 AIC Model 
STin2 
12/12 156 (46.6%) 118 (41.1%) 1.00 
0.17 (1) 860.7 Dominant 
10/12-10/10 179 (53.4%) 169 (58.9%) 1.25 (0.91-1.72) 
rs2020939 
C/C-C/T 259 (81.2%) 214 (79%) 1.00 
0.5 (1) 817.5 Recessive 
T/T 60 (18.8%) 57 (21%) 1.15(0.77-1.72) 
rs2020936 
T/T 204 (59.8%) 211 (70.8%) 1.00 
0.0045 
(0.0495) 
878.1 Codominant 
T/C 128 (37.5%) 76 (25.5%) 0.57 (0.41-0.81) 
C/C 9 (2.6%) 11 (3.7%) 1.18 (0.48-2.91) 
rs2066713 
C/C 156 (45.6%) 121 (40.6%) 1.00 
0.2 (1) 886.6 Dominant 
C/T-T/T 186 (54.4%) 177 (59.4%) 1.23 (0.90-1.68) 
rs4251417 
G/G 269 (85.7%) 234 (87%) 1.00 
0.64 (1) 808.5 N/A 
A/G 45 (14.3%) 35 (13%) 0.89 (0.56-1.44) 
5-HTTLPR 
(including 
rs25531) 
low/low 257 (75.4%) 239 (80.2%) 1.00 
0.14 (1) 884.8 Recessive high/low-
high/high 
84 (24.6%) 59 (19.8%) 0.76 (0.52-1.10) 
rs12945042 
G/G-G/A 285 (90.5%) 253 (94%) 1.00 0.11 
(0.99) 
807.4 Recessive 
A/A 30 (9.5%) 16 (6%) 0.60 (0.32-1.13) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
Table R26. Comparison of the genotypic distributions of SLC6A4 polymorphisms in hallucinatory patients 
and healthy controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Hallucinatory
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs3813034 
T/T 93 (27.2 %) 67 (30.4%) 1.00 
0.4 (1) 755.7 Dominant 
G/T-G/G 249 (72.8%) 153 (69.5%) 0.85 (0.59-1.24) 
rs1042173 
T/T-T/G 268 (78.6%) 168 (76.4%) 1.00 
0.54 (1) 755 Recessive 
G/G 73 (21.4%) 52 (23.6%) 1.14 (0.76-1.70) 
rs140700 
G/G 265 (84.1%) 184 (89.8%) 
0.59 (0.35-0.04)
a
 
0.047 
(0.47) 
697.5 Additive 
A/G-A/A 48 (15.2%) 21 (10.2%) 
A/A 2 (0.6%) 0 (0%) 
rs2020942 
G/G 156 (45.8%) 86 (39.1%) 
1.24 (0.27-1.59)
a
 
0.084 
(0.756) 
752.4 Additive 
A/G 146 (42.8%) 101 (45.9%) 
A/A 39 (11.4%) 33 (15%) 
STin2 
12rep/12rep 156 (46.6%) 85 (40.1) 
1.23 (0.96-1.58)
a
 
0.11 
(0.88) 
731.8 Additive 
10rep/12rep 142 (42.4%) 97 (45.8%) 
10rep/10rep 37 (11%) 30 (14.2%) 
rs2020939 
C/C-C/T 259 (81.2%) 160 (78%) 1.00 
0.38 (1) 704.7 Recessive 
T/T 60 (18.8%) 45 (21.9%) 1.21(0.79-1.87) 
rs2020936 
T/T 204 (59.8%) 154 (70%) 1.00 0.014 
(0.154) 
749.3 Dominant 
T/C-C/C 137 (40.2%) 66 (30%) 0.64 (0.44-0.92) 
rs2066713 
C/C 156 (45.6%) 88 (40%) 1.00 
0.19 (1) 754.7 Dominant 
C/T-T/T 186 (54.4%) 132 (60%) 1.26 (0.89-1.77) 
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Table R26 (continuation). Comparison of the genotypic distributions of SLC6A4 polymorphisms in 
hallucinatory patients and healthy controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Hallucinatory
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs4251417 
G/G 269 (85.7%) 184 (89.8%) 1.00 
0.17 (1) 698.5 N/A 
A/G 45 (14.3%) 21 (10.2%) 0.68 (0.39-1.18) 
5-HTTLPR 
(including 
rs25531)* 
low/low 257 (75.4%) 176 (80%) 1.00 
0.2 (1) 753.8 Recessive high/low-
high/high 
84 (24.6%) 44(20%) 0.76 (0.51-1.15) 
rs12945042 
G/G-G/A 285 (90.5%) 190 (92.7%) 1.00 
0.38 (1) 700.6 Recessive 
A/A 30 (9.5%) 15 (7.3%) 0.75 (0.39-1.43) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
Regarding the remaining case-control comparisons, there were some significant associations 
which are shown in table R27. However, neither of the significant values resisted the sequential 
Bonferroni correction. Furthermore, like the comparisons of the allelic frequencies, due to the 
small number of patients without AH (N = 77) and patients with chronic AH (N = 81), the 
reliability of some of the results shown in table R27 should be considered to be very low. 
 
 
Table R27. Summary of the significant associations found for the remaining case-control comparisons. 
Comparison Polymorphism P Value
a
 Model 
Patients without AH vs controls rs2020936 0.022 (0.22) Codominant 
Patients without AH vs controls rs12945042 0.011 (0.121) Codominant 
Patients without AH vs patients with AH rs4251417 0.019 (0.209) N/A 
Schizophrenic patients vs controls rs2020936 0.022 (0.242) Codominant 
Schizophrenics with AH vs controls rs2020936  0.021 (0.231) Additive 
Schizophrenics with AH vs controls rs140700 0.049 (0.49) Dominant 
Patients with cronic AH vs controls rs2020942 0.0071 (0.07881) Additive 
Patients with cronic AH vs controls STin2 0.0084 (0.084) Additive 
Patients with cronic AH vs controls rs2020936 0.015 (0.135) Dominant 
Patients with cronic AH vs controls rs2066713 0.046 (0.368) Additive 
Patients with cronic AH vs patients without AH rs3813034 0.039 (0.312) Dominant 
Patients with cronic AH vs patients without AH rs2020942 0.06 (0.176) Recessive 
Patients with cronic AH vs patients without AH Stin2 0.029 (0.261) Recessive 
Patients with cronic AH vs patients without AH rs2020939 0.018 (0.18) Codominant 
Patients with cronic AH vs patients without AH rs4251417 0.048 (0.336) N/A 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: AH, auditory hallucinations; vs, versus; N/A, not applicable. 
 
3.2.3. Haplotype analysis. 
The most common 11-marker haplotypes detected in our sample can be consulted at table R28.  
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Table R28. Overview of the most common SLC6A4 haplotypes observed in the Spanish sample. 
Haplotype
a
 Patients frequency Controls frequency 
G-G-G-G-12rep-T-T-C-G-SA-G 0.323 0.3047 
T-T-G-A-10rep-C-T-T-G-LA-A 0.1372 0.1447 
T-T-G-A-10rep-C-T-T-G-SA-G 0.0659 0.07106 
G-G-G-G-12rep-T-T-C-A-LA-G 0.05848 0.06504 
T-T-G-G-12rep-C-C-C-G-LA-G 0.04269 0.05642 
T-T-G-A-10rep-C-T-T-G-LA-G 0.0687 0.0543 
T-T-G-G-12rep-C-C-C-G-SA-G 0.06713 0.04565 
G-G-G-G-12rep-T-T-C-G-LA-G 0.02738 0.04309 
T-T-A-G-12rep-C-C-C-G-LA-A 0.0134 0.04147 
T-T-A-G-12rep-C-C-C-G-SA-A 0.01771 0.03379 
All rare (freq < 0.03) 0.17841 0.13978 
Note: global P value (uncorrected) was 0.084 (ns). The patients' data refer to the whole sample of psychotic patients.  
a. The order of the polymorphisms corresponds to the order in the previous tables (R22 to R27). 
Abbreviations: freq, frequency. 
 
 
However, to reduce the number of polymorphisms and therefore to increase the power of our 
results, three SNPs were discarded from the haplotype association analysis because they were in 
very high LD (r2 > 0.94) with other polymorphisms (see table R12). The eliminated 
polymorphisms were rs1042173 (located in the 3’UTR region), STin2 (intron 2) and rs2066713 
(intron 1A). Thus, the haplotype analysis was finally performed with 8 polymorphisms and 
sliding windows of two, three and four-marker haplotypes, as it was explained in the Materials 
and Methods section. The haplotypes which were significantly associated with the disease can 
be found at tables R29 (all patients compared to controls) and R30 (hallucinatory patients 
compared to controls). 
 
 
Table R29. SLC6A4 haplotypes significantly associated with psychosis in the Spanish sample. 
HAPLOTYPE
a
 
Patients 
frequency 
Controls 
frequency 
df 
Global 
P value 
Haplotype 
P value
b
 
rs
3
8
1
3
0
3
4
 
rs
1
0
4
2
1
7
3
 
rs
1
4
0
7
0
0
 
rs
2
0
2
0
9
4
2
 
ST
in
2
 
rs
2
0
2
0
9
3
9
 
rs
2
0
2
0
9
3
6
 
rs
2
0
6
6
7
1
3
 
rs
4
2
5
1
4
1
7
 
5
-H
TT
LP
R
 
rs
1
2
9
4
5
0
4
2
 
T  A         0.0466 0.0825 2 0.0361 0.0139 (0.06194) 
  A G        0.0466 0.0825 2 0.0263 0.0139 (0.06194) 
T  A G        0.0437 0.0825 4 0.0458 0.0139 (0.09191) 
T  A G  C      0.0407 0.0861 3 0.0211 0.01058  (> 0.06) 
    A G  C C     0.0463 0.0861 3 0.0480 0.00869  (0.06693) 
Significant P values (P < 0.05) are indicated in bold. 
a. The polymorphisms which were discarded from the analysis are shown in grey. 
b. The corrected P value after 1000 permutations is indicated in brackets. 
Abbreviation: df, degrees of freedom. 
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Table R30. SLC6A4 haplotypes significantly associated with hallucinatory psychosis in the Spanish sample. 
HAPLOTYPE
a
 
Hallucinatory 
patients 
frequency 
Controls 
frequency 
df 
Global 
P value 
Haplotype 
P value
b
 
rs
3
8
1
3
0
3
4
 
rs
1
0
4
2
1
7
3
 
rs
1
4
0
7
0
0
 
rs
2
0
2
0
9
4
2
 
ST
in
2
 
rs
2
0
2
0
9
3
9
 
rs
2
0
2
0
9
3
6
 
rs
2
0
6
6
7
1
3
 
rs
4
2
5
1
4
1
7
 
5
-H
TT
LP
R
 
rs
1
2
9
4
5
0
4
2
 
  A G        0.0490 0.0825 2 0.0387 0.0379 (0.1029) 
Significant P values (P < 0.05) are indicated in bold. 
a. The polymorphisms which were discarded from the analysis are shown in grey. 
b. The corrected P value after 1000 permutations is indicated in brackets. 
Abbreviation: df, degrees of freedom. 
 
 
According to the information provided by tables R29 and R30, several protective haplotypes 
were found (five haplotypes when all patients were considered and one haplotype for the 
comparison between hallucinatory patients and controls). However, after a 1000-permutation 
run, all results became not significant, although a trend can be still observed in many cases. 
With regard to the comparison between the haplotype frequencies of controls and the subset of 
schizophrenic patients (according to DSM-IV criteria), a protective haplotype (rs3813034 
T/rs140700 A/rs2020942 G/rs2020939 C) was found (global p = 0.02873; haplotype p = 0.2424, 
not significant after 1000 permutations). This haplotype had been also detected when all 
patients were considered (see table R29). 
It should be noted that all those protective haplotypes, which were more frequent in controls, 
were variable combinations of the same SNPs and alleles. Interestingly, allele A from SNP 
rs140700 (previously found to be associated with psychosis in the analysis of allelic and 
genotypic frequencies) was present in all haplotypes. 
 
 
3.3. HTR2A gene 
3.3.1. Allelic frequencies. 
Tables R31 and R32 contain the results from the case-control analysis of the allelic frequencies 
between all patients and controls (table R31) and the patients with AH and controls (table R32). 
In this case, the results were negative for both comparisons, as well as for the remaining 
comparisons (data not shown).  
 
 
Table R31. Comparison of the allelic frequencies of HTR2A SNPs in psychotic patients and healthy controls 
from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs6313 
C 0.5654 0.5614 1 
0.0211 0.8846 (1) 
T 0.4346 0.4386 0.9837 (0.7883 - 1.228) 
rs6311 
A 0.4631 0.4488 1 
0.261 0.6094 (1) 
G 0.5369 0.5512 0.9441 (0.7573 - 1.177) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
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Table R32. Comparison of the allelic frequencies of HTR2A SNPs in hallucinatory psychotic patients and 
healthy controls from the Spanish sample. 
Polymorphism Allele 
Hallucinatory 
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs6313 
C 0.5568 0.5614 1 
0.0228 0.8799 (0.88) 
T 0.4432 0.4386 1.019 (0.8004 - 1.297) 
rs6311 
A 0.4773 0.4488 1 
0.872 0.3504 (0.7) 
G 0.5227 0.5512 0.8919 (0.7014 - 1.134) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
3.3.2. Genotypic frequencies. 
The results were negative for the 8 case-control comparisons. The complete results for the two 
main comparisons (all patients vs. controls and hallucinatory patients vs. controls) can be found 
at tables R33 and R34, respectively. 
 
 
Table R33. Comparison of the genotypic distributions of the two HTR2A polymorphisms in psychotic 
patients and healthy controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs6313 
C/C 105 (30.7%) 95 (31.9%) 1.00 
0.75 (1) 888.1 Dominant 
T/C - T/T 237 (69.3%) 203 (68.1%) 0.95 (0.68-1.32) 
rs6311 
G/G 96 (28.1%) 79 (26.5%) 
1.07 (0.85-1.34)
a
 0.59 (1) 887.9 Additive A/G 185 (54.1%) 162 (54.4%) 
A/A 61 (17.8%) 57 (19.1%) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Table R34. Comparison of the genotypic distributions of the two HTR2A polymorphisms in psychotic 
patients with AH and healthy controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Hallucinatory 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs6313 
C/C - T/C 279 (81.6%) 175 (79.5%) 1.00 0.55 
(0.66) 
756 Recessive 
T/T 63 (18.4%) 45 (20.4%) 1.14 (0.74 - 1.74) 
rs6311 
G/G 96 (28.1%) 55 (25%) 
1.13 (0.88-1.46)
a
 
0.33 
(0.66) 
755.4 Additive A/G 185 (54.1%) 120 (54.5%) 
A/A 61 (17.8%) 45 (20.4%) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
3.3.3. Haplotype analysis. 
Table R35 and R36 show the haplotype frequencies estimated by the Unphased program in 
control subjects, all patients and the subset of patients with AH. In all samples, there are three 
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common haplotypes as well as a rare haplotype (frequency < 0.03). However, no differences in 
the haplotype frequencies between patients and controls (table R35) or between hallucinatory 
patients and controls (table R36) were found (global P values < 0.05). With regard to the 
comparison between schizophrenic patients and controls, the results are also negative (data not 
shown). However, in the three case-control comparisons, there is a risk haplotype (C-A), which 
shows a slight trend toward association, with a higher frequency in the patients group. 
 
 
Table R35. Results from the HTR2A haplotype association analysis between all patients and healthy 
subjects. 
Haplotype
a
 Patients frequency Controls frequency OR (95% CI) χ
2
 P 
C-A 0.03026 0.01618 1 2.867 0.09043 
T-A 0.4328 0.4326 0.5351 (0.2481 – 1.154) 2.564E-005 0.996 
C-G 0.5352 0.5452 0.5251 (0.2443 – 1.128) 0.1304 0.718 
T-G 0.001733 (rare) 0.005951 (rare) 0.1558 (0.01545 - 1.57) N/A N/A 
Note: the global P value (uncorrected) was 0.244 (not significant). 
a. The order of the SNPs in the haplotype is rs6313-rs6311. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
Table R36. Results from the HTR2A haplotype association analysis between hallucinatory patients and 
healthy subjects. 
Haplotype
a
 
Hallucinatory patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P 
C-A 0.03645 0.01618 1 4.696 0.03024 
T-A 0.4408 0.4326 0.4524 (0.2055 – 0.9957) 0.07268 0.7875 
C-G 0.5204 0.5452 0.4238 (0.1932 – 0.9293) 0.6656 0.4146 
T-G 0.002361 (rare) 0.005951 (rare) 0.11762 (0.0174 - 1.785) N/A N/A 
Significant P values (P < 0.05) are indicated in bold. 
The global P value (uncorrected) was 0.093 (not significant). 
a. The order of the SNPs in the haplotype is rs6313-rs6311. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
3.4. TPH2 gene 
3.4.1. Allelic frequencies. 
As it can be seen at tables R37 and R38, no significant differences in the allelic frequencies were 
found between all psychotic patients and controls (table R37) or between hallucinatory patients 
and controls (table R38). With regard to the other comparisons, in coherence with the other 
results, no significant differences were found (data not shown). 
 
 
Table R37. Comparison of the allelic frequencies of the TPH2 SNP in psychotic patients and healthy 
controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P 
rs4570625 
G 0.8473 0.8174 1 
2.089 0.1484 
T 0.1527 0.1826 0.8069 (0.6029 - 1.08)  
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
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Table R38. Comparison of the allelic frequencies of theTPH2 SNP in hallucinatory psychotic patients and 
healthy controls from the Spanish sample. 
Polymorphism Allele 
Hallucinatory 
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P 
rs4570625 
G 0.8432 0.8174 1 
1.275 0.2589 
T 0.1568 0.1826 0.8328 (0.6059 - 1.144) 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
3.4.2. Genotypic frequencies. 
When the genotypic frequencies of rs4570625 in controls were compared to those observed in 
the whole group of psychotic patients (table R39) and the subsample of hallucinatory patients 
(table R40), no significant differences were detected.  
 
 
Table R39. Comparison of the genotypic distributions of the TPH2 SNP in psychotic patients and healthy 
controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value AIC Model 
rs4570625 
G/G 243 (66.2%) 214 (71.8%) 1.00 
0.12 916.3 Dominant 
G/T - T/T 124 (33.8%) 84 (28.2%) 0.77 (0.55-1.07) 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Table R40. Comparison of the genotypic distributions of the TPH2 SNP in psychotic patients with AH and 
healthy controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Hallucinatory 
patients 
frequency 
OR (95% CI) P Value AIC Model 
rs4570625 
G/G 243 (66.2%) 158 (71.8%) 1.00 
0.16 778.5 Dominant 
G/T - T/T 124 (33.8%) 62 (28.2%) 0.77 (0.53-1.11) 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
With regard to the other case-control comparisons, the results were once again negative (data 
not shown). 
 
3.5. NOS1 gene 
3.5.1. Allelic frequencies. 
Tables R41 and R42 include the results about the distribution of the allelic frequencies in 
controls, all the sample of patients and the subsample of hallucinatory cases. There were no 
differences in those frequencies between controls and all psychotic patients (table R41) or 
between controls and the group of patients with AH (table R42). In coherence with these results, 
the other case-control analyses did not give significant results (data not shown). 
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Table R41. Comparison of the allelic frequencies of the NOS1 VNTR in psychotic patients and healthy 
controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P 
NOS1 Ex1f-VNTR 
L 0.5276 0.5356 1 
0.06727 0.7953 
S 0.4724 0.4644 1.033 (0.8096 - 1.317) 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; L, long alleles; S, short alleles. 
 
 
Table R42. Comparison of the allelic frequencies of the NOS1 VNTR in hallucinatory psychotic patients and 
healthy controls from the Spanish sample. 
Polymorphism Allele 
Hallucinatory 
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P 
NOS1 Ex1f-VNTR 
L 0.5317 0.5356 1 
0.01308 0.909 
S 0.4683 0.4644 1.016 (0.7798 - 1.322) 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; L, long alleles; S, short alleles. 
 
 
3.5.2. Genotypic frequencies. 
In this case, no differences were found in the genotypic frequencies of healthy subjects and 
psychotic patients (table R43) or between healthy subjects and patients with AH (table R44). 
 
 
 Table R43. Comparison of the genotypic distributions of the NOS1 VNTR in psychotic patients and healthy 
controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value AIC Model 
NOS1 Ex1f-VNTR 
L/L 80 (30%) 72 (28.4%) 1.00 
0.68 725.8 Dominant 
S/L - S/S 187 (70%) 182 (71.7%) 1.08 (0.74-1.58) 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; L, long alleles; S, short alleles. 
 
 
Table R44. Comparison of the genotypic distributions of the NOS1 VNTR in psychotic patients with AH and 
healthy controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Hallucinatory 
patients frequency 
OR (95% CI) P Value AIC Model 
NOS1 Ex1f-VNTR 
L/L 80 (30%) 53 (28%) 1.00 
0.66 622.5 Dominant 
S/L - S/S 187 (70%) 136 (72%) 1.10 (0.73-1.66) 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; L, long alleles; S, short alleles. 
 
 
Regarding the remaining case-control comparisons, the results were also negative and very 
similar to those shown in tables R43 and R44 (data not shown). 
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3.6. STMN1 gene 
3.6.1. Allelic frequencies. 
The results from the association analysis of allelic frequencies are shown at tables R45 (all 
patients against controls) and R46 (patients with AH against controls). There were no significant 
differences between all patients and controls, or between hallucinatory patients and controls. 
The same negative findings were obtained for the other case-control comparisons (data not 
shown). 
 
 
Table R45. Comparison of the allelic frequencies of STMN1 SNPs in psychotic patients and healthy 
controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs12037513 
 
T 0.7379 0.6911 1 
3.104 
0.07809 
(0.156) C 0.2621 0.3089 0.7945 (0.615 - 1.026) 
rs182455 
C 0.5755 0.5503 1 
0.8515 
0.3561 
(0.356) T 0.4245 0.4497 0.9025 (0.7258 - 1.122) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Table R46. Comparison of the allelic frequencies of STMN1 SNPs in hallucinatory psychotic patients and 
healthy controls from the Spanish sample. 
Polymorphism Allele 
Hallucinatory 
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs12037513 
 
T 0.722 0.6911 1 1.133 
 
0.2872 
(0.3016) 
 C 0.278 0.3089 0.8616 (0.6548 - 1.134) 
rs182455 
C 0.5932 0.5503 1 
2.064 
0.1508 
(0.3016) T 0.4068 0.4497 0.8391 (0.6606 - 1.066) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
3.6.2. Genotypic frequencies. 
Results were mainly negative for the 8 case-control comparisons. The complete results for the 
two main comparisons (all patients vs. controls and hallucinatory patients vs. controls) are 
negative and can be found at tables R47 and R48, respectively.  However, despite the negative 
results, a trend can be observed when controls are compared with the complete sample of 
patients (see table R47): T/T homozygotes for rs12037513, as well as individuals with at least 
one copy of allele C from rs182455, tend to be more frequent in the patients group. However, 
this trend became significant for rs182455 when the control sample was compared with a 
subset of those patients diagnosed as schizophrenics according to DSM-IV criteria (see table 
R49).  
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Table R47. Comparison of the genotypic distributions of STMN1 polymorphisms in psychotic patients and 
healthy controls from the Spanish sample. 
SNP Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs12037513 
T/T 149 (47.5%) 144 (53.5%) 
0.79 (0.61-1.02)
a
 
0.074 
(0.124) 
814.3 Additive T/C 136 (43.3%) 109 (40.5%) 
C/C 29 (9.2%) 16 (6%) 
rs182455 
C/C - T/C 285 (77.5%) 248 (83.2%) 1.00 0.062 
(0.124) 
925.4 Recessive 
T/T 83 (22.6%) 50 (16.8%) 1.07 (0.85-1.34) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence interval. 
 
 
Table R48. Comparison of the genotypic distributions of STMN1 polymorphisms in hallucinatory patients 
and healthy controls from the Spanish sample. 
SNP Genotype 
Controls 
frequency 
Hallucinatory 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs12037513 
T/T 149 (47.5%) 107 (52.2%) 
0.86 (0.65-1.13)
a
 0.28 (0.28) 699.3 Additive T/C 136 (43.3%) 82 (40%) 
C/C 29 (9.2%) 16 (7.8%) 
rs182455 
C/C - T/C 285 (77.5%) 184 (83.6%) 1.00 0.067 
(0.134) 
778.1 Recessive 
T/T 83 (22.6%) 36 (16.4%) 0.67 (0.44-1.04) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence interval. 
 
 
Table R49. Comparison of the genotypic distributions of STMN1 polymorphisms in schizophrenic patients 
and healthy controls from the Spanish sample. 
SNP Genotype 
Controls 
frequency 
Schizophrenic 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs12037513 
T/T 149 (47.5%) 107 (52.2%) 
0.86 (0.65-1.13)
a
 
0.28 
(0.28) 
699.3 Additive T/C 136 (43.3%) 82 (40%) 
C/C 29 (9.2%) 16 (7.8%) 
rs182455 
C/C - T/C 285 (77.5%) 185 (84.9%) 1.00 0.027 
(0.54) 
772.7 Recessive 
T/T 83 (22.6%) 33 (15.1%) 0.61 (0.39-0.95) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence interval. 
 
 
3.6.3. Haplotype analysis. 
Tables R50 and R51 show the comparisons of the haplotype frequencies (estimated by the 
Unphased program) between a) control subjects and all patients and b) control subjects and the 
subset of patients with AH. Four common haplotypes (frequency > 0.03) were detected. 
However, there were no significant differences in the haplotype distribution between patients 
and controls (table R50) or between hallucinatory patients and controls (table R51). Regarding 
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the case-control association study between schizophrenic patients and controls, the results are 
similar and also negative (data not shown).  
 
Table R50. Results from the STMN1 haplotype association analysis between all patients and healthy 
subjects. 
Haplotype
a
 Patients frequency Controls frequency OR (95% CI) χ
2
 P 
T-C 0.4823 0.4437 1 1.906 0.1675 
T-T 0.2584 0.2474 0.9611 (0.7025 - 1.315) 0.1974 0.6568 
C-C 0.09049 0.104 0.8001 (0.4897 - 1.307) 0.809 0.3684 
C-T 0.1688 0.2049 0.7583 (0.5472 - 1.051) 2.769 0.09609 
Note: the global P value (uncorrected) was 0.3055 (not significant). 
a. The order of the SNPs in the haplotype is rs12037513-rs182455. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Table R51. Results from the STMN1 haplotype association analysis between hallucinatory patients and 
healthy subjects. 
Haplotype
a
 
Hallucinatory 
patients frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P 
C-A 0.4743 0.4437 1 1.373 0.2412 
T-A 0.2512 0.2474 0.9503 (0.6743 – 1.339) 0.002098 0.9635 
C-G 0.1115 0.104 1.003 (0.6078 – 1.655) 0.0192 0.8898 
T-G 0.163 0.2049 0.7443 (0.5197 - 1.066) 2.516 0.1127 
Note: the global P value (uncorrected) was 0.444 (not significant). 
a. The order of the SNPs in the haplotype is rs12037513-rs182455. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
3.7. ASPM gene 
3.7.1. Case-control analysis of the allelic frequencies. 
3.7.1.1. Spanish Sample 
The results from the case-control comparisons of the allelic frequencies can be found at tables 
R52 (all patients against controls) and R53 (hallucinatory patients against controls). 
Unfortunately, no differences were found for any SNP or case-control comparison. 
Table R52. Comparison of the allelic frequencies of ASPM polymorphisms in psychotic patients and 
healthy controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs6700180 
T 0.4927 0.4624 1 
1086 0.2973 (1) 
C 0.5073 0.5376 0.8855 (0.7046 - 1.113) 
rs3762271 
A 0.3977 0.4267 1 
1106 0.293 (1) 
C 0.6023 0.5733 1.127 (0.9016 - 1.41) 
rs12138336 
C 0.08725 0.06745 1 
1761 0.1845 (1) 
G 0.9128 0.9326 0.7567 (0.5007 - 1.143) 
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Table R52 (continuation). Comparison of the allelic frequencies of ASPM polymorphisms in psychotic 
patients and healthy controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs41310927 
A 0.6023 0.5881 1 
0.2786 0.5976 (1) 
G 0.3977 0.4119 0.9425 (0.7564 - 1.174) 
rs10922163 G 0.4926 0.4524 1 
1.881 0.1703 (1) 
 A 0.5074 0.5476 0.851 (0.6758 - 1.072) 
rs4915337 
A 0.8909 0.9032 1 
0.5219 0.47 (1) 
T 0.1091 0.09677 1.142 (0.7958 - 1.64) 
rs6677082 
T 0.8959 0.8921 1 
0.04526 0.8315 (1) 
C 0.1041 0.1079 0.9602 (0.6606 - 1.396) 
rs9726778 
C 0.1208 0.1085 1 
0.4756 0.4904 (1) 
G 0.8792 0.8915 0.8858 (0.6274 - 1.251) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Table R53. Comparison of the allelic frequencies of ASPM polymorphisms in hallucinatory psychotic 
patients and healthy controls from the Spanish sample. 
Polymorphism Allele 
Hallucinatory
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs6700180 
T 0.5 0.4624 1 
1428 0.232 (1) 
C 0.5 0.5376 0.8601 (0.6716 - 1.101) 
rs3762271 
A 0.4023 0.4267 1 
0.6556 0.4181 (1) 
C 0.5977 0.5733 1.106 (0.8668 - 1.411) 
rs12138336 
C 0.07955 0.06745 1 
0.5843 0.4446 (1) 
G 0.9205 0.9326 0.8369 (0.53 - 1.322) 
rs41310927 
A 0.5932 0.5881 1 
0.02971 0.8632 (1) 
G 0.4068 0.4119 0.9791 (0.7701 - 1.245) 
rs10922163 
G 0.4927 0.4524 1 
1.62 0.2031 (1) 
A 0.5073 0.5476 0.8506 (0.663 - 1.091) 
rs4915337 
A 0.9 0.9032 1 
0.03147 0.8592 (1) 
T 0.1 0.09677 1.037 (0.6939 - 1.55) 
rs6677082 
T 0.9 0.8921 1 
0.1667 0.683 (1) 
C 0.1 0.1079 0.9183 (0.6099 - 1.383) 
rs9726778 
C 0.1114 0.1085 1 
0.0224 0.881 (1) 
G 0.8886 0.8915 0.9712 (0.6624 - 1.424) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
3.7.1.2. American Sample 
As it can be seen at table R54, there were no significant differences in the allelic frequencies of 
any SNP between schizophrenic patients and healthy subjects. These results are in accordance 
with the results from the Spanish subjects. 
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Table R54. Comparison of the allelic frequencies of ASPM polymorphisms in schizophrenic patients and 
healthy controls from the American sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs3762271 
C 0.6094 0.5881 1 
0.803 0.3702 (0.744) 
A 0.3906 0.4119 0.9152 (0.754 - 1.111) 
rs12138336 
G 0.9146 0.9291 1 
1.225 0.2684 (0.744) 
C 0.08537 0.07094 1.222 (0.8563 - 1.745) 
rs41310927 
A 0.606 0.5767 1 
1.519 0.2177 (0.744) 
G 0.394 0.4233 0.8855 (0.7298 - 1.074) 
rs10922163 
A 0.4882 0.5299 1 
2.985 0.0840 (0.504) 
G 0.5118 0.4701 1.181 (0.9778 - 1.428) 
rs12116571 
G 0.8925 0.8658 1 
2.85 0.09137 (0.504) 
A 0.1075 0.1342 0.7772 (0.5793 - 1.043) 
rs6677082 
T 0.9159 0.8973 1 
1.749 0.186 (0.744) 
C 0.08413 0.1027 0.8025 (0.5787 - 1.113) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
3.7.2. Case-control analysis of the genotypic frequencies. 
3.7.2.1. Spanish Sample 
Genotypic frequencies of the different subsets were compared and the main results can be 
found at tables R55 (all patients against control subjects) and R56 (hallucinatory patients against 
control subjects). There were significant differences in the genotypic frequencies of two SNPs: 
rs6700180 (intron 19) and rs10922163 (intron 17). Positive associations were found when the 
whole sample of patients was considered (table R55) but also when the subset of patients with 
hallucinations was compared to the control group (table R56). Interestingly, almost all the 
significant P values resisted the sequential Bonferroni correction (the only exception was 
rs6700180 when all patients were compared to controls, but a clear trend is still observed).  
 
 
Table R55. Comparison of the genotypic distributions of ASPM polymorphisms in psychotic patients and 
healthy controls from the Spanish sample. 
Marker Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs6700180 
C/C 102 (32%) 62 (22.9%) 1.00 0.0091 
(0.0637) 
810.6 Codominant T/C 139 (43.6%) 151 (55.7%) 1.79 (1.21-2.64) 
T/T 78 (24.4%) 58 (21.4%) 1.22 (0.77-1.95) 
rs3762271 
C/C - A/C 275 (80.7%) 253 (84.9%) 1.00 0.16 
(0.84) 
884.9 Recessive 
A/A 66 (19.4%) 45 (15.1%) 0.74 (0.49-1.12) 
rs12138336 
G/G 298 (87.4%) 248 (83.2%) 1.00 0.14 
(0.84) 
884.7 Dominant 
C/G - C/C 43 (12.6%) 50 (16.8%) 1.40 (0.90-2.17) 
rs41310927 
A/A - A/G 302 (81.8%) 253 (84.9%) 1.00 
0.29 (1) 920 Recessive 
G/G 67 (18.2%) 45 (15.1%) 0.80 (0.53-1.21) 
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Table R55 (continuation). Comparison of the genotypic distributions of ASPM polymorphisms in psychotic 
patients and healthy controls from the Spanish sample. 
Marker Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs10922163 
A/A 104 (33%) 61 (22.7%) 1.00 0.005 
(0.04) 
801.4 Codominant G/A 137 (43.5%) 151 (56.1%) 1.88 (1.27-2.78) 
G/G 74 (23.5%) 57 (21.2%) 1.31 (0.82-2.10) 
rs4915337 
A/A 277 (81.2%) 235 (78.9%) 
1.15 (0.79-1.67)
a
 0.46 (1) 886.4 Additive A/T 62 (18.2%) 61 (20.5%) 
T/T 2 (0.6%) 2 (0.7%) 
rs6677082 
T/T 248 (78.7%) 214 (79.5%) 
0.96 (0.65-1.41)
a
 0.82 (1) 809.9 Additive T/C 66 (20.9%) 54 (20.1%) 
C/C 1 (0.3%) 1 (0.4%) 
rs9726778 
G/G 269 (78.9%) 229 (76.8%) 
1.14 (0.80-1.62)
a
 0.48 (1) 886.4 Additive C/G 70 (20.5%) 66 (22.1%) 
C/C 2 (0.6%) 3 (1%) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
Table R56. Comparison of the genotypic distributions of ASPM SNPs in hallucinatory patients and healthy 
controls from the Spanish sample. 
Marker Genotype 
Controls 
frequency 
Hallucinatory 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs6700180 
C/C 102 (32%) 43 (21%) 1.00 
0.0031 
(0.0217) 
695.9 Codominant T/C 139 (43.6%) 119 (58%) 2.03 (1.32-3.13) 
T/T 78 (24.4%) 43 (21%) 1.31 (0.78-2.19) 
rs3762271 
C/C - A/C 275 (80.7%) 187 (85%) 1.00 
0.18 (1) 753.6 Recessive 
A/A 66 (19.4%) 33 (15%) 0.74 (0.47-1.16) 
rs12138336 
G/G 298 (87.4%) 186 (84.5%) 1.00 
0.34 (1) 754.5 Dominant 
C/G - C/C 43 (12.6%) 34 (15.4%) 1.27 (0.78-2.06) 
rs41310927 
A/A - A/G 302 (81.8%) 186 (84.5%) 1.00 
0.4 (1) 781.7 Recessive 
G/G 67 (18.2%) 34 (15.4%) 0.82 (0.52-1.29) 
rs10922163 
A/A 104 (33%) 44 (21.5%) 1.00 
0.0021 
(0.0168) 
691.1 Codominant G/A 137 (43.5%) 120 (58.5%) 2.07 (1.35-3.18) 
G/G 74 (23.5%) 41 (20%) 1.31 (0.78-2.20) 
rs4915337 
A/A - A/T 339 (99.4%) 219 (99.5%) 1.00 
0.83 (1) 755.4 Recessive 
T/T 2 (0.6%) 1 (0.4%) 0.77 (0.07-8.59) 
rs6677082 
T/T 248 (78.7%) 165 (80.5%) 
0.91 (0.60-1.40)
a
 0.67 (1) 701.2 Additive T/C 66 (20.9%) 39 (19%) 
C/C 1 (0.3%) 1 (0.5%) 
rs9726778 
G/G - C/G 339 (99.4%) 219 (99.5%) 1.00 
0.83 (1) 755.4 Recessive 
C/C 2 (0.6%) 1 (0.4%) 0.77 (0.07-8.59) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
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Moreover, there were some significant associations in the remaining comparisons, which also 
involved SNPs rs6700180 and rs10922163. These findings are summarized in table R57. 
 
 
Table R57. Significant results from the case-control association analysis which compared the genotypic 
distribution of ASPM polymorphisms between different groups from the Spanish sample. 
Comparison Polymorphism P Value
a
 Model 
Schizophrenic patients vs controls rs6700180 0.0018 (0.0112) Codominant 
Schizophrenic patients vs controls rs10922163 0.0014 (0.0126) Codominant 
Schizophrenic patients with AH vs controls rs6700180 0.0015 (0.012) Codominant 
Schizophrenic patients with AH vs controls rs10922163 0.0016 (0.012) Dominant 
Patients with chronic AH vs controls rs6700180 0.011 (0.077) Dominant 
Patients with chronic AH vs controls rs10922163 0.0058 (0.046) Dominant 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: vs, versus; AH, auditory hallucinations. 
 
 
However, these findings should be taken cautiously, since the two significant SNPs are not in 
HWE in patients and controls, therefore they could be representing a false positive. 
 
 
3.7.2.2. American Sample 
We also found significant differences in the case-control association analysis (table R58). SNP 
rs12116571 gave the most significant association (P = 0.001 for the Fisher’s exact test; P = 0.008 
for the logistic regression analysis), while the genotypic frequencies between cases and controls 
also differed slightly for two other SNPs: rs10922163 (logistic regression P = 0.042) and 
rs6677082 (Fisher’s exact test P = 0.03). However, only the significant associations of 
rs12116571 survived the correction for multiple testing. With regard to SNP rs10922163, this 
SNP was also found to be associated with schizophrenia in the Spanish sample and in both cases 
the A/A individuals were significantly less frequent in the affected group. 
 
 
Table R58. Case-control association analysis for ASPM SNPs in the American Sample. 
SNP Genotype 
CONTROLS 
frequency 
CASES 
frequency 
Fisher’s exact 
test 
P value
a,b
 
OR (95% CI) 
Logistic 
regression 
P value
b
 
rs3762271 
C/C 149 (34.57%) 151 (37.94%) 
0.580 (1) 
0.927  
(0.672-1.279)
c
 
0.646 (1)
c
 
C/A 209 (48.49%) 185 (46.48%) 
0.831  
(0.541 - 1.279)
d
 
0.401 (0.813)
d
 
A/A 73 (16.94%) 62 (15.58%) 
rs12138336 
G/G 371 (86.08%) 324 (83.08%) 
0.417 (1) 
1.263  
(0.838 - 1.901)
c
 
0.264 (1)
c
 
C/G 58 (13.46%) 65 (16.67%) 
0.659  
(0.0386-11.254)
d
 
0.774 (0.813)
d
 
C/C 2 (0.46%) 1 (0.26%) 
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Table R58 (continuation). Case-control association analysis for ASPM SNPs in the American Sample. 
SNP Genotype 
CONTROLS 
frequency 
CASES 
frequency 
Fisher’s exact 
test 
P value
a,b
 
OR (95% CI) 
Logistic 
regression 
P value
b
 
rs41310927 
A/A 143 (33.18%) 148 (37.47%) 
0.397 (1) 
0.910  
(0.659 - 1.257)
c
 
0.568 (1)
c
 
A/G 211 (48.96%) 185 (46.84%) 
0.786 
 (0.512 - 1.206)
d
 
0.271 (0.813)
d
 
G/G 77 (17.87%) 62 (15.70%) 
rs10922163 
A/A 119 (27.74%) 89 (21.92%) 
0.135 (0.54) 
1.441  
(1.012 - 2.049)
c
 
0.042 (0.21)
c
 
A/G 218 (50.82%) 217 (53.45%) 
1.481  
(0.975 - 2.248)
d
 
0.065 (0.325)
d
 
G/G 92 (21.45%) 100 (24.63) 
rs12116571 
G/G 321 (75.65%) 320 (81.42%) 
0.001 (0.006) 
0.604  
(0.416 - 0.877)
c
 
0.008 (0.048)
c
 
G/A 105 (24.42%) 61 (15.52%) 
2.508  
(0.769 - 8.179)
d
 
0.127 (0.508)
d
 
A/A 4 (0.93%) 12 (3.05%) 
rs6677082 
T/T 353 (80.78%) 329 (83.29%) 
0.03 (0.15) 
0.829  
(0.536 - 1.22)
c
 
0.344 (1)
c
 T/C 77 (17.62%) 66 (16.71%) 
C/C 7 (1.60%) 0 (0.00%) 
Significant P values (P < 0.05) are indicated in bold. 
a. Results from the Fisher’s exact test, which compares the genotypic frequencies of cases and controls, assuming a 
codominant model.  
b. The corrected P value is indicated in brackets. 
c. Results from the logistic regression analysis when the homozygotes for the most frequent allele are compared with 
the heterozygotes . 
d. Results from the logistic regression analysis when the homozygotes for the major allele are compared with the 
homozygotes for the minor allele.  
Abbreviations: OR, Odds Ratio. 
 
3.7.3. Case-control haplotype analysis. 
3.7.3.1. Spanish Sample 
Four common 8-marker haplotypes were found in the Spanish sample (table R59), although no 
differences were found between patients and controls.  
Table R59. Overview of the most common ASPM haplotypes observed in the Spanish sample. 
HAPLOTYPE
a
 
Patients 
frequency 
Controls 
frequency 
rs
6
7
0
0
1
8
0
 
rs
3
7
6
2
2
7
1
 
rs
1
2
1
3
8
3
3
6
 
rs
4
1
3
1
0
9
2
7
 
rs
1
0
9
2
2
1
6
3
 
rs
4
9
1
5
3
3
7
 
rs
6
6
7
7
0
8
2
 
rs
9
7
2
6
7
7
8
 
G A G G T A A G 0.385 0.4035 
A C G A C A A G 0.4153 0.3812 
G C G A T T G C 0.09735 0.09156 
A C C A C A A G 0.07312 0.06727 
All rare (freq < 0.03) 0.02923 0.05647 
Note: the global P value was 0.77834 (uncorrected). Patients’ data refer to the whole sample of psychotic patients. 
a. The SNPs which deviated from HWE are marked in grey. 
Abbreviations: freq, frequency; OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
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A case-control analysis of the 2, 3 and 4-marker haplotype frequencies was finally performed 
with 6 SNPs and eliminating those SNPs out of Hardy-Weinberg Equilibrium (rs6700180 and 
rs10922163). However, no differences were found between patients and controls, hallucinatory 
patients and controls or between schizophrenic patients and controls (data not shown). For this 
reason, we decided to repeat the haplotype analysis but including those two SNPs out of HWE 
(table R60). In this case, two protective haplotypes were found (one 3-marker haplotype and 
one 4-marker haplotype which was an extension of the previous one). Both haplotypes still 
remained significant after 1000 permutations and included allele A from rs10922163, which was 
shown to be less frequent in patients in the comparison of the genotypic frequencies. Moreover, 
the same risk haplotypes were found when the subset of hallucinatory patients was considered 
(data not shown). 
 
 
Table R60. ASPM haplotypes significantly associated with psychosis in the Spanish sample. 
HAPLOTYPE
a
 
Patients 
frequency 
Controls 
frequency 
df 
Global 
 P value 
Haplotype 
P value
b
 
rs
6
7
0
0
1
8
0
 
rs
3
7
6
2
2
7
1
 
rs
1
2
1
3
8
3
3
6
 
rs
4
1
3
1
0
9
2
7
 
rs
1
0
9
2
2
1
6
3
 
rs
4
9
1
5
3
3
7
 
rs
6
6
7
7
0
8
2
 
rs
9
7
2
6
7
7
8
 
   A A A   0.005597 0.0381 3 0.0008104 
0.0002358 
(0.001995) 
  G A A A   0.005597 0.0381 4 0.002275 
0.0002358 
(0.003996) 
Significant P values (P < 0.05) are indicated in bold. 
a. The SNPs which deviated from HWE are marked in grey. 
b. The corrected P value after 1000 permutations is indicated in brackets. 
Abbreviation: df, degrees of freedom. 
 
 
3.7.3.2. American Sample 
There were also two three-marker haplotypes which differed significantly between groups (table 
R61): rs41310927(allele A)/ 10922163(allele G)/ rs12116571(allele G) and rs10922163(alleleG)/ 
SNP5(alleleG)/ SNP6(alleleT). As it can be seen, these risk haplotypes included the three 
polymorphisms previously reported to be associated with schizophrenia in the CBDB case-
control data set.  
 
 
Table R61. ASPM haplotypes significantly associated with schizophrenia in the American sample.  
HAPLOTYPE 
Haplotype frequency df Z score 
Global 
P value 
Haplotype 
P value
a
 
rs
3
7
6
2
2
7
1
 
rs
1
2
1
3
8
3
3
6
 
rs
4
1
3
1
0
9
2
7
 
rs
1
0
9
2
2
1
6
3
 
rs
1
2
1
1
6
5
7
1
 
rs
6
6
7
7
0
8
2
 
  A G G  0.370 3 2.9197 0.0347 0.0035 (0.014) 
   G G T 0.370 3 2.7875 0.0294 0.0053 (0.0212) 
a. Significant P values (P < 0.05) are indicated in bold. The corrected P value is indicated in brackets. 
Abbreviation: df, degrees of freedom. 
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3.7.4. Family-based analyses. 
Regarding to the family-based association studies, FBAT program detected that the A allele of 
the SNP rs6677082 was slightly overtransmitted (Z = 2.132, P = 0.038) from parents to affected 
offspring (table R62). We also detected a trend for overtransmission of allele C of SNP 
rs10922163 (Z = -2.017, P = 0.071). 
 
 
Table R62. Family based Transmission disequilibrium test results for ASPM polymorphisms in the 
American families. 
Polymorphism 
Overtransmitted 
allele 
No. 
Families
a
 
Statistic
b
 
Expected 
statistic
c
 
Z score P
d
 
rs3762271 C 144 179.000 170.281 1.206 0.21 (0.8) 
rs12138336 C 64 37.000 34.000 0.688 0.53 (1) 
rs41310927 A 150 187.000 176.348 1.444 0.20 (0.8) 
rs10922163 C 157 173.000 157.898 2.017 0.071 (0.355) 
rs12116571 G 76 108.000 106.550 0.280 0.75 (1) 
rs6677082 A 71 118.000 108.667 2.132 0.038 (0.228) 
Significant P values (P < 0.05) are indicated in bold. 
a. Number of informative families. 
b. Test statistic from FBAT for the observed number of transmitted alleles. 
c. Expected value of the statistic under the null hypothesis (no association). 
d. The corrected P value is indicated in brackets. 
 
 
The three-marker haplotype analysis revealed an overtransmission of two common haplotypes 
(table R63): rs4131027(allele A)/ rs10922163(allele G)/ rs12116571(allele G) and 
rs10922163(allele G)/ rs12116571(allele G)/ rs6677082(allele T). It is noteworthy that one of 
these two haplotypes also included SNP rs6677082 mentioned above. Moreover, these two risk 
haplotypes were also detected in the case-control haplotype analysis (see table R61), giving 
more strength to the finding. 
 
 
Table R63. Significant results for the family-based haplotype analysis of ASPM gene in the American 
sample.  
HAPLOTYPE 
Global P value Haplotype P value Frequency Obs/exp 
rs
3
7
6
2
2
7
1
 
rs
1
2
1
3
8
3
3
6
 
rs
4
1
3
1
0
9
2
7
 
rs
1
0
9
2
2
1
6
3
 
rs
1
2
1
1
6
5
7
1
 
rs
6
6
7
7
0
8
2
 
  A G G  0.034 0.006 0.394 193.981/ 175.611 
   G G T 0.019 0.006 0.393 202.030/183.872 
Significant P values (P < 0.05) are indicated in bold. 
Abbreviation: Obs/exp, Observed/expected. 
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3.7.5. Pooled case-control association analysis. 
The Spanish and the American samples were pooled in order to perform a case-control 
association analysis, as explained in the Materials and Methods section.  The pooled sample 
included all the Spanish and American control subjects. With regard to the patients, all the 
American patients were included, as well as those Spanish patients diagnosed as schizophrenics.  
The five ASPM SNPs which had been genotyped in both the Spanish and the American 
individuals were included in this study. 
The results from the association analysis are shown at table R64. According to the Cochran-
Mantel-Haenszel tests for IxJxK stratified tables, the American and the Spanish samples 
presented a similar genotypic distribution of ASPM polymorphisms (heterogeneity P values > 
0.05). Thus, the use of a pooled (American-Spanish) sample can be considered to be a valid 
option. With regard to the comparison of the genotypic frequencies between cases and 
controls, the SNP rs10922163 showed significant differences in the genotypic frequencies of 
schizophrenic patients and controls. Although this result did not resist the sequential Bonferroni 
correction, it is interesting, since this SNP was also associated with the risk for schizophrenia in 
both the Spanish and the American sample separately. 
Table R64. Results from the case-control association analysis between ASPM SNPs and schizophrenia 
when studying the pooled sample of American and Spanish schizophrenic patients. 
SNP Genotype 
Schizophrenic
patients 
frequency 
Controls 
frequency 
Heterogeneity 
P value
a,b
 
χ
2 c
 
Caco 
P value
b
 
OR 
(95% CI) 
rs3762271 
C/C 228 (37.01%) 265 (34.33%) 
0.6353 (1) 1.911 
0.1668 
(0.595) 
0.898  
(0.770 - 1.046) 
A/C 296 (48.05%) 368 (47.67%) 
A/A 92 (14.94%) 139 (18.01%) 
rs12138336 
G/G 504 (82.89%) 669 (86.66%) 
0.9414 (1) 2.085 
0.1488 
(0.595) 
1.23  
(0.928 - 1.628) 
C/G 103(16.94%) 98 (12.69%) 
C/C 1 (0.16%) 5 (0.65%) 
rs41310927 
A/A 225 (36.70%) 275 (34.38%) 
0.7769 (1) 2.016 
0.1557 
(0.595) 
0.896  
(0.769 - 1.043) 
A/G 296 (48.29%) 381 (47.63%) 
G/G 92 (15.01%) 144 (18%) 
rs10922163 
A/A 130 (21.38%) 223 (29.97%) 
0.7074 (1) 4.714 
0.02993 
(0.149) 
1.184  
(1.017 - 1.378) 
G/A 335 (55.1%) 355 (47.72%) 
G/G 143 (23.52%) 166 (22.31%) 
rs6677082 
T/T 494(82.75%) 601 (80.03%) 
0.6024 (1) 2068 
0.1504 
(0.595) 
0.826 
(0.637 - 1.072) 
T/C 102 (17.09%) 143 (19.04%) 
C/C 1 (0.17%) 7 (0.93%) 
Significant P values (P < 0.05) are indicated in bold. 
a. Statistic for the Cochran-Mantel-Haenszel test for IxJxK stratified tables, which evaluates whether the ASPM SNPs 
vary between the Spanish and American clusters. 
b. The corrected P value is indicated in brackets. 
c. Statistic for the Cochran-Mantel-Haenszel test for 2x2xK stratified tables, which evaluates the existence of 
associations with the disease. 
Abbreviations: OR, Odds Ratio; CI, confidence interval; Caco, case-control. 
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3.8. PDE4D gene 
3.8.1. Allelic frequencies. 
3.8.1.1. Spanish Sample 
The results from the comparisons of the allelic frequencies between a) controls and all patients 
and b) controls and hallucinatory patients can be found at tables R65 and R66, respectively.  
According to this information, there were no significant differences in the allelic frequencies 
between controls and patients, or between hallucinatory patients and controls. However, 
rs12656462 (marker 7) shows a trend toward association, with a P value (uncorrected) of 0.07. 
However, this trend turned into a significant result when the control sample was compared to 
the sample of schizophrenic patients (see table R67), although it not resisted sequential 
Bonferroni correction.  
 
 
Table R65. Comparison of the allelic frequencies of PDE4D polymorphisms in psychotic patients and 
healthy controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs17291089 
C 0.07237 0.0581 1 
0.8542 0.3554 (1) 
A 0.9276 0.9419 0.7907 (0.48 - 1.302) 
rs829259 
A 0.3777 0.3475 1 
1.025 0.3114 (1) 
T 0.6223 0.6525 0.8772 (0.6806 - 1.131) 
rs17719378 
G 0.369 0.3845 1 
0.2612 0.6093 (1) 
A 0.631 0.6155 1.068 (0.8294 - 1.376) 
rs10055954 
G 0.8515 0.8512 1 
0.00020 0.9886 (1) 
C 0.1485 0.1488 0.9975 (0.7067 - 1.408) 
rs10461656 
G 0.6987 0.7038 1 
0.03218 0.8576 (1) 
A 0.3013 0.2962 1.025 (0.7837 - 1.34) 
rs7713345 
G 0.1513 0.1314 1 
0.8189 0.3655 (1) 
C 0.8487 0.8686 0.8484 (0.594 - 1.212) 
rs12656462 
T 0.9258 0.9531 1 
3.219 0.0727 (0.655) 
A 0.07424 0.04687 1.631 (0.9516 - 2.794) 
rs4700316 
G 0.1812 0.2082 1 
1.164 0.2807 (1) 
C 0.8188 0.7918 1.188 (0.8686 - 1.625) 
rs7714708 
T 0.3283 0.3496 1 
0.511 0.4747 (1) 
C 0.6717 0.6504 1.1 (0.8468 - 1.429) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
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Table R66. Comparison of the allelic frequencies of PDE4D polymorphisms in hallucinatory psychotic 
patients and healthy controls from the Spanish sample. 
Polymorphism Allele 
Hallucinatory 
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs17291089 
C 0.0625 0.0581 1 
0.07691 0.7815 (1) 
A 0.9375 0.9419 0.9252 (0.5342 - 1.603) 
rs829259 
A 0.3737 0.3475 1 
0.6817 0.409 (1) 
T 0.6263 0.6525 0.8926 (0.6814 - 1.169) 
rs17719378 
G 0.3763 0.3845 1 
0.06363 0.8008 (1) 
A 0.6237 0.6155 1.035 (0.7915 - 1.354) 
rs10055954 
G 0.8522 0.8512 1 
0.00158 0.9683 (1) 
C 0.1478 0.1488 0.9926 (0.6879 - 1.432) 
rs10461656 
G 0.6935 0.7038 1 
0.1136 0.736 (1) 
A 0.3065 0.2962 1.05 (0.7904 - 1.395) 
rs7713345 
G 0.1568 0.1314 1 
1.169 0.2795 (1) 
C 0.8432 0.8686 0.8137 (0.5597 - 1.183) 
rs12656462 
T 0.9274 0.9531 1 
2.619 0.1056 (0.95) 
A 0.07258 0.04687 1.591 (0.9027 - 2.805) 
rs4700316 
G 0.1774 0.2082 1 
1.345 0.2462 (1) 
C 0.8226 0.7918 1.219 (0.872 - 1.704) 
rs7714708 
T 0.3306 0.3496 1 
0.3562 0.5506 (1) 
C 0.6694 0.6504 1.088 (0.8242 - 1.437) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Table R67. Significant results from the case-control association analysis which compared the allelic 
frequencies of PDE4D polymorphisms in schizophrenic patients and healthy controls from the Spanish 
sample. 
Polymorphism Allele 
Schizophrenic 
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs12656462 
T 0.918 0.9531 1 
4.477 
0.03285 
(0.309) A 0.08197 0.04687 1.815 (1.043 – 3.161) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Regarding the remaining case-control comparisons, there were no significant associations. 
3.8.1.2. German Sample 
The results from the comparisons of the allelic frequencies between controls and the whole 
sample patients can be found at table R68. In agreement with the results obtained with the 
Spanish sample, no significant differences were found. The results were also negative when the 
controls were compared with the subsets of schizophrenic patients or bipolar patients, for this 
reason these data are not shown. 
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Table R68. Comparison of the allelic frequencies of PDE4D polymorphisms in psychotic patients and 
healthy controls from the German sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs17291089 
C 0.07034 0.06497 1 
0.1863 0.666 (1) 
A 0.9297 0.935 0.9184 (0.624 - 1.352) 
rs829259 
A 0.4061 0.4045 1 
0.004152 0.9486 (1) 
T 0.5939 0.5955 0.9935 (0.8153 - 1.211) 
rs17719378 
G 0.3308 0.3511 1 
0.7475 0.3873 (1) 
A 0.6692 0.6489 1.095 (0.8918 - 1.344) 
rs10055954 
G 0.8308 0.8287 1 
0.01353 0.9074 (1) 
C 0.1692 0.1713 0.9848 (0.7608 - 1.275) 
rs10461656 
G 0.6707 0.6629 1 
0.111 0.739 (1) 
A 0.3293 0.3371 0.9656 (0.786 - 1.186) 
rs7713345 
G 0.1585 0.1657 1 
0.1542 0.6946 (1) 
C 0.8415 0.8343 1.054 (0.8094 - 1.374) 
rs12656462 
T 0.9 0.9107 1 
0.5523 0.4574 (1) 
A 0.1 0.08929 1.133 (0.8146 - 1.577) 
rs10056492 
T 0.1069 0.1306 1 
1.837 0.1753 (1) 
C 0.8931 0.8694 1.255 (0.9032 - 1.743) 
rs4700316 
G 0.1955 0.1998 1 
0.04872 0.8253 (1) 
C 0.8045 0.8002 1.028 (0.8053 - 1.312) 
rs7714708 
T 0.3535 0.363 1 
0.1623 0.6871 (1) 
C 0.6465 0.637 1.042 (0.8514 - 1.276) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
3.8.2. Genotypic frequencies. 
3.8.2.1. Spanish Sample 
The results from the comparisons of the genotypic frequencies are summarized in tables R69 (all 
patients against controls) and R70 (hallucinatory patients against controls). No significant 
associations were found, although rs12656462, as in the comparisons of the allelic frequencies, 
shows a trend toward association (p = 0.066) when all patients are compared to controls (where 
the A/T genotype is more frequent in the patient group than in the control group). The 
differences for this SNP become significant when only the schizophrenic patients are considered, 
although the significant P value did not survive sequential Bonferroni correction (see table R71). 
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Table R69. Comparison of the genotypic distributions of PDE4D SNPs in psychotic patients and healthy 
controls from the Spanish sample. 
Polymorphism Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs17291089 
A/A 253 (89.1%) 197 (86%) 1.00 
0.3 (1) 708.2 Dominant 
C/A-C/C 31 (10.9%) 32 (14%) 1.33 (0.78-2.25) 
rs829259 
T/T-A/T 264 (89.5%) 197 (85.7%) 1.00 
0.18 (1) 722 Recessive 
A/A 31 (10.5%) 33 (14.3%) 1.43 (0.84-2.41) 
rs17719378 
A/A - A/G 248 (85.5%) 200 (87%) 1.00 
0.64 (1) 717.7 Recessive 
G/G 42 (14.5%) 30 (13%) 0.89 (0.53-1.47) 
rs10055954 
G/G-C/G 286 (99%) 227 (98.7%) 1.00 
0.78 (1) 716.7 Recessive 
C/C 3 (1%) 3 (1.3%) 1.26 (0.25-6.30) 
rs10461656 
G/G-A/G 268 (93.4%) 210 (91.3%) 1.00 
0.38 (1) 713.6 Recessive 
A/A 19 (6.6%) 20 (8.7%) 1.34 (0.70-2.58) 
rs7713345 
C/C 209 (76.3%) 167 (72.9%) 1.00 
0.39 (1) 696.5 Dominant 
G/C - G/G 65 (23.7%) 62 (27.1%) 1.19 (0.80-1.79) 
rs12656462 
T/T 232 (90.6%) 196 (85.2%) 1.00 0.066 
(0.594) 
673 N/A 
A/T 24 (9.4%) 34 (14.8%) 1.68 (0.96-2.92) 
rs4700316 
C/C 174 (61.9%) 155 (67.4%) 1.00 
0.2 (1) 705.6 Dominant 
C/G - G/G 107 (38.1%) 75 (32.6%) 0.79 (0.55-1.13) 
rs7714708 
C/C 115 (41.7%) 104 (45%) 
0.90 (0.69-1.17)
a
 0.44 (1) 702.3 Additive T/C 129 (46.7%) 103 (44.6%) 
T/T 32 (11.6%) 24 (10.4%) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
Table R70. Comparison of the genotypic distributions of PDE4D SNPs in hallucinatory patients and healthy 
controls from the Spanish sample. 
SNP Genotype 
Controls 
frequency 
Hallucinatory 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs17291089 
A/A 253 (89.1%) 162 (88%) 1.00 
0.73 (1) 631.1 Dominant 
C/A-C/C 31 (10.9%) 22 (12%) 1.11 (0.62-1.98) 
rs829259 
T/T-A/T 264 (89.5%) 160 (86%) 1.00 
0.26 (1) 644.6 Recessive 
A/A 31 (10.5%) 26 (14%) 1.38 (0.79-2.42) 
rs17719378 
A/A - A/G 248 (85.5%) 162 (87.1%) 1.00 
0.63 (1) 640.7 Recessive 
G/G 42 (14.5%) 24 (12.9%) 0.87 (0.51-1.50) 
rs10055954 
G/G-C/G 286 (99%) 185 (99.5%) 1.00 
0.55 (1) 639.6 Recessive 
C/C 3 (1%) 1 (0.5 %) 0.52 (0.05-4.99) 
rs10461656 
G/G-A/G 268 (93.4%) 170 (91.4%) 1.00 
0.42 (1) 637.3 Recessive 
A/A 19 (6.6%) 16 (8.6%) 1.33 (0.66-2.65) 
rs7713345 
C/C 209 (76.3%) 133 (71.9%) 1.00 
0.29 (1) 621.8 Dominant 
G/C - G/G 65 (23.7%) 52 (28.1%) 1.26 (0.82-1.92) 
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Table R70 (continuation). Comparison of the genotypic distributions of PDE4D SNPs in hallucinatory 
patients and healthy controls from the Spanish sample. 
SNP Genotype 
Controls 
frequency 
Hallucinatory 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs12656462 
T/T 232 (90.6%) 159 (85.5%) 1.00 0.097 
(0.873) 
602.9 N/A 
A/T 24 (9.4%) 27 (14.5%) 1.64 (0.91-2.95) 
rs4700316 
C/C 174 (61.9%) 125 (67.2%) 
0.81 (0.58-1.15)
a
 0.23 (1) 630.5 Additive C/G 97 (34.5%) 56 (30.1%) 
G/G 10 (3.6%) 5 (2.7%) 
rs7714708 
C/C 115 (41.7%) 81 (43.5%) 
0.92 (0.69-1.22)
a
 0.54 (1) 626.5 Aditive T/C 129 (46.7%) 87 (46.8%) 
T/T 32 (11.6%) 18 (9.7%) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
Table R71. Significant results from the case-control association analysis which compared the genotypic 
distribution of PDE4D polymorphisms in schizophrenic patients and healthy controls from the Spanish 
sample. 
Polymorphism Genotype 
Controls 
frequency 
Schizophrenic 
patients 
frequency 
OR (95% CI) P Value
a AIC Model 
rs12656462 
T/T 232 (90.6%) 153 (83.6%) 1.00 0.028 
(0.252) 
595.6 N/A 
A/T 24 (9.4%) 30 (16.4%) 1.90 (1.07-3.37) 
a. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
3.8.2.2. German Sample 
The genotypic distribution in the whole sample of patients was compared to the distribution in 
the control group (table R72). However, no differences or were found.  The results were very 
similar when only the subset of schizophrenic patients was considered (data not shown).  
 
 
Table R72. Comparison of the genotypic distributions of PDE4D SNPs in psychiatric patients and healthy 
controls from the German sample. 
Polymorphism Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs17291089 
A/A 466 (87.8%) 283 (86.5%) 1.00 
0.6 (1) 1144.2 Dominant 
C/A-C/C 65 (12.2%) 44 (13.5%) 1.11 (0.74-1.68) 
rs829259 
T/T 184 (34.5%) 114 (34.5%) 
1.01 (0.82-1.23)
a
 0.95 (1) 1153.1 Additive A/T 268 (50.2%) 164 (49.7%) 
A/A 82 (15.4%) 52 (15.8%) 
rs17719378 
A/A 220 (41.2%) 148 (44.7%) 1.00 
0.31 (1) 1154 Dominant 
A/G - G/G 314 (58.8%) 183 (55.3%) 0.87 (0.66-1.14) 
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Table R72 (continuation). Comparison of the genotypic distributions of PDE4D SNPs in psychiatric patients and 
healthy controls from the German sample. 
Polymorphism Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs10055954 
G/G 365 (68.3%) 227 (68.6%) 
0.98 (0.76-1.28)
a
 0.91 (1) 1155 Additive C/G 155 (29%) 96 (29%) 
C/C 14 (2.6%) 8 (2.4%) 
rs10461656 
G/G 232 (43.5%) 146 (44.1%) 
0.96 (0.78-1.19)
a
 0.74 (1) 1154.9 Additive A/G 244 (45.7%) 152 (45.9%) 
A/A 58 (10.9%) 33 (10%) 
rs7713345 
C/C 373 (69.8%) 236 (72%) 1.00 
0.51 (1) 1148.8 Dominant 
G/C - G/G 161 (30.1%) 92 (28.1%) 0.90 (0.67-1.22) 
rs12656462 
T/T 442 (83.1%) 267 (80.9%) 1.00 
0.42 (1) 1150.6 Dominant 
A/T - A/A 90 (16.9%) 63 (19.1%) 1.16 (0.81-1.65) 
rs10056492 
C/C 268 (75.3%) 267 (80.4%) 1.00 
0.1 (1) 954.3 Dominant 
C/T - T/T 88 (24.7%) 65 (19.6%) 0.74 (0.52-1.07) 
rs4700316 
C/C - C/G 514 (96.4%) 315 (95.5%) 1.00 
0.48 (1) 1151.7 Recessive 
G/G 19 (3.6%) 15 (4.5%) 1.29 (0.65-2.57) 
rs7714708 
C/C 211 (39.6%) 146 (44.1%) 1.00 
0.11 (1) 1151.7 Codominant T/C 257 (48.2%) 136 (41.1%) 0.76 (0.57-1.03) 
T/T 65 (12.2%) 49 (14.8%) 1.09 (0.71-1.67) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
By contrast, when we compared the genotypic frequencies of controls and bipolar patients (table 
R73), three SNPs appeared to be associated with the disease. These SNPs were rs10056492, 
rs4700316 and rs7714708, located in intron 6. Interestingly, the associations of rs10056492 and 
rs7714708 with bipolar disorder remained significant even after the correction for multiple testing. 
However, the small size of the bipolar sample (around 85 individuals, depending on the efficiency of 
the genotyping process) should be taken into account. 
 
 
Table R73. Comparison of the genotypic distributions of PDE4D SNPs in bipolar patients and healthy controls 
from the German sample. 
Polymorphism Genotype 
Controls 
frequency 
Bipolar 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs17291089 
A/A 466 (87.8%) 70 (82.3%) 1.00 
0.18 (1) 496.6 Dominant 
C/A-C/C 65 (12.2%) 15 (17.6%) 0.65 (0.35-1.20) 
rs829259 
T/T 184 (34.5%) 33 (37.9%) 1.00 
0.53 (1) 506.8 Dominant 
A/T - A/A 350 (65.5%) 54 (62.1%) 1.16 (0.73-1.86) 
rs17719378 
A/A 220 (41.2%) 37 (42%)  
0.79 (1) 511 Additive A/G 253 (47.4%) 42 (47.7%) 1.05 (0.74-1.48)
a
 
G/G 61 (11.4%) 9 (10.2%)  
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Table R73 (continuation). Comparison of the genotypic distributions of PDE4D SNPs in bipolar patients and 
healthy controls from the German sample. 
Polymorphism Genotype 
Controls 
frequency 
Bipolar 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs10055954 
G/G 365 (68.3%) 64 (72.7%)  
0.32 (1) 510.1 Additive C/G 155 (29%) 23 (26.1%) 1.26 (0.79-1.99)
a
 
C/C 14 (2.6%) 1 (1.1%)  
rs10461656 
G/G 232 (43.5%) 46 (52.3%)  
0.12 
(0.840) 
508.6 Additive A/G 244 (45.7%) 35 (39.8%) 1.32 (0.93-1.89)
a
 
A/A 58 (10.9%) 7 (8%)  
rs7713345 
C/C 373 (69.8%) 63 (73.3%)  
0.38 (1) 502.5 Additive G/C 145 (27.1%) 22 (25.6%) 1.22 (0.77-1.94) 
G/C 16 (3%) 1 (1.2%)  
rs12656462 
T/T 442 (83.1%) 68 (77.3%) 1.00 
0.2 (1) 508.8 Dominant 
A/T - A/A 90 (16.9%) 20 (22.7%) 0.69 (0.40-1.20) 
rs10056492 
C/C 268 (75.3%) 80 (90.9%)  
0.0004 
(0.004) 
433.7 Additive C/T 83 (23.3%) 8 (9.1%) 3.23 (1.52-6.83)
a
 
T/T 5 (1.4%) 0 (0%)  
rs4700316 
C/C - C/G 339 (63.6%) 67 (76.1%) 1.00 0.019 
(0.152) 
505.3 Dominant 
G/G 194 (36.4%) 21 (23.9%) 1.83 (1.08-3.07) 
rs7714708 
C/C 211 (39.6%) 49 (55.7%) 1.00 0.0049 
(0.041) 
502.9 Dominant 
T/C - T/T 322 (60.4%) 39 (44.3%) 1.92 (1.22-3.02) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
3.8.3. Haplotype analysis. 
3.8.3.1. Spanish Sample 
 
The most common 9-marker haplotypes detected in our sample can be consulted at table R74. 
The frequencies of these seven common haplotypes did not differ between patients and 
controls. However, this association analysis is not robust due to the high number of markers 
included in the haplotype and the sample size, which can be considered low for such haplotype 
window size. 
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Table R74. Overview of the most common PDE4D haplotypes observed in the Spanish sample. 
HAPLOTYPE 
Patients 
frequency 
Controls 
frequency 
rs
1
7
2
9
1
0
8
9
 
rs
8
2
9
2
5
9
 
rs
1
7
7
1
9
3
7
8
 
rs
1
0
0
5
5
9
5
4
 
rs
1
0
4
6
1
6
5
6
 
rs
7
7
1
3
3
4
5
 
rs
1
2
6
5
6
4
6
2
 
rs
4
7
0
0
3
1
6
 
rs
7
7
1
4
7
0
8
 
A T G G G C T C C 0.3682 0.3813 
A T A G G C T C C 0.1807 0.1567 
A A A G A G T C T 0.146 0.1314 
A T A G G C T G T 0.07155 0.1104 
A A A C A C T G T 0.07301 0.07553 
C A A G G C T C C 0.07301 0.05902 
A A A C A C A C C 0.04846 0.03438 
All rare (freq < 0.03) 0.039067 0.05127 
Note: the global P value (uncorrected) was 0.3581 (not significant). The patients' data refer to the whole sample of 
psychotic patients. 
Abbreviations: freq, frequency; OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
The analysis of the haplotype frequencies was finally performed with 8 polymorphisms and 
sliding windows of two, three and four-marker haplotypes, as it was explained in the Materials 
and Methods section. Unfortunately, we did not found any haplotype significantly associated to 
psychosis or hallucinatory psychosis. Only when the subsample of schizophrenic patients was 
compared to controls (see table R75), one protective haplotype (more frequent in the control 
group) and one risk haplotype (more frequent in the schizophrenic group) were found. Both 
haplotypes involved SNPs rs12656462 and rs7713345. However, despite one of the haplotypes is 
more frequent in controls and the other is more frequent in patients, both haplotypes share 
allele C from rs7713345 and only differ in SNP rs12656462, which seems to be the SNP 
responsible for the significance observed in the analysis. Moreover, as it is shown in sections 
3.8.1 and 3.8.2, this SNP was also associated with schizophrenia in the analysis of allelic and 
genotypic frequencies.  
 
 
Table R75. PDE4D haplotypes significantly associated with schizophrenia in the Spanish sample. 
HAPLOTYPE 
Schizophrenic 
patients 
frequency 
Controls 
frequency 
df 
Global 
P value 
Haplotype 
 P value
a
 
rs
1
7
2
9
1
0
8
9
 
rs
8
2
9
2
5
9
 
rs
1
7
7
1
9
3
7
8
 
rs
1
0
0
5
5
9
5
4
 
rs
1
0
4
6
1
6
5
6
 
rs
7
7
1
3
3
4
5
 
rs
1
2
6
5
6
4
6
2
 
rs
1
0
0
5
6
4
9
2
 
rs
4
7
0
0
3
1
6
 
     C T   0.761 0.8219 2 0.0453 0.0287 (0.0659) 
     C A   0.08242 0.04656 2 0.0453 0.03106 (0.07) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value after 1000 permutations is indicated in brackets. 
Abbreviation: df, degrees of freedom. 
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3.8.3.2. German Sample 
The most common 10-marker haplotypes inferred in the German samples, as well as their 
frequencies in both the control and the patient sample, can be found at table R76. No 
differences were found between both groups. Moreover, no differences in the frequencies of 
the 2, 3 and 4-marker haplotypes were detected between patients and controls, or between 
schizophrenic patients and controls (data not shown). 
Table R76. Overview of the most common PDE4D haplotypes observed in the German sample. 
HAPLOTYPE 
Patients 
frequency 
Controls 
frequency 
rs
1
7
2
9
1
0
8
9
 
rs
8
2
9
2
5
9
 
rs
1
7
7
1
9
3
7
8
 
rs
1
0
0
5
5
9
5
4
 
rs
1
0
4
6
1
6
5
6
 
rs
7
7
1
3
3
4
5
 
rs
1
2
6
5
6
4
6
2
 
rs
1
0
0
5
6
4
9
2
 
rs
4
7
0
0
3
1
6
 
rs
7
7
1
4
7
0
8
 
A T G G G C T C C C 0.326 0.3523 
A A A G A G T C C T 0.1537 0.1671 
A T A G G C T C C C 0.1879 0.1437 
A A A C A C T T G T 0.0667 0.07708 
C A A G G C T C C C 0.06677 0.06571 
A A A C A C A C C C 0.05744 0.06072 
A T A G G C T C G T 0.04683 0.04929 
A T A G G C T T G T 0.0308 0.04411 
A A A C A C A C G T 0.03728 0.02071 
All rare (freq < 0.03) 0.039067 0.05127 
Note: the global P value (uncorrected) was 0.2921 (not significant). The patients' data refer to the whole sample of 
psychiatric patients. 
Abbreviations: freq, frequency; OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
3.8.4. Pooled case-control association analysis. 
A case-control association analysis was performed by combining the German and the Spanish 
samples and including all control subjects and those patients diagnosed as schizophrenics. The 
nine SNPs which had been genotyped in both the German and Spanish subjects were included in 
the analysis.  
The genotypic frequencies of both patients and controls were compared with a Cochran-Mantel-
Haenszel test for 2x2xK stratified tables. Moreover, the heterogeneity between samples 
depending on their country of origin was evaluated with a Cochran-Mantel-Haenszel test for 
IxJxK stratified tables (for more information, see the corresponding Materials and Methods 
section). 
The results from this association analysis can be found at table R77. Three SNPs (rs829259, 
rs7713345 and rs12656462) showed significant between-study heterogeneity. However, no 
differences were found between patients or controls for any of the nine SNPs. 
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Table R77. Results from the case-control association analysis between PDE4D SNPs and schizophrenia 
when studying the pooled sample of German and Spanish schizophrenic patients. 
SNP Genotype 
Schizophrenic
patients 
frequency 
Controls 
frequency 
Heterogeneity 
P value
a,b
 
χ
2 c
 
Caco 
 P 
value
b
 
OR 
(95% CI) 
rs17291089 
A/A 369 (87.23%) 719 (88.22%) 
0.856 (1) 0.283 
0.595 
(1) 
1.097 
(0.78 - 1.544) 
C/A 51 (12.06%) 90 (11.04%) 
C/C 3 (0.71%) 6 (0.73%) 
rs829259 
T/T 148 (34.74%) 305 (36.79%) 
0.032 (0.256) 1.449 
0.229 
(1) 
1.112 
(0.936 - 1.321) 
A/T 211 (49.53%) 411 (49.58%) 
A/A 67 (15.73%) 113 (13.63%) 
rs17719378 
A/A 188 (44.13%) 329 (39.98%) 
0.134 (0.668) 1.299 
0.254 
(1) 
0.902 
(0.756 - 1.077) 
A/G 186 (43.66%) 392 (47.57%) 
G/G 52 (12.21%) 103 (12.5%) 
rs10055954 
G/G 290 (68.08%) 571 (69.38%) 
0.326 (1) 0.085 
0.771 
(1) 
1.034 
(0.826 - 1.295) 
G/C 126 (29.58%) 235 (28.55%) 
C/C 10 (2.35%) 17 (2.07%) 
rs10461656 
G/G 184 (43.19%) 368 (44.82%) 
0.059 (0.357) 0.646 
0.422 
(1) 
1.077 
(0.899 - 1.289) 
A/G 198 (46.48%) 376 (45.80%) 
A/A 44 (10.33%) 77 (9.38%) 
rs7713345 
C/C 304 (71.70%) 582 (72.03%) 
0.043 (0.303) 0.922 
0.337 
(1) 
1.122 
(0.888 - 1.417) 
G/C 103(24.29%) 203 (25.12%) 
G/G 17 (4.01%) 23 (2.85%) 
rs12656462 
T/T 352 (82.82%) 674 (85.53%) 
0.025 (0.224) 1.417 
0.234 
(1) 
1.206 
(0.887 - 1.639) 
A/T 70 (16.47%) 109 (13.83%) 
A/A 3 (0.71%) 5 (0.63%) 
rs4700316 
C/C 269 (63.29%) 513 (63.02%) 
0.929 (1) 0.0043 
0.998 
(1) 
1 
(0.811 - 1.233) 
C/G 136 (32.00%) 272 (33.42%) 
G/G 20 (4.71%) 29 (3.56%) 
rs7714708 
C/C 175 (41.08%) 326 (40.30%) 
0.253 (1) 0.308 
0.579 
(1) 
1.051 
(0.881 - 1.254) 
T/C 189 (44.37%) 386 (47.71%) 
T/T 62 (14.55%) 97 (11.99%) 
Significant P values (P < 0.05) are indicated in bold. 
a. Statistic for the Cochran-Mantel-Haenszel test for IxJxK stratified tables, which evaluates whether the PDE4D SNPs 
vary between the German and Spanish clusters. 
b. The corrected P value is indicated in brackets. 
c. Statistic for the Cochran-Mantel-Haenszel test for 2x2xK stratified tables, which evaluates the existence of 
associations with the disease. 
Abbreviations: OR, Odds Ratio; CI, confidence interval; Caco, case-control. 
 
 
3.9. PLEKHB1 and RAB6A genes 
3.9.1. Allelic frequencies. 
3.9.1.1. Spanish Sample 
The following two tables show the results from the comparisons of the allelic frequencies 
between the whole sample of patients and controls (table R78) and between the subsample of 
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hallucinatory patients and controls (table R79).  The main finding is the association of rs663303 
(a SNP located upstream of PLEKHB1) with psychosis. As it can be seen in table R78, the T allele 
is more frequent in the patients group. However, this significance did not survive sequential 
Bonferroni correction. Moreover, despite there were not significant differences when 
hallucinatory patients were compared to controls (table R79), rs663303 still shows a trend 
toward association (p = 0.0593 uncorrected). 
 
 
Table R78. Comparison of the allelic frequencies of PLEKHB1-RAB6A polymorphisms in psychotic patients 
and healthy controls from the Spanish sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs663303 
C 0.8624 0.9077 1 
5.083 0.02416 (0.145) 
T 0.1376 0.09225 1.569 (1.058 - 2.328) 
rs940828 
G 0.2171 0.2058 1 
0.1875 0.665 (1) 
T 0.7829 0.7942 0.9343 (0.6867 - 1.271) 
rs3741147 
G 0.152 0.1954 1 
3.281 0.07007 (0.350) 
T 0.848 0.8046 1.355 (0.9747 - 1.884) 
rs12274970 
C 0.3013 0.319 1 
0.3722 0.5418 (1) 
T 0.6987 0.681 1.086 (0.833 - 1.416) 
rs11235876 
A 0.4847 0.5 1 
0.2373 0.6261 (1) 
G 0.5153 0.5 1.063 (0.8312 - 1.36) 
rs7127066 
  
C 0.2402 0.2238 1 
0.377 0.5392 (1) 
G 0.7598 0.7762 0.9123 (0.6806 – 1.223)  
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Table R79. Comparison of the allelic frequencies of PLEKHB1-RAB6A polymorphisms in hallucinatory 
psychotic patients and healthy controls from the Spanish sample. 
Polymorphism Allele 
Hallucinatory 
patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs663303 
C 0.8683 0.9077 1 
3.558 0.0593 (0.356) 
T 0.1317 0.09225 1.493 (0.9825 – 2.268) 
rs940828 
G 0.2108 0.2058 1 
0.03337 0.8551 (1) 
T 0.7892 0.7942 0.9699 (0.6986 – 1.346) 
rs3741147 
G 0.1522 0.1954 1 
2.85 0.0914 (0.457) 
T 0.8478 0.8046 1.353 (0.9517 – 1.924) 
rs12274970 
C 0.2957 0.319 1 
0.5737 0.4488 (1) 
T 0.7043 0.681 1.116 (0.8406 – 1.48) 
rs11235876 
A 0.4866 0.5 1 
0.1627 0.6867 (1) 
G 0.5134 0.5 1.055 (0.8126 – 1.37) 
rs7127066 
C 0.2231 0.2238 1 
0.00064 0.9798 (1) 
G 0.7769 0.7762 1.004 (0.7325 – 1.376) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
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Interestingly, when other subsets of patients were considered, the T allele of SNP rs663303 was 
significantly associated with those disease traits, as it can be seen in table R80. 
 
 
Table R80. Significant results from the remaining case-control association analysis which compared the 
allelic frequencies of PLEKHB1-RAB6A polymorphisms between different groups from the Spanish sample. 
Comparison Polymorphism P Value
a
 
Schizophrenic patients vs controls rs663303 0.02817 (0.169) 
Patients without AH vs controls rs663303 0.04932 (0.296) 
Schizophrenic patients with AH vs controls rs663303 0.04557 (0.273) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviation: vs, versus; AH, auditory hallucinations. 
 
 
3.9.1.2. German Sample 
In contrast to the findings obtained with the Spanish individuals, no differences in the allelic 
frequencies were found when the controls and patients of German origin were compared to 
each other (table R81). Results also remained not significant when only the subset of 
schizophrenics or the group of bipolar patients were compared to controls (data not shown). 
 
 
Table R81. Comparison of the allelic frequencies of PLEKHB1-RAB6A polymorphisms in psychiatric patients 
and healthy controls from the German sample. 
Polymorphism Allele 
Patients 
frequency 
Controls 
frequency 
OR (95% CI) χ
2
 P
a
 
rs663303 
C 0.8807 0.8736 1 
0.1884 0.6642 (1) 
T 0.1193 0.1264 0.9365 (0.6963 - 1.259) 
rs4944850 
A 0.8571 0.846 1 
0.332 0.5645 (1) 
C 0.1429 0.154 0.9159 (0.6793 - 1.235) 
rs591804 
A 0.6864 0.6746 1 
0.2159 0.6422 (1) 
G 0.3136 0.3254 0.9475 (0.7548 - 1.189) 
rs6592527 
C 0.247 0.2183 1 
1.576 0.2093 (1) 
G 0.753 0.7817 0.8515 (0.6625 - 1.095) 
rs940828 
G 0.234 0.2137 1 
0.9704 0.3246 (1) 
T 0.766 0.7863 0.8897 (0.7051 - 1.123) 
rs3741147 
G 0.1136 0.1105 1 
0.04078 0.84 (1) 
T 0.8864 0.8895 0.9688 (0.7126 - 1.317) 
rs12274970 
C 0.2205 0.2341 1 
0.4244 0.5148 (1) 
T 0.7795 0.7659 1.08 (0.8565 - 1.362) 
rs10736793 
A 0.1627 0.1704 1 
0.1492 0.6993 (1) 
C 0.8373 0.8296 1.058 (0.796 - 1.405) 
rs11235876 
A 0.4335 0.4204 1 
0.2879 0.5916 (1) 
G 0.5665 0.5796 0.9478 (0.7791 - 1.153) 
rs11235880 
A 0.1934 0.1784 1 
0.5095 0.4754 (1) 
C 0.8066 0.8216 0.9057 (0.69 - 1.189) 
rs7127066 
C 0.2553 0.2378 1 
0.6744 0.4115 (1) 
G 0.7447 0.7622 0.9103 (0.7273 - 1.139) 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
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3.9.2. Genotypic frequencies. 
3.9.2.1. Spanish Sample 
The results from the main comparisons of the genotypic frequencies can be found at tables R82 
(all patients against controls) and R83 (hallucinatory patients against controls). According to the 
findings explained in the previous section, SNP rs663303, located upstream of the PLEKHB1 
gene, was associated with psychosis when all the samples of patients were considered (table 
R82). According to an additive model, genotypes including the T allele were found to be more 
frequent in the psychotic group, although the significance was lost after the correction for 
multiple testing.  
However, when the subsample of patients with AH was compared to the control group (table 
R83), the significance of rs663303 disappeared and only became a trend (p = 0.06). 
 
 
Table R82. Comparison of the genotypic distributions of PLEKHB1-RAB6A SNPs in psychotic patients and 
healthy controls from the Spanish sample. 
SNP Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs663303 
C/C 223 (82.3%) 171 (74.3%) 
1.57 (1.05-2.34)
a
 
0.025 
(0.15) 
690.2 Additive T/C 46 (17%) 55 (23.9%) 
T/T 2 (0.7%) 4 (1.7%) 
rs940828 
T/T 161 (61.9%) 138 (60.3%) 
1.07 (0.78-1.47)
a
 0.68 (1) 679.8 Additive G/T 91 (35%) 83 (36.2%) 
G/G 8 (3.1%) 8 (3.5%) 
rs3741147 
T/T 187 (65.8%) 163 (71.5%) 
0.75 (0.55-1.04)
a
 
0.085 
(0.425) 
704.7 Additive G/T 83 (29.2%) 60 (26.3%) 
G/G 14 (4.9%) 5 (2.2%) 
rs12274970 
T/T - T/C 254 (87.6%) 205 (89.1%) 1.00 
0.59 (1) 717.6 Recessive 
C/C 36 (12.4%) 25 (10.9%) 0.86 (0.50-1.48) 
rs11235876 
G/G - G/A 209 (73.3%) 177 (77%) 1.00 
0.34 (1) 711.2 Recessive 
A/A 76 (26.7%) 53 (23%) 0.82 (0.55-1.23) 
rs7127066 
G/G 167 (60.3%) 133 (57.8%) 
1.10 (0.82-1.47)
a
 0.51 (1) 702.1 Additive C/G 96 (34.7%) 83 (36.1%) 
C/C 14 (5%) 14 (6.1%) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
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Table R83. Comparison of the genotypic distributions of PLEKHB1-RAB6A SNPs in hallucinatory patients 
and healthy controls from the Spanish sample. 
SNP Genotype 
Controls 
frequency 
Hallucinatory 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs663303 
C/C 223 (82.3%) 140 (75.3%) 
1.50 (0.98-2.29)
a
 
0.06 
(0.36) 
618.1 Additive T/C 46 (17%) 43 (23.1%) 
T/T 2 (0.7%) 3 (1.6%) 
rs940828 
T/T 161 (61.9%) 114 (61.6%) 
1.03 (0.74-1.45)
a
 0.85 (1) 608.2 Additive G/T 91 (35%) 64 (34.6%) 
G/G 8 (3.1%) 7 (3.8%) 
rs3741147 
T/T 187 (65.8%) 133 (72.3%) 
0.75 (0.53-1.06)
a
 
0.098 
(0.49) 
628.5 Additive G/T 83 (29.2%) 46 (25%) 
G/G 14 (4.9%) 5 (2.7%) 
rs12274970 
T/T - T/C 254 (87.6%) 168 (90.3%) 1.00 
0.35 (1) 640.1 Recessive 
C/C 36 (12.4%) 18 (9.7%) 0.76 (0.42-1.38) 
rs11235876 
G/G - G/A 209 (73.3%) 144 (77.4%) 1.00 
0.32 (1) 635 Recessive 
A/A 76 (26.7%) 42 (22.6%) 0.80 (0.52-1.24) 
rs7127066 
G/G - C/G 263 (95%) 175 (94.1%) 1.00 
0.69 (1) 627.7 Recessive 
C/C 14 (5%) 11 (5.9%) 1.18 (0.52-2.66) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
Moreover, there were some significant associations in the remaining comparisons which also 
involved the SNP rs663303. A summary of these positive results can be found at table R84. 
 
 
Table R84. Significant results from the case-control association analysis which compared the genotypic 
distribution of PLEKHB1-RAB6A polymorphisms between different groups from the Spanish sample. 
Comparison Polymorphism P Value
a
 Model 
Schizophrenic patients vs controls rs663303 0.027 (0.162) Additive 
Patients without AH vs controls rs663303 0.048 (0.282) Additive 
Schizophrenic patients with AH vs controls rs663303 0.045 (0.270) Additive 
a. The corrected P value is indicated in brackets. 
Abbreviations: vs, versus; AH, auditory hallucinations. 
 
 
3.9.2.2. German Sample 
The results from the case-control analysis of the genotypic frequencies can be found at tables 
R85 (all patients against controls), R86 (schizophrenic patients compared to controls) and R87 
(bipolar patients against controls). In the three comparisons some significant associations have 
been found: 
- There are significant differences in the genotypic distribution of rs6592527 (PLEKHB1 
gene) between the whole sample of patients and controls (table R85) and between the 
subset of bipolar patients and controls (table R87). In both cases the genotypic 
Results 175 
 
distribution fitted a recessive inheritance model, where the C/C genotype was found to be 
more frequent in the affected group.  
- SNP rs940828 (PLEKHB1 gene) gave significant findings in the three comparisons (tables 
R85-R87). In summary, individuals who were homozygotes for the G allele were more 
frequent in the affected group.  
- Regarding to rs7127066 (RAB6A gene), there were significant differences when all 
patients were compared to controls (table R85) and when the subsample of schizophrenic 
subjects was compared to the control group (table R86). In both situations, the C/C 
genotype was more frequent in the affected group than in the control group. However, 
when bipolar patients were compared to control subjects (table R87) this significant result 
became only a trend.  
- Finally, the SNP rs4944850 was found to be associated to bipolar disorder (table R87), 
since the C/C genotype was found to be more frequent in the bipolar group than in the 
control group.  
However, all these findings should be taken cautiously due to the low frequency of the four risk 
genotypes. Moreover, neither of the P values resisted the sequential Bonferroni correction for 
multiple testing. 
 
 
Table R85. Comparison of the genotypic distributions of PLEKHB1-RAB6A SNPs in psychiatric patients and 
healthy controls from the German sample. 
SNP Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
a
 AIC Model 
rs663303 
C/C 408 (76.4%) 260 (78.5%) 1.00 
0.46 (1) 1154.5 Dominant 
T/C - T/T 126 (23.6%) 71 (21.4%) 0.88 (0.64-1.23) 
C/C - T/C 525 (98.3%) 323 (97.6%) 1.00 
0.46 (1) 1154.5 Recessive 
T/T 9 (1.7%) 8 (2.4%) 1.44 (0.55-3.78) 
rs4944850 
A/A 255 (72%) 248 (75.4%) 1.00 
0.32 (1) 948.9 Dominant 
C/A - C/C 99 (28%) 81 (24.6%) 0.84 (0.60-1.18) 
rs591804 
A/A 162 (45.6%) 157 (47.6%) 1.00 
0.61 (1) 952.4 Dominant 
A/G - G/G 193 (54.4%) 173 (52.4%) 0.92 (0.68-1.25) 
rs6592527 
G/G - C/G 341 (96.1%) 304 (92.1%) 1.00 0.027 
(0.243) 
947.8 Recessive 
C/C 14 (3.9%) 26 (7.9%) 2.08 (1.07-4.06) 
rs940828 
T/T - G/T 510 (96%) 302 (91.8%) 1.00 0.0094 
(0.103) 
1141.6 Recessive 
G/G 21 (4%) 27 (8.2%) 2.17 (1.21-3.91) 
rs3741147 
T/T 422 (79%) 258 (78.2%) 1.00 
0.77 (1) 1153 Dominant 
G/T - G/G 112 (21%) 72 (21.8%) 1.05 (0.75-1.47) 
T/T - G/T 528 (98.9%) 327 (99.1%) 1.00 
0.76 (1) 1153 Recessive 
G/G 6 (1.1%) 3 (0.9%) 0.81 (0.20-3.25) 
rs12274970 
T/T 315 (59%) 204 (61.6%) 1.00 
0.44 (1) 1154.5 Dominant 
T/C - C/C 219 (41%) 127 (38.4%) 0.90 (0.68-1.19) 
rs10736793 
C/C - C/A 346 (97.5%) 326 (98.2%) 1.00 
0.51 (1) 955.2 Recessive 
A/A 9 (2.5%) 6 (1.8%) 0.71 (0.25-2.01) 
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Table R85 (continuation). Comparison of the genotypic distributions of PLEKHB1-RAB6A SNPs in 
psychiatric patients and healthy controls from the German sample. 
SNP Genotype 
Controls 
frequency 
Patients 
frequency 
OR (95% CI) P Value
a
 AIC Model 
rs11235876 
G/G - G/A 447 (83.7%) 267 (80.7%) 1.00 
0.25 (1) 1153.8 Recessive 
A/A 87 (16.3%) 64 (19.3%) 1.23 (0.86-1.76) 
rs11235880 
C/C - C/A 343 (96.3%) 311 (94%) 1.00 
0.14 (1) 953.3 Recessive 
A/A 13 (3.6%) 20 (6%) 1.70 (0.83-3.47) 
rs7127066 
G/G - C/G 506 (94.8%) 300 (90.6%) 1.00 0.021 
(0.21) 
1149.8 Recessive 
C/C 28 (5.2%) 31 (9.4%) 1.87 (1.10-3.17) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence intervals. 
 
 
Table R86. Comparison of the genotypic distributions of PLEKHB1 and RAB6A SNPs in schizophrenic 
patients and healthy controls from the German sample. 
SNP Genotype 
Controls 
frequency 
Schizophrenic 
patients 
frequency 
OR (95% CI) 
P 
Value
b
 
AIC Model 
rs663303 
C/C 408 (76.4%) 191 (78.6%) 1.00 
0.5 (1) 969 Dominant 
T/C - T/T 126 (23.6%) 52 (21.4%) 0.88 (0.61-1.27) 
rs4944850 
A/A 255 (72%) 188 (78%) 1.00 0.099 
(0.891) 
804.5 Dominant 
C/A - C/C 99 (28%) 53 (22%) 0.73 (0.50-1.07) 
rs591804 
A/A 162 (45.6%) 119 (49%) 
0.87 (0.68-1.12)
a
 0.28 (1) 810.8 Additive A/G 155 (43.7%) 104 (42.8%) 
G/G 38 (10.7%) 20 (8.2%) 
rs6592527 
G/G - C/G 341 (96.1%) 226 (93%) 1.00 0.1 
(0.891) 
809.2 Recessive 
C/C 14 (3.9%) 17 (7%) 1.83 (0.89-3.79) 
rs940828 
T/T - G/T 510 (96%) 223 (92.5%) 1.00 0.045 
(0.495) 
958.6 Recessive 
G/G 21 (4%) 18 (7.5%) 1.96 (1.02-3.75) 
rs3741147 
T/T 422 (79%) 196 (80.7%)  
0.56 (1) 969.1 Additive G/T 106 (19.9%) 45 (18.5%) 0.90 (0.63-1.28)
a
 
G/G 6 (1.1%) 2 (0.8%)  
rs12274970 
T/T 315 (59%) 153 (63%) 1.00 
0.29 (1) 968.4 Dominant 
T/C - C/C 219 (41%) 90 (37%) 0.85 (0.62-1.16) 
rs10736793 
C/C - C/A 346 (97.5%) 240 (98.4%) 1.00 
0.45 (1) 813.1 Recessive 
A/A 9 (2.5%) 4 (1.6%) 0.64 (0.20-2.10) 
rs11235876 
G/G - G/A 447 (83.7%) 199 (81.9%) 1.00 
0.53 (1) 969.1 Recessive 
A/A 87 (16.3%) 44 (18.1%) 1.14 (0.76-1.69) 
rs11235880 
C/C - C/A 343 (96.3%) 229 (93.8%) 1.00 
0.16 (1) 812.8 Recessive 
A/A 13 (3.6%) 15 (6.2%) 1.73 (0.81-3.70) 
rs7127066 
G/G - C/G 506 (94.8%) 221 (91%) 1.00 0.051 
(0.51) 
965.6 Recessive 
C/C 28 (5.2%) 22 (9.1%) 1.80 (1.01-3.21) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: OR, Odds Ratio; CI, confidence interval. 
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Table R87. Comparison of the genotypic distributions of PLEKHB1 and RAB6A SNPs in bipolar patients and 
healthy controls from the German sample. 
SNP Genotype 
Controls 
frequency 
Bipolar 
patients 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs663303 
C/C - T/C 525 (98.3%) 85 (96.6%) 1.00 
0.32 (1) 510.1 Recessive 
T/T 9 (1.7%) 3 (3.4%) 0.49 (0.13-1.83) 
rs4944850 
A/A - C/A 344 (97.2%) 81 (92%) 1.00 0.04 
(0.36) 
441 Recessive 
C/C 10 (2.8%) 7 (8%) 0.34 (0.12-0.91) 
rs591804 
A/A - A/G 317 (89.3%) 73 (83.9%) 1.00 0.18 
(0.9) 
440.6 Recessive 
G/G 38 (10.7%) 14 (16.1%) 0.63 (0.32-1.21) 
rs6592527 
G/G - C/G 341 (96.1%) 78 (89.7%) 1.00 0.027 
(0.27) 
437.5 Recessive 
C/C 14 (3.9%) 9 (10.3%) 0.36 (0.15-0.85) 
rs940828 
T/T 325 (61.2%) 57 (64.8%) 1.00 
0.024 
(0.264) 
504.8 Codominant G/T 185 (34.8%) 22 (25%) 1.47 (0.87-2.49) 
G/G 21 (4%) 9 (10.2%) 0.41 (0.18-0.94) 
rs3741147 
T/T 422 (79%) 62 (71.3%) 1.00 0.11 
(0.77) 
504.7 Dominant 
G/T - G/G 112 (21%) 25 (28.7%) 0.66 (0.40-1.09) 
rs12274970 
T/T 315 (59%) 51 (58%) 1.00 
0.86 (1) 511.1 Dominant 
T/C - C/C 219 (41%) 37 (42%) 0.96 (0.61-1.51) 
T/T - T/C 503 (94.2%) 83 (94.3%) 1.00 
0.96 (1) 511.1 Recessive 
C/C 31 (5.8%) 5 (5.7%) 1.02 (0.39-2.71) 
T/T 315 (59%) 51 (58%)  
0.9 (1) 511.1 Additive T/C 188 (35.2%) 32 (36.4%) 0.98 (0.67-1.41)
a
 
C/C 31 (5.8%) 5 (5.7%)  
rs10736793 
C/C 243 (68.5%) 58 (65.9%) 1.00 
0.65 (1) 445.5 Dominant 
C/A - A/A 112 (31.6%) 30 (34.1%) 0.89 (0.54-1.46) 
rs11235876 
G/G - G/A 447 (83.7%) 68 (77.3%) 1.00 0.15 
(0.9) 
509 Recessive 
A/A 87 (16.3%) 20 (22.7%) 0.66 (0.38-1.15) 
rs11235880 
C/C - C/A 343 (96.3%) 82 (94.2%) 1.00 
0.4 (1) 442.2 Recessive 
A/A 13 (3.6%) 5 (5.8%) 0.62 (0.22-1.79) 
rs7127066 
G/G - C/G 506 (94.8%) 79 (89.8%) 1.00 0.089 
(0.712) 
508.2 Recessive 
C/C 28 (5.2%) 9 (10.2%) 0.49 (0.22-1.07) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: OR, Odds Ratio; CI, confidence interval. 
 
 
Unfortunately, when comparing the results obtained in the Spanish and the German sample for the 
SNPs which had been genotyped in both samples, no similarities have been found, since the 
positive SNPs are completely different between both samples. 
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3.9.3. Haplotype analysis. 
3.9.3.1. Spanish Sample 
The seven common 6-marker haplotypes from the Spanish sample, inferred from the genotypic 
data, can be found at table R88. Frequencies of these seven common haplotypes did not differ 
between patients and controls.  
 
 
Table R88. Overview of the most common PLEKHB1-RAB6A haplotypes observed in the Spanish sample. 
HAPLOTYPE 
Patients frequency Controls frequency 
rs
6
6
3
3
0
3
 
rs
9
4
0
8
2
8
 
rs
3
7
4
1
1
4
7
 
rs
1
2
2
7
4
9
7
0
 
rs
1
1
2
3
5
8
7
6
 
rs
7
1
2
7
0
6
6
 
C T T T G G 0.5057 0.5095 
C T G C A G 0.1349 0.1719 
C T T C A C 0.06742 0.07122 
C G T T A C 0.06643 0.06333 
T G T T A G 0.05211 0.04293 
T G T C A C 0.08056 0.0414 
C T T T A G 0.04314 0.03793 
All rare (freq < 0.03) 0.04974 0.06179 
Note: the global P value (uncorrected) was 0.2093 (not significant). The patients' data refer to the whole sample of 
psychotic patients. 
Abbreviations: freq, frequency; OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
A case-control analysis of the 2, 3 and 4-marker haplotype frequencies was finally performed 
with the 6 SNPs, according to the methodology explained in the Materials and Methods section. 
As it is shown in table R89, two risk haplotypes were found, implicating SNPs rs663303, 
rs940828 and rs3741147. Haplotype C-G-G is especially interesting because it remained 
significant after a 1000-permutation run. Curiously, despite both haplotypes have a higher 
frequency in patients, they contain different alleles for rs663303 and rs3741147, suggesting that 
the real risk allele would be allele G from rs940828, as it was detected in the analysis of the 
allelic and genotypic frequencies. Moreover, the same risk haplotypes were found when the 
subsets of hallucinatory patients or schizophrenic patients were considered (data not shown). 
 
 
Table R89. PLEKHB1-RAB6A haplotypes significantly associated with psychosis in the Spanish sample. 
HAPLOTYPE 
Patients 
frequency 
Controls 
frequency 
df 
Global 
P value 
Haplotype 
P value
a
 
rs
6
6
3
3
0
3
 
rs
9
4
0
8
2
8
 
rs
3
7
4
1
1
4
7
 
rs
1
2
2
7
4
9
7
0
 
rs
1
1
2
3
5
8
7
6
 
rs
7
1
2
7
0
6
6
 
C G G    0.007113 0.03069 4 0.0235 0.00785 (0.04795) 
T G T    0.1394 0.09426 4 0.0235 0.03088 (> 0.05) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value after 1000 permutations is indicated in brackets. Abbreviation: df, degrees of freedom. 
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3.9.3.2. German Sample 
Eight common 11-marker haplotypes (frequency > 0.03) were inferred from the genotype data 
in the German samples. Frequencies of those haplotypes in both patients and healthy subjects 
can be found at table R90. However, no significant differences were found between both groups 
in the frequencies of 2, 3 and 4-marker haplotypes (data not shown).  
 
 
Table R90. Overview of the most common PLEKHB1-RAB6A haplotypes observed in the German sample. 
HAPLOTYPE 
Patients frequency Controls frequency 
rs
6
6
3
3
0
3
 
rs
4
9
4
4
8
5
0
 
rs
5
9
1
8
0
4
 
rs
6
5
9
2
5
2
7
 
rs
9
4
0
8
2
8
 
rs
3
7
4
1
1
4
7
 
rs
1
2
2
7
4
9
7
0
 
rs
1
0
7
3
6
7
9
3
 
rs
1
1
2
3
5
8
7
6
 
rs
1
1
2
3
5
8
8
0
 
rs
7
1
2
7
0
6
6
 
C A A G T T T C G C G 0.5138 0.5252 
C C G G T G C A A C G 0.08073 0.09569 
T A G C G T C C A A C 0.07609 0.07428 
C A A C G T T C A C C 0.05745 0.04607 
C A G G T T C C A A C 0.04658 0.04713 
C C G G T T T C G C G 0.04348 0.04579 
T A G C G T T A A C G 0.0372 0.03851 
C A A C G T T C A A C 0.03106 0.01849 
All rare (freq < 0.03) 0.11361 0.10884 
Note: the global P value (uncorrected) was 0.7793 (not significant). The patients' data refer to the whole sample of 
psychiatric patients. 
Abbreviations: freq, frequency; OR, Odds Ratio; CI, confidence intervals; N/A, not applicable. 
 
 
3.9.4. Pooled case-control association analysis. 
The German and the Spanish samples were combined to perform an association analysis of the 
genotypic frequencies according to the methodology explained in the Materials and Methods 
section. All control subjects, as well as those patients diagnosed as schizophrenics, were 
included in this part of the study. 
The six SNPs from PLEKHB1 and RAB6A genes which had been genotyped in both the Spanish 
and the German sample were included. 
The results from the analysis with the pooled sample of patients and controls are shown at table 
R91. As it is shown, the distribution of three SNPs (rs3741147, rs12235876 and rs11235876) 
showed highly significant differences depending on the country of origin (the corrected P value 
from the Cochran-Mantel-Haenszel test for IxJxK stratified tables was also significant for these 
SNPs). These differences can make it difficult to perform and interpret a study with a pooled 
sample of individuals from different origin. 
In any case, no differences were found between patients or controls for any of the six SNPs. 
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Table R91. Results from the case-control association analysis between PLEKHB1-RAB6A SNPs and 
schizophrenia when studying the pooled sample of German and Spanish schizophrenic patients. 
SNP Genotype 
Schizophrenic
patients 
frequency 
Controls 
frequency 
Heterogeneity 
P value
a,b
 
χ
2 c
 
Caco 
P value
b
 
OR 
(95% CI) 
rs663303 
C/C 326 (76.53%) 631 (78.39%) 
0.284 (0.584) 0.847 
0.357 
(1) 
1.132  
(0.871 - 1.47) 
T/C 92 (21.60%) 163 (20.25%) 
T/T 8 (1.88%) 11 (1.37%) 
rs940828 
T/T 253 (59.81%) 486 (61.44%) 
0.509 (0.589) 1.313 
0.252 
(1) 
1.128  
(0.918 - 1.384) 
G/T 145 (34.38%) 276 (34.89%) 
G/G 25 (5.91%) 29 (3.67%) 
rs3741147 
T/T 326 (76.71%) 609 (74.45%) 
0.000143 
(0.00086) 
2.747 
0.0974 
(0.585) 
0.808  
(0.627 - 1.041) 
G/T 93 (21.88%) 189 (23.11%) 
G/G 6 (1.41%) 20 (2.44%) 
rs12274970 
T/T 246 (57.75%) 456 (55.34%) 
0.00478 
(0.019) 
1.936 
0.164 
(0.821) 
0.870  
(0.715 - 1.058) 
T/C 150 (35.21%) 301 (36.53%) 
C/C 30 (7.04%) 67 (8.13%) 
rs11235876 
G/G 123 (28.87%) 248 (30.28%) 
0.00107 
(0.0053) 
0.0088 
0.925 
(1) 
1.008  
(0.851 - 1.195) 
G/A 219 (51.41%) 408 (49.82%) 
A/A 84 (19.72%) 163 (19.90%) 
rs7127066 
G/G 249 (58.45%) 475 (58.57%) 
0.195 (0.584) 0.933 
0.334 
(1) 
1.103  
(0.904 - 1.345) 
C/G 144 (33.80%) 294 (36.25%) 
C/C 33 (7.75%) 42 (5.18%) 
Significant P values (P < 0.05) are indicated in bold. 
a. Statistic for the Cochran-Mantel-Haenszel test for IxJxK stratified tables, which evaluates whether the PLEKHB1-
RAB6A SNPs vary between the German and Spanish clusters. 
b. The corrected P value is indicated in brackets. 
c. Statistic for the Cochran-Mantel-Haenszel test for 2x2xK stratified tables, which evaluates the existence of 
associations with the disease. 
Abbreviations: OR, Odds Ratio; CI, confidence interval; Caco, case-control. 
 
 
 
4. Analysis of quantitative variables and other disease traits. 
We used the clinical information available for the Spanish patients to investigate the effects of 
genetic variation on the scores of several clinical scales (BPRS, KGV, PANSS, PSYRATS for AH and 
delusions) as well as other disease traits (age of onset and response to treatment against AH). 
Furthermore, information about seven cognitive factors derived from different 
neuropsychological tests (as it is explained in the Materials and Methods section) was available 
for a subset of individuals (including both control subjects and schizophrenic patients) from the 
American sample and it was used to test the effect of ASPM gene on the cognitive performance 
of those individuals. 
4.1. Estimation of the statistical power 
Before the association analysis, the statistical power to detect association between genetic 
polymorphisms and quantitative variables was also calculated (table R92). This power was low 
when we considered that the proportion of variation explained by each polymorphism (Rg
2) was 
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around 1%. However, for percentages of explained variance around 30% the power to detect 
association was found to be very high. However, it is less probable than one SNP explains such a 
high percentage of the variance of a quantitative trait.  
Table R92. Estimation of the statistical power for association studies with quantitative variables. 
Type of study Sample N 
Statistical Power 
Rg
2
 = 0.01 Rg
2
 = 0.3 
Analysis of quantitative variables: KGV scale Spanish 270 patients 0.3774 0.9999 
Analysis of quantitative variables: BPRS and PANSS scales Spanish 130 patients 0.2079 0.9999 
Analysis of quantitative variables: PSYRATS for AH Spanish 210 patients 0.3063 0.9999 
Analysis of quantitative variables: PSYRATS for delusions Spanish 155 patients 0.2328 0.9999 
Analysis of quantitative variables: Cognitive factors American 
430 Controls 0.5473 0.9999 
350 Patients 0.4664 0.9999 
Rg
2
: proportion of variation in the quantitative variable explained by the effect of certain polymorphism. 
 
 
4.2. SLC6A4 gene 
The following tables show the significant findings from the lineal regression analyses between 
SLC6A4 polymorphisms and different quantitative variables corresponding to different clinical 
scales. 
4.2.1. KGV scale. 
Table R93 shows the significant results for the KGV scale items.  In summary, 5-HTTLPR 
promoter polymorphism was associated with 3 parameters (Total Score, Anxiety item and 
Delusions item) and fitted an additive or dominant model, whereas other polymorphisms where 
associated with other items (rs2066713 with Total Score, rs2020942 and STin2 with 
Hallucinations item and both rs12945042 and rs2020936 with Incoherence of Speech). 
Unfortunately, any result remained significant after correction for multiple testing. 
Table R93. Significant results from the association analysis of SLC6A4 polymorphisms and KGV scale parameters. 
Polymorphism 
Genotypic  
distribution 
Average  
response 
(SE) 
Difference  
(95% CI) 
Model P Value
b
 BIC 
KGV total score 
5-HTTLPR 
high/high : 78 9.77 (0.66) 
-1.06 (-2.02 - -0.10)
a
 Additive 
0.031 
(0.341) 
1689.7 high/low : 135 8.76 (0.48) 
low/low : 54 7.78 (0.68) 
rs2066713 
C/C - C/T : 236 8.61 (0.35) 0.00 
Recessive 
0.046 
(0.46) 
1690.4 
T/T : 31 10.68 (1.14) 2.12 (0.04 - 4.19) 
KGV - hallucinations 
rs2020942 
G/G -A/G : 231 1.29 (0.11) 0.00 
Recessive 
0.025 
(0.275) 
1062.3 
A/A : 36 1.97 (0.31) 0.69 (0.09 - 1.29) 
STin2 
12/12 - 12/10 : 222 1.3 (0.11) 0.00 
Recessive 0.03 (0.3) 1018.1 
10/10:34 1.97 (0.32) 0.69 (0.07 - 1.30) 
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Table R93 (continuation). Significant results from the association analysis of SLC6A4 polymorphisms and KGV 
scale parameters. 
Polymorphism 
Genotypic  
distribution 
Average  
response 
(SE) 
Difference  
(95% CI) 
Model P Value
b
 BIC 
KGV - anxiety 
5-HTTLPR 
low/low : 78 1.72 (0.119) 0.00 
Dominant 
0.04 
(0.44) 
789 
high/low-high/high: 135 1.44 (0.08) -0.29 (-0.57 - -0.01) 
KGV - delusions 
5-HTTLPR 
low/low : 78 1.6 (0.18) 
-0.36 (-0.62 - -0.09)
a
 Additive 
0.008 
(0.088) 
994.5 high/low : 135 1.43 (0.13) 
high/high : 54 0.91 (0.17) 
KGV - incoherence of speech 
rs12945042 
G/G : 119 0.87 (0.11) 0.00 
Dominant 
0.037 
(0.37) 
741.4 
G/A -G/G : 120 0.57 (0.09) -0.30 (-0.58 - -0.02) 
rs2020936 
T/T : 190 0.75 (0.08) 
-0.26 (-0.49 - -0.03)
a
 Additive 
0.025 
(0.275) 
799.5 T/C : 66 0.48 (0.1) 
C/C : 11 0.27 (0.19) 
  Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: SE, standard error; CI, confidence interval. 
 
4.2.2. BPRS scale. 
Regarding BPRS scale (see table R94), two polymorphisms (5-HTTLPR, located in the promoter 
region, and rs4251417, in intron 1A) were found to be associated with the BPRS total score. 
However, after Bonferroni sequential correction, P values are not significant. 
 
 
Table R94. Significant results from the association analysis of SLC6A4 polymorphisms and BPRS 
parameters. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
BPRS total score 
rs4251417 
G/G : 88 46.1 (1.28) 0.00 
N/A 
0.011 
(0.121) 
842.4 
A/G : 20 39.6 (2.13) -7.17 (-12.58 - -1.76) 
5-HTTLPR 
low/low : 37 47.16 (2.08) 
-3.24 (-5.99 - -0.50)
a
 Additive 
0.022 
(0.22) 
1012.9 high/low : 61 43.9 (1.6) 
high/high : 31 40.68 (1.83) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: SE, standard error; CI, confidence interval; N/A, not applicable. 
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4.2.3. PANSS. 
Table R95 shows those polymorphisms which were significantly associated with the different 
PANSS scale parameters. Given the high number of items and polymorphisms, the number of 
positive findings is also high. However, some of these results are not reliable, since the number 
of individuals in one of the genotypic groups is low. This can be applied to the associations 
between rs2020942, STin2 and rs2066713 with Guilt item (G3); rs12945042 and item N6 
(Spontaneity and flow of conversation); rs2066713 and item P6 (Suspiciousness); and finally, all 
associations implicating SNP rs140700. By contrast, the most interesting findings are the 
associations of 5-HTTLPR with three parameters from de the positive subscale: PANSS positive 
score (p = 0.0079, not significant after correction but showing a trend), P4 – Excitement (p = 
0.015, corrected value) and P7 – Hostility (p = 0.0044, corrected value). 
 
 
Table R95. Significant results from the association analysis of SLC6A4 polymorphisms and PANSS 
parameters. 
Polymorphism 
Genotypic  
distribution 
Average  
response (SE) 
Difference 
 (95% CI) 
Model P Value
b
 BIC 
PANSS total score 
rs4251417 
G/G : 88 62.07 (1.84) 0.00 
N/A 
0.029 
(0.319) 
920.9 
A/G : 20 54.25 (3.01) -8.77 (-16.56 - -0.99) 
PANSS General score 
rs4251417 
G/G : 88 31.72 (0.89) 0.00 
N/A 
0.041 
(0.451) 
772.6 
A/G : 20 27.9 (1.7) -4.14 (-8.06 - -0.23) 
PANSS G3 - Guilt feelings 
rs2020942 
G/G - A/G: 116 1.65 (0.1) 0.00 
Recessive 
0.0004 
(0.004) 
418.1 
A/A : 13 2.77 (0.39) 1.15 (0.48 - 1.81) 
STin2 
12/12-10/12: 110 1.68 (0.11) 0.00 
Recessive 
0.0041 
(0.041) 
407.6 
10/10 : 14 2.64 (0.39) 0.98 (0.32 - 1.63) 
rs2066713 
C/C - C/T : 119 1.69 (0.11) 0.00 
Recessive 
0.015 
(0.135) 
423.4 
T/T : 10 2.6 (0.45) 0.96 (0.20 - 1.73) 
PANSS G4 - Tension 
rs140700 
G/G : 96 1.83 (0.1) 0.00 
N/A 
0.0004 
(0.044) 
331.1 
A/G : 12 3 (0.46) 1.17 (0.55 - 1.80) 
rs2020936 
T/T : 92 1.83 (0.09) 0.00 
Dominant 
0.021 
(0.21) 
393.3 
T/C - C/C : 37 2.3 (0.23) 0.48 (0.08 - 0.88) 
PANSS G7 -Motor retardation 
rs12945042 
G/G : 54 1.74 (0.12) 
0.40 (0.02 - 0.79)
a
 Additive 
0.044 
(0.484) 
353.6 G/A : 50 2.02 (0.19) 
A/A :4 3 (0.71) 
PANSS G9 -Unusual thoughts 
rs140700 
G/G : 96 1.43 (0.1) 0.00 
N/A 
0.0051 
(0.0561) 
349.3 
A/G : 12 2.42 (0.57) 0.99 (0.31 - 1.67) 
PANSS G10 -Disorientation 
rs2020936 
T/T : 92 1.61 (0.09) 0.00 
Dominant 
0.025 
(0.275) 
318.7 
T/C - C/C : 37 1.27 (0.08) -0.35 (-0.64 - -0.05) 
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Table R95 (continuation). Significant results from the association analysis of SLC6A4 polymorphisms and 
PANSS parameters. 
Polymorphism 
Genotypic  
distribution 
Average  
response (SE) 
Difference 
 (95% CI) 
Model P Value
b
 BIC 
PANSS G14 - Poor impulse control 
rs140700 
G/G : 96 1.7 (0.11) 0.00 
N/A 
0.037 
(0.333) 
345.8 
A/G : 12 2.42 (0.36) 0.72 (0.05 - 1.39) 
rs2020939 
C/C : 33 2 (0.2) 0.00 
Codominant 
0.023 
(0.231) 
352.6 C/T : 56 1.46 (0.12) -0.53 (-1.00 - -0.06) 
T/T : 21 2.14 (0.3) 0.13 (-0.47 - 0.74) 
5-HTTLPR 
low/low : 37 2.11 (0.21) 0.00 
Dominant 
0.021 
(0.231) 
398.9 high/low-
high/high:92 
1.63 (0.1) -0.48 (-0.89 - -0.08) 
PANSS N5 - Difficulty in abstract thinking 
rs3813034 
T/T : 40 3.33 (0.31) 0.00 
Dominant 
0.04 
(0.4) 
532.4 
G/T - G/G : 89 2.62 (0.18) -0.70 (-1.37 - -0.04) 
STin2 
12rep/12rep : 48 2.46 (0.24) 
0.48 (0.01 - 0.96)
a
 Additive 
0.049 
(0.441) 
508.6 10rep/12rep : 62 2.84 (0.22) 
10rep/10rep : 14 3.5 (0.56) 
rs2066713 
C/C : 51 2.43 (0.23) 
0.57 (0.06 - 1.08)
a
 Additive 
0.029 
(0.319) 
531.8 C/T : 68 3.06 (0.23) 
T/T : 10 3.4 (0.54) 
PANSS N6 - Spontaneity and flow of conversation 
rs2020939 
C/C - C/T : 89 1.71 (0.1) 0.00 
Recessive 
0.044 
(0.440) 
348.6 
T/T : 21 2.29 (0.34) 0.55 (0.02 - 1.07) 
rs12945042 
G/G - A/G : 104 1.77 (0.1) 0.00 
Recessive 
0.007 
(0.077) 
341.2 
A/A : 4 3.25 (0.95) 1.53 (0.44 - 2.63) 
PANSS Positive score 
rs4251417 
G/G :88 14.59 (0.68) 0.00 
N/A 
0.031 
(0.31) 
704.3 
A/G : 20 11.8 (1.11) -3.18 (-6.04 - -0.32) 
5-HTTLPR 
low/low : 37 15.54 
-1.96 (-3.39 - -0.54)
a
 Additive 
0.0079 
(0.0869) 
843.9 high/low : 61 13.97 
high/high : 31 11.58 
PANSS P4 - Excitement 
5-HTTLPR 
low/low : 37 2.43 (0.18) 0.00 
Dominant 
0.0014 
(0.015) 
394.3 high/low-
high/high:92 
1.77 (0.11) -0.67 (-1.07 - -0.27) 
PANSS P6 - Suspiciousness 
rs3813034 
T/T : 40 2.67 (0.25) 
-0.42 (-0.75 - -0.08)
a
 Additive 
0.016 
(0.176) 
468.5 G/T : 61 2.16 (0.19) 
G/G :28 1.86 (0.24) 
rs1042173 
T/T : 37 2.7 (0.27) 
-0.42 (-0.75 - -0.08)
a
 Additive 
0.018 
(0.180) 
468.7 T/G: 63 2.14 (0.18) 
G/G:29 1.93 (0.24) 
rs2066713 
C/C - C/T : 119 2.2 (0.13) 0.00 
Recessive 
0.035 
(0.280) 
469.9 
T/T : 10 2.9 (0.6) 1.00 (0.08 - 1.92) 
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Table R95 (continuation). Significant results from the association analysis of SLC6A4 polymorphisms and 
PANSS parameters. 
Polymorphism 
Genotypic  
distribution 
Average  
response (SE) 
Difference 
 (95% CI) 
Model P Value
b
 BIC 
PANSS P6 - Suspiciousness 
5-HTTLPR 
low/low : 37 2.57 (0.27) 
-0.41 (-0.74 - -0.07)
a
 Additive 
0.018 
(0.180) 
468.8 high/low : 61 2.33 (0.2) 
high/high : 31 1.74 (0.18) 
PANSS P7 - Hostility 
5-HTTLPR 
low/low : 37 2.19 (0.2) 0.00 
Dominant 
0.0004 
(0.0044) 
364.9 high/low - high/high 
: 92 
1.53 (0.09) -0.67 (-1.03 - -0.32) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval; N/A, not applicable. 
 
4.2.4. PSYRATS subscale for auditory hallucinations. 
Finally, the significant results from the association analysis between the 11 SLC6A4 
polymorphisms and PSYRATS scale for AH can be found at table R96. In this case, three 
polymorphisms gave significant results with the subscale for AH: 
- SNP rs2020939, located in intron 1A, was found to be associated with three different 
items (Location, p = 0.04; Amount of Distress, p = 0.025; and Intensity of Distress, p = 
0.046). However, the corrected P values were not significant. 
- SNP rs12945042 was associated with the amount of distress caused by AH (p = 0.036, 
not significant after correction for multiple testing). 
- The most interesting results are the associations of the functional polymorphism 5-
HTTLPR and the three emotional items from PSYRATS scale: Amount of Distress (p = 
0.011), Intensity of Distress (p = 0.0061) and Disruption to Life (p = 0.012). In all cases, 
those patients with a low expression genotype scored higher than the other patients 
and this finding is in agreement with the positive associations found with PANSS, BPRS 
and KGV scale. However, although the three tests became not significant after the 
correction, the association with the Intensity of Distress item still showed a trend (p = 
0.0671). 
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Table R96. Significant results from the association analysis of SLC6A4 polymorphisms and PSYRATS scale 
parameters for auditory hallucinations. 
Polymorphism 
Genotypic  
distribution 
Average 
response 
(SE) 
Difference 
(95% CI) 
Model P Value
b
 BIC 
PSYRATS AH - Location 
rs2020939 
C/C : 62 1.92 (0.22) 0.00 
Dominant 0.04 (0.44) 760.7 
C/T - T/T : 132 1.39 (0.14) -0.52 (-1.02 - -0.03) 
PSYRATS AH - Amount of distress 
rs2020939 
C/C - C/T : 151 1.28 (0.13) 0.00 
Recessive 
0.025 
(0.25) 
753.4 
T/T : 43 1.88 (0.27) 0.63 (0.08 - 1.18) 
5-HTTLPR 
low/low : 68 1.78 (0.21) 0.00 
Dominant 
0.011 
(0.121) 
799.5 
high/low-high/high:140 1.21 (0.13) -0.61 (-1.08 - -0.14) 
rs12945042 
G/G : 103 1.68 (0.17) 
-0.39(-0.75 - -0.03)
a
 Additive 
0.036 
(0.324) 
749.2 G/A : 76 1.24 (0.18) 
A/A : 14 1 (0.36) 
PSYRATS AH - Intensity of distress 
rs2020939 
C/C - C/T : 151 1.28 (0.13) 0.00 
Recessive 
0.046 
(0.46) 
745.8 
T/T : 43 1.81 (0.26) 0.55 (0.01 - 1.09) 
5-HTTLPR 
low/low : 68 1.79 (0.2) 0.00 
Dominant 
0.0061 
(0.0671) 
790.1 
high/low-high/high:140 1.18 (0.13) -0.65 (-1.11 - -0.19) 
PSYRATS AH - Disruption to life 
5-HTTLPR 
low/low : 68 1.84 (0.18) 0.00 
Dominant 
0.012 
(0.132) 
765.3 
high/low-high/high:140 1.28 (0.12) -0.56 (-0.99 - -0.13) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: SE, standard error; CI, confidence interval; AH, auditory hallucinations. 
 
 
4.3. HTR2A gene 
The effects of the HTR2A SNPs on the scores of several clinical scales (BPRS, KGV, PANSS, 
PSYRATS for AH and delusions) as well as other disease traits (age of onset and response to 
treatment against AH) were tested. The significant results can be consulted at tables R97 to R99.  
 
4.3.1. KGV and BPRS scales. 
The significant results for KGV and BPRS scales are summarized in table R97. As it can be seen, 
both SNPs were associated with three items of KGV scale (Poverty of Speech, Depression and 
Anxiety) as well as one item of BPRS scale (Anxiety). Interestingly, the association with the KGV 
parameters Anxiety and Depression remained significant after sequential Bonferroni correction.  
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Table R97. Significant results from the association analysis of HTR2A polymorphisms and parameters from 
KGV and BPRS scales. 
SNP 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
KGV - poverty of speech 
rs6313 
C/C - T/C : 217 0.86 (0.07) 0.00 
Recessive 0.034 (0.052) 785.6 
T/T : 50 0.52 (0.11) -0.34 (-0.66 - -0.03) 
rs6311 
G/G - A/G : 216 0.87 (0.07) 0.00 
Recessive 0.026 (0.052) 785.1 
A/A : 51 0.51 (0.11) -0.36 (-0.67 - -0.04) 
KGV - anxiety 
rs6313 
C/C : 87 1.75 (0.11) 0.00 
Dominant 0.014 (0.014) 781.6 
T/C - T/T : 180 1.42 (0.08) -0.33 (-0.59 - -0.07) 
rs6311 
G/G : 72 1.82 (0.12) 0.00 
Dominant 0.0041 (0.0082) 779.4 
A/G - A/A : 195 1.42 (0.07) -0.40 (-0.68 - -0.13) 
KGV - depression 
rs6313 
C/C : 87 1.09 (0.11) 
-0.22 (-0.38 - -0.05)
a
 Additive 0.011 (0.022) 756.3 T/C : 130 0.93 (0.09) 
T/T : 50 0.64 (0.11) 
rs6311 
G/G - A/G : 216 1 (0.07) 0.00 
Recessive 0.022 (0.022) 757.6 
A/A : 51 0.65 (0.11) -0.35 (-0.65 - -0.05) 
BPRS - anxiety 
rs6313 
C/C : 52 3.38 (0.21) 
-0.32 (-0.63 - -0.02)
a
 Additive 0.041  (0.06) 652 T/C : 93 2.96 (0.14) 
T/T : 34 2.76 (0.27) 
rs6311 
G/G : 53 3.4 (0.2) 
-0.34 (-0.64 - -0.04)
a
 Additive 0.03 (0.06) 651.5 A/G : 91 2.96 (0.14) 
A/A : 35 2.74 (0.26) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: SE, standard error; CI, confidence interval. 
 
 
4.3.2. PANSS scale. 
Table R98 show those PANSS scale parameters which were significantly influenced by the HTR2A 
SNPs. In summary, both SNPs were associated with several items from the General Subscale: 
General score, Anxiety, Disturbing of Volition and Preoccupation. Moreover, after applying the 
correction for multiple testing, the association with the PANSS General Score, as well as the 
items Anxiety and Preoccupation, were still significant. 
Table R98. Significant results from the association analysis of HTR2A SNPs and PANSS parameters. 
SNP 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
PANSS General score 
rs6313 
C/C : 39 33.26 (1.53) 
-2.81 (-4.94 - -0.68)
a
 Additive 0.011 (0.0138) 928.5 T/C : 67 30.24 (0.96) 
T/T : 23 27.7 (1.67) 
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Table R98 (continuation). Significant results from the association analysis of HTR2A SNPs and PANSS 
parameters. 
SNP 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
PANSS General score 
rs6313 
C/C : 39 33.26 (1.53) 
-2.81 (-4.94 - -0.68)
a
 Additive 0.011 (0.0138) 928.5 T/C : 67 30.24 (0.96) 
T/T : 23 27.7 (1.67) 
rs6311 
G/G : 39 33.26 (1.53) 
-2.95 (-5.05 - -0.84)
a
 Additive 0.0069 (0.0138) 927.7 A/G : 66 30.41 (0.96) 
A/A : 24 27.33 (1.64) 
PANSS G2 – Anxiety 
rs6313 
C/C : 39 3.18 (0.22) 
-0.50 (-0.80 - -0.19)
a
 Additive 0.0021 (0.0038) 430.7 T/C : 67 2.6 (0.14) 
T/T : 23 2.22 (0.25) 
rs6311 
G/G : 39 3.18 (0.22) 
-0.50 (-0.80 - -0.19)
a
 Additive 0.0019 (0.0038) 430.4 A/G : 66 2.61 (0.14) 
A/A : 24 2.21 (0.24) 
PANSS G13 - Disturbing of volition 
rs6313 
C/C : 39 2.54 (0.21) 
-0.31 (-0.62 - -0.00)
a
 Additive 0.052 (0.102) 429.4 T/C : 67 2.12 (0.15) 
T/T : 23 1.96 (0.24) 
rs6311 
G/G : 39 2.54 (0.21) 
-0.31 (-0.61 - -0.00)
a
 Additive 0.051 (0.102) 429.4 A/G : 66 2.12 (0.15) 
A/A : 24 1.96 (0.23) 
PANSS G15 - Preoccupation 
rs6313 
C/C : 39 3.08 (0.23) 0.00 
Dominant 0.012 (0.024) 457.8 
T/C - T/T : 90 2.41 (0.14) -0.67 (-1.18 - -0.16) 
rs6311 
G/G : 39 3.08 (0.23) 0.00 
Dominant 0.012 (0.024) 457.8 
A/G - A/A : 90 2.41 (0.14) -0.67 (-1.18 - -0.16) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: SE, standard error; CI, confidence interval. 
 
 
4.3.3. PSYRATS scale. 
Finally, rs6311 was associated with one item from the PSYRATS subscale for AH (see table R99). 
This item was Intensity of Distress to AH. However, the P value did not survive sequential 
Bonferroni correction. 
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Table R99. Significant results from the association analysis of HTR2A SNPs and PSYRATS scale parameters 
for auditory hallucinations. 
SNP 
Genotypic 
distribution 
Average response 
(SE) 
Difference (95% CI) Model P Value
b
 BIC 
PSYRATS AH - Intensity of distress 
rs6311 
G/G : 53 1.74 (0.24) 
-0.33 (-0.64 - -0.01)
a
 Additive 0.042 (0.084) 788.2 A/G : 112 1.32 (0.14) 
A/A : 43 1.09 (0.23) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets 
Abbreviations: SE, standard error; CI, confidence interval; AH, auditory hallucinations. 
 
 
As a final observation, it is remarkable that these two SNPs located in the HTR2A gene have 
been associated in this study with several items (of different scales: KGV, BPRS, PANSS, 
PSYRATS) which evaluate alterations in the emotional response of psychotic patients. 
 
 
4.4. TPH2 gene 
The association analysis of the SNP rs4570625 with several disease traits mainly gave negative 
results. Only for some items of PSYRATS scale for AH, there was a trend toward association, 
which turned into significant when only a more restricted sample (which only included those 
hallucinatory patients diagnosed as schizophrenics) was tested. In that case (see table R100), the 
SNP rs4570625 was found to be associated with the total score as well as the items Duration, 
Location, Intensity, Degree of Negative Content and Amount of Distress. The model which best 
adjusted to the results was always the codominant one, according to the BIC scores, and in all 
cases the heterozygotes scored higher than the homozygotes G/G. 
 
 
Table R100. Significant results from the association analysis of the TPH2 SNP and PSYRATS scale 
parameters for auditory hallucinations. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value BIC 
PSYRATS AH - Total score 
rs4570625 
G/G : 124 16.94 (1.38) 1.00 
Codominant 0.037 1446.5 G/T : 43 22.98 (2.41) 6.03 (0.69 - 11.38) 
T/T : 5 9 (5.51) -7.94 (-21.72 - 5.83) 
PSYRATS AH - Duration 
rs4570625 
G/G : 124 1.62 (0.15) 1.00 
Codominant 0.031 684.1 G/T : 43 2.35 (0.26) 0.73 (0.15 - 1.31) 
T/T : 5 1 (0.63) -0.62 (-2.12 - 0.88) 
PSYRATS AH - Location 
rs4570625 
G/G : 124 1.47 (0.14) 1.00 
Codominant 0.042 668.2 G/T : 43 2.07 (0.26) 0.60 (0.05 - 1.16) 
T/T : 5 0.6 (0.4) -0.87 (-2.30 - 0.57) 
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Table R100 (continuation). Significant results from the association analysis of the TPH2 SNP and PSYRATS 
scale parameters for auditory hallucinations. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value BIC 
PSYRATS AH - Intensity 
rs4570625 
G/G : 124 1.24 (0.11) 1.00 
Codominant 0.043 588.4 G/T : 43 1.67 (0.21) 0.43 (-0.01 - 0.87) 
T/T : 5 0.4 (0.24) -0.84 (-1.98 - 0.30) 
PSYRATS AH - Degree of negative content 
rs4570625 
G/G : 124 1.49 (0.15) 1.00 
Codominant 0.037 675.5 G/T : 43 2.16 (0.26) 0.67 (0.10 - 1.24) 
T/T : 5 0.8 (0.49) -0.69 (-2.16 - 0.77) 
PSYRATS AH - Amount of distress 
rs4570625 
G/G : 124 1.33 (0.14) 1.00 
Codominant 0.02 665.8 G/T : 43 2 (0.25) 0.67 (0.12 - 1.22) 
T/T : 5 0.4 (0.4) -0.93 (-2.35 - 0.49) 
The results correspond to the subsample of schizophrenic hallucinatory patients. 
Significant P values (P < 0.05) are indicated in bold. 
Abbreviations: SE, standard error; CI, confidence interval; AH, auditory hallucinations. 
 
4.5. NOS1 gene 
Results were mainly negative for the majority of scales, with the exception of PANSS. As it is 
shown in table R101, the VNTR was associated with some items: General score, Anxiety (G2), 
Guilt Feelings (G3), Preoccupation (G15), Lack of Spontaneity and Flow of Conversation (N6), 
Suspiciousness/persecution (P6) and Hostility (P7). The most significant associations were found 
with items Guilt Feelings (P = 0.0012) and Suspiciousness/persecution (P = 0.0018). 
In all cases, individuals with short alleles obtained the highest scores for all items. However, the 
sample size was extremely low, so these findings should be taken with precaution. 
 
 
Table R101. Significant results from the association analysis of the NOS1 polymorphism and PANSS 
parameters. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference 
 (95% CI) 
Model 
P 
Value 
BIC 
PANSS General score 
NOS1 Ex1f-VNTR 
L/L - S/L : 78 30.14 (1.04) 0.00 
Recessive 0.048 750.7 
S/S : 24 34.38 (1.74) 4.23 (0.09 - 8.38) 
PANSS G2 - Anxiety 
NOS1 Ex1f-VNTR 
L/L - S/L : 78 2.55 (0.15) 0.00 
Recessive 0.044 353.4 
S/S : 24 3.17 (0.26) 0.62 (0.02 - 1.21) 
PANSS G3 - Guilt feelings 
NOS1 Ex1f-VNTR 
L/L - S/L : 78 1.54 (0.11) 0.00 
Recessive 0.0012 325.9 
S/S : 24 2.42 (0.32) 0.88 (0.36 - 1.39) 
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Table R101 (continuation). Significant results from the association analysis of the NOS1 polymorphism 
and PANSS parameters. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference 
 (95% CI) 
Model 
P 
Value 
BIC 
PANSS G15 - Preoccupation 
NOS1 Ex1f-VNTR 
L/L : 35 2.2 (0.2) 
0.46 (0.11 - 0.82)
a
 Additive 0.012 365.5 S/L : 43 2.67 (0.23) 
S/S : 24 3.12 (0.28) 
PANSS N6 - Lack of spontaneity and flow of conversation 
NOS1 Ex1f-VNTR 
L/L : 35 2.09 (0.23) 0.00 
Dominant 0.032 309.8 
S/L - S/S : 67 1.61 (0.1) -0.47 (-0.90 - -0.05) 
PANSS P6 - Suspiciousness / persecution 
NOS1 Ex1f-VNTR 
L/L - S/L : 78 2.08 (0.15) 0.00 
Recessive 0.0018 378.4 
S/S : 24 3.17 (0.37) 1.09 (0.42 - 1.76) 
PANSS P7 - Hostility 
NOS1 Ex1f-VNTR 
L/L : 35 1.51 (0.16) 
0.30 (0.03 - 0.56)
a
 Additive 0.029 304.1 S/L : 43 1.7 (0.15) 
S/S : 24 2.12 (0.23) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
Abbreviations: SE, standard error; CI, confidence interval. 
 
4.6. STMN1 gene 
We tested the influence of both STMN1 markers on several disease traits (items from BPRS, 
KGV, PANSS and PSYRATS for AH and delusions, as well as age of onset and response to 
treatment against AH). Positive associations can be found at tables R102 to R104. 
4.6.1.  KGV scale. 
SNP rs182455 was found to be associated with two items of KGV scale (table R102): Flattened 
affect and Incoherence of speech. In those cases, T/T homozygotes scored less than C/C 
homozygotes, although the model which best adjusted to the data (according to BIC parameter) 
was different on each case. Significant p values did not survive sequential Bonferroni correction. 
 
 
Table R102. Significant results from the association analysis of STMN1 SNPs and items from KGV scale. 
SNP 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
a
 BIC 
KGV -  Flattened Affect 
rs182455 
C/C - T/C : 222 1.29 (0.07) 0.00 
Recessive 0.038 (0.076) 813.1 
T/T : 45 0.93 (0.15) -0.37 (-0.71 - -0.02) 
KGV - Incoherence of Speech 
rs182455 
C/C : 85 0.87 (0.13) 0.00 
Dominant 0.027 (0.054) 799.6 
T/C - T/T : 182 0.57 (0.07) -0.31 (-0.58 - -0.04) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. Abbreviations: SE, standard error; CI, confidence interval. 
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4.6.2.  PANSS scale. 
Furthermore, table R103 summarizes the positive associations between STMN1 markers and 
PANSS items. In this case, rs182455 was significantly associated with 4 parameters (G16 - Active 
Social Avoidance, Negative score, N6 - Lack of spontaneity and flow of conversation and P6 - 
Suspiciousness / persecution). As in table R104 with KGV, individuals who were T/T 
homozygotes got lower mean scores than C/C homozygotes. Furthermore, the other marker, 
rs12037513, was associated with G1 – Somatic Concern, N1 – Blunted Affect and P3 – 
Hallucinatory Behavior. However, the association with Hallucinatory cannot be considered a 
reliable finding, since the number of C/C homozygotes is only 2. In summary, the most 
interesting results of table R103 are the associations of a) rs12037513 with Blunted affect and b) 
rs182455 with Suspiciousness / Persecution, since they survived the correction for multiple 
testing. 
 
 
Table R103. Significant results from the association analysis of STMN1 SNPs and PANSS parameters. 
SNP 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
a
 BIC 
PANSS G1 - Somatic concern 
rs12037513 
T/T : 63 1.49 (0.12) 0.00 
Dominant 
0.029 
(0.058) 
345.8 
T/C - C/C : 45 1.98 (0.19) 0.48 (0.06 - 0.91) 
PANSS G16 - Active social avoidance 
rs182455 
C/C - T/C : 106 1.96 (0.15) 0.00 
Recessive 
0.027 
(0.054) 
471.4 
T/T : 23 1.26 (0.16) -0.73 (-1.36 - -0.09) 
PANSS Negative score 
rs182455 
C/C - T/C : 106 15.57 (0.61) 0.00 
Recessive 0.05 (0.1) 840.7 
T/T : 23 12.96 (0.94) -2.70 (-5.36 - -0.03) 
PANSS N1 - Blunted affect 
rs12037513 
T/T : 63 2.43 (0.16) 0.00 
Dominant 
0.015 
(0.03) 
352 
T/C - C/C : 45 1.91 (0.15) -0.55 (-0.99 - -0.11) 
PANSS N6 - Lack of spontaneity and flow of conversation 
rs182455 
C/C - T/C : 106 1.83 (0.11) 0.00 
Recessive 
0.029 
(0.058) 
395.7 
T/T : 23 1.3 (0.12) -0.54 (-1.01 - -0.06) 
PANSS P3 - Hallucinatory behavior 
rs12037513 
T/T - T/C : 106 2.32 (0.2) 0.00 
Recessive 
0.023 
(0.046) 
480.7 
C/C : 2 6 (0) 3.45 (0.52 - 6.38) 
PANSS P6 - Suspiciousness / persecution 
rs182455 
C/C : 38 1.76 (0.17) 0.00 
Codominant 
0.0013 
(0.0026) 
465.6 T/C : 68 2.68 (0.19) 0.91 (0.37 - 1.45) 
T/T : 23 1.83 (0.32) 0.03 (-0.68 - 0.73) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval. 
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4.6.3. PSYRATS scale. 
Finally, SNP rs182455 was also associated with two items of PSYRATS scale for AH (table R104): 
Beliefs about Origin and Intensity of Distress, although the significance was lost after the 
correction for multiple testing. Once again, individuals with at least one copy of T allele scored 
higher than C/C hallucinatory patients. 
 
 
Table R104. Significant results from the association analysis of STMN1 SNPs and PSYRATS scale 
parameters for auditory hallucinations. 
SNP 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
a
 BIC 
PSYRATS AH - Beliefs about origin 
rs182455 
C/C : 70 1.43 (0.2) 0.00 
Dominant 0.041 (0.082) 832 
T/C - T/T : 138 1.94 (0.15) 0.52 (0.02 - 1.01) 
PSYRATS AH - Intensity of distress 
rs182455 
C/C : 70 1.07 (0.17) 0.00 
Dominant 0.044 (0.088) 793.6 
T/C - T/T : 138 1.54 (0.14) 0.46 (0.02 - 0.91) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval; AH, auditory hallucinations. 
 
 
4.7. ASPM gene 
4.7.1. Spanish Sample. 
The exhaustive clinical information available for the Spanish patients was used to study the 
effect of ASPM variation on several disease traits. The significant findings can be found in the 
following tables. 
4.7.1.1. Age of onset 
As it is shown in table R105, four SNPs (located in the region between intron 17 and intron 19) 
were associated with the age of onset of the disease, although any results survived the 
sequential Bonferroni correction. 
 
 
Table R105. Significant results from the association analysis of ASPM SNPs with the age of onset of the 
disease. 
SNP Genotype 
Early-onset 
group 
frequency 
Late-onset 
group 
frequency 
OR (95% CI) P Value
a
 AIC Model 
rs6700180 
C/C- T/C 85 (85%) 128 (74.8%) 1.00 0.021 
(0.168) 
354.1 Recessive 
T/T 15 (15%) 43 (25.1%) 2.12 (1.09 - 4.10) 
rs3762271 
C/C 31 (28.7%) 75 (39.5%) 1.00 
0.036 
(0.245) 
389.1 Codominant A/C 31 (28.7%) 83 (43.7%) 0.53 (0.31 - 0.90) 
A/A 13 (12%) 32 (16.8%) 0.95 (0.44 - 2.06) 
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Table R105 (continuation). Significant results from the association analysis of ASPM SNPs with the age of 
onset of the disease. 
SNP Genotype 
Early-onset 
group 
frequency 
Late-onset 
group 
frequency 
OR (95% CI) P Value
a
 AIC Model 
rs41310927 
A/A 32 (29.6%) 74 (39%) 1.00 
0.035 
(0.245) 
389 Codominant A/G 64 (59.3%) 83 (43.7%) 0.55 (0.33 - 0.94) 
G/G 12 (11.1%) 33 (17.4%) 1.13 (0.51 - 2.47) 
rs10922163 
A/A - A/G 84 (84.8%) 128 (75.3%) 1.00 0.035 
(0.245) 
351.4 Recessive 
G/G 15 (15.2%) 42 (24.7%) 1.99 (1.03 - 3.85) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: CI, confidence interval. 
 
 
4.7.1.2. KGV and BPRS scales 
The significant associations with BPRS and KGV items are shown at table R106. In this case, two 
SNPs in high LD (rs10922163 and rs6700180) were found to be slightly associated with the item 
Flattened Affect from KGV scale, where the homozygotes for the minor allele got lower scores. 
Moreover, SNP rs4915337 (exon 14) had a small but significant effect on the scores for the 
Anxiety item (BPRS scale) and those individuals who were homozygotes for the A allele scored 
higher than the other patients.  
 
 
Table R106. Significant results from the association analysis of ASPM SNPs and KGV scale parameters. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
a
 BIC 
KGV - flattened affect 
rs6700180 
C/C - T/C : 189 1.38 (0.08) 0.00 
Recessive 
0.031 
(0.248) 
739.2 
T/T : 51 1.04 (0.14) -0.38 (-0.71 - -0.04) 
rs10922163 
A/A - G/A : 189 1.36 (0.08) 0.00 
Recessive 
0.049 
(0.343) 
721.3 
G/G : 50 1.04 (0.14) -0.34 (-0.68 - -0.00) 
BPRS - anxiety 
rs4915337 
A/A : 136 3.17 (0.12) 0.00 
Dominant 
0.033 
(0.264) 
656.5 
A/T - T/T : 43 2.65 (0.22) -0.55 (-1.05 - -0.05) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval. 
 
 
4.7.1.3. PANSS scale 
Table R107 shows all the significant associations between ASPM polymorphisms and PANSS 
items. Due to the high number of items, the number of positive associations is high and all SNPs 
were associated with at least one item. Nevertheless, the majority of positive findings did not 
resist the correction for multiple testing, with three exceptions: 
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- The association of rs9726778 (located in the putative promoter region of the ASPM 
gene) with the General Score. In this case, G/G homozygotes scored higher on average 
than C/G - C/C group. 
- Two SNPs in almost complete LD (rs67008180 and rs10922163) were associated with the 
negative item Blunted Affect (P = 0.042 and P = 0.49, corrected values). In this case, 
homozygotes for the minor allele obtained lower scores than the other genotypes. 
 
 
Table R107. Significant results from the association analysis of ASPM SNPs and PANSS items. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
PANSS total score 
rs4915337 
A/A : 95 61.83 (1.87) 0.00 
Dominant 0.03 (0.24) 1102.9 
A/T - T/T : 34 53.53 (2.16) -7.20 (-13.62 - -0.77) 
rs9726778 
G/G : 94 61.94 (1.89) 0.00 
Dominant 0.031 (0.24) 1103 
C/G - C/C:35 53.49 (2.1) -7.11 (-13.50 - -0.73) 
PANSS general score 
rs4915337 
A/A : 95 31.96 (0.94) 0.00 
Dominant 
0.0089 
(0.0623) 
926.4 
A/T - T/T:34 27.18 (0.96) -4.39 (-7.64 - -1.15) 
rs9726778 
G/G : 94 32.07 (0.94) 0.00 
Dominant 
0.0056 
(0.0448) 
925.5 
C/G - C/C:35 27 (0.95) -4.62 (-7.83 - -1.41) 
PANSS G2 - Anxiety 
rs12138336 
G/G : 107 2.81 (0.12) 
-0.59 (-1.10 - -0.09)
a
 Additive 0.023 (0.264) 439.9 C/G : 20 2.25 (0.27) 
C/C : 2 1.5 (0.5) 
PANSS G5 - Mannerism and posturing 
rs6700180 C/C - T/C:87 1.55 (0.08) 0.00 
Recessive 0.017 (0.136) 255.8 
 T/T : 23 1.17 (0.1) -0.41 (-0.75 - -0.08) 
rs3762271 C/C : 49 1.22 (0.07) 0.00 
Dominant 0.017 (0.136) 286.1 
 A/C - A/A:80 1.52 (0.09) 0.30 (0.06 - 0.55) 
rs41310827 A/A : 49 1.22 (0.07) 0.00 
Dominant 0.019 (0.136) 286.3 
 A/G - G/G:80 1.52 (0.09) 0.30 (0.05 - 0.54) 
rs10922163 A/A - G/A:84 1.55 (0.09) 0.00 
Recessive 0.022 (0.136) 252.1 
 G/G : 24 1.17 (0.1) -0.39 (-0.72 - -0.06) 
PANSS G7 - Motor retardation 
 C/C : 49 1.65 (0.12)  
Additive 0.05 (0.4) 417.9 rs3762271 A/C : 60 1.97 (0.16) 0.29 (0.00 - 0.57)
a
 
 A/A : 20 2.2 (0.33)  
PANSS G11 - Poor attention 
rs12138336 
G/G : 107 1.91 (0.1) 
0.45 (0.03 - 0.86)
a
 Additive 0.036 (0.288) 389.4 C/G : 20 2.2 (0.28) 
C/C : 2 3.5 (0.5) 
PANSS G12 - Lack of judgment and insight 
rs4915337 
A/A : 95 2.67 (0.16) 0.00 
Codominant 0.014 (0.098) 485.3 A/T : 33 1.97 (0.27) -0.60 (-1.19 - -0.02) 
T/T : 1 6 (0) 3.07 (0.17 - 5.96) 
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Table R107 (continuation). Significant results from the association analysis of ASPM SNPs and PANSS. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
PANSS G12 - Lack of judgment and insight 
rs9726778 
G/G : 94 2.69 (0.16) 0.00 
Codominant 0.012 (0.096) 484.8 C/G : 34 1.94 (0.26) -0.63 (-1.21 - -0.05) 
C/C : 1 6 (0) 3.06 (0.17 - 5.95) 
PANSS G16 - Active social avoidance 
rs4915337 
A/A : 95 2 (0.16) 
-0.54 (-1.07 - -0.01)
a
 Additive 0.048 (0.352) 472.4 A/T : 33 1.39 (0.19) 
T/T : 1 1 (0) 
rs6677082 
T/T : 81 1.98 (0.17) 0.00 
N/A 0.046 (0.352) 397.9 
T/C : 27 1.3 (0.19) -0.64 (-1.26 - -0.02) 
rs9726778 
G/G : 94 2.01 (0.16) 
-0.55 (-1.08 - -0.02)
a
 Additive 0.044 (0.352) 472.3 C/G : 34 1.38 (0.19) 
C/C : 1 1 (0) 
PANSS negative score 
rs3762271 
C/C : 49 13.84 (0.73) 
1.63 (0.16 - 3.09)
a
 Additive 0.031 (0.217) 839.9 A/C : 60 15.58 (0.81) 
A/A : 20 16.75 (1.59) 
rs41310927 
A/A : 49 13.69 (0.74) 
1.77 (0.31 - 3.22)
a
 Additive 0.019 (0.152) 839 A/G : 60 15.58 (0.81) 
G/G : 20 17.1 (1.54) 
PANSS N1 - Blunted affect 
rs6700180 
C/C - T/C: 87 2.36 (0.13) 0.00 
Recessive 
0.0053 
(0.0424) 
354.6 
T/T : 23 1.7 (0.16) -0.76 (-1.28 - -0.24) 
rs41310927 
A/A : 49 1.88 (0.14) 
0.32 (0.04 - 0.59)
a
 Additive 0.026 (0.156) 410.1 A/G : 60 2.28 (0.15) 
G/G : 20 2.45 (0.31) 
rs10922163 
A/A - G/A:84 2.37 (0.14) 0.00 
Recessive 0.007 (0.049) 350.6 
G/G : 24 1.67 (0.16) -0.73 (-1.24 - -0.21) 
PANSS P6 - Suspiciousness / persecution 
rs10922163 A/A - G/A:84 2.07 (0.14) 0.00 
Recessive 0.04 (0.24) 386.7 
 G/G : 24 2.75 (0.34) 0.65 (0.04 - 1.26) 
PANSS P7 - Hostility 
rs6700180 
C/C : 29 1.28 (0.11) 0.00 Dominant 0.02 (0.16) 327.2 
T/C - T/T : 81 1.88 (0.12) 0.52 (0.09 - 0.95)    
rs10922163 
A/A : 27 1.33 (0.12) 0.00 
Dominant 0.039 (0.273) 323.5 
G/A - G/G : 81 1.88 (0.12) 0.47 (0.03 - 0.92) 
rs4915337 
A/A : 95 1.84 (0.11) 0.00 
Dominant 0.041 (0.273) 373.9 
A/T - T/T : 34 1.38 (0.13) -0.40 (-0.78 - -0.02) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval; N/A, not applicable. 
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4.7.1.4. PSYRATS subscale for AH 
When the effect of ASPM SNPs on PSYRATS subscales for AH and delusions was analyzed, there 
were two positive findings: the SNP rs3762271 (non-synonymous SNP located in exon 18) was 
slightly associated with the item Duration of AH, while the SNP rs41310927, also a non-
synonymous change from exon 18, was related with the item Frequency of AH (table R108). In 
both cases, the homozygotes for the minor allele presented hallucinations with a lower duration 
and frequency than the other genotypic groups. However, both associations were very weak and 
possibly represent a false positive. 
 
 
Table R108. Significant results from the association analysis of ASPM polymorphisms and PSYRATS scale 
parameters for auditory hallucinations. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
a
 BIC 
PSYRATS AH - Duration 
rs3762271 
C/C - A/C : 177 1.79 (0.13) 0.00 
Recessive 0.05 (0.4) 824.7 
A/A : 31 1.13 (0.26) -0.65 (-1.30 - -0.00) 
PSYRATS AH - Frequency 
rs41310827 
A/A - A/G : 176 1.83 (0.13) 0.00 
Recessive 0.05 (0.4) 829.8 
G/G : 32 1.19 (0.26) -0.65 (-1.30 - -0.01) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval; AH, auditory hallucinations. 
 
 
 
4.7.2. American Sample. 
We studied the effects of the 6 ASPM polymorphisms on the performance of the seven cognitive 
factors derived from different neuropsychological tests (as it is explained in the Materials and 
Methods section). Table R109 shows the results for the three positive phenotypes, which can be 
considered as measures of working memory. The three non-synonymous SNPs located in exon 
18 were associated with different cognitive measures: rs3762271 and rs41310927, which were 
in high LD, were associated with the Wisconsin Card Sorting Test (WCST) factor in controls. In 
detail, the homozygotes for the major allele scored higher for the WCST factor than 
heterozygotes (P = 0.017 uncorrected for rs3762271 and P = 0.048 corrected for rs41310927). 
Moreover, rs12138336 had an effect on other measures in cases and controls; for N Back, 
heterozygotes for the SNP rs12138336 scored higher than G/G homozygotes in the control 
sample (P = 0.011 uncorrected), while, in patients, homozygotes G/G had a better performance 
for Digit Span when compared to the heterozygotes (P = 0.023 uncorrected). 
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Table R109. Effect of ASPM SNPs in schizophrenic patients and normal controls on several cognitive 
factors.  
Polymorphism Contrast Regression Coeff. P Value
a
 Subset 
N Back 
rs12138336 C/C vs C/A -1.748 0.011 (0.066) Controls 
WCST 
rs3762271 C/C vs C/A -1.609 0.017 (0.085) Controls 
rs41310927 A/A vs A/G -1.834 0.008 (0.048) Controls 
Digit Span 
rs12138336 G/G vs G/A -1.616 0.023 (0.138) Patients 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: WCST, Wisconsin Card Sorting Test; Coef, coefficient for the linear regression analysis; vs, versus. 
 
 
4.8. PDE4D gene 
We used the clinical information available for the Spanish sample to investigate the effect of 
PDE4D SNPs on several disease traits. Tables R110 to R113 show all the positive associations 
detected during the analysis. 
4.8.1. Age of onset. 
As it can be seen in table R110, two SNPs were associated with the age of onset of the psychotic 
symptoms. Genotype A/A for rs17291089 was more frequent in those patients with early-onset 
psychosis, while, regarding SNP rs7713345, those individuals with at least one copy of the G 
allele were more frequent in the early-onset group. However, after sequential Bonferroni 
correction, the significance was lost. Moreover, another factor which should be taken into 
account when valuating these findings is the small size of the early-onset psychosis sample. 
 
 
Table R110. Significant results from the association analysis of PDE4D polymorphisms with the age of 
onset of the disease. 
SNP Genotype 
Early-onset 
group 
frequency 
Late-onset 
group 
frequency 
OR (95% CI) P Value
b
 AIC Model 
rs17291089 
A/A 81 (93.1%) 115 (81.6%) 
3.03 (1.21 - 7.58)
a
 
0.0093 
(0.0744) 
300.4 Additive C/A 6 (6.9 %) 25 (17.7%) 
C/C 0 (0%) 1 (0.7%) 
rs7713345 
C/C 56 (64.4%) 110 (78%) 1.00 0.026 
(0.182) 
302.2 Dominant 
G/C - G/G 31 (35.6%) 31 (22%) 0.51 (0.28 - 0.92) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: CI, confidence interval. 
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4.8.2. KGV and BPRS scales. 
Table R111 shows the significant results for the KGV and BPRS items.  In summary, SNP 
rs17719378 appeared to be associated with 2 parameters: Incoherence of Speech, from the KGV 
scale, an Anxiety, from the BPRS scale. In both cases, G/G genotype was associated with higher 
scores of both items. However, the model which best adjusted to the results was different in 
each case. Unfortunately, any result remained significant after correction for multiple testing. 
 
 
Table R111. Significant results from the association analysis of PDE4D polymorphisms and parameters 
from KGV and BPRS scales. 
SNP 
Genotypic 
distribution 
Average response 
(SE) 
Difference  
(95% CI) 
Model P Value
b
 BIC 
KGV - incoherence of speech 
rs17719378 
A/A : 80 0.55 (0.1) 
0.30 (0.08 - 0.52)
a
 Additive 
0.0089 
(0.0712) 
589.2 A/G : 93 0.77 (0.12) 
G/G : 25 1.2 (0.26) 
BPRS - anxiety 
rs17719378 
A/A - A/G : 109 3.09 (0.14) 0.00 
Recessive 0.025 (0.2) 435.2 
G/G : 12 4.08 (0.36) 0.99 (0.13 - 1.85) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval. 
 
 
4.8.3. PANSS scale. 
Table R112 shows those polymorphisms which were significantly associated with the different 
PANSS scale parameters. However, some of these results are not reliable, since the number of 
individuals in one of the genotypic groups is low. This can be applied to the associations 
between rs10461656 and rs7714708 with Uncooperativeness item (G8), and rs17719378 and 
item G11 (Poor Attention). In these three cases, the only significant model was the recessive one 
but the size of the group homozygote for the recessive allele was very low. 
By contrast, the most interesting findings are the associations of polymorphism rs17719378 with 
different items from the positive subscale: PANSS positive score (p = 0.045 corrected), P1 – 
Delusions (p = 0.037, corrected value), P3 – Hallucinations (p = 0.024 uncorrected) and P5 – 
Grandiosity (p = 0.026, uncorrected value). In all cases, the individuals with the A/A genotype 
got the lowest mean scores. 
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Table R112. Significant results from the association analysis of PDE4D SNPs and PANSS items. 
SNP 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
PANSS total score 
rs17719378 
A/A : 37 59.32 (2.9) 0.00 
Dominant 
0.034 
(0.272) 
676.8 
A/G - G/G : 42 67.26 (2.33) 7.94 (0.71 - 15.16) 
PANSS G8 - Uncooperativeness 
rs10461656 
G/G - A/G : 72 1.11 (0.04) 0.00 
Recessive 
0.0042 
(0.0294) 
130.9 
A/A : 7 1.71 (0.57) 0.60 (0.20 - 1.00) 
rs4700316 
C/C : 49 1.08 (0.04) 
0.22 (0.01 - 0.43)
a
 Additive 0.04 (0.24) 135 C/G : 27 1.26 (0.16) 
G/G : 3 1.67 (0.33) 
rs7714708 
C/C - T/C : 71 1.1 (0.04) 0.00 
Recessive 
0.0023 
(0.0184) 
130.5 
T/T : 9 1.67 (0.44) 0.57 (0.21 - 0.92) 
PANSS G11 - Poor attention 
rs17719378 
A/A -A/G : 74 2.03 (0.13) 0.00 
Recessive 
0.002 
(0.016) 
245.1 
G/G : 5 3.6 (0.24) 1.57 (0.61 - 2.54) 
PANSS G14 - Poor impulse control 
rs4700316 
C/C : 49 2.1 (0.17) 0.00 
Dominant 
0.028 
(0.224) 
249.3 
C/G - G/G : 30 1.53 (0.18) -0.57 (-1.07 - -0.07) 
rs7714708 
C/C : 34 2.18 (0.2) 0.00 
Dominant 
0.037 
(0.259) 
252.5 
T/C - T/T: 46 1.65 (0.15) -0.52 (-1.01 - -0.04) 
PANSS G16 - Active social avoidance 
rs7714708 
C/C : 34 2.59 (0.35) 0.00 
Dominant 
0.021 
(0.168) 
316.4 
T/C - T/T: 46 1.72 (0.19) -0.87 (-1.59 - -0.15) 
PANSS N7 - Stereotyped thinking 
rs829259 
T/T : 30 1.87 (0.21) 0.00 
Codominant 
0.016 
(0.128) 
230.6 
A/T : 36 1.28 (0.09) -0.59 (-1.05 - -0.13) 
A/A : 13 2 (0.36) 0.13 (-0.49 - 0.75) 
rs10461656 
G/G : 38 1.76 (0.18) 0.00 
Codominant 
0.028 
(0.196) 
231.8 
A/G : 34 1.32 (0.1) -0.44 (-0.88 - 0.00) 
A/A : 7 2.29 (0.57) 0.52 (-0.25 - 1.29) 
PANSS Positive score 
rs17719378 
A/A : 37 13.49 (0.87) 0.00 
Codominant 
0.0057 
(0.0456) 
516.4 
A/G : 37 17.38 (1.07) 3.89 (1.25 - 6.54) 
G/G : 5 11 (1.05) -2.49 (-7.90 - 2.93) 
PANSS P1 - Delusions 
rs17719378 
A/A : 37 2.03 (0.27) 0.00 
Codominant 
0.0046 
(0.0368) 
336.2 
A/G : 37 3.3 (0.35) 1.27 (0.42 - 2.12) 
G/G : 5 1.2 (0.2) -0.83 (-2.56 - 0.91) 
PANSS P3 - Hallucinatory behaviour 
rs17719378 
A/A : 37 2.16 (0.33) 0.00 
Codominant 
0.024 
(0.192) 
360.2 
A/G : 37 3.27 (0.39) 1.11 (0.12 - 2.09) 
G/G : 5 1 (0) -1.16 (-3.18 - 0.85) 
PANSS P5 - Grandiosity 
rs17719378 
A/A : 37 1.54 (0.2) 0.00 
Dominant 
0.026 
(0.208) 
304.3 
A/G - G/G : 42 2.33 (0.28) 0.79 (0.11 - 1.48) 
Significant P values (P < 0.05) are indicated in bold. 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval. 
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4.8.4. PSYRATS subscales for AH and delusions. 
Finally, the significant results from the association analysis between the 9 PDE4D SNPs and 
PSYRATS subscales for AH and delusions can be found at table R113. In this case, only one SNP 
(rs17719378) gave significant results. This SNP was found to be associated with one item of the 
AH subscale (Controllability of Voices) and 6 items from the delusions subscale. Regarding the 
delusions subscale, the A/A genotype was associated with a lower score in all cases. 
Nevertheless, neither of the values survived the sequential Bonferroni correction. 
 
 
Table R113. Significant results from the association analysis of PDE4D SNPs and parameters from PSYRATS 
subscales for auditory hallucinations and delusions. 
SNP 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
a
 BIC 
PSYRATS AH - Grade of control 
rs17719378 
A/A - A/G : 154 2.09 (0.14) 0.00 
Recessive 
0.046 
(0.414) 
717.1 
G/G : 22 1.27 (0.37) -0.82 (-1.62 - -0.02) 
PSYRATS Delusions - Total score 
rs17719378 
A/A : 44 4.14 (1.01) 0.00 
Dominant 0.03 (0.24) 695.8 
A/G - G/G : 54 7.69 (1.2) 3.55 (0.39 - 6.71) 
PSYRATS Delusions - Conviction 
rs17719378 
A/A : 44 0.84 (0.21) 0.00 
Dominant 0.035 (0.28) 376.9 
A/G - G/G : 54 1.52 (0.23) 0.68 (0.06 - 1.30) 
PSYRATS Delusions – Duration of preoccupation 
rs17719378 
A/A : 44 0.77 (0.19) 0.00 
Dominant 
0.048 
(0.384) 
364.8 
A/G - G/G : 54 1.37 (0.22) 0.60 (0.01 - 1.18) 
PSYRATS Delusions - Disruption 
rs17719378 
A/A : 44 0.59 (0.15) 0.00 
Dominant 
0.013 
(0.104) 
330.9 
A/G - G/G : 54 1.22 (0.19) 0.63 (0.14 - 1.12) 
PSYRATS Delusions – Amount of preoccupation 
rs17719378 
A/A : 44 0.73 (0.18) 0.00 
Dominant 
0.055, ns 
(0.44) 
361.8 
A/G - G/G : 54 1.3 (0.22) 0.57 (-0.01 - 1.14) 
PSYRATS Delusions – Intensity of distress 
rs17719378 
A/A : 44 0.57 (0.15) 0.00 
Dominant 
0.018 
(0.144) 
329.8 
A/G - G/G : 54 1.17 (0.19) 0.60 (0.11 - 1.09) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval; ns, not significant; AH, auditory hallucinations. 
 
 
4.9. PLEKHB1 and RAB6A genes 
We investigated the effect of PLEKHB1 and RAB6A SNPs on several disease traits which had been 
assessed on the Spanish patients. Tables R114 to R116 show all the significant associations 
found during the analysis. 
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4.9.1. KGV and BPRS scales. 
The positive associations with BPRS and KGV scales can be found at table R114. As it can be 
seen, the SNP rs7127066 was found to be associated with three items, Hallucinations and 
Psychomotor Retardation from KGV scale and the BPRS total score. However, only the 
association with Hallucinations should be taken into account, since the two other findings are 
based on the existence of genotypic groups of very small size (8 and 4 individuals with C/C 
genotype, respectively). 
 
 
Table R114. Significant results from the association analysis of PLEKHB1-RAB6A polymorphisms and 
parameters from KGV and BPRS scales. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference  
(95% CI) 
Model P Value
a
 BIC 
KGV - hallucinations 
rs7127066 
G/G : 116 1.84 (0.16) 0.00 
Dominant 
0.02 
(0.12) 
789.2 
C/G - C/C : 82 1.26 (0.18) -0.58 (-1.07 - -0.09) 
KGV - anxiety 
rs940828 
T/T : 121 1.73 (0.09) 0.00 
Dominant 
0.051, ns 
(0.306) 
580.5 
G/T - G/G : 76 1.43 (0.11) -0.29 (-0.59 - -0.00) 
KGV - psychomotor retardation 
rs7127066 
G/G - C/G : 190 0.95 (0.08) 0.00 
Recessive 
0.038 
(0.228) 
596.9 
C/C : 8 1.75 (0.49) 0.80 (0.05 - 1.54) 
BPRS - total score 
rs7127066 
G/G - C/G : 75 46.2 (1.18) 0.00 
Recessive 
0.038 
(0.228) 
616.1 
C/C : 4 58.25 (12.16) 12.05 (0.85 - 23.25) 
BPRS - anxiety 
rs3741147 
T/T : 83 2.95 (0.16) 0.00 
Dominant 
0.014 
(0.084) 
435.4 
G/T - G/G : 36 3.67 (0.24) 0.71 (0.15 - 1.27) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval; ns, not significant. 
 
 
4.9.2. PANSS scale. 
Table R115 shows those polymorphisms which were significantly associated with the different 
PANSS scale parameters. Due to the high number of different items, there are an important 
number of positive associations. However, only some of these results should be considered, 
because many of the positive associations are not reliable due to the low number of individuals 
in one of the groups.  
In summary, the most interesting findings are the following: 
- The polymorphism rs11235876, located in intron 3 from the RAB6A gene, was 
associated with 6 different items (two negative items and the negative global score, two 
positive items and one item from the general subscale). In all cases, individuals who 
were A/A homozygotes scored higher than G/G homozygotes. 
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- The SNP rs663303, located 5’ upstream of PLEKHB1, was found to be associated with 
one positive item, three negative items and two general items. Interestingly, the T/T 
genotype always scored higher than the other genotypes. 
- The SNP rs7127066 (intron 1 from RAB6A gene) was associated with two positive items: 
Conceptual Disorganization and Hallucinatory Behaviour. The association with the 
Hallucinations item is very interesting since it is in coherence with the association with 
the Hallucinations item from KGV scale. Moreover, in the two cases the G/G 
homozygotes scored higher in average than the other genotypic groups. 
- rs940828 (intron 5 from PLEKHB1 gene) was associated with item P6- 
Suspiciousness/Persecution, and fitted a dominant model where the individuals with at 
least one copy of the G allele obtained higher scores. 
- The polymorphism rs12274970 (located in the intergenic region between PLEKHB1 and 
RAB6A genes) was associated with the General item Disturbing of Volition, and followed 
a dominant model. 
However, despite the high number of findings, only four of them survived sequential Bonferroni 
correction (table R115), as expected. These results were the three associations of rs11235876 
with Hostility, Passive/Apathetic Social Withdrawal and Disturbing of Volition; and the 
association of rs12274970 with the General item Disturbing of Volition.  
Another handicap to be taken into account is the low number of subjects with genotype 
information who have been evaluated for the PANSS. 
 
 
Table R115. Significant results from the association analysis of PLEKHB1-RAB6A SNPs and PANSS 
parameters. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
PANSS negative score 
rs11235876 
G/G : 18 14.5 (1.2) 
2.18 (0.29 - 4.08)
a
 Additive 
0.027 
(0.135) 
515.4 G/A : 42 15.83 (0.94) 
A/A :19 18.84 (1.43) 
PANSS P2 - Conceptual disorganization 
rs663303 
C/C : 56 1.54 (0.12) 
0.53 (0.08 - 0.99)
a
 Additive 
0.023 
(0.138) 
244.3 T/C : 21 2.1 (0.3) 
T/T : 2 2.5 (1.5) 
PANSS P3 - Hallucinatory behavior 
rs7127066 
G/G : 39 3.03 (0.37) 0.00 
Codominant 
0.038 
(0.228) 
361.2 C/G : 36 1.97 (0.32) -1.05 (-2.04 - -0.07) 
C/C : 4 4.25 (1.25) 1.22 (-1.01 - 3.46) 
PANSS P6 - Suspiciousness / persecution 
rs940828 
T/T : 44 2.07 (0.19) 0.00 
Dominant 0.04 (0.16) 284.7 
G/T - G/G : 35 2.71 (0.25) 0.65 (0.04 - 1.25) 
rs11235876 
G/G : 18 1.67 (0.27) 0.00 
Dominant 
0.016 
(0.096) 
283.1 
G/A - A/A : 61 2.56 (0.18) 0.89 (0.18 - 1.60) 
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Table R115 (continuation). Significant results from the association analysis of PLEKHB1-RAB6A SNPs and 
PANSS parameters. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference (95% CI) Model P Value
b
 BIC 
PANSS P6 - Suspiciousness / persecution 
rs7127066 
G/G : 39 2.05 (0.19) 
0.60 (0.09 - 1.10)
a
 Additive 
0.024 
(0.12) 
283.8 C/G : 36 2.56 (0.25) 
C/C : 4 3.5 (0.87) 
PANSS P7 - Hostility 
rs11235876 
G/G - G/A : 60 1.33 (0.18) 0.00 
Dominant 
0.0094 
(0.047) 
242.7 
A/A :19 2.08 (0.14) 0.75 (0.20 - 1.30) 
PANSS N2 - Emotional withdrawal 
rs663303 
C/C : 56 2.54 (0.16) 
0.57 (0.01 - 1.12)
a
 Additive 
0.049 
(0.205) 
277.3 T/C : 21 3.14 (0.36) 
T/T : 2 3.5 (0.5) 
rs11235876 
G/G : 18 2.55 (0.16) 0.00 
Dominant 
0.037 
(0.205) 
277 
G/A - A/A : 61 3.26 (0.35) 0.71 (0.04 - 1.38) 
PANSS N3 - Poor rapport 
r663303 
C/C : 56 1.73 (0.13) 
0.51 (0.08 - 0.95)
a
 Additive 
0.022 
(0.132) 
236.7 T/C : 21 2.19 (0.25) 
T/T : 2 3 (0) 
PANSS N4 - Passive / apathetic social withdrawal 
rs663303 
C/C : 56 2.62 (0.2) 0.00 
Dominant 
0.017 
(0.068) 
305.3 
T/C - T/T : 23 3.57 (0.37) 0.94 (0.18 - 1.70) 
rs11235876 
G/G : 18 2.06 (0.33) 
0.68 (0.18 - 1.18)
a
 Additive 
0.0093 
(0.0465) 
304.2 G/A : 42 3.02 (0.25) 
A/A :19 3.42 (0.34) 
PANSS G8 - Uncooperativeness 
rs663303 
C/C : 56 1.09 (0.04) 
0.23 (0.00 - 0.46)
a
 Additive 
0.049 
(0.245) 
135.3 T/C : 21 1.33 (0.2) 
T/T : 2 1.5 (0.5) 
PANSS G9 - Unusual thought content 
rs663303 
C/C : 56 1.46 (0.15) 
0.67 (0.12 - 1.22)
a
 Additive 
0.019 
(0.114) 
275.3 T/C : 21 2.1 (0.33) 
T/T : 2 3 (2) 
PANSS G13 - Disturbing of volition 
rs12274970 
T/T : 67 1.83 (0.19) 0.00 
Dominant 
0.0065 
(0.0325) 
275.9 
C/C : 12 2.65 (0.21) 0.82 (0.25 - 1.39) 
rs11235876 
G/G : 18 1.67 (0.21) 
0.67 (0.26 - 1.08)
a
 Additive 
0.0021 
(0.0126) 
273.8 G/A : 42 2.21 (0.21) 
A/A :19 3 (0.31) 
a. The indicated value corresponds to the difference which can be attributed to each allele in the additive model.  
b. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval. 
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4.9.3. PSYRATS subscales for AH and delusions. 
Regarding PSYRATS for AH and delusions, there was only one positive finding: the SNP 
rs7127066 (located in intron 1 from RAB6A gene) appeared to be associated with the item 
Intensity of distress to AH (table R116).  The results fitted a recessive inheritance model where 
the recessive homozygote genotype significantly scored higher than the other genotypes. 
However, this significant finding did not survive the correction for multiple testing. 
 
 
Table R116. Significant results from the association analysis of PLEKHB1-RAB6A SNPs and PSYRATS scale 
parameters for auditory hallucinations and delusions. 
Polymorphism 
Genotypic 
distribution 
Average 
response (SE) 
Difference  
(95% CI) 
Model P Value
a
 BIC 
PSYRATS AH - Intensity of distress 
rs7127066 
G/G - C/G : 166 1.42 (0.12) 0.00 
Recessive 
0.036 
(0.216) 
673.3 
C/C : 58 2.5 (0.56) 1.08 (0.08 - 2.09) 
Significant P values (P < 0.05) are indicated in bold. 
a. The corrected P value is indicated in brackets. 
Abbreviations: SE, standard error; CI, confidence interval; AH, auditory hallucinations. 
 
 
 
5. Gene-gene interaction analyses. 
5.1. Emotional variables. 
We performed a gene-gene interaction analysis to study the epistatic effects of several 
polymorphisms which had been associated to emotional variables in this study and/or in other 
independent studies. The selected polymorphisms were: 
- 5-HTTLPR (including rs25531), from the serotonin transporter gene: this polymorphism 
was associated in our study with several emotional items from the PSYRATS scale for 
auditory hallucinations, as well as the Anxiety item from KGV scale. Moreover, there are 
previous studies which clearly relate this functional polymorphism with the neural 
mechanisms of the emotional response. 
- The SNP rs6313, located in the first exon from the HTR2A gene. In the present study, this 
polymorphism (as well as the SNP rs6311, in high LD with rs6313) was repeatedly 
associated with the emotional items from different scales (KGV, BPRS, PANSS, 
PSYRATS…); moreover, the HTR2A gene is also an important component of the 
serotonergic system, together with the serotonin transporter gene. 
- The SNP rs4570625 from the TPH2 gene. Although our results were mainly negative 
(with the exception of a slight association with the item Amount of Distress from 
PSYRATS scale for AH), other authors (Herrmann et al., 2006) have found an association 
of this SNP with the modulation of emotional processing. Moreover, this polymorphism 
is also a key element of the serotonergic system. 
- The polymorphism rs182455 from the STMN1 gene. This polymorphism was also 
considered for the interaction analysis because of the previous findings from other 
206 Results 
 
authors (Shumyatsky et al., 2005) who demonstrated its high expression in limbic areas 
and its essential role in the regulation of both innate and learned fear.  
- Finally, the ability of the NO system to affect the serotonin transporter activity (Kiss and 
Vizi, 2001; Kilic et al., 2003) led us to include the functional VNTR from the NOS1 in the 
gene-gene interaction analysis. Particularly, a NOS1 x SLC6A4 interaction analysis was 
performed for the variables described below. 
Variables which were included in the analysis of pair wise polymorphism interactions were: 
1. The comparison of the genotypic frequencies among patients and controls. 
2. The Anxiety and Depression items from KGV, BPRS and PANSS. 
3. Three emotional items from PSYRATS subscale for AH: Amount of Distress, Intensity of 
Distress and Disruption. 
4. Two items from PSYRATS subscale for delusions: Disruption and Amount of Distress.  
Table R117 shows all the significant findings from the pair wise gene-gene interaction analysis. 
According to this information, there was an interaction between 5-HTTLPR and rs6313 which 
had an impact on several measures (the three items from the PSYRATS subscale for AH, as well 
as the Anxiety items from BPRS and KGV, see figure R10 for a graphical representation of the 
mean scores). Moreover, the distribution of the genotypic frequencies among patients and 
controls also seemed to be affected by this interaction. Furthermore, an interaction between 
rs4570625 from TPH2 and rs6313 from HTR2A was also detected. This interaction affected the 
mean scores for both items from the PSYRATS subscale for delusions, as well as the Depression 
item from PANSS (see table R117 and figure R11). However, the only significant interactions 
which survived the correction for multiple testing were those affecting the items Intensity of 
Distress and Amount of Distress to AH, from the PSYRATS scale. 
 
 
Table R117. Significant results from the pair wise interaction analysis among four polymorphisms related to 
emotionality. 
Polymorphism 1 
(gene) 
Polymorphism 2 
(gene) 
Response Variable OR or β
a
 Statistic P
b
 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) All cases versus controls 1.506 5.426 0.0198 (0.119) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) 
PSYRATS for AH - Intensity of 
distress 
0.6877 9.921 0.0016 (0.0098) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) 
PSYRATS for AH - Amount of 
distress 
0.6726 9.058 0.0026 (0.0156) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) PSYRATS for AH - Disruption 0.4607 4.94 0.0263 (0.1575) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) BPRS - Anxiety 0.4756 4.184 0.0408 (0.2448) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) KGV - Anxiety 0.2709 4.127 0.0422 (0.2533) 
rs4570625 (TPH2) rs6313 (HTR2A) 
PSYRATS for delusions - 
Disruption 
0.6679 5.62 0.0178 (0.1065) 
rs4570625 (TPH2) rs6313 (HTR2A) 
PSYRATS for delusions – 
Amount of distress 
0.6692 5.462 0.0194 (0.1166) 
rs4570625 (TPH2) rs6313 (HTR2A) PANSS G6 - Depression 0.6451 3.86 0.0495 (0.2967) 
Significant P values (P < 0.05) are indicated in bold. 
a. This value refers to the pair wise odds ratios (case-control variables) or β values (quantitative traits) which 
represent the magnitude of the epistasis. 
b. The corrected P value is indicated in brackets. 
Abbreviation: OR, Odds ratio. 
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Figure R10. Effect of SLC6A4-HTR2A interactions on the mean scores for different clinical measures. Graphs represent all 
the gene-gene interaction analyses with a significant result. Graphs a to c correspond to the effect on three emotional 
items of the PSYRATS subscale for AH, while graphs d and e refer to the influence of a genetic interaction on the Anxiety 
items from BPRS and KGV scales, respectively.  
Abbreviations: AH, auditory hallucinations. 
Abreviati 
LEGEND 
a b 
c d 
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e 
208 Results 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
  
 
5.2. Other gene-gene interaction analyses. 
Other polymorphisms and variables were also considered to be interesting. Particularly, when 
two or more polymorphisms were significantly associated (after the correction for multiple 
testing) with certain variable (quantitative or binary), a pair wise gene-gene interaction analysis 
was performed for those SNPs and variables. The selected polymorphisms and variables were 
the following: 
- The single SNP analysis showed that three SNPs (rs2020936, from the SLC6A4 gene, as 
well as rs6700180 and rs10922163, from the ASPM gene) were significantly associated 
(after Bonferroni sequential correction) with the risk for schizophrenia. For this reason, 
an analysis was performed to evaluate whether the genotypic distributions among cases 
LEGEND 
a b 
c 
Figure R11. Effect of HTR2A-TPH2 interactions on the mean scores for different clinical measures. Graphs represent all the 
gene-gene interaction analyses which resulted in a significant finding. Graphs a and b correspond to the effect on two 
emotional items of the PSYRATS subscale for delusions, while graph c refer to the influence of the genetic interaction on 
the Depression item from PANSS.  
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and controls were influenced by an ASPM x SLC6A4 interaction. It should be remarked 
that both SNPs located in ASPM (rs6700180 and rs10922163) are in perfect LD (r2 = 1). 
Therefore, only rs10922163 was selected for the interaction analysis, together with the 
serotonin transporter gene polymorphism. 
- We also studied the likely effect of a NOS1 x 5-HTTLPR interaction on the PANSS variable 
Hostility, a positive item from the PANSS. 
- The effect of an interaction between the SNPs rs9726778 (ASPM gene) and rs6313 
(HTR2A gene) on the PANSS general score was also analyzed. 
- Both the NOS1 ex1-VNTR and the SNP rs182455 from the STMN1 gene were found to be 
associated with the positive PANSS item Suspiciousness-Persecution. For this reason, the 
effect of an interaction of both genes on this parameter was also evaluated. 
- Finally, we studied the existence of pair wise gene-gene interactions which could affect 
the score for one negative item from the PANSS: Blunted Affect. The selected SNPs 
were: rs12037513 (STMN1), rs6700180 (ASPM) and rs10922163 (ASPM).  
Table R118 shows a summary of the significant findings resulting from these gene-gene 
interaction analyses. An interaction of ASPM x SLC6A4 appears to affect the genotypic 
distributions in cases and controls. Unfortunately, this significant value did not resist the 
correction for multiple testing. Moreover, a trend towards association (P = 0.07 uncorrected) 
was also found for the interaction STMN1 x NOS1 on the score for the PANSS item “Blunted 
Affect”.   
 
 
Table R118. Significant results from the pair wise interaction analysis among those polymorphisms which 
were associated with several response variables during the single SNP association analysis. 
Polymorphism 1 
(gene) 
Polymorphism 2 
(gene) 
Response Variable OR or β
a
 Statistic P
b
 
rs10922163 (ASPM) rs2020936 (SLC6A4) All cases versus controls 1.615 4.733 
0.0296 
(0.139) 
rs182455 (STMN1) Ex1f-VNTR (NOS1) 
PANSS P6 – 
Suspiciousness/Persecution 
0.6451 3.281 
0.0701 
(0.252) 
Significant P values (P < 0.05) are indicated in bold. 
a. This value refers to the pair wise odds ratios (case-control variables) or β values (quantitative traits) which 
represent the magnitude of the epistasis. 
b. The corrected P value is indicated in brackets. 
Abbreviation: OR, Odds ratio. 
 
 
 
The genotypic distributions in patients and controls for the SNP rs2020936 (intron 1A of the 
SLC6A4 gene) depending on the genotype for the SNP rs10922163 (ASPM gene) can be also 
observed in table R119. 
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Table R119. Genotypic frequencies in patients and controls for the SNP rs2020936 (SLC6A4 gene), 
depending on the genotype for the SNP rs10922163 (ASPM gene).  
rs2020936 rs10922163 CONTROLS PATIENTS OR (95% CI) 
 
G/G 60 44 1.00 
T/T A/G 81 112 1.89 (1.16-3.06) 
 
A/A 49 32 0.89 (0.49-1.61) 
 
G/G 41 14 1.00 
T/C A/G 54 35 1.90 (0.90-3.98) 
 
A/A 22 20 2.66 (1.13-6.27) 
 
G/G 3 2 1.00 
C/C A/G 2 4 3 (0.25-35.34) 
 
A/A 3 5 2.50 (0.25-24.72) 
The ORs for each rs2020936 genotypic group are indicated. 
Abbreviation: OR, Odds ratio. CI, confidence interval. 
 
 
 
6. Correlation with neuroimaging variables 
6.1. SLC6A4 gene 
6.1.1. Effect of 5-HTTLPR polymorphism on brain morphometry. 
We explored the influence of the promoter polymorphism in brain structure measured by voxel-
based morphometry (VBM). The effect of 5-HTTLPR on both control subjects and schizophrenic 
patients was studied. However, it should be noted that, for this analysis, the variation of SNP 
rs25531 was not taken into account. Therefore, subjects were only classified as l/l, l/s or s/s and 
grouped in two categories: on the one hand, l/l homozygotes and, on the other hand, the s-
carriers (l/s and s/s subjects). 
A region of interest (ROI) around the limbic system was defined. This region included the 
cingulate cortex, fornix, hippocampus, parahippocampal gyrus and amygdala.  
Table R120 shows information about the main clinical, genetic and demographic variables for 
the 30 controls and 24 patients included in this neuroimaging analysis. There were no significant 
differences in age between control subjects with the l/l genotype and s-carriers (F=0.94, p=0.55). 
Moreover, no differences were found between schizophrenic patients with l/l genotype and s-
carriers in age (F=0.18, p=0.67), age of first hallucinations (F=0.78, p=0.78), illness duration 
(F=0.12, p=0.72), BPRS general score (F=0.82, p=0.34), PSYRATS general score (F=1.07, p=0.31), 
PANSS total (F=0.59, p=0.45), PANSS positive (F=1.27, p=0.27), PANSS negative (F=0.34, p=0.56) 
and PANSS general (F=0.05, p=0.81). 
 
 
 
 
Results 211 
 
Table R120. Clinical and demographic data from control subjects and schizophrenic patients included in 
the correlation study between 5-HTTLPR and VBM data from limbic areas.  
Control subjects 
 l/l group (N = 9) l/s + s/s group (N = 21) 
Age (years) 29.78 ± 11.68 32.05 ± 7.21 
Schizophrenic patients 
 l/l group (N = 6) l/s + s/s group (N = 18) 
Age (years) 40.67 ± 6.92 38.89 ± 9.20 
Age first hallucinations 20.33 ± 11.57 21.78 ± 10.81 
Illness duration 15.67 ± 7.91 14.47 ± 6.85 
BPRS total score 47.00 ± 12.34 51.61 ± 9.44 
PSYRATS for AH total score 32.50 ± 1.73 29.93 ± 4.77 
PANSS total score 64.00 ± 20.14 70.00 ± 15.34 
PANSS positive score 15.33 ± 5.31 18.33 ± 5.71 
PANSS negative score 16.00 ± 7.53 18.11 ± 7.60 
PANSS general score 32.67 ± 9.30 33.56 ± 7.61 
Data are displayed as mean ± SD. 
Abbreviations: SD, standard deviation; BPRS, Brief Psychiatric Rating Scale; PSYRATS, Psychotic Symptom Rating Scale; 
PANSS, Positive and Negative Syndrome Scale. 
 
 
 
6.1.1.1. Effect of 5-HTTLPR in healthy subjects 
The results from the VBM analysis in healthy subjects can be found at table R121 and figure R12. 
Significant (p<0.05 FDR corrected, k=34) gray matter (GM) differences were found between 
control subjects with l/l genotype and s-carriers, revealing that healthy subjects with at least 
one copy of the short allele showed GM density reductions in hippocampus (bilateral, Brodmann 
areas 20, 36 and 35) and left parahippocampus (BA 30) when compared with l/l homozygote 
subjects. By contrast, there were no significant areas where the s-carriers showed greater GM 
density values than subjects with l/l genotype. 
 
 
Table R121. Significant areas with GM density reduction in healthy subjects who were s-carriers (l/s + s/s) 
when compared to healthy subjects with l/l genotype.  
Coordinates  (mm) 
X Y Z 
Label Hemisphere t value P (corrected) BA  
30 -7 -24 Hippocampus R 5.56 0.00 20, 36 
-25 -10 -21 Hippocampus L 5.32 0.00 35 
-24 -26 -17 Parahippocampus L 4.14 0.01 30 
p < 0.05 FDR corrected k=34. Corrected P values are given at cluster level. 
Abbreviations: R, right; L, left; GM, gray matter; FDR, false discovery rate; BA, Brodmann area. 
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6.1.1.2. Effect of 5-HTTLPR in schizophrenic patients 
 
GM density reduction was found in patients who had at least one copy of the short allele (table 
R122, figure R13). The most relevant area that showed significant reduction of GM density was 
the anterior cingulate gyrus, specifically Brodmann areas 24 and 32 (p<0.05 FDR corrected, 
k=34). Analogously to the control group, the schizophrenic s group did not show any regions of 
greater GM values, compared with the l/l group. 
 
 
Table R122. Significant areas with GM density reduction in schizophrenic patients with at least one short 
allele when compared to healthy subjects with l/l genotype.  
Coordinates  (mm) 
X Y Z 
Label Hemisphere t value P (corrected) BA 
-3 42 14 Anterior cingulate gyrus L 4.72 0.01 24,32 
p < 0.05 FDR corrected k=34. Corrected P values are given at cluster level. 
Abbreviations: L, left; GM, gray matter; FDR, false discovery rate; BA, Brodmann area. 
Figure R12. Areas of GM density reduction in healthy control subjects with a short 
copy of the 5-HTTLPR polymorphism and LSD plot of normalized GM values in the 
hippocampus (bilateral) and parahippocampal gyrus (left). p < 0.05 FDR corrected 
k=34. 
Abbreviations: GM, gray matter; LSD, least significant difference; FDR, false discovery 
rate; R, right; L, left. 
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Figure R13. Areas of GM density reduction in schizophrenic patients with a short 
copy of the 5-HTTLPR polymorphism and LSD plot of normalized GM values in the 
anterior cingulated gyrus. p < 0.05 FDR corrected k=34. Abbreviations: GM, gray 
matter; LSD, least significant difference; FDR, false discovery rate; R, right; L, left. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.1.2. Effect of 5-HTTLPR polymorphism on a functional neuroimaging phenotype. 
An exploratory and preliminary analysis to study the effect of the promoter polymorphism on 
the emotional response to voices (evaluated through an emotional-auditory functional 
neuroimaging paradigm) was performed on a group of 26 male right-handed schizophrenic 
subjects (DSM-IV criteria) from the Spanish sample. All patients were under antipsychotic 
treatment in the moment of evaluation. Some demographic and clinical characteristics from 
these patients (depending on their genotype) can be found at table R123. 
As in the VBM study, SNP rs25531 was not considered for the fMRI analysis and patients were 
only characterized as l/l, l/s or s/s. Particularly, the genotypic distribution was 6 homozygotes l/l, 
12 heterozygotes (l/s) and 8 homozygotes s/s. No differences were found between 
schizophrenic patients depending on the genotype in age (F=0.43, p=0.66), age of first 
hallucinations (F=1.78, p=0.21), illness duration (F=0.33, p=0.72), PANSS positive (F=0.78, 
p=0.47), PANSS negative (F=2.23, p=0.13) and PSYRATS general score (F=0.54, p=0.59). By 
contrast, significant differences, depending on genotype for 5-HTTLPR, were found in BPRS 
general score (F=3.53, p=0.047), PANSS total (F=4.77, p=0.019) and PANSS general (F=7.09, 
p=0.0042), probably due to the small sample size of l/l and s/s groups.  
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Table R123. Clinical and demographic data from the schizophrenic patients included in the correlation 
study between 5-HTTLPR and fMRI data.  
 l/l group (N = 6) l/s group (N = 15)  s/s group (N = 4) 
Age (years) 44.3±6.28 46.4±13.08 51.25±11.81 
Age first hallucinations 25.75±9.39 17.1±13.03 31.33±14.01 
Illness duration 17.5±4.97 17.6±8.71 14.25±4.03 
BPRS total score 42.8±13.8 46.7±9.12 59.75±7.54  
PSYRATS for AH total score 15.66±17.23 17.4±15.15 25.75±17.48 
PANSS total score 55.16±17.2 60.66±10.97 82±19.91 
PANSS positive score 14.66±7.52 16.8±6.16 19.75±4.5 
PANSS negative score 11.83±4.16 13.26±4.07 18.25±8.3 
PANSS general score 28.66±8.40 30.6±5.97 44±7.87 
Data are displayed as mean ± SD. 
Abbreviations: SD, standard deviation; BPRS, Brief Psychiatric Rating Scale; PSYRATS, Psychotic Symptom Rating Scale; 
PANSS, Positive and Negative Syndrome Scale. 
 
 
A region of interest (ROI) which included the left and the right amygdala was considered. 
The most interesting finding (figure R14) was the greater right amygdala activation to emotional 
words in the s/s group, compared to the l/s and l/l genotypes (P < 0.0001 uncorrected, MNI 
coordinates 32 -2 -12). However, there was no significant effect of 5-HTTLPR on the activation of 
the left amygdala. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure R14. Differences in the right amygdala activation in schizophrenic patients according to their 
5-HTTLPR genotype. 
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6.2. ASPM gene 
6.2.1. Effect of ASPM gene on brain volume. 
To analyse the effect of ASPM variation on brain morphology, we considered to be interesting 
those polymorphisms which were associated with risk for schizophrenia, but also the SNPs 
significantly associated with cognitive performance. Moreover, in order to get more reliable 
results, only those significant SNPs with a balanced genotypic distribution were studied: on one 
hand, rs10922163 (located in intron 17 and slightly associated with schizophrenia in both case-
control and family-based association analyses) and, on the other hand, rs41310927 and 
rs3762271 (located in exon 18 and associated with WCST performance).  
Table R124 shows information about the main clinical, genetic and demographic variables for 
the 153 controls and 169 patients from the American sample included in this neuroimaging 
analysis.   
 
 
Table R124. Clinical and demographic data from the control subjects and schizophrenic patients included 
in the correlation study between ASPM polymorphisms and VBM data.  
Control subjects (N = 153) 
Age (years) 32.78 ± 9.61 
Gender 78 males, 75 females 
Education years 16.98 ± 3.21 
WAIS-R IQ 106.43 ± 15.09 
Genotypic distribution 
rs41310927: 49 A/A; 67 A/G; 26 G/G 
rs3762271: 51 C/C; 65 C/A; 24 A/A 
rs10922163: 43 A/A; 75 A/G; 35 G/G 
Schizophrenic patients (N = 169) 
Age (years) 37.00 ± 9.70 
Gender 131 males, 38 females 
Education years 14.38 ± 2.20 
Diagnosis 146 schizophrenics, 21 schizoaffective disorder, 2 other psychoses 
WAIS-R IQ 94.89 ± 11.29 
Genotypic distribution 
rs41310927: 61 A/A; 82 A/G; 23 G/G 
rs3762271: 61 C/C; 80 C/A; 25 A/A 
rs10922163: 37 A/A; 91 A/G; 41 G/G 
Data are displayed as mean ± SD. 
Abbreviations: SD, standard deviation; WAIS-R, Wechsler Adults Intelligence Scale revised; IQ, intelligence quotient. 
 
 
We did not find any effect of genotype on total intracranial volume from patients or controls for 
any SNP. By contrast, we found a significant effect of the three SNPs on regional volumes in 
healthy subjects and schizophrenic patients: 
- rs41310927 (table R125): With regard to control subjects, allele G carriers showed a reduced 
volume in prefrontal cortex (Brodmann Area 9) when compared to A/A homozygotes as well 
as an increased volume in the subgenual cingulate cortex (Brodmann Area 25). By contrast, 
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schizophrenic patients who were allele G carriers had greater cerebellum volumes as well as 
a reduced gray matter volume in prefrontal cortex (Brodmann area 9) compared with A/A 
homozygote patients. 
 
 
Table R125. Significant areas with GM density differences depending on the genotype for rs41310927. 
Coordinates  (mm) 
X Y Z 
Label (Brodmann area) Contrast Sample Hemisphere Z K 
-10 14 -2 
Subgenual Cingulate cortex (BA25)  A/A < A/G + G/G Controls L 
3.99 
1822 -18 11 -5 3.50 
-11 3 12 3.49 
56 24 31 Prefrontal cortex (BA9) A/A > A/G + G/G Controls R 3.47 134 
55 -63 -32 
Cerebellum A/A < A/G + G/G Patients R 
4.02 
1446 
52 -61 -44 3.98 
-55 8 33 Prefrontal cortex (BA9) A/A > A/G + G/G Patients L 3.51 239 
P = 0.000 uncorrected. 
Abbreviations: L, left; R, right; GM, gray matter; BA, Brodmann area. 
 
 
- rs3762271: The analysis performed on the control sample (table R126; figure R15) showed 
that allele A carriers had a reduced volume in prefrontal cortex (Brodmann Area 9) when 
compared to C/C homozygotes, as well as an increased volume in the subgenual cingulate 
cortex (Brodmann Area 25). However, the differences in regional volumes observed in 
schizophrenic patients were different from those in healthy subjects (table R126, figure R16): 
those patients with at least one copy of allele A had greater cerebellum volumes as well as a 
reduced gray matter volume in prefrontal cortex (Brodmann area 9) compared with C/C 
homozygote patients. 
 
 
Table R126. Significant areas with GM density differences depending on the genotype for rs3762271. 
Coordinates  (mm) 
X Y Z 
Label (Brodmann area) Contrast Sample Hemisphere Z K 
-9 16 -3 
Subgenual Cingulate cortex (BA25)  C/C < C/A + A/A Controls L 
3.84 
1403 -16 12 -5 3.61 
-6 5 -8 3.20 
56 26 33 Prefrontal cortex (BA9) C/C > C/A + A/A Controls R 3.69 265 
55 -65 -30 
Cerebellum C/C < C/A + A/A Patients R 
3.88 
1097 
52 -61 -44 3.70 
-55 8 33 
Prefrontal cortex (BA9) C/C > C/A + A/A Patients L 
3.63 
360 
-62 1 31 3.18 
P = 0.000 uncorrected. 
Abbreviations: L, left; R, right; GM, gray matter; BA, Brodmann area. 
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- We also found a significant effect of SNP rs10922163 on regional brain volumes. Those 
control subjects with at least one copy of allele G (G-carriers) showed significant reductions 
in basal ganglia (caudate nucleus) and subgenual cingulate cortex (Brodmann area 25) 
when compared to A/A homozygotes (table R127). Moreover, we also detected an effect of 
rs10922163 in schizophrenic patients. In this case, allele G carriers had a significant 
reduction in cerebellum (table R127). 
 
Figure R16. Correlation between VBM data and SNP rs3762271 in schizophrenic patients. Allele A 
carriers (a) have a reduced volume in prefrontal cortex (Brodmann area 9) compared with C/C 
homozygotes, as well as an increased volume (b) in the cerebellum. 
Map threshold: P < 0.001 uncorrected.  
C/C > C/A + A/A  
 
C/C < C/A + A/A  
 
Figure R15. Correlation between VBM data and SNP rs3762271 in healthy subjects. Allele A 
carriers (a) showed a reduced volume in prefrontal cortex (Brodmann area 9) compared with C/C 
homozygotes, as well as an increased volume (b) in the subgenual cingulate cortex (Brodmann area 
25).  
Map threshold: P < 0.001 uncorrected.  
C/C > C/A + A/A  
 
C/C < C/A + A/A  
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Table R127. Significant areas with GM density differences depending on the genotype for rs10922163.  
Coordinates  (mm) 
X Y Z 
Label (Brodmann area) Contrast Sample Hemisphere Z K 
-5 19 -7 
Basal ganglia (caudate) 
Subgenual cingulate cortex (BA25) 
A/A > A/G + G/G Controls L 
3.92 
2525 -7  8 -8 3.70 
-10 2 3 3.67 
52 -61 -44 Cerebellum A/A > A/G + G/G Patients R 3.64 454 
P = 0.000 uncorrected. 
Abbreviations: L, left; R, right; GM, gray matter; BA, Brodmann area. 
 
 
6.2.2. Effect of ASPM gene on a functional neuroimaging phenotype. 
Given the effect of ASPM genotype on brain morphology, we hypothesized that ASPM variation 
would also correlate with an effect on neural activation of prefrontal areas during N Back task in 
healthy subjects. For this purpose, 79 healthy subjects were included in the study. These 
subjects did not differ in N Back performance depending on their genotype (table R128). 
 
 
Table R128. Performance of healthy subjects during the 2 back task associated to the fMRI procedure.  
rs41310927 
 A/A (N = 21) A/G (N= 41) G/G (N = 9) P
a
 
% correct 2-back 0.99±0.002 0.99±0.002 0.99±0.003 0.71 
Reaction Time (s)  0.57±0.04 0.60±0.030 0.58±0.06 0.81 
rs3762271 
 C/C (N = 31) C/A (N= 41) A/A (N = 7) P
a
 
% correct 2-back 0.99±0.002 0.99±0.002 0.99±0.003 0.68 
Reaction Time (s)  0.58±0.04 0.60±0.030 0.57±0.07 0.93 
rs10922163 
 A/A (N = 31) A/G (N= 41) G/G (N = 7) P
a
 
% correct 2-back 0.99±0.002 0.99±0.002 0.99±0.002 0.52 
Reaction Time (s)  0.54±0.04 0.62±0.030 0.56±0.07 0.23 
Data are displayed as mean ± SE. 
a. An Analysis of Variance (ANOVA) test was performed to compare the mean values of each genotypic group. 
 
 
Consistent with our initial hypothesis, we found a significant effect of ASPM genotypic variation 
on working memory performance. The most significant effect was caused by SNP rs10922163. 
During the N Back working memory task, healthy subjects with two copies of the A allele showed 
greater activation in the anterior cingulate cortex (Brodmann area 32), compared with allele G 
carriers (table R129, figure R17). 
 
 
Table R129. Significant differences in brain activation during a N Back task depending on the genotype for 
ASPM SNP rs10922163.  
Coordinates  (mm) 
X Y Z 
Label (Brodmann area) Contrast Hemisphere Z 
P 
(uncorrected) 
K 
-8 19 30 Anterior cingulate cortex (BA32) A/A > A/G > G/G L 4.00 0.000 39 
Abbreviations: L, left; BA, Brodmann area. 
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Moreover, slightly significant results were also found for SNPs rs41310927 (table R130) and 
rs3762271 (table R131): those individuals who were A/A homozygotes for rs41310927 showed 
less activation in anterior cingulate cortex (Brodmann area 32) and prefrontal cortex (Brodmann 
area 9) when compared to allele G carriers (table R130). Moreover, a decrease in prefrontal 
cortex (Brodmann area 9) activation was also observed for those individuals who had at least 
one A allele from SNP rs3762271 (table R131). However, the reliability of these results is limited 
given the low P values, especially for the prefrontal cortex findings. 
 
 
Table R130. Significant differences in brain activation during an N Back task depending on the genotype 
for ASPM SNP rs41310927.  
Coordinates  (mm) 
X Y Z 
Label (Brodmann area) Contrast Hemisphere Z 
P 
(uncorrected) 
K 
-8 19 30 Anterior cingulate cortex (BA32) A/A < A/G + G/G L 3.24 0.001 21 
45 8 18 Prefrontal cortex (BA9) A/A < A/G + G/G R 2.78 0.003 13 
Abbreviations: L, left; R, right; BA, Brodmann area. 
 
 
Table R131. Significant differences in brain activation during an N Back task depending on the genotype 
for ASPM SNP rs3762271.  
Coordinates  (mm) 
X Y Z 
Label (Brodmann area) Contrast Hemisphere Z 
P 
(uncorrected) 
K 
45 11 24 Prefrontal cortex (BA9) C/C < C/A + A/A R 2.66 0.004 6 
Abbreviations: R, right; BA, Brodmann area. 
 
 
 
 
 
 
 
Figure R17. Effects of ASPM 
rs10922163 genotype on 
brain physiological 
responses. Genotype-based 
parametric comparisons of 
BOLD fMRI data 
demonstrate significantly 
greater left anterior 
cingulate cortex activation 
of A/A subjects during the 
performance of a working 
memory task (the N Back 
task). 
 
A/A > A/G > G/G 
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DISCUSSION 
1. Initial considerations 
This doctoral thesis project is part of a multidisciplinary research effort whose general 
objective is to better understand the underlying causes of schizophrenia and other related 
psychoses, with a special interest in the genetic causes of this disorder. Prior to the discussion 
of our results, there are several issues and limitations that need to be acknowledged and 
considered to fully understand the conclusions of this study. These limitations concern 
different aspects of the study, such as the alternative phenotypes and sample features, the 
clinical information available from each dataset, the genotyping process, marker coverage and 
statistical analysis.  
1.1. About the samples and phenotypes considered in this study 
The complexity and the probable lack of utility of the clinical definition of schizophrenia are 
unquestionable handicaps which had led to the use of complementary approaches in the study 
of the genetic bases of this disorder. Among these approaches, the use of alternative 
phenotypes can be especially useful. For this reason, several alternative phenotypes have been 
selected and several samples have been used in the present study.  
Auditory hallucinations (AH) are one of the alternative phenotypes tackled in this study. As 
explained in the Introduction, AH are one of the hallmarks of psychoses and, despite they can 
be detected in other types of patients (neurological, drug abusers) or even in healthy subjects, 
the phenomenology of AH has particular features in psychotic patients. Given our interest in 
studying the genetics of AH in psychotic patients, a sample of Caucasian psychotic patients and 
control subjects from Valencia (Spain) began to be collected some years ago by our group at 
the Departments of Medicine and Genetics from the University of Valencia. The main interest 
of this sample is that the clinical characteristics of AH have been studied in great detail on 
every patient. We consider that auditory hallucinations are a multidimensional phenomenon 
and therefore it cannot be evaluated through a presence/absence item (as it happens in 
general scales such as PANSS, BPRS or KGV). For this reason, all hallucinatory patients were 
assessed through the PSYRATS scale for auditory hallucinations (Haddock et al., 1999; González 
et al., 2003b), which is composed of 11 different items which cover the different dimensions of 
auditory hallucinations, and also including three parameters which evaluate the emotional 
response to this positive symptom (Intensity of Distress, Amount of Distress and Disruption to 
life). Moreover, a small subset of these patients (as well as a group of healthy controls) was 
also subjected to magnetic resonance (MR) protocols, in an attempt to evaluate the presence 
of changes in brain volume or brain activity correlating with variation at the selected candidate 
genes. The fMRI emotional-auditory paradigm elaborated by our group (Sanjuán et al., 2007) 
also provides a good way to evaluate how patients respond to auditory hallucinations. In 
conclusion, the sample of Spanish patients and controls allows the study of the genetics of 
auditory hallucinations from three different levels: a) case-control association studies, which 
evaluate the existence of different allelic, genotypic or haplotype distributions in hallucinatory 
patients compared to other groups (controls, patients without AH…); b) association analyses 
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between genetic polymorphisms and items from PSYRATS subscale for AH; and c) association 
analyses with neuroimaging MR phenotypes (sMRI-VBM and fMRI). However, an important 
disadvantage is that the number of patients without hallucinations is still low in our sample. 
Although this type of patients is necessary for comparison purposes, the high frequency of 
auditory hallucinations in psychotic patients makes the search for non-hallucinatory patients 
difficult. For this reason, the search for psychiatric patients without AH led us to include some 
patients with bipolar disorder. However, the homogeneity of the sample, with regard to the 
absence/presence of auditory hallucinations, is guaranteed.  
Other Caucasian samples of different origin have also been included in this study. The 
American sample collected at the Clinical Brain Disorders Branch (National Institute of Mental 
Health) is of special interest because exhaustive clinical information on cognitive variables is 
available. Due to its high impact on patients’ life quality, cognitive impairment is the second 
alternative phenotype considered of interest for this doctoral thesis project. Thus, it is possible 
to study the effect of genetic variation on several cognitive factors corresponding to different 
cognitive domains (Genderson et al., 2007). Furthermore, an important number of individuals 
from the CBDB dataset were also subjected to several MR procedures, including morphometry 
as well as functional neuroimaging measures during the performance of several cognitive 
tasks. For the present study, several SNPs on ASPM gene were genotyped during my stay at 
the CBDB, thus allowing the study of how ASPM variation influences schizophrenia and 
cognition by using different approaches: case-control and family-based studies; linear 
regression studies with cognitive factors; and correlation studies with neuroimaging data.  
The third sample which has been also included in this study is a German case-control dataset 
from the Department of Psychiatry and Psychotherapy at the University of Würzburg. In this 
case, we have no information regarding auditory hallucinations or cognition; however, the 
results from the case-control association studies can be compared to those obtained in the 
Spanish sample. Particularly, PDE4D, PLEKHB1 and RAB6A genes were genotyped in this 
sample and included in the present study. 
Although the study of AH and emotionality was our primary goal, other aspects were also 
analyzed in the Spanish sample. As it was explained before, Spanish patients underwent an 
exhaustive clinical examination through different clinical scales. Some of them were general 
(PANSS, BPRS, KGV), while others focused on specific disease traits, such as the PSYRATS 
subscales for auditory hallucinations and delusions. It is important to remark that all these 
variables provide information about the emotional state of the schizophrenic patients, and an 
effect of genotype on positive and negative symptoms can also be studied. However, although 
the search for association with these measures can provide us with a lot of information, this 
approach also presents several limitations. First, these traits are extraordinarily variable and 
can change over time without following a logical pattern (Cuesta and Peralta, 2005). Thus, our 
measures represent a photograph, a static capture of a complex process. As a result, it is 
particularly hard to define the effect of genetic variation on these disease traits. Second, it may 
be argued that these measures do not have biological correlates and are away from the 
genetic etiology of psychoses (Sanjuán, 2007). Although this may be true for some measures, 
many clinical items may help us to know if certain polymorphism has a role on general 
behavioral dimensions, such as impulsivity, emotionality or cognition. A clear example is the 
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HTR2A gene, which was found to be associated with an important number of measures from 
different scales related to emotionality (see tables R97 to R99). Third, the analysis of such a 
huge number of variables drastically increases the chance of spurious associations (type I 
error). This scenario would explain the high number of nominal associations found with clinical 
scores. It is also likely that the sequential Bonferroni correction is too permissive. However, the 
number of positive findings after correction for multiple testing is small and may help us to 
know which measures are really influenced by the genotype.   
We are also aware that our sample size is relatively small and the statistical power to detect 
associations is reduced. Thus, small effect sizes, or marginal effects in case interactions exist, 
may be difficult to detect, particularly for those polymorphisms with a low minor allele 
frequency. For example, the Spanish case-control data set provides 99% power to detect 
association if the OR is 2 for a polymorphism with a risk allele frequency of at least 0.1. 
However, this power drastically reduces to 0.33 if the OR is 1.3. This power is even more 
dramatically reduced (7.6%) for those polymorphisms with a very small frequency of the risk 
allele (0.01), if the OR that have been considered are small. This could be the case for 
polymorphisms such as rs12138336 (ASPM) or rs17291089 (PDE4D) 
Particular cases are certain subgroups, such as the non-hallucinatory patients. This subset is 
extremely small (only 77 individuals). Given the high prevalence of AH among psychotic 
patients (Slade and Bentall, 1988; Andreasen and Flaum, 1991), it is extremely difficult to 
collect a group of non-hallucinatory patients with enough size for reliable association studies. 
Analogously, the number of patients who underwent clinical evaluation through certain scales, 
namely PANSS and PSYRATS subscale for delusions, is also relatively small. This small sample 
size could explain the high number of significant associations obtained for the PANSS items. 
The difficulty to collect certain individuals or clinical measures emphasizes the importance of 
performing cooperative studies involving different research groups, in an attempt to gather 
larger samples (Levinson et al., 2000; McInnis et al., 2003; Vilella et al., 2008). According to this 
idea, this study presents data from several Caucasian samples from Spain, Germany and the 
United States of America. The use of pooled samples can be useful to improve the power to 
detect associations. In our study, the use of a combined Spanish-American sample confirmed 
the association with SNP rs10922163 (from the ASPM gene) which had been detected in both 
samples separately (table R64). However, despite the use of larger samples in combination 
with GWA studies, there is still uncertainty into the field of psychiatric genetics, since each 
new large scale study has obtained a different result (Sullivan et al., 2008; O’Donovan et al., 
2008; Shifman et al., 2008b; Allen et al., 2008). Nevertheless, it is necessary to remark that all 
GWA studies for psychiatric diseases such as schizophrenia and bipolar disorder (Lencz et al., 
2007; Sullivan et al., 2008) have used modest sample sizes, in comparison with other diseases, 
such as type-2 diabetes mellitus (more than 38,000 cases and controls) or obesity (more than 
30,000 subjects) (Burmeister et al., 2008; Thorleifsson et al., 2009;). Thus, it is likely that we 
are still far from obtaining coherent findings through this approach.  
Population stratification is another central issue of population-based association studies 
(Langefeld and Fingerlin, 2007; Tian et al., 2008). It may be due to the existence of 
subpopulations with different rates of disease or allele frequencies, or because of admixture, 
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when the sample is composed of individuals with differing fractions of ancestry from distinct 
populations, and the genetic admixture differs between patients and controls (Langefeld and 
Fingerlin, 2007). In the present study, affected and control subjects were carefully matched on 
ethnicity (all Caucasian), gender (with the exception of the American sample, where females 
were more abundant in the control group) and age (mean age was similar among cases and 
controls). However, the possibility of a potential effect of population stratification on the 
association results still exists, particularly due to the small sample size.  
Unfortunately, the confounding effects of population stratification may be clearer when two 
samples of different geographical origin are combined. However, in order to minimize this 
effect in our combined association analyses, we performed a specific test which allows 
controlling potential confounding factors due to a different geographical origin.   
1.2. Genotyping methodologies: advantages and disadvantages 
Nowadays, researchers can count on a wide variety of genotyping techniques to fulfill the 
requirements and aims of each study design. Examples of these techniques are the RFLP-
genotyping methods, single strand conformation polymorphisms (SSCPs), sequencing 
methods, Taqman SNP genotyping Assays, iPLEX-MassArray genotyping and Illumina 
GoldenGate Genotyping Assay, among others. 
During this study, some of these methodologies were used to genotype the different samples. 
Particularly, three methods have been mainly used: RFLP-genotyping, Taqman SNP genotyping 
Assays and iPLEX-MassArray genotyping. This variability is due to the fact that different parts 
of the study were carried out at different laboratories. All these genotyping techniques are 
based on different processes and present different features (table D1) which should be 
considered when designing an association study.  
 
Table D1. Features of the different genotyping methods used in the present study. 
Method Infrastructure 
Simplicity of  
experiment 
design and 
optimization 
Simplicity 
of the 
whole 
process 
Speed 
Number of 
SNPs or 
samples 
(throughput 
level) 
Accuracy Price 
RFLPs + ++ ++ ++ + +++ variable 
Taqman 
assays 
+++ ++++ + +++ +++ +++ ++ 
Iplex-
MassArray 
++++ +++ ++ ++++ ++++ +++ +++ 
Each feature has been evaluated from + (low) to ++++ (very high). 
It should be noted that the ratings may be subjective. 
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RFLP-based genotyping methods are based on the differential digestion of PCR products, 
depending on the genotype for the SNP of interest. In the present study, this method was used 
to genotype some polymorphisms from the SCL6A4, HTR2A, TPH2, ASPM and STMN1 genes. 
One of the most important advantages of this traditional technique is that it does not require 
any specific or expensive infrastructure.  Thus, it is eligible as an initial option to start out 
genotyping, as it was the case in the present study. The optimization of each genotyping 
protocol can take a long time, since the assay conditions (PCR conditions, restriction enzyme…) 
are generally specific to each polymorphism. However, nowadays there is a wide variety of 
computer utilities which may help in the election of the best primer sequences, PCR conditions 
or the most suitable restriction endonuclease.  
By contrast, once the conditions are set, the genotyping process is easy to perform and does 
not require specific training. But compared to other techniques, it is a slow process with 
several steps (amplification, PCR testing, digestion and separation of digestion products). 
Therefore, it can take more time than other methods.  
Despite its simplicity, this is a low-throughput genotyping method which does not allow 
handling a huge number of DNA samples at the same time. For this reason, it is not suitable for 
large sample sizes.  
Our own experience suggests that the accuracy of RFLP-genotyping is more than 98% and the 
reliability of the results is high. Moreover, the number of fails is low, particularly when the 
amplification conditions have been perfectly established. However, it has been reported that 
the concentration of magnesium chloride in the PCR reaction mix can be of vital importance 
for the genotyping of VNTRs, such as 5-HTTLPR or STin2 (from the SLC6A4 gene), since a 
preferential amplification of one of the alleles of heterozygous individuals can happen under 
certain MgCl2 concentrations (Kaiser et al., 2002; Yonan et al., 2006). The use of different Mg
2+ 
concentrations did not appear to affect the genotyping of those polymorphisms in our study, 
however. Other factors which could produce genotyping errors are the use of restriction 
endonucleases with star activity (relaxed specificity under certain incubation conditions) and 
the use of enzymes which are affected by DNA methylation. 
Finally rare restriction endonucleases become particularly expensive and the final price of the 
entire process can increase spectacularly. In this latter case, this methodology would not be 
advisable. 
In conclusion, this methodology would be appropriate for low to medium sample sizes and for 
cheap restriction enzymes. If both conditions are not fulfilled, other methods should be used.  
Taqman SNP genotyping assays are based on the use of a 5' nuclease assay to discriminate 
between two alleles of a specific SNP (Livak et al., 1995a). This methodology was used to 
genotype the ASPM SNPs in the American sample. The overall performance of this technique is 
pretty satisfactory. In contrast with the gel-based methods, this high-throughput genotyping 
approach needs more infrastructures, such as a Real-Time PCR System (compulsory) or 
automated systems to dispense DNA samples on 384-well plates or to prepare amplification 
reactions. These latter automated systems, although optional, can substantially reduce the 
preparation time, allowing the genotyping of a huge number of samples in one day (Livak et 
al., 1995b). 
The simplicity of the protocol (only reduced to two main steps: amplification reaction and 
plate read) is substantially important because it reduces the possibility of contamination. 
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Moreover, the entire process is also faster than other existing genotyping methods. 
Interestingly, this technology can be considered of high throughput and it is suitable for high 
sample sizes, since it has been designed to work with up to 384-well plates.   
Compared to other genotyping approaches, one of the most important advantages of this 
technique is that there is no need of optimization, since each assay is functionally tested by 
the manufacturer. Moreover, the marker coverage of these assays is huge and includes over 
3.5 million genome-wide SNPs; furthermore, other SNPs not included in the catalogue can be 
also genotyped with this methodology by using a custom assay service. Unfortunately, our 
own experience shows that, for a small percentage of SNPs, the assay quality is not as the 
manufacturer had declared, and the clusters can be hardly distinguished, thus making the 
assignment of genotypes particularly difficult (see figure D1). In those cases, genotyping 
accuracy can be compromised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, the price, higher than in agarose-based methods, can be another inconvenient, 
particularly if the number of fails for certain assay is high and requires repeating the entire 
process. Moreover, if the number of fails exists but it is not very high, the regenotyping of fails 
may be not profitable. This can be a real problem if we are working with a small dataset, due 
b 
c 
Figure D1. Some plots corresponding to plate 
reads for different Taqman® SNP genotyping 
assays. While the first plot (a) presents an almost 
perfect separation of clusters, and the number of 
undetermined samples is low, the two remaining 
plots (b and c) present hardly distinguishable 
clusters. Moreover, the 1/1 and 1/2 clusters from 
plot c are not well-defined. As a result, genotype 
calls resulting from assays b and c should be 
repeated or discarded.  
Legend 
• Homozygote for allele 1  
• Heterozygote 
• Homozygote for allele 2 
 Negative control  
x Undetermined sample 
a b 
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to the loss of genotypic information. In summary, Taqman SNP genotyping assays are an 
excellent alternative for large datasets. 
The third technique which was used in the present study (for PDE4D, PLEKHB1, RAB6A, STMN1 
and SLC6A4 genes) uses the iPLEX-MassArray® technology from Sequenom. It is based on the 
generation of single base extension (SBE) products, which can be subsequently read by MALDI-
TOF mass spectrometry (Ross et al., 1998). The most striking advantage of this genotyping 
technology is the possibility of genotyping up to 29 SNPs at the same time in a multiplex 
reaction protocol. However, one of the most important disadvantages of iPLEX assays is that 
expensive equipment (MALDI-TOF mass spectrometer, MassARRAY® Nanodispenser) is 
required. It is also highly recommendable the use of additional equipment, such as a PCR 
workstation to prepare the reaction mix and an automated system to dispense solutions onto 
384-well plates.  
However, despite the initial outlay, this approach can be considered of great utility. Its 
hallmark is the possibility of performing up to 29-plex reactions in 384-well samples (Oeth et 
al., 2005). Thus, the number of DNA samples and SNPs which can be processed at the same 
time is hardly unbeatable by the preceding genotyping methods described above. This 
technique may be highly eligible for GWA studies.  
The assay design requires specific software to ensure multiplexing efficiency. This software is 
easy to use and the resulting primers are usually good to achieve a high accuracy. However, 
the subsequent steps are not as easy to perform as the Taqman SNP genotyping assays: a 
previous training is highly recommendable to ensure that all the devices (particularly the 
MALDI-TOF mass spectrometer) are correctly calibrated and used. Finally, data are analyzed 
through intuitive and useful specific software. Unfortunately, it should be remarked that the 
use of this technology may be problematical to genotype polymorphisms located in highly 
repetitive or low complexity genomic regions.  
Despite the disadvantages, iPLEX assays are one of the best alternatives to perform large scale 
association studies with medium to large samples.     
1.3. About the association studies 
One of the most important aims of an association study design is to ensure a high level of 
coverage for each gene. For this reason, an indirect approach (The International HapMap 
Consortium, 2003), based on the selection of tagSNPs, was combined with the selection of 
certain additional polymorphisms which appeared to have functional implications. However, 
there are three genes (HTR2A, TPH2 and NOS1), which do not accomplish these criteria, since 
only some representative and/or functional polymorphisms were selected and analyzed. 
Undoubtedly, this fact can be a problem and we cannot rule out the possibility that other 
polymorphisms may have an effect on the vulnerability to schizophrenia or specific disease 
traits.   
Moreover, despite using the exhaustive genotypic information publicly available at the 
HapMap Project database (http://www.hapmap.org/), it may be possible that the selected tags 
are not sufficient to capture all the variability of certain genomic region of interest, due to the 
existence of unknown polymorphisms with an important role on gene functioning. Moreover, 
another limitation is related to the use of CEPH-CEU samples as the reference population for 
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tag selection. Despite this population (Utah residents with ancestry from northern and western 
Europe) is of Caucasian origin, it is unclear whether these samples share a highly similar 
genetic structure and LD patterns with current European populations. Thus, this fact could also 
affect tag selection. However, this population was the best alternative for our study, although 
this issue should be taken into account.    
Another important problem related to any association analysis lies in the limitation of the 
current statistical tools to cope with the complexity of genetic-environmental models of 
complex mental disorders (Balding, 2006). As much as possible, we have tried to use valid 
statistical tools, such as the SNPstats program (Solé et al., 2006), which considers different 
inheritance models and allows the use of covariates by applying a logistic regression approach 
(for case-control comparisons) or a lineal regression approach (for quantitative disease traits). 
The possibility of testing multiple inheritance models (recessive, dominant, additive, 
codominant and overdominant) is extremely useful, because it prevents the loss of 
information when only a codominant model is tested. However, different inheritance models 
for the same significant SNP depending on the response variable have been observed in the 
present study. One example is the serotonin transporter promoter polymorphism 5-HTTLPR, 
which equally fitted to both additive and dominant models depending on the clinical variable 
associated with the polymorphism. However, this fact should not lead to confusion, 
particularly if all associations show the same trend (namely, if the same genotypes or alleles 
are always associated with an increase in scores, even though different inheritance models 
have been observed).  
Haplotype analysis is also a particular case. Many approaches have been developed to deal 
with haplotypes (Zhao et al., 2003; Balding, 2006; Langefeld and Fingerlin, 2007). The most 
important problem is that the phase is generally unknown. Thus, the first difficulty is to infer 
the haplotype phase from genotypic data. Several methods have been developed for this 
purpose, although their efficiency depends on several factors, such as the heterozigosity of 
each subject and the LD levels among polymorphisms. The second problem is haplotype 
complexity. There are several methods to reduce the number of haplotypes considered in 
association studies (Zhao et al., 2003). For this study, a 2-, 3- and 4-marker sliding-window 
analysis was used. From our point of view, this was the more appropriate model, since each 
window has less haplotypes than the whole candidate region and the computation 
requirements are lower. Moreover, the statistical power to detect association is increased. 
However, we are aware that this methodology does not take into account the evolutionary 
history of the population and the linkage disequilibrium patterns. Moreover, the small sample 
size, together with the elimination of rare haplotypes (frequency < 0.03) from the case-control 
analysis, can lead to a loss of information. 
Finally, the high number of polymorphisms and variables analyzed in this study can increase 
type I errors (false positives) due to multiple testing. Multiple testing is one of the most 
difficult issues in statistical genetics. There are different ways to control the increase of type I 
error. One possibility is the Bonferroni correction. However, this correction tends to be 
extremely conservative and can increase the number of false negatives (type II error), 
particularly when we are dealing with a high number of tests. By contrast, some research 
groups consider that it is not necessary to apply corrections. However, there is a practical 
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alternative, which consists in applying less conservative correction methods, such as the false 
discovery rate correction (FDR) (Storey and Tibshirani, 2003) or the sequential Bonferroni 
correction (Rice, 1989). With these corrections, the risk of a false positive is higher, although 
the power is higher too. In the present study, the sequential Bonferroni correction was 
applied. As a result, the original number of significant associations was drastically reduced. 
However, it may be argued that the other possibilities (Bonferroni or absence of correction) 
would be also recommendable.   
Moreover, an important difficulty related to association studies is the lack of replication 
among studies and populations. As a result of this observation, two explanations arise: are 
there different risk variants depending on the population? or is the lack of replication a result 
of a bad study design? In the present study, we have considered different populations, all of 
them of Caucasian origin, in order to have more complete information about each candidate 
gene.  
Despite the replication of the association or the SNP rs10922163 in both the American and the 
Spanish sample, results are usually enormously different. Several reasons can be invoked to 
explain these differences and some of them have been discussed previously: a) differences in 
the genetic structure of each population, which would lead to the existence of different risk 
alleles and genotypes on each group; b) increase in type I error (chance of positive 
associations) due to the reduced sample size. Moreover, a third reason could be the use of 
different statistical programs, which are based on different assumptions and algorithms. This 
situation would apply to the analysis of ASPM variation, since different programs were used 
for the Spanish and the American sample.      
1.4. About the correlation with neuroimaging phenotypes 
Some issues commented above can be also applied to our neuroimaging studies (Flint and 
Munafò, 2006; Glahn et al., 2007; Pell et al., 2008). These limitations are a) the small sample 
size in the Spanish dataset (particularly for control subjects); b) the likely effect of multiple 
comparisons; c) the limitations of current statistical utilities to work with such a complex 
combination of multimodal imaging parameters and genetic information. 
Other variables, such as age, gender or education years, have been described to have an effect 
on neuroimaging measures (Pell et al., 2008;). However, the subjects included in this study 
were carefully matched by all these variables and age and sex were used as covariates in the 
statistical analysis. Therefore, a small effect of these factors is expected. However, the only 
exception is the existence of an imbalanced sex ratio in the American dataset. The use of sex 
as a covariate is expected to minimize the effect of sex on our results. 
However, the greatest problem is the small sample size. Although there is much debate on 
adequate sample sizes to evaluate the potential role of structural brain abnormalities as 
endophenotypes, a review of the relevant literature suggests that sample sizes of 
approximately 50–100 patients are sufficient to report consistent findings (Van Haren et al., 
2008). Thus, one of our goals is to increase this sample for future research projects. 
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2. Genes and polymorphisms related to emotionality: Serotonergic 
system genes, NOS1 and STMN1.  
2.1. Serotonergic system genes: SLC6A4 gene  
The hypothesis that schizophrenia and psychoses are related to dysfunctions in serotonergic 
neurotransmission was formulated by Wooley and Shaw in 1957. Since then, the serotonergic 
hypothesis of schizophrenia has been developed and many studies have been done to 
understand how the 5-HT system can be involved in the pathogenesis of schizophrenia. 
For the present study, 12 polymorphisms in the serotonin transporter gene (SLC6A4) were 
selected, genotyped and analyzed in the Spanish case-control dataset. These polymorphisms 
were supposed to capture all the variability from this gene, according to the information 
available at the HapMap Project database (http://www.hapmap.org/). Several significant 
associations were found. The significance and relevance of these findings will be commented 
above.  
Case-control single-SNP association analyses revealed that two SNPs (rs140700 and 
rs2020936) were associated with psychosis and hallucinatory psychosis in the comparisons 
of allelic as well as genotypic frequencies (tables R22, R23, R25 and R26). Moreover, other 
significant results were found when other comparisons were made. These findings also 
included SNP rs2020936 in almost all comparisons, as well as rs140700 and other 
polymorphisms. However, almost all these findings did not survive Bonferroni sequential 
correction. Curiously, the promoter functional polymorphism 5-HTTLPR was not found to be 
associated with psychosis or AH in any comparison. This finding is indeed in coherence with 
the previous literature, since the implication of this functional polymorphism in the 
vulnerability to schizophrenia is still unclear (for meta-analyses, see Fan and Sklar, 2005; and 
Levinson, 2005) 
Although an important number of nominally significant associations have been found, many of 
these findings should be taken into account, since the number of individuals in some 
subsamples is particularly limited. This can be applied to patients without AH (N = 77) and 
patients with chronic AH (N = 81). In such cases, the statistical power to detect a true 
association is extremely low and therefore the results from these comparisons are subject to 
the effects of genotypic and allelic distributions clearly away from the real distribution of those 
polymorphisms in the population they are supposed to represent. Moreover, another issue is 
that only a few significant values resisted Bonferroni sequential correction. An increase in the 
number of comparisons probably leads to an increase in the type I error, which is directly 
related to the number of false positives, because it is highly likely that at least one null 
hypothesis will be rejected incorrectly. 
Thus, according to these ideas, the most interesting finding from the case-control comparisons 
would be the association of SNP rs2020936 with psychosis. A different distribution of 
genotypic frequencies of SNP rs2020936 among the whole sample of patients and controls (P = 
0.049 corrected) was detected. In this case, C-carriers were less abundant in the affected 
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group than in the control group (OR = 0.57). This finding was confirmed in the remaining 
comparisons, with a lower significance. However, the relationship among this SNP, located in 
intron 1A, and schizophrenia, had not been previously studied, although Kim et al. (2002) 
found a preferential transmission of the T allele in an autistic sample, which supports our 
results, since we found that the T allele was more abundant in the psychotic group compared 
to the control group. However, McCauley and colleagues (2004) did not replicate this initial 
finding (although they found a preferential transmission of allele G from rs140700 from 
parents to their autistic children, also in accordance with our findings). Nevertheless, our 
results regarding rs2020936 should be also considered cautiously, because this SNP was found 
to be slightly out of HWE in controls. Although this significant deviation from HWE did not 
survive the correction for multiple testing, further studies on bigger or additional samples 
would be necessary to confirm or discard this initial finding. There is still uncertainty about the 
functionality of this SNP, since our analysis with the online utility PupaSuite (Conde et al., 
2006) showed that this polymorphism did not seem to affect any regulatory sequence. 
However, we cannot discard the possibility that this SNP, or another variation in high LD with 
it, may alter the serotonin transporter expression. 
Regarding haplotype analysis, several 2-, 3- and 4-marker protective haplotypes were found. 
These haplotypes were variable combinations of the same alleles from SNPs rs3813034, 
rs140700, rs2020942, rs2020939 and rs2020936 and they were around 50% more frequent in 
the control group. As expected, all these haplotypes included allele A from rs140700, and one 
haplotype also included allele C from rs2020936, in agreement with single-SNP analyses. 
However, after a 1000-permutation run, all haplotypes became not significant. Although a 
trend can still be observed, the results are not strong enough to completely ensure that these 
are really protective haplotypes. Up to now only a few studies have tackled the impact of 
haplotype variation at SLC6A4 locus and schizophrenia, and most of them have been focused 
on the functional polymorphisms 5-HTTLPR and STin2 (Stöber et al., 1998; Dubertret et al., 
2005), although some of them have studied other additional SNPs (Zaboli et al., 2008). 
Interestingly, in the present study we have found some novel protective haplotypes which had 
not been previously described.    
With regard to the analysis of quantitative variables and other disease traits, several 
associations were detected. Many SNPs were found to be associated with at least one item of 
KGV scale, being the nature of the items (positive, negative, related to language abilities) 
extremely variable. Remarkably, the functional promoter polymorphism 5-HTTLPR was found 
to be associated with the total KGV score, as well as with the Anxiety and Delusions scores. 
Unfortunately, all results remained not significant after correction for multiple testing. 
However, a trend toward association can be observed among 5-HTTLPR and the Delusions 
score.  The results obtained for both BPRS and PANSS are also very similar:  a high number of 
associations affecting different polymorphisms and items emerged. However, the number of 
individuals who underwent an evaluation through PANSS and BPRS scales was low (around 
100-120) and some genotypic groups contained only a few individuals. As a result, many 
significant results appear unreliable. By contrast, some findings are especially interesting, 
namely the associations of 5-HTTLPR with three parameters from the PANSS positive 
subscale: PANSS positive score (p = 0.0079, not significant after correction but still showing a 
trend), P4 – Excitement (p = 0.015, corrected value) and P7 – Hostility (p = 0.0044, corrected 
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value). Particularly, low expression alleles (SA, SG and LG) were associated with higher scores 
in all cases. It should be noted that Excitement and Hostility are two items from the Excited 
Component from PANSS, according to Kay and Sevy (1990). 
Finally, we also found some nominal associations between three SLC6A4 polymorphisms 
(rs2020939, rs12945042 and 5-HTTLPR) and several items from the PSYRATS subscale for AH. 
Among these positive associations, the most interesting findings were the association of the 5-
HTTLPR polymorphism with the three emotional items from this scale: Intensity of Distress 
(p = 0.0061), Amount of Distress (p =0.011), and Disruption to Life (p = 0.012). In all cases, 
those patients with a low expression genotype scored higher than the other patients and this 
fact is in agreement with the significant associations found with PANSS, BPRS and KGV scales. 
Moreover, although the three tests became not significant after the correction, the association 
with the Intensity of Distress item still showed a clear trend (p = 0.0671). Interestingly, similar 
results were also obtained in our preliminary analysis with a smaller sample of patients and 
controls (Sanjuán et al., 2006b). In this study, the short allele of 5-HTTLPR appeared to be 
more frequent in the psychotic group and it was also found to be associated with the 
emotional response to AH measured through PSYRATS scale. Although in the present study we 
have not been able to replicate the association of the short allele with risk for schizophrenia, 
the association of this allele with the emotional response to AH still remains significant, giving 
more strength to our finding. These preliminary findings encouraged us to study deeply the 
impact of SLC6A4 variation in the emotional aspects of AH.  
The literature about the molecular genetics of AH in psychotic patients is brief. In this study, 
we tackled the analysis of the relationship among the serotonin transporter gene and auditory 
hallucinations, but especially with its emotional dimension. Until now, there was only one 
previous report (Malhotra et al., 1998) that had analyzed the association between SLC6A4 and 
AH in psychosis. In this case, the long allele of the 5-HTTLPR polymorphism was found to be 
associated with the intensity of hallucinations in schizophrenic patients. However, we did not 
find an association of 5-HTTLPR with any of the items of the PSYRATS scale directly related to 
the physical dimension of AH (such as Location, Duration or Intensity of AH, among others). In 
our opinion, these results are not surprising, if we consider that there are different 
mechanisms (and genes) controlling different aspects of AH. Furthermore, this previous report 
from Malhotra should be considered carefully. First of all, the small sample size, along with the 
lack of ethnical homogeneity, could have led to a false positive association. Moreover, the 
differences in the clinical assessment of AH could also explain the differences between our 
study and Malhotra’s finding. 
In summary, our results point out a relationship between higher emotionality in psychotic 
patients and the presence of low-expression 5-HTTLPR alleles. Ansorge et al. (2004) proposed 
that those genetic polymorphisms that reduce SERT expression may exert their effects during 
the early development of the CNS by altering the maturation of circuits that modulate the 
emotional response to novelty and stress. Our present findings are also in agreement with 
many prior association reports. There is a large body of evidence about the implication of the 
short, low-expressing allele of 5-HTTLPR in the emotional response to stressful situations. The 
short allele of the 5-HTTLPR has been described before as a risk allele for the development of 
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affective disorders (Anguelova et al., 2003; Lasky-Su et al., 2005; Cervilla et al., 2006; Dick et 
al., 2007), whereas the long allele seems to act as a protective factor.  
The significant results involving 5-HTTLPR and emotional response to AH encouraged us to 
study further the effect of this functional polymorphism. The use of neuroimaging techniques 
to study those brain regions involved in emotionality represents an important research 
strategy to understand emotional dysfunction in schizophrenia. For this reason, functional and 
structural magnetic resonance studies were performed. With regard to fMRI, we found greater 
right amygdala activation to emotional words in the S/S affected group, compared to the 
remaining genotypes. Moreover, we have also demonstrated that both schizophrenic patients 
with auditory hallucinations and healthy controls carrying at least one S allele of the 5-HTTLPR 
polymorphism have a reduced gray matter density. However, involved areas are different (ACC 
in patients; hippocampus and parahippocampus in controls).   
To the best of our knowledge, no previous neuroimaging study has reported data about the 
effect of serotonin transporter genetic variation in patients with schizophrenia and auditory 
hallucinations. Thus, our study would be the first attempt to discover the underlying genetic 
mechanisms of auditory hallucinations in psychosis.  
The amygdala is a key structure in the generation of both normal and pathological emotional 
behaviours. It is densely innervated by serotonergic neurons and 5-HT receptors are 
particularly abundant. Previous studies have related different activation patterns on amygdala 
and other related brain regions depending on 5-HTTLPR genotype: it has been shown that the s 
allele of 5-HTTLPR produces an increased amygdala response to fearful stimuli in healthy 
individuals (Hariri et al., 2002; Hariri et al., 2005; Canli et al., 2005b; Canli et al., 2006; Heinz et 
al., 2005; Heinz et al., 2007; Rao et al., 2007). This overactivation could be indicative of 
oversensitivity to threat-related signals in S allele carriers (Aleman et al., 2008). Furthermore, 
higher amygdala activation associated with the s allele has been also found in several 
pathological conditions, such as social phobia (Furmark et al., 2004) and panic disorders 
(Domschke et al., 2006). All these findings are in agreement with the fMRI results presented in 
this study. However, all these previous reports have used emotional paradigms based on visual 
stimuli. By contrast, our fMRI paradigm is of auditory nature, in an attempt to mimic the 
auditory hallucinations suffered by schizophrenic patients. In the light of our findings, it can be 
suggested that auditory hallucinations are stressful events, and the final response to them can 
be modulated by the patient’s genetic background. In addition to the neuroimaging 
approaches, there are also clear evidences relating vulnerability to environmental stress with 
variations in the SLC6A4 gene (Caspi et al., 2003; Eley et al., 2004; Kaufman et al., 2004; Grabe 
et al., 2005; Kendler et al., 2005; Cervilla et al., 2007). Studies with a primate (Macacca mulata 
or Rhesus monkey) model also support the existence of a gene x environment interaction: an 
interaction between rearing conditions and genotype for the rhesus monkey promoter 
variation (rh5-HTTLPR) has a significant effect on 5-HIAA concentrations in cerebrospinal fluid 
(Bennett et al., 2002), as well as in behavioral parameters from nursery-reared monkeys when 
compared to mother-reared monkeys (Champoux et al., 2002).  
Our results in the structural imaging-VBM analysis also support an effect of the serotonin 
transporter promoter polymorphism in gray matter volumes from limbic areas. The reduction 
of the GM density in the ventral and dorsal anterior cingulate cortex (ACC) of patients from the 
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S group can be considered a relevant finding since this structure is abnormally reduced in 
patients with schizophrenia and plays a key role in the neurobiological bases of this disease 
(Baiano et al., 2007). Moreover, ACC is involved in the processing of emotional stimuli and 
mood regulation and these processes are known to be abnormal in patients suffering from 
schizophrenia or auditory hallucinations. Therefore, we can hypothesize that patients suffering 
from schizophrenia and AH present a disturbed emotional processing modulated by 5-HTTLPR 
and expressed by an ACC GM reduction. Supporting this hypothesis, our group has recently 
reported a coincidence cluster in the right anterior cingulate gyri showing at the same time a 
reduction in GM density and an increased hemodynamic response to an emotional auditory 
paradigm in patients with schizophrenia (Martí-Bonmatí et al., 2007). Thus, the genetically-
driven effect observed in ACC volume could be directly related to the differences we have 
observed in right amygdala activation. Pezawas et al. (2005) studied the effect of 5-HTTLPR 
variation in the functional connectivity of ACC and amygdala in healthy subjects. Interestingly, 
they found a diminished functional coupling between these two regions in S allele carriers. As 
a result, it has been proposed that the decrease in the functional connectivity of amygdala and 
ACC leads to a dysregulation of amygdala response to emotional (negative) stimuli, which may 
result in a reduced ability to integrate arousal in cognition and behaviour (Pezawas et al., 2005; 
Hariri and Holmes, 2006).  Moreover, Pezawas and colleagues (2005) also found a reduced GM 
volume in S-allele carriers in ACC and amygdala. Unfortunately, no differences in amygdala GM 
volume depending on 5-HTTLPR have been detected in our study. Several reasons, such as a 
sex or sample size effect, could explain these differences. Furthermore, it would be particularly 
interesting to study the effect of 5-HTTLPR variation on the activation of other limbic areas 
different from the amygdala, such as the anterior cingulate cortex.  
However, the results from our sMRI analysis in control subjects have been different to the 
schizophrenic group, since hippocampal and parahippocampal volumetric reductions 
associated to the s allele have been found. This finding is in clear contrast to other prior 
studies, such as the study from Pezawas et al. (2005), as well as another report from Canli et 
al. (2005b), who also found an effect of s allele on the pregenual region of ACC. Once again, 
sex effects could also help to explain our discordant results. Both studies also included females 
while our sample was only comprised of male subjects. Medication effects could also be a 
confounding factor. Moreover, since our sample was relatively small, a type II error cannot 
either be ruled out.  
The potential role of stress may be a possible explanation for our findings in healthy subjects. 
The biological effects of stress are mediated by the hypothalamic-pituitary-adrenal (HPA) axis, 
which regulates the release of cortisol. Accordingly, higher cortisol levels in s allele carriers 
might be contributing to hippocampal GM deficits. Interestingly, the serotonergic system is 
implicated in the augmentation of hippocampal glucocorticoid receptors during certain 
developmental periods. Moreover, it has been recently shown that an interaction between the 
s allele and high waking cortisol causes lower hippocampal volumes (O'Hara et al., 2007). 
These authors suggested that a) s allele carrier status could increase vulnerability to negative 
effects of higher cortisol levels on hippocampal volume, and b) neuronal development in s 
allele carriers might increase vulnerability to dysregulation of HPA function with a subsequent 
negative effect on hippocampal volume. Finally, severe stress early in life has been associated 
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with smaller hippocampal volumes (Stein et al., 1997; Vythilingam et al., 2002) and with 
persistent changes in the hypothalamic-pituitary-adrenal axis (Heim et al., 2001). 
Somewhat surprisingly, we did demonstrate a GM deficit in hippocampus in our control group 
but not in patients. This may indicate the existence of other additional risk factors which are 
contributing to the determination of volume in ACC and medial temporal structures. In 
particular, other genes may play a role in determining the volume of these brain structures. 
Some examples are neurotrophin 3 (NTF3), brain-derived neurotrophic factor (BDNF) and 
disrupted in schizophrenia 1 (DISC1) (Szeszko  et al., 2005; Agartz  et al., 2006; Callicott et al., 
2005), among others. Moreover, it should be also considered that the environmental 
conditions influencing a schizophrenic phenotype can greatly differ from those in a healthy 
subject.  
It would be interesting to perform the fMRI study in healthy subjects, since the particular 
phenomenology of schizophrenia could be masking the real effects of serotonin transporter 
genetic variation on the activity of limbic areas. 
In summary, we have found two SNPs (rs140700 and rs2020936), as well as several protective 
haplotypes, associated with psychosis and psychosis with auditory hallucinations. The 
significance is especially high for rs2020936, although its slight deviation from HWE generates 
reasonable doubts about the validity of this finding. Moreover, the functional promoter 
polymorphism, 5-HTTLPR appears to be associated with the emotional dimension of auditory 
hallucinations, with the low expression alleles (LG, SA and SG) associated with a higher 
emotional response. This initial finding obtained in the linear regression analysis of PSYRATS 
scale was subsequently confirmed through the use of a fMRI auditory-emotional paradigm as 
well as a structural neuroimaging approach; in those cases, we found a higher amygdala 
response to emotional voices in s/s patients, while an effect of 5-HTTLPR s allele on brain 
regional volumes could also be detected (ACC gray matter reductions in schizophrenia, and 
both hippocampal and parahippocampal gyri gray matter deficits in healthy controls). In 
conclusion, our findings suggest the existence of an effect of the serotonin transporter genetic 
variation on those neural circuits implicated in the regulation of emotionality in both healthy 
and schizophrenic conditions. It could be also interesting to study in the future the effect of 
the SNP rs2020936 on brain imaging phenotypes. 
2.2. Other serotonergic system genes: the exploratory analysis of HTR2A and 
TPH2 genes shows an effect of genetic variation on emotionality 
Only two polymorphisms from HTR2A gene, rs6311 (also known as -1438 A/G) and rs6313 
(known as T102C) were selected and genotyped in the Spanish dataset. Both SNPs are located 
in the 5’ region of the gene (promoter and exon 1, respectively) and they are two of the most 
studied polymorphisms in the 5-HT2A receptor gene. Our results show that, in agreement with 
the prior reports, these two SNPs are in almost perfect LD. With regard to TPH2 gene, only one 
SNP, rs4570625 (also known as -703G/T), was selected and genotyped in the Spanish sample. 
However, none of the three SNPs can be considered as tag SNPs, as they do not capture all the 
variability in those genes. The reason to choose only some representative SNPs instead of a set 
of tag SNPs is that this was an exploratory analysis whose objective was to evaluate the 
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involvement of other loci different from the serotonin transporter gene in the vulnerability to 
schizophrenia and auditory hallucinations.  
Unfortunately, no significant associations were found in the case-control association analysis 
for none of the two HTR2A SNPs and only some trends can be observed in the haplotype 
analysis. By contrast, the most suggestive findings are the associations between both HTR2A 
SNPs and different quantitative variables related to emotionality: BPRS Anxiety item, KGV 
Anxiety and Depression items, PANSS Anxiety and Preoccupation items and Intensity of 
Distress to AH (from PSYRATS subscale for AH).  In all cases, G/G (rs6311) and C/C (rs6313) 
individuals got higher scores. The association is particularly strong for both Anxiety items from 
PANSS and BPRS. Remarkably, an extraordinary coherence among the different scales can be 
observed, thus giving more strength to our finding. Our study of the HTR2A gene is in 
agreement with the previous literature. Despite the important role of the serotonin receptor 
5-HT2A in the pharmacological treatment of schizophrenia (Worrel et al., 2000) and the 
existence of several genetic functional variants, there is still uncertainty about the involvement 
of HTR2A variation in the susceptibility to schizophrenia (for meta-analyses, see Williams et al., 
1997; Lohmueller et al., 2003; Abdolmaleky et al., 2004; Li et al., 2006). However, there are 
many studies which had also related this gene to mood disorders, such as depression (Choi et 
al., 2004), some personality traits of bipolar disorder (Ni et al., 2006), seasonal affective 
disorder (Levitan et al., 2002), and panic disorder (Unschuld et al., 2007).  Another study from 
Golimbet et al. (2002) is particularly interesting, since they also found that, in complete 
agreement with our present results, the rs6313 polymorphism was associated with some 
personality traits, including Anxiety and Neuroticism, in psychotic patients. However, a meta-
analysis from Anguelova et al. (2003) has not detected the existence of association between 
HTR2A polymorphisms and affective disorders. Other complementary approaches will be 
necessary to better understand how this serotonin receptor is influencing emotional 
responses. As an example, it should be mentioned the study from Weisstaub and colleagues 
(Weisstaub et al., 2006), who found that the global disruption of 5-HT2A receptor signalling in 
mice affects anxiety-like behaviours. Functional neuroimaging studies could also be an 
interesting approach. It would be useful to study in the near future the effect of HTR2A 
variation in the response to emotional voices through our emotional-auditory fMRI paradigm 
(Sanjuan et al., 2007).  
Regarding the functional TPH2 polymorphism rs4570625, the results have been mainly 
negative. Only a slight association between this SNP and several items from the PSYRATS 
subscale for AH has been found. These items are: Total Score, Duration, Location, Intensity, 
Degree of Negative Content and Amount of Distress. However, several criticisms can be made 
to these results. First, the associations are significant only when the subset of schizophrenic 
patients is considered, and become only a trend if the whole hallucinatory sample is included 
in the linear regression analysis. This fact could be indicating that this polymorphism has an 
effect on the pathogenesis of specific schizophrenia symptoms rather than in psychosis as a 
general phenomenon; however, P values (between 0.02 and 0.043) are not significant enough 
to ensure this hypothesis.  Another explanation could be that the sample size is too small and 
the differences among all patients and schizophrenic patients are the result of a slight random 
variation in the genotypic distributions which result in spurious associations. The MAF of 
rs4570625 is relatively small (0.15 in patients), therefore the number of G/T and T/T 
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schizophrenic patients with AH is low (43 G/T individuals and 5 T/T individuals). Further studies 
would be necessary to understand the role of this SNP on the vulnerability to AH in 
schizophrenic patients.  
Anyway, the fact that G/T genotype is associated with higher distress to AH (compared with 
G/G individuals) is a really interesting finding, since it is in coherence with the literature. 
Gutknecht et al. (2007) found that the T allele from rs4570625 was associated with the 
personality trait Harm Avoidance, which is directly related to anxiety. Moreover, several fMRI 
studies (Brown et al., 2005; Canli et al., 2005a) support the involvement of this SNP in the 
responsiveness of amygdala to emotional stimuli. However, our finding is of small relevance 
and it would need to be confirmed by means of functional neuroimaging approaches or with 
the use of larger samples of patients. 
In conclusion, our results do not strongly support an effect of the genes of the serotonergic 
pathway on the vulnerability to psychosis and/or auditory hallucinations. By contrast, several 
small evidences suggest that these three genes, and more especially the serotonin transporter 
and the 5-HT2A receptor genes, may be partially responsible for the emotional dysregulation 
suffered by psychotic patients. This emotional dysregulation would also affect how these 
patients respond to auditory hallucinations.   
2.3.  Likely effect of NOS1 genetic variation on several disease traits. 
One polymorphism, the VNTR located in exon 1f from the neural nitric oxide synthase gene 
(NOS1 Ex1f VNTR), was genotyped in the Spanish case-control dataset. Our main goal was to 
perform an exploratory analysis with a representative functional polymorphism, to evaluate 
the likely implication of this gene in the vulnerability to schizophrenia or auditory 
hallucinations in our sample. 
Unfortunately, no significant results were found in the case-control comparisons of allelic and 
genotypic frequencies. With regard the linear regression analysis with quantitative variables, 
the polymorphism was found to be associated with several items from PANSS scale: three 
General items from the Depressive component (Kay and Sevy, 1990): Preoccupation, Guilt 
Feelings and Anxiety; a negative item (Lack of Spontaneity and Flow of Conversation); and two 
positive items: Suspiciousness/Persecution and Hostility. The most significant results were the 
associations with Guilt Feelings and Suspiciousness/Persecution. Moreover, the PANSS 
General score was also associated to this VNTR. In all cases, S/S homozygote patients scored 
higher, showing a great coherence among items. However, no association was found with the 
remaining scales. 
Although we have not detected any association between the NOS1 Ex1f VNTR and risk for 
psychosis or schizophrenia, it is likely that the NOS1 functional promoter polymorphism has an 
effect on symptom severity, due to its association with some emotional-depressive, positive 
and negative measures, with the short alleles associated with higher scores on these 
measures. These findings are in agreement with those reported by Reif et al. (2006). 
Particularly, they found that the low expression S/S genotype was associated with higher 
values for the PANSS positive subscale and the Hamilton depression rating scale. However, 
despite the coherence with previous findings, our results should be considered cautiously, due 
240 Discussion 
 
to the small sample size (N = 102) and the fact that no association was found with other 
related items from other psychopathological scales (BPRS, KGV). Therefore, the possibility of a 
false positive cannot be discarded. Moreover, it would be interesting to analyze additional 
polymorphisms located on this gene to fully discard the involvement of NOS1 genetic variation 
on the liability to schizophrenia. Many previous reports have found an association between 
other NOS1 polymorphisms (different from NOS1 Ex1f-VNTR) and schizophrenia. Thus, it is 
plausible that certain polymorphisms could have a role on the vulnerability to schizophrenia 
itself, while other polymorphisms such as the Ex1f-VNTR may modulate the severity of the 
disease.  
In summary, our findings support the implication of the NOS1 gene in the severity of certain 
symptoms of schizophrenic patients, such as the positive symptoms, although the significance 
is weak.  
2.4. Involvement of the STMN1 gene in the severity of negative symptoms. 
The stathmin1 gene is a very small gene located in chromosome 1. According to the linkage 
disequilibrium pattern around this area, two tag SNPs (rs182455 and rs12037513) were 
selected and genotyped in the Spanish sample. As far as we know, this is the first attempt to 
study the effect of this gene on the etiology of psychoses. The results from the association 
analysis will be commented below. 
The most interesting result from the case-control association analysis is the nominal 
association between the SNP rs182455 (located in the putative 5’ regulatory region of 
STMN1) and risk for schizophrenia. According to the information presented in table R48, T/T 
homozygotes were less frequent (OR = 0.67, P = 0.027 uncorrected) in the DSM-IV 
schizophrenic group compared with the control group. This association was also found when 
only hallucinatory schizophrenic patients were considered. However, this association became 
only a trend when all psychotic patients were considered in the comparison. Moreover, 
neither of the significant P values resisted the correction for multiple testing. Although the SNP 
rs182455 may have an effect on the vulnerability to schizophrenia, other case-control studies 
with additional independent and larger samples would be necessary to confirm this statement. 
The study of the effect of STMN1 variation on several quantitative disease traits may be a 
complementary approach to case-control analyses, since it could provide us with additional 
information about how this gene can modulate particular aspects of the symptomatology of 
schizophrenia. According to this idea, we found that the SNP rs182455 was nominally 
associated with several negative items, namely Flattened Affect and Incoherence of Speech 
from the KGV scale, as well as Active Social Avoidance, Lack of Spontaneity and Flow of 
conversation from PANSS, and, finally, the PANSS Negative score. In all cases, the C/C genotype 
correlated with higher scores. Moreover, this SNP was also highly associated with the positive 
item Suspiciousness/Persecution, which also survived the Bonferroni Sequential correction (P 
= 0.0026 corrected). However, in this case, those individuals who were C/C homozygotes 
scored lower than T/C homozygotes. With regard to AH, the polymorphism rs182455 was 
found to be nominally associated with two items from PSYRATS subscale for AH: Beliefs 
about the Origin and Intensity of Distress. Regarding SNP rs12037513, the most reliable 
findings are the nominal associations with two items from PANSS scale: Somatic Concern, a 
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depression-related item; and Blunted Affect, from the Negative subscale. Interestingly, the 
association with this last item also survived the correction from multiple testing (P = 0.03).   
These findings suggest that STMN1 variation could be implicated in the severity of Negative 
symptoms, since an important number of correlations among STMN1 SNPs and negative items 
has emerged. However, whether these or other polymorphisms in STMN1 gene have a 
functional implication is an unknown issue.  
Negative symptoms in schizophrenic patients can be considered as a type of emotional 
alteration: a decrease in the general response of the individual to different stimuli. According 
to our findings, this gene may also have a role in the emotional dysfunction suffered by 
schizophrenic patients, due to the existence of several associations with emotional items. 
The role of stathmin in the emotional dimension of schizophrenia would also involve the 
emotional response to auditory hallucinations. It has been reported that STMN1 is highly 
expressed in the lateral nucleus of the amygdala, as well as in those thalamic and cortical 
structures which process information related to conditioned and unconditioned stimuli 
(Shumyatsky et al., 2005). The disruption of STMN1 expression in a murine model 
subsequently leads to the alteration of those behavioral patterns associated with fear and 
threat assessment of the environment (Shumyatsky et al., 2005; Martel et al., 2008). As a 
result, social behaviors, such as maternal care and social interactions, are also severely 
affected. Interestingly, schizophrenia is a clear example of a human disease where normal 
emotional responses and social interactions are clearly compromised. Therefore, alterations 
on STMN1 gene expression or regulation could be involved, in conjunction with other genetic 
and environmental factors, in those pathological manifestations. Our findings would be also in 
coherence with this hypothesis. However, our results are particularly limited, given the small 
sample size and the use of a purely clinical approach. Other complementary approaches of 
functional nature would be of great utility to study the contribution of Stathmin variation to 
schizophrenia. 
In conclusion, according to our results, STMN1 variation appears to impact on the liability to 
schizophrenia, as well as the severity of negative symptoms, although these findings need to 
be checked through other approaches. 
2.5. Effect of the gene x gene epistasis on the emotional processing. 
The significant associations between certain polymorphisms of the serotonergic pathway and 
different items related to emotionality led us to investigate the effect of gene-gene epistasis 
on these emotional factors. Epistasis refers to the non-additive interaction between genes at 
different loci affecting a phenotype. For our purpose, we selected three polymorphisms (5-
HTTLPR from the serotonin transporter gene, rs6313 from the HTR2A gene and rs4570625 
from the TPH2 gene) as well as different response variables. As we hypothesized, some gene-
gene interactions arose: there was an effect of SLC6A4xHTR2A interaction on several items 
(All cases versus controls; PSYRATS for AH - Intensity of distress; PSYRATS for AH - Amount of 
distress; PSYRATS for AH – Disruption; BPRS – Anxiety; and KGV – Anxiety), while the 
TPH2xHTR2A interaction affected the following emotional parameters: PSYRATS for delusions 
– Disruption; PSYRATS for delusions – Amount of distress; and PANSS G6 – Depression. These 
are really interesting findings. Among them, the most significant findings are the effect of 
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SLC6A4xHTR2A interaction on the Intensity and Amount of Distress to auditory hallucinations. 
As it can be seen in figure R10, the effect of the serotonin transporter promoter polymorphism 
is clearly influenced by the genotype for rs6313. By contrast, no significant results were 
obtained for STMN1 or NOS1 genes 
According to our evidences, it is likely that multiple genetic polymorphisms are acting in the 
same or in opposite directions to model certain emotion-related behavioral phenotype. 
Moreover, several evidences supporting our findings have emerged in the last years. For 
example, interactions between 5-HTTLPR, COMT and DRD4 have been found to influence the 
personality trait of Novelty Seeking (Benjamin et al., 2000; Strobel et al., 2003), and 
interactions between 5-HTTLPR, COMT and MAOA appear to influence the regulation of HPA-
axis response to acute psychological and endocrine challenges (Jabbi et al., 2007). The effect of 
gene-gene epistasis on the activity of emotional brain circuits has also been tackled. An effect 
of a 5-HTTLPR x TPH2 interaction on the response to emotional visual stimuli has been 
reported (Herrmann et al., 2007). In an fMRI study with healthy subjects, Smolka and 
colleagues (2007) also showed an additive effect of COMT Val/Met and 5-HTTLPR 
polymorphisms on the differential activation of limbic regions in response to emotional 
negative stimuli. Finally, studies in mice also support interacting effects of the serotonin 
transporter genes with the dopamine transporters (slc6a3) the MAOA gene (maoa), the 5-
HT1B receptor gene (htr1b) and the BDNF gene (bdnf) (Murphy et al., 2008). 
In summary, our results, in coherence with many previous studies, suggest the existence of a 
genetically driven interaction between different elements of the serotonergic system which 
have a key role in the processing of emotional stimuli.  
3. ASPM gene as an example of a positive selection gene with an 
effect on schizophrenia phenotype.  
Whereas much of the sequence of the ASPM gene is substantially conserved among primates, 
specific segments are subject to strong positive selection. This fact can be related to the 
progressive increasing of the relative brain size in the course of primate evolution. As an 
important part of this PhD project, we have studied the impact of ASPM variation on risk for 
schizophrenia. Moreover, we also assessed how ASPM genotypes affected some 
endophenotypes related to cognition and brain morphology, which are known to be abnormal 
in patients with schizophrenia as well as their healthy siblings (Cannon et al., 1998; Kremen et 
al., 1994; Egan et al., 2001b). We tested 8 SNPs in the Spanish sample and 6 SNPs in the 
American CBDB dataset (five of them were common to both samples: rs3762271, rs12138336, 
rs41310927, rs10922163, rs6677082) and we found association for schizophrenia for some 
SNPs and haplotypes in both datasets. Moreover, some polymorphisms were found to be 
associated with several disease traits available in the Spanish patients. Finally, the SNPs 
located in exon 18 were found to affect performance on some cognitive phenotypes, which 
also correlated to variations in regional gray matter volumes and cortical function. 
Although we have not obtained a highly significant association with the risk for schizophrenia, 
the results are enormously coherent: 
Discussion 243 
 
- When the Spanish sample was analyzed, two SNPs (rs6700180 and rs10922163) were 
found to be associated with psychosis and psychosis with AH. The same associations were 
subsequently found when only schizophrenic patients were compared with controls. In all 
cases, C/C genotype from rs6700180 and A/A genotype from rs10922163 were significantly 
more common in the control group. It should be remarked that these associations resisted 
the correction for multiple testing. By contrast, no significant results were found for the 
remaining SNPs (see Rivero et al., 2006, for a preliminary analysis with 5 SNPs). Moreover, 
several common protective haplotypes (which included allele A from rs10922163, in 
coherence with the single-SNP analysis) were also found. Moreover, several SNPs were 
found to be nominally associated with the age at onset of the disease, as well as with 
several clinical scores from BPRS, PANSS and PSYRATS; however, only some associations 
remained significant after correction: the associations of both rs4915337 and rs972778 
with the PANSS general score and the associations of rs10922163 and rs6700180 with the 
Negative item from PANSS “Blunted affect”. Despite the uncertainty surrounding these 
correlations, the high number of associations with negative rather than positive items 
remarks the likely implication of ASPM variation on the pathophysiology of the negative 
dimension of schizophrenia. This issue should be studied deeply through the use of other 
approaches. In conclusion, according to all these findings, the SNPs rs10922163 and 
rs6700180 (or other variations in high LD with them) appear to be interesting elements 
which may modulate the risk for schizophrenia. It is nevertheless true that both 
polymorphisms were found to be out of HWE in the control sample as well as in the 
affected group. Although this deviation was slight (not significant after correction), this 
detail should be taken into consideration. The deviation from HWE could be indicating two 
situations: on the one hand, it could be an indicator of a genotyping error; on the other 
hand, it could be the consequence of HWE-modifying factors escaping from our control. 
Among these factors, we cannot discard the possibility that these polymorphisms are under 
the effects of a positive selection process. There are evidences that suggest that ASPM is 
still undergoing positive selection (Mekel-Bobrov et al., 2005). However, even if the 
deviation of HWE of those polymorphisms is related to positive selection processes, it is 
difficult to establish, with our tools, a relationship among this deviation and variation in the 
liability to schizophrenia.  
- With regard to the association analysis of the American sample, allele T from SNP 
rs6677082 was associated with schizophrenia in both case-control and family-based 
studies. The great coherence between both association approaches would allow us to 
support with more strength that rs6677082 (or another variation in high linkage 
disequilibrium with it) is really associated with the disease. We also found that allele G 
carriers for SNP rs10922163 were more frequent in the patients’ sample compared to the 
control subset. Although the odds ratio is not very high (1.44), there was also a trend 
toward overtransmission of the same allele from parents to affected offspring in the family-
based study. Moreover, we observed two common haplotypes which also increased the risk 
for schizophrenia in both approaches. Interestingly, one of these haplotypes included allele 
T for SNP rs6677082 and the allele G for SNP rs10922163.  Finally, SNP rs12116571 was 
found to be associated with schizophrenia, with an increase of genotype G/G in the 
patients’ sample. Although this polymorphism gave the higher statistical evidence (P = 
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0.001), this finding could be a false positive, because this SNP was out of HWE in the 
patients’ sample. Hence, the reliability of this result is uncertain. However, our 
understanding is that the possibility of a genotyping error is low. Therefore, we cannot 
discard the possibility that the lack of HWE in patients is a manifestation of a real 
association of this polymorphism with the disease. 
There are some encouraging coincidences between both samples. The polymorphism 
rs10922163 was found to be associated to schizophrenia in both the Spanish and the American 
samples. Moreover, in both cases, allele G carriers were more frequent in the affected group. 
Interestingly, the SNP rs10922163 was also found to be significantly associated with 
schizophrenia when a case-control analysis with a pooled sample that included American and 
Spanish cases and controls was performed. However, there are striking differences among 
both case-control datasets. Particularly, the significant haplotypes differ among the two 
studies and other polymorphisms different from rs10922163 have been found to be associated 
with schizophrenia in one of the samples but not in the other. As it was previously commented 
in the Introduction, the lack of strict replication is a common issue across genetic studies on 
schizophrenia, in contrast with other complex diseases such as type-2 diabetes mellitus (Florez 
et al., 2003) or age-related macular degeneration (Edwards et al., 2005; Haines et al., 2005; 
Hageman et al., 2005). This fact suggests several explanations for our results, including the 
possibility of false positives. However, another reasonable explanation is that the variability in 
the genetic structure among different populations can be influencing which are the risk 
genotypes and haplotypes in each population. Although our results show that there is a great 
similarity in the genetic structure of ASPM among both the Spanish and the American sample, 
the existence of differences in other interacting genes (related to both the ASPM gene and/or 
the risk for schizophrenia) can be the underlying cause of the heterogeneous results between 
both datasets.  
Our findings would support the relationship between the ASPM gene and vulnerability to 
schizophrenia, although the statistical evidence is weak. This fact is not surprising if we 
consider that some of the SNPs have a low minor allele frequency and therefore, in these 
cases, the power to detect association is reduced. Furthermore, it is worth mentioning that the 
association with clinical phenotypes has a limited power to identify causative genes for 
complex diseases such as schizophrenia, since each gene is expected to have a low effect on 
the observed clinical phenotype (Risch, 1990; Riley and Mc Guffin, 2000; Weiss and Terwilliger, 
2000). In our opinion, this is especially clear for ASPM, because, in contrast with other genes 
possibly related to schizophrenia, this gene is expressed in the developing brain, but not in the 
adult one (Kouprina et al., 2005). As a result, ASPM exerts its effects only during 
neurodevelopment and especially during cortex formation. Therefore, we would expect that 
its effect would be more influenced by other genetic or environmental factors. We think that it 
is necessary to test the effects of variation in ASPM on other cognitive and morphological 
phenotypes. Many previous reports (Hariri et al., 2002; Egan et al., 2004; Fusar-Poli et al., 
2007) have shown that genes associated with neuropsychiatric disorders show greater effects 
at these intermediate phenotypes. This approach is a good complement to the family-based 
and case-control association analyses because such underlying traits have more power to 
detect the influence of candidate genes on cognition. Thus, we first explored how ASPM 
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genotypes affected cognition and we found that three polymorphisms (rs3762271, 
rs12138336 and rs41310927) influenced the scores of several cognitive measures studied on 
the American sample: WCST and N-Back in controls and Digit Span in patients. Interestingly, 
those three polymorphisms are located in exon 18, which codes for the most important part of 
the calmodulin-binding domain, consisting of long and short isoleucine-glutamine (IQ) repeats 
(Kouprina et al., 2005). The IQ domain has experienced the highest evolution rate in the ASPM 
protein (Kouprina et al., 2004) and it has been speculated that this domain could have an 
important role in microtubule polymerization during cell division in the central nervous system 
(Kouprina et al., 2005). Even more, Mekel-Bobrov et al. (2005) showed that rs3762271 and 
rs41310927 (which are in almost complete linkage disequilibrium with each other) are subject 
to recent positive selection in humans. Therefore, those nonsynonymous changes tested in 
this study may have functional implications which could explain our results in the association 
analysis with the cognitive dimensions. Since the discovery by Mekel-Bobrov and colleagues, 
several authors have explored how these SNPs affect general intelligence measures (Mekel-
Bobrov et al., 2007; Rushton et al., 2007). Unfortunately, no clear association between these 
nonsynonymous changes and intelligence has been found in all these studies. Our 
understanding is that, despite its high heritability (Bouchard and McGue, 2003; Toga and 
Thompson, 2005), intelligence is not a good target phenotype, as it is composed of different 
cognitive dimensions, each of them likely modulated by genetic and environmental factors, 
which can be partly common to the different dimensions but probably acting in a different 
manner or degree. Following this idea, we analysed the impact of ASPM on seven cognitive 
factors which represented different domains of cognition. As a result of this approach, we have 
found association with three cognitive dimensions (WCST, N Back and Digit Span) which are 
directly related to working memory. In conclusion, this approach appears to be more powerful 
to detect the contribution of genetic variation on cognitive phenotypes. Our results also 
suggest that subtle variations in the ASPM sequence may have an impact on the formation of 
those CNS structures with an important role in cognition.   
Surprisingly, these 3 SNPs associated with changes in cognitive performance were not 
associated with the risk for schizophrenia (with the exception of SNP rs41310927, which was 
part of a risk haplotype). It is difficult to explain this finding, but it can be related to differences 
in the characteristics of each sample which could affect the statistical power to detect 
association. Moreover, we cannot discard the possibility that each polymorphism or haplotype 
can have a different effect. We then decided to study the effect of three ASPM SNPs 
(rs3762271, rs41310927 and rs10922163) on VBM and fMRI phenotypes. As we expected, we 
did not detect an effect of ASPM variation in global intracranial volume. This finding is 
coherent with previous reports (Woods et al., 2006; Rushton et al., 2007; Timpson et al., 2007; 
Dobson-Stone et al., 2007; Wang et al., 2008). As general intelligence, global brain size is too 
complex because an important number of genetic and environmental factors, also interacting 
with each other, are influencing and modelling the final phenotype. However, in our study, we 
have been able to find an association of three ASPM SNPs with changes in regional volumes. 
Basal ganglia, prefrontal cortex, namely Brodmann area (BA) 9, and subgenual cingulate cortex 
(BA25) are affected in controls, while, in patients, there are differences in PFC (BA9) and 
cerebellum volumes. Moreover, in the BOLD fMRI assay during the N Back task, allele G from 
SNP rs10922163 was also associated with a poorer hemodynamic response of the anterior 
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cingulate cortex (BA32) in control subjects. All these findings show a great coherence. 
Prefrontal cortex, especially dorsolateral prefrontal cortex (DLPFC), which includes Brodmann 
areas 9 and 46, plays a key role in a wide variety of functions. It is also connected with 
different cortical and subcortical circuits, which include the striatum (caudate and putamen) 
(Alexander et al., 1986). This prefrontal-midbrain functional network is crucial for cognitive 
function and specially working memory (Alexander et al., 1986; Dunnett et al., 2005). 
Moreover, it has been also shown that the anterior cingulate cortex, also well connected with 
the DLPFC, plays an outstanding role in a several brain functions, including motor control as 
well as cognitive and working memory related tasks, such as N Back task (Paus, 2001; Callicott 
et al., 1999). Furthermore, the DLPFC dysfunction has been widely accepted as a key feature of 
schizophrenia (Weinberger et al., 2001). Our results support the correlation between ASPM 
variation and morphological and functional alterations in those areas directly related to 
working memory, both in patients and healthy subjects. Moreover, an effect of ASPM 
genotype on cerebellar volume in schizophrenic patients has been also detected. This finding is 
in complete agreement with the preliminary report presented by Andreasen’s group in the 
International Congress on Schizophrenia Research held in Colorado in 2007. In this report, an 
effect of SNP rs3762271 on cerebellar volumes (AA > AC > CC) was found. Previous hypotheses 
have pointed out the possible role of cerebellum in the “cognitive dysmetria” observed in 
schizophrenic patients (Andreasen et al., 1998). This model proposed by Andreasen more than 
ten years ago is supported by evidences from different fields. First, the cerebellum is well 
connected with neurocortical regions which include the prefrontal cortex (Middleton and 
Strick, 1994; Andreasen et al., 1998). Second, neuropathological abnormalities in the 
cerebellum of schizophrenic patients have also been reported (Picard et al., 2008). Finally, 
functional brain imaging studies have suggested the implication of cortico-cerebellar networks 
in several domains of cognition (Picard et al., 2008). Thus, our data could be indicating a role 
of ASPM in the development of cortical, subcortical and cerebellar structures which would 
account for the differences in cognitive performance and brain structure detected in this 
study. Moreover, the differences observed between patients and controls suggest the 
existence of other genetic and/or environmental susceptibility factors which are modulating 
the manifestation of the phenotype observed in patients.    
In summary, although there are authors who have suggested that the ASPM gene could  have 
been positively selected for its function outside the brain (Woods et al., 2006; Dobson-Stone et 
al., 2007), we provide evidences of the role of the ASPM gene in cognition and brain size as 
well as in the risk for schizophrenia. All our data suggest that the ASPM gene, through its key 
role during neurodevelopment, has an effect in the size and function of certain brain areas 
which are critical in the pathogenesis of schizophrenia. These findings would also correlate 
with our association analysis results. Our results support our initial working hypothesis; 
therefore, ASPM variation could be related to the increase of the cognitive abilities throughout 
human evolution. As a result, ASPM could have also had a role in the origin of schizophrenia 
and the cognitive dysfunction associated to this disorder.   
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4. Effects of other novel candidate genes on schizophrenia and 
other related phenotypes 
4.1. PDE4D gene 
PDE4D can be considered to be an interesting candidate gene in psychiatric genetics research 
for several reasons. First, PDE4D has been found to be a partner of DISC1, which is one of the 
most promising schizophrenia candidate genes (Murdoch et al., 2007). Moreover, all PDE4 
isoforms can be inhibited by rolipram, a drug with important effects as an antidepressant. 
Finally, a CNV study performed by Professor Lesch at the Department of Psychiatry and 
Psychotherapy from the University of Würzburg showed that the smallest, brain-expressed 
PDE4D isoform (PDE4D6, according to Wang et al., 2003b) was associated to another 
psychiatric condition, namely the attention-deficit hyperactivity disorder or ADHD (personal 
communication). All these premises encouraged us to study the effect of several SNPs, located 
in the PDE4D6 isoform, on the risk for schizophrenia. Two samples were used for this purpose, 
the Spanish sample and the German sample, both of Caucasian origin. Nine SNPs were 
analyzed in the Spanish case-control sample, while ten polymorphic variants (the nine SNPs 
genotyped in the Spanish sample plus an additional SNP, rs10056492) were studied in the 
German sample.  
The results from our case-control association analyses are mainly negative. Regarding the 
Spanish sample, only the SNP rs12656462 was found to be nominally associated with DSM-IV 
schizophrenia, although the significant value became a trend when all psychotic patients were 
considered. Moreover, a 2-marker protective haplotype as well as a 2-marker risk haplotype, 
both differing only in the SNP rs12656462, were also found. However, these findings should 
not be considered, since the SNP rs12656462 has a low MAF (0.047 in controls) and the 
number of A/A individuals is extremely low. Thus, the statistical power to detect association 
with this SNP is very limited and our positive findings could be in fact false positives. With 
regard to the case-control association analyses performed on the German case-control 
dataset, only three SNPs (rs10056492, rs4700316 and rs7714708) were found to be associated 
with bipolar disorder. Although the significance was relatively high and resisted the sequential 
Bonferroni correction, these findings need to be considered cautiously, however. The reason is 
that only 88 German patients with bipolar disorder were available and it is very risky to draw 
any conclusion from that finding. However, it would be interesting to continue the study of the 
impact of PDE4D variation on the vulnerability to bipolar disorder. In this respect, it is worth 
mentioning the study from Sun and colleagues (Sun et al., 2004), who found that lithium, a 
drug commonly used for the treatment of bipolar disorder, decreased the expression of PDE4D 
in lymphoblasts from bipolar patients. Moreover, bipolar disorder symptoms also include 
several mood alterations which may be partly mediated by alterations in cAMP signaling. 
Since case-control association studies did not provide us with any clear conclusion, we tackled 
the study of how PDE4D variation could influence several clinical measures and disease traits. 
As a result, two PDE4D polymorphisms (rs17291089 and rs7713345) were nominally 
associated with the age at onset, although the association did not survive the correction for 
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multiple testing. Particularly, patients who were A/A homozygotes for the SNP rs17291089 
were more frequent in the Early-Onset group (the first psychotic outbreak took place before 
21 years old). Regarding rs7713345, G-carriers were significantly more frequent in the Early-
Onset group. These findings could be interpreted as evidences of different risk factors for 
psychosis depending on the age of onset. However, the number of subjects with early-onset 
psychosis included in the comparison is small (around 90) and the minor allele frequency of 
the SNP rs17291089 is also low. Due to these limitations, it is difficult to draw any clear 
conclusion from these data.  
Moreover, several PDE4D SNPs were also associated with a wide variety of clinical measures. 
The polymorphism rs17719378 is undoubtedly of special interest, since it has been related to a 
high number of measures, including the following: 
- All items from the PSYRATS subscale for delusions. 
- The “Anxiety” item from BPRS. 
- “Incoherence of Speech” from the KGV scale.   
- Several scores from the PANSS: Total score, “Poor Attention” (G11), Positive score, 
“Delusions” (P1), “Hallucinatory behavior” (P3) and “Grandiosity” (P5).    
In all cases, A/A genotype was associated with lower scores than A/G genotype. Moreover, it is 
remarkable the fact that the SNP rs17719378 was especially associated with positive 
symptoms, rather than other type of clinical manifestations, suggesting the possibility that this 
polymorphism (or another variation in high LD with this SNP) may have a role, together with 
other interacting elements, in the severity of positive symptoms, particularly delusions. 
Furthermore, the association with the Anxiety item from BPRS is also particularly encouraging, 
due to the previous evidences that have related this gene with depression and neuroticism 
(Henkel-Tigges and Davis, 1990; Shifman et al., 2008; Heck et al., 2008). Nevertheless, it should 
be reminded that the number of patients who underwent a clinical evaluation through 
PANSS is low. Another problem was the important number of fails during the genotyping 
process of PDE4D SNPs. As a result, sample size was reduced considerably.  
In summary, although our exploratory analysis suggests that genetic variation affecting the 
PDE4D6 isoform may have a role in bipolar disorder and psychotic symptoms, additional 
studies are necessary. Particularly, an association study covering the complete PDE4D genomic 
sequence could also provide us with useful information. Finally, the use of larger samples 
would be also useful. In this regard, although the association analysis performed with a pooled 
sample of schizophrenic patients and controls from Spain and Germany did not give any 
significant result, this finding could be related to differences in the genetic structure of both 
populations (Seldin et al., 2006; Heath et al., 2008). In fact, the distribution of three SNPs was 
found to be significantly different between the German and the Spanish sample. The use of 
larger, homogeneous and non-stratified samples would be helpful to achieve a better 
understanding of the role of PDE4D variation in the vulnerability to a wide spectrum of 
psychiatric disorders.  
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4.2. PLEKHB1 and RAB6A genes 
As a result of a search for copy number variations (CNVs) in a sample of ADHD patients and 
controls of German origin, the research group from professor Lesch (University of Würzburg, 
Germany) detected differences among patients and controls in a region located at 
chromosome 11 which included two small adjacent genes, PLEKHB1 and RAB6A (unpublished 
results). For this reason, these two genes were also considered to be interesting candidate 
genes for the present study. As a result, an exploratory analysis was made to investigate the 
existence of a relationship among variation in those genes and vulnerability to psychosis. 
Several polymorphisms were selected to be studied in both the Spanish and the German case-
control datasets. However, some polymorphisms were monomorphic in those samples, and an 
additional SNP was completely out of HWE, probably due to genotyping problems. These 
variations were therefore discarded for the statistical analysis. Finally, 6 SNPs were studied in 
the Spanish cohort, while 11 SNPs were studied in the German sample. 
With regard to the Spanish dataset, one polymorphism was found to be associated with 
psychosis: rs663303 (located in the putative 5’ regulatory region from PLEKHB1) and 
rs3741147 (located in intron 5 from PLEKHB1 gene). This SNP presented significant differences 
in the distribution of both genotypic and allelic frequencies. The same results were obtained 
when the subset of hallucinatory patients was considered, suggesting that the effect of this 
SNP would be related to the global psychotic process rather than the hallucinatory process in 
particular. A risk haplotype (T-G-T) as well as a protective haplotype (C-G-G), both including 
SNPs rs663303, rs940828 and rs3741147, respectively, were also found. These haplotypes 
were in coherence with the single SNP analysis. Unfortunately, despite all the suggestive 
findings regarding the PLEKHB1 gene, neither of the significant results resisted the correction 
for multiple testing, excepting the protective haplotype (P = 0.047 corrected). Another issue 
which should be taken into account is that the low MAF of rs663303 (0.09 in controls) 
drastically reduces the statistical power of the association analysis.   
Regarding the German sample, some nominally significant findings (not significant after 
correction) arose, although the significant SNPs were different from the Spanish dataset. 
Particularly, one polymorphism from the PLEKHB1 gene (rs940828, located in intron 5) was 
found to be associated with schizophrenia and bipolar disorder. Interestingly, this SNP is also 
located in the same area as SNP rs663303, the polymorphism which was significantly 
associated with psychosis in the Spanish sample, although the LD among both markers is 
moderate (D’ = 1; r2 = 0.436). Moreover, two other SNPs from the PLEKHB1 gene (rs4944850 
and rs6592527) were found to be associated with bipolar disorder in the German sample. 
Furthermore, one SNP located in the first intron from the RAB6A gene (rs7127066) was 
nominally associated with schizophrenia and bipolar disorder. However, no risk or protective 
haplotypes were found, and all results became not significant when Bonferroni sequential 
correction was applied.  
It is important to remark that several nominal associations were found in both the Spanish and 
the German cohort, particularly involving the PLEKHB1 gene. However, we can only refer to 
these findings as a partial replication, since the significant polymorphisms differ between both 
samples. The only coincident polymorphism is rs940828, which appeared to be associated with 
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schizophrenia in both samples (as a single SNP in the German cohort, as a part of two 
haplotypes in the Spanish dataset). However, this SNP is particularly problematic, since the 
same allele was found to be part of a risk as well as a protective haplotype, so it can be 
hypothesized that the contribution of this SNP to both haplotypes is nonexistent. Finally, the 
use of a pooled sample with German and Spanish subjects did not give significant results.   
Although the lack of strict replication is not an isolated finding (it has been documented by 
many researchers in the genetic psychiatrics field, see the Introduction, section 2.3.3., as a 
reminder), it is difficult to explain why two relatively close populations present such 
differences. One of the most plausible explanations would be the existence of a false positive, 
probably related to the insufficient sample size or the extremely low minor allele frequencies. 
Moreover, the existence of false negatives cannot be discarded. Furthermore, it should be also 
considered that the differences in the genetic structure of Spanish and German populations 
can involve other genetic interacting factors, which, in turn, may modulate the effect of the 
polymorphism of interest on the vulnerability to a complex disease. Although European 
populations share an important part of their genetic structure, they also present clear 
differences which should be taken into account when a case-control association analysis is 
designed (Marchini et al., 2004; Seldin et al., 2006; Heath et al., 2008). In agreement with this 
idea, we found enormous differences in the distribution of certain PLEKHB1 and RAB6A SNPs 
(rs3742247, rs12274970 and rs11235876) between the German and the Spanish datasets. 
These differences, together with other differences in the genetic patterns among European 
populations, can explain our divergences between samples.  
In conclusion, several PLEKHB1 SNPs and one RAB6A SNP were nominally associated with 
psychosis and bipolar disorder. The main evidences are focused on the PLEKHB1 gene, 
although the significance is relatively low due to the small sample size and the low MAFs of 
certain polymorphisms, such as rs663303. Moreover, it is risky to establish a causal 
relationship between this gene and mental disorders, since a likely role of this gene on 
behavior and mental disorders has not been explored yet. As far as we know, this is the first 
study which has tried to find a link between this gene and psychoses. Moreover, little is known 
about the function of this membrane protein with a pleckstrin homology domain. It has been 
suggested that this protein, expressed in different cells with a sensory function (Xu et al., 1999; 
Xu et al., 2004), may have a role in modifying signal transduction processes in photoreceptors 
(Xu et al., 2004). According to this probable role, we can hypothesize that alterations on this 
gene may have an active role in the development of hallucinations. Furthermore, high 
PLEKHB1 expression has been documented in fetal and adult brain. Interestingly, according to 
the microarray expression data available at Genomics Institute of the Novartis Research 
Foundation website (http://symatlas.gnf.org/), this expression is particularly high in those 
regions which appear to have a role in the physiopathology of schizophrenia, such as temporal 
lobe, prefrontal cortex, cingulate cortex, thalamus and hypothalamus, among others. These 
evidences, together with our results from the case-control analysis, encouraged us to go 
further into the study of this region located at chromosome 11.  
The impact of PLEKHB1-RAB6A genetic variation on several disease traits was also assessed 
through linear regression analysis. As a result, an important number of nominal associations, 
involving the six polymorphisms genotyped in the Spanish patients, were found. However, 
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many significant findings should not be considered as relevant, especially when the significant 
model is the recessive one and the number of individuals who were homozygotes for the 
minor allele is extremely low. Despite this fact, some significant findings resisted the correction 
for multiple testing.  These include: 
- The association of the SNP rs12274970 (located in the intergenic region between 
PLEKHB1 and RAB6A) and the PANSS item G13 - disturbing of volition (P = 0.032 
corrected).  
- The association of the SNP rs11235976 (located in the third intron of the RAB6A gene) 
and the following PANSS items: G13 - disturbing of volition (P = 0.032 corrected); N4 – 
apathetic-social withdrawal (P = 0.046 corrected); P7 – Hostility (P = 0.047 corrected)  
The disease traits which appear to be modulated by these SNPs are of varied nature. Thus, it 
is difficult to elaborate a hypothesis about the real meaning of these associations. Anyway, 
these SNPs are different from those associated with the liability to schizophrenia. Moreover, 
neither of these polymorphisms seems to be functional, according to the results obtained from 
PupaSuite (Conde et al., 2006) (data not shown). It could be also possible that these SNPs are 
in high LD with other functional variants. Another disadvantage is that the number of patients 
with genotypic information who were assessed for PANSS is very low. Thus, another possibility 
which should be also considered is that these are false positive findings.  
Unfortunately, although we hypothesized that the PLEKHB1 gene may be implicated in the 
vulnerability to auditory hallucinations, no clear association between any PLEKHB1 SNP and 
hallucinations has been found. 
 In conclusion, the evidences in favor of a relationship between PLEKHB1 and RAB6A genes and 
psychosis are weak, mainly due to the small sample sizes and low minor allele frequencies. 
However, some nominal associations involving PLEKHB1 have been found in both cohorts. A 
more profound study would be necessary to confirm these findings. 
 
5. Towards a general model of vulnerability  
When studying a common and complex disease, such as schizophrenia, which is characterized 
by a non-Mendelian inheritance and a high prevalence in human populations, one of the most 
feasible etiopathogenic explanations is the Common Disease - Common Variant (CDCV) 
hypothesis. The CDCV hypothesis predicts that the spectrum of allelic variants which confer 
susceptibility to a complex disease is made up of common variants, each of them with a 
moderate effect on the disease liability and shared by different subpopulations. This 
hypothesis is indeed the framework of the present study and for this reason we have focused 
on the study of different genetic polymorphisms located in several candidate genes involved in 
different neural processes which could be related to the pathophysiology of schizophrenia and 
other psychoses. We expected that the contribution of these candidate genes would be 
modest, and our results are in coherence with our initial assumption.  
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Despite all the considerations we have taken into account, some interesting and coherent 
findings have been found in the present study. As a result, our overall findings support a 
possible integrative model of vulnerability (figure D2). First, there is a general vulnerability to 
psychoses which would be influenced by an important number of several genetic and non-
genetic factors. We have evidences that the serotonin transporter gene (SLC6A4) and ASPM 
gene may have an important role on this general vulnerability through single-gene as well as 
epistatic effects, since several highly significant SNPs have been detected (rs140700 and 
rs2020936 from the SLC6A4 gene; the replicated SNP rs10922163 from the ASPM gene). Thus, 
according to this scenario, the serotonin transporter and the ASPM protein may have an effect 
on those neural systems which are known to be involved in the appearance of the 
schizophrenic manifestations. Anyway, other genes, such as STMN1 or PLEKHB1, could also 
have an impact on the liability to schizophrenia, however, there are less evidences on this 
respect, since the polymorphisms located on these genes did not reach the significance 
threshold for multiple testing. The existence of such different types of genes may also help to 
explain the great variability in the clinical manifestation of schizophrenia among patients. 
Second, genetic variation on several polymorphic variants appeared to impact symptom 
severity (see also figure D2). A clear example is the effect of STMN1 variation on the severity 
of negative symptoms. Moreover, slight evidences suggest a possible impact of NOS1 and 
PDE4D genes on positive symptoms. These findings are not surprising, particularly if we 
consider the existence of different types of risk alleles and genes with a different impact on the 
disease (Fanous and Kendler, 2005). Therefore, according to the model presented by Fanous 
and Kendler, some genes would increase the liability to suffer schizophrenia without altering 
or impacting its associated clinical features (susceptibility genes), while other genes would 
affect these clinical features without modifying the susceptibility to illness by themselves 
(modifier genes).  
Furthermore, it is worth mentioning that this study also contributes to the vulnerability to 
psychosis with a new approach. This approach, which we named “deconstructing the 
symptom”, allows the study of the neurobiological systems implicated in the most 
characteristic symptoms of psychosis, such as auditory hallucinations (one of the most specific 
symptoms suffered by schizophrenic patients), cognitive impairment (one of the most 
disabling features of schizophrenia) and the emotional disturbances and affective 
deterioration associated to this pathology. We believe it is necessary to study psychoses from 
a categorical but also from a dimensional point of view. Current classification of mental 
disorders (based on the classical Kraepelinian assumptions) appears to be partially valid in 
neurobiological and genetic research. The unstability of psychoses over time, as well as the 
existence of intermediate conditions (such as schizoaffective disorder), can be justified by a 
continuum of psychotic manifestations, ranging from nonaffective psychoses to psychotic 
mood disorders (Peralta and Cuesta, 2008). Therefore, the deconstruction of symptoms into 
subsymptoms is a necessary step to unravel the neurobiological processes underlying 
schizophrenia (Cuesta and Peralta, 2008). Following this methodology, some interesting 
findings have been found in the present study.  
With regard to cognition, an effect of ASPM variation on several cognitive abilities and 
neuroanatomical variables has been found (figure D2), suggesting an important role of this 
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gene during the development of those brain regions implicated in the pathogenesis of 
schizophrenia. Thus, it can be hypothesized that abnormal expression of the ASPM gene during 
neurodevelopment would affect the normal formation of different brain areas clearly 
associated with the cognitive deficits associated to schizophrenia, such as the prefrontal 
cortex, the anterior cingulate cortex or the basal ganglia. Furthermore, apart from pathological 
conditions, we can argue that ASPM has a necessary role in normal cognition and can be 
considered as a strong candidate for understanding human brain evolution. In conclusion, the 
active role of ASPM in the evolution of human brain function and cognition may have 
triggered, somehow as a collateral effect, the emergence of cognitive deficits and mental 
disturbances associated to schizophrenia.  
Moreover, of particular interest is the relationship between variation in the serotonergic 
system and emotional alterations. Our overall results suggest that the alteration of the 
expression of several key elements of this system, namely the serotonin transporter, the 
serotonin receptor 2A and, to less extent, the tryptophan hydroxylase 2, leads to an altered 
emotional state in those patients. Moreover, stathmin protein may also be involved in the 
pathogenesis of affective disturbances observed in schizophrenic patients, although in this 
case the evidences are weaker. All these findings support the emotional nature of 
schizophrenia and other psychotic disorders. The understanding of schizophrenia as an 
emotional disorder should be integrated together with cognitive hypotheses for a better 
understanding of the psychotic phenotype.   
 
 
 
 
 
 
 
 
 
 
 
 
Finally, this study supports the involvement of several polymorphic variants in the 
pathogenesis of auditory hallucinations. Particularly, this study is part of a more ambitious 
project whose main objective is to disentangle, from a dimensional point of view, the 
molecular mechanisms responsible for the vulnerability to auditory hallucinations. As a 
Figure D2. General model of vulnerability to schizophrenia which 
integrates the findings obtained in the present study.  
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consequence of our results in this field, we have developed a possible model that integrates 
all our findings (figure D3), allowing us to provide an explanation for the aetiopathogenesis of 
AH. According to this model, two different pathways can be considered to be involved in the 
genetic vulnerability to AH in psychosis. The first of them is a vulnerability to language 
disorders, which could increase the probability of hearing voices. This vulnerability could be 
due to changes in the FOXP2 gene, among others (Sanjuán et al., 2006a). FOXP2 is the first 
gene that has been related to a language disorder and is associated with functional and 
structural abnormalities in the temporal lobe (Liegeois et al., 2003; Vargha-Khadem et al., 
2005). Second, there is another important dimension in the neurobiology of AH, which is one 
of the central aspects of our present work: the vulnerability to abnormal emotional 
responses. We have reasons to support the role of emotional processing in the 
pathophysiology of AH. In a previous work, our group designed an auditory emotional 
functional magnetic resonance imaging (fMRI) paradigm to elicit the emotional states 
experienced by schizophrenic patients when suffering from AH (Sanjuán et al., 2007). In that 
work, an enhanced activation of limbic and frontal brain areas was detected in a group of 
persistent hallucinatory patients in response to emotional words. Thus, we hypothesized that 
a) this activation is directly related to the emotional response that occurs when suffering from 
auditory hallucinations and b) this emotional response is partially controlled by genetic 
variation in certain candidate genes. Interestingly, the present study correlates our previous 
and presents results in the genetics of the emotional response to AH: analogously to the effect 
of genetic variation on the general emotional state of schizophrenic patients, we have also 
noticed an important effect of several serotonergic genes on the emotional response to 
auditory hallucinations (Sanjuán et al., 2006b). Finally, environmental factors cannot be 
discarded from this model. Particularly, cultural aspects can influence the content and social 
adjustment of voices (Sanjuán et al., 2005; Sanjuán, 2006; Aleman and Larøi, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D3. Ethiopathogenic general model of vulnerability to auditory 
hallucinations. Adapted from Sanjuan and Aguilar, 2007. 
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However, despite the present study as well as other prior studies may have unmasked some 
key elements in the pathogenesis of schizophrenia, many other elements remain unclear: 
there is still a lot of uncertainty and several unknown factors of genetic, epigenetic and 
environmental nature are waiting to be discovered and understood. However, in the light of 
recent findings, association studies (classical or genome-wide) appear to be a limited tool, at 
least with the current sample sizes and statistical methodologies. Moreover, it is also very 
plausible that severe mental disorders are due to a mutation-selection balance: old harmful 
and rare mutations that have yet to go extinct, which are transmitted from parents to their 
offspring (Keller and Miller, 2006). This hypothesis appears to be consistent with the data on 
mental disorder prevalence rates, fitness costs, the likely rarity of susceptibility alleles, and the 
increased risks of mental disorders with brain trauma, inbreeding, and paternal age. Moreover 
this scenario would help to understand schizophrenia from an evolutionary point of view. New 
approaches, such as the search for copy number variations, the use of animal models, 
epigenetic studies, whole expression analyses, neuroimaging studies, or gene x environment 
interaction approaches, are required to unravel the neurophysiological mechanisms which are 
responsible for one of the most severe mental diseases.  
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In summary, taken together our results support the following conclusions: 
 
1. Case-control association analysis indicates the existence of association between SNP 
rs2020936 from the serotonin transporter gene and psychosis. Several protective 
haplotypes, which are more frequent in the control group than in the affected group, 
have also been found. 
 
2. Results from the present study suggest a strong relationship between variation at 5-
HTTLPR locus and abnormal emotional response in schizophrenic patients. Particularly, 
low expression alleles have been associated with a higher score in emotional items 
from PSYRATS subscale for auditory hallucinations. The S allele has been also 
associated with higher amygdala activation in response to emotional words as well as 
a lower gray matter density in limbic areas (anterior cingulate cortex in schizophrenic 
patients; hippocampus and parahippocampus in healthy subjects).   
 
3. HTR2A gene appears to have an effect on emotionality in psychotic patients, assessed 
through several psychopathological scales: PANSS, BPRS and PSYRATS. TPH2 gene has 
been also associated with some items from PSYRATS subscale for auditory 
hallucinations, although in this latter case evidences are weaker. 
 
4. Interaction analyses point out the existence of epistatic effects involving three genes 
from the serotonergic system: SLC6A4, HTR2A and TPH2. These interactions appear to 
modulate different variables related to the emotional processing, especially the 
emotional response to auditory hallucinations. 
 
5. An effect of NOS1 ex1f-VNTR on the scores of several PANSS items (three items from 
the Depressive component and two positive items) has been detected.  
 
6. STMN1 gene is weakly associated with the liability for schizophrenia, as well as with 
several clinical items mainly related to the negative/affective symptomatology of 
schizophrenia. 
 
7. Through both case-control and family-based association analyses in two different 
datasets, ASPM gene has been found to be associated with the risk for schizophrenia. 
Particularly, SNP rs10922163 has been associated with schizophrenia in both samples. 
ASPM gene has been also associated with several cognitive measures mainly related to 
working memory, as well as with the physiological response of the anterior cingulate 
cortex during a working memory task. Finally, ASPM variation has an effect on gray 
matter volumes from certain areas related to cognition and pathogenesis of 
schizophrenia, such as cerebellum, prefrontal cortex, subgenual anterior cingulate 
cortex and basal ganglia.    
 
8. One SNP located at the PDE4D locus has been weakly associated with schizophrenia in 
the Spanish sample, while different SNPs have been associated with bipolar disorder in 
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the German case-control dataset. This gene has been also associated with the severity 
of different symptoms, mainly of positive nature. 
 
9. Several SNPs located at the PLEKHB1 gene have been found to be associated with the 
risk for schizophrenia and bipolar disorder.  
 
10. Overall, our findings support a general model of vulnerability. According to this model, 
certain genes would have a major effect on the vulnerability to suffer from 
schizophrenia, while other genes would have an effect on symptom severity. 
Regarding auditory hallucinations, there is a genetic vulnerability to aberrant 
emotional response, which is modulated by variation in different genes, namely the 
serotonin transporter gene, among others.  
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Introducción  
El término esquizofrenia fue acuñado por Eugen Bleuler en 1908 para referirse a un grupo de 
desórdenes caracterizados por graves síntomas de naturaleza cognitiva, emocional y 
comportamental (Bleuler, 1911). Los síntomas de la esquizofrenia afectan a diferentes 
dominios y pueden agruparse en tres categorías: a) síntomas positivos o psicóticos: 
manifestaciones clínicas que siguen un patrón episódico y que no están presentes en la 
población normal: alucinaciones, delirios y trastorno del pensamiento; b) síntomas negativos: 
se refieren a la ausencia o afectación de ciertos comportamientos como la interacción social, 
motivación o la habilidad para experimentar placer (Wong y Van Tol, 2003); c) deterioro 
cognitivo, que afecta a la atención, la función ejecutiva y la memoria. Esta variada 
sintomatología lleva a una gran heterogeneidad clínica, la cual es el origen de importantes 
problemas a la hora de abordad esta enfermedad desde un punto de vista biológico.  
Debido a su naturaleza crónica, severidad, incidencia (entre el 1.6% y el 4.3% en todas las 
poblaciones según Jablenski et al., 1992) e inicio temprano, la esquizofrenia, así como las 
psicosis en general, implican un alto coste humano y económico (UK National Health Service 
Executive, 1996). Esto ha generado también un gran interés por estudiar los mecanismos 
neurofisiopatológicos subyacentes a este trastorno. Hasta el momento, se conocen numerosos 
factores que pueden aumentar el riesgo de padecer esquizofrenia, (Jablensky, 2003). Estas 
variaciones apoyan la existencia de modelos de interacción vulnerabilidad x estrés. 
Asimismo, existen hasta el momento un importante número de hallazgos neuropatológicos 
relacionados con la esquizofrenia. Lamentablemente, estos hallazgos no pueden ser usados 
como criterios diagnósticos, puesto que también pueden aparecer en sujetos sanos, y además 
no se dan en todos los pacientes. Entre los hallazgos más importantes destacan los siguientes:  
 Anormalidades de tipo morfológico. Destacan la reducción global del tamaño cerebral 
(Harrison et al., 2003), engrosamiento de los ventrículos tercero y lateral (Elkis et al., 1995; 
Harrison et al., 2003), ausencia de gliosis (Iritani, 2007) y, por último, reducciones en el 
neurópilo (Selemon y Goldman-Rakic, 1999). También se han hallado reducciones 
regionales de materia gris, que afectan principalmente los lóbulos temporal medial y 
superior (Honea et al., 2005), el córtex prefrontal (PFC) y el tálamo (Tandon et al., 2008).   
 Los estudios sobre los mecanismos de acción de los medicamentos antipsicóticos llevaron 
también al desarrollo de diferentes hipótesis sobre el origen de la esquizofrenia. Una de las 
más importantes es la hipótesis dopaminérgica (Weinberger, 1987), que postula la 
existencia de un desequilibrio de los niveles de dopamina en diferentes áreas del cerebro, 
lo cual explicaría la existencia de los síntomas positivos y negativos. Una reformulación 
llevó a la hipótesis glutamatérgica, que considera que el causante de los desequilibrios en 
los niveles de dopamina es la existencia de un desajuste en los niveles de glutamato. Por 
último, también se han descrito alteraciones en el sistema serotoninérgico. 
 
 Los estudios de neuroimagen funcional, mediante el empleo de diferentes paradigmas y 
tareas cognitivas, han supuesto una aproximación muy interesante. Mediante estas 
técnicas, se ha encontrado una hipoactivación a nivel del córtex prefrontal en pacientes 
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esquizofrénicos (Weinberger et al., 1986; Glahn et al., 2005). Además, estudios de 
espectroscopía de resonancia magnética nuclear (Wong y Van Tol, 2003) han detectado 
alteraciones en los niveles de algunos metabolitos como el N-Acetil aspartato (marcador de 
integridad glial y pérdida neuronal). 
 
Todos los hallazgos comentados anteriormente sugieren que la esquizofrenia es el resultado 
de la compleja interacción entre la predisposición biológica de cada individuo (determinada 
por factores genéticos) y ciertos factores ambientales. Por este motivo, en las últimas décadas 
se han venido realizando importantes esfuerzos para comprender mejor los factores genéticos 
subyacentes y para entender cómo éstos interaccionan con el ambiente para producir el 
fenotipo esquizofrénico. Por ello, se han realizado diferentes aproximaciones al campo de la 
genética de la esquizofrenia. Los estudios de epidemiología genética (estudios familiares, de 
gemelos y de adopción) fueron la primera aproximación a la genética de los trastornos 
mentales. Mediante estos estudios, se ha podido constatar que la esquizofrenia es una 
enfermedad heredable (heredabilidad en torno al 80%) y que los parientes de pacientes 
esquizofrénicos, especialmente los de primer grado, tienen un riesgo mayor de padecer la 
enfermedad que la población general (Kendler y Diehl, 1993; Shih et al., 2004; Burmeister et 
al., 2008). Sin embargo, el patrón de herencia es complejo y no se ajusta al patrón mendeliano 
de las enfermedades monogénicas.  
 
La aparición de los marcadores moleculares en las décadas de 1980 y 1990 permitió el 
desarrollo de los análisis de ligamiento, que permitían localizar de los loci causantes de 
enfermedades monogénicas mediante el empleo de grandes genealogías (Knowlton et al., 
1985; Guilford et al., 1994). Desafortunadamente, los resultados de los análisis de ligamiento 
no han sido tan satisfactorios en el caso de enfermedades complejas, debido a la herencia 
poligénica de estas enfermedades. En el caso de la esquizofrenia, aunque se han encontrado 
diferentes picos de ligamiento a lo largo de todo el genoma, los resultados son muy 
controvertidos, debido a la existencia de resultados contradictorios o no replicados 
(Burmeister et al., 2008). Además la realización de meta-análisis tampoco ha ayudado a 
clarificar la situación. Son por tanto necesarios otros enfoques para dilucidar cuáles son 
realmente los genes implicados en la susceptibilidad a padecer esquizofrenia.  
Hace 13 años, Risch y Merinkangas demostraron que, para poder estudiar variantes genéticas 
con un efecto pequeño sobre el fenotipo (como es el caso de la esquizofrenia), existe una 
aproximación más potente que los estudios de ligamiento: los estudios de asociación (Risch y 
Merikangas, 1996). Estos estudios se basan en el uso de polimorfismos genéticos localizados 
en los genes de interés, seleccionados bien por su localización cercana a un pico de ligamiento 
(genes candidatos posicionales) o bien porque se sospecha que su función podría estar 
relacionada con la patogénesis de la enfermedad (genes candidatos biológicos) (Burmeister et 
al., 2008). Una vez seleccionados estos polimorfismos, se evalúa si cierto alelo, genotipo o 
haplotipo aparece en mayor frecuencia de lo esperado en la población de afectados. En este 
caso, se considera que ese alelo, genotipo o haplotipo está asociado con la enfermedad. Los 
polimorfismos empleados en los estudios de asociación pueden ser de diferente naturaleza: 
variaciones en el número de repeticiones en tándem (VNTRs), inserciones-deleciones (indels) 
y, más comúnmente, polimorfismos de un único nucleótido (SNPs), estos últimos ampliamente 
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distribuidos por todo el genoma. En un primer momento, la mayoría de los estudios de 
asociación se centraron en el estudio de variantes funcionales, las cuales eran consideradas 
como probables variantes causales (o “polimorfismos candidatos”). Sin embargo, esta 
“aproximación directa” (Risch, 2000) presenta dificultades, puesto que no siempre se conocen 
cuáles son la variantes funcionales de un gen, y además la búsqueda de estas variantes es 
especialmente costosa. Por ello, existe otra alternativa (“aproximación indirecta”), que 
consiste en el análisis de polimorfismos genéticos sin tener en cuenta  su funcionalidad. Esta 
técnica aprovecha la estructura de desequilibrio de ligamiento (LD) del genoma humano para 
seleccionar aquellos polimorfismos que permiten capturar toda la variabilidad genética 
existente en una determinada zona. Estos SNP reciben el nombre de tagSNPs (de Bakker et al., 
2005). Es también importante remarcar que esta técnica sería casi imposible sin la existencia 
del proyecto Hapmap (Internacional Hapmap Consortium, 2003). 
 
Hay diferentes tipos de asociación, dependiendo del tipo de muestra con el que se trabaje. 
Uno de los estudios más comunes es el estudio de asociación caso-control, que compara dos 
grupos de individuos no relacionados (uno afectado y uno control) que presentan 
características similares (sexo, edad, etnia…) para evitar problemas de estratificación 
(Langefeld y Fingerlin, 2007). El análisis se basa en testar la hipótesis nula de ausencia de 
diferencias en las frecuencias alélicas, genotípicas o haplotípicas entre ambos grupos. Hay 
diferentes maneras de testar la hipótesis nula, como el test de Pearson, el test exacto de 
Fisher, el test Cochran-Armitage o el análisis de regresión logística (Balding, 2006). Asimismo, 
también es interesante calcular un parámetro como la “Odds Ratio” (OR), que permite evaluar 
el impacto de cada factor genético sobre el riesgo de padecer la enfermedad. Sin embargo, 
también es posible realizar estudios de asociación basados en familias. En este caso, los 
familiares sanos pueden ser usados como controles internos, por lo que se reduce el riesgo de 
estratificación de la muestra (Langefeld y Fingerlin, 2007). Uno de los tests basados en familias 
más usados es el test de desequilibrio de transmisión  o TDT (Spielman et al., 1993), que 
permite evaluar si alguno de los alelos se transmite con mayor frecuencia de la esperada a los 
hijos enfermos. Otro test bastante popular es el test de asociación basado en familias o FBAT 
(Laird et al., 2000), cuya peculiaridad reside en el hecho de que puede funcionar con datos 
parentales ausentes. Esto es especialmente importante para enfermedades de inicio más bien 
tardío como la esquizofrenia. 
 
Desde que comenzaron a realizarse los primeros estudios de asociación en esquizofrenia y 
hasta la actualidad, el número anual de trabajos y genes analizados ha crecido enormemente. 
Pero al mismo tiempo también ha ido creciendo la incertidumbre por la falta de replicación en 
algunos casos. Sin embargo, hay ciertos genes candidatos que presentan una mayor evidencia 
de asociación con esquizofrenia. Entre ellos, cabe destacar la Neurorregulina1 (NRG1), la 
disbindina (DTNBP1), los genes DAOA y DAAO, el gen “Regulator of G protein signaling” 
(RGS4), la catecol-O-metil transferasa (COMT) y el gen Disrupted in Schizophrenia 1 (DISC1) 
(Harrison and Weinberger, 2005; Norton et al., 2006; Lang et al., 2007; Burmeister et al., 
2008).  Estos genes cumplen importantes funciones en el sistema nervioso central y están muy 
relacionados con las hipótesis dopaminérgica y glutamatérgica. Sin embargo, a pesar de los 
datos procedentes de los estudios de asociación que apoyan la implicación de estos y otros 
genes en la patogénesis de la esquizofrenia, existen todavía un importante número de 
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resultados inconsistentes, debido a la existencia de resultados negativos incluso para los genes 
anteriormente citados. Asimismo, además de los resultados negativos, hay también 
inconsistencias entre los trabajos positivos, puesto que dependiendo del estudio, el 
polimorfismo significativo también es diferente. Por ello, en un intento de dar respuesta a 
estos problemas, en los últimos años se han realizado estudios de asociación de genoma 
amplio (GWAS) que analizan polimorfismos localizados a lo largo de todo el genoma en 
muestras de gran tamaño. Sin embargo, esta nueva aproximación tampoco ha conseguido 
clarificar la situación, al menos en el campo de las enfermedades psiquiátricas (Burmeister et 
al., 2008), puesto que los genes asociados con la enfermedades varian de unos estudios a 
otros. 
 
Las inconsistencias en los estudios de asociación plantean una serie de interrogantes: ¿son los 
estudios de asociación una aproximación adecuada? ¿Esta heterogeneidad en los resultados se 
debe a diferencias entre poblaciones? ¿Es la esquizofrenia una enfermedad más heterogénea 
que otras enfermedades complejas como la diabetes? Hay diversas razones para explicar esta 
existencia de inconsistencias en los estudios de asociación. En primer lugar, la heterogeneidad 
en los resultados puede ser una señal de la heterogeneidad genética de la esquizofrenia, 
aunque tampoco se debe descartar la existencia de falsos positivos (error de tipo I) y falsos 
negativos (error de tipo II), como resultado del uso de muestras muy pequeñas o muestras 
estratificadas de diferente origen genético, lo que podría haber llevado a una distorsión de los 
resultados. Asimismo, tampoco se puede olvidar que la esquizofrenia es una enfermedad muy 
heterogénea también a nivel clínico, lo que todavía dificulta más su estudio. Por último, otros 
factores importantes a tener en cuenta serían la existencia de mecanismos epigenéticos o 
ambientales, que podrían estar actuando en solitario o a través de interacciones con los 
factores genéticos (Caspi y Moffitt, 2006).  
 
Como se ha visto, la complejidad fenotípica y genética de la esquizofrenia, unido a la probable 
falta de validez de la actual clasificación clínica (Cuesta y Peralta, 2008), hace necesario el uso 
de otras aproximaciones complementarias a los estudios clásicos de asociación. Una de estas 
aproximaciones es centrarse en el síntoma. A este respecto, no puede olvidarse que, en 
neuropsiquiatría, el síntoma está pobremente estudiado. Además, la deconstrucción de la 
esquizofrenia en elementos más simples podría permitir disminuir la complejidad. Asimismo, 
es necesario buscar fenotipos más cercanos a los procesos biológicos, para facilitar el 
descubrimiento de aquellos genes implicados en la fisiopatología de la esquizofrenia. De esta 
necesidad de nuevos fenotipos alternativos surgió el concepto de endofenotipo hace más de 
30 años (Gottesman y Shields, 1973). El endofenotipo se define como un rasgo interno que 
está presumiblemente más cercano al gen que la patología global y puede ser detectado a 
través de tests bioquímicos o microscópicos. Asimismo, otro concepto relacionado es el de 
“fenotipo alternativo”, que se refiere al uso de síntomas clínicos en vez de los criterios 
diagnósticos tradicionales. 
Para el presente estudio se han seleccionado dos fenotipos alternativos: las alucinaciones 
auditivas y el deterioro cognitivo. 
 
Las alucinaciones auditivas son el tipo más común de alucinación en los pacientes psicóticos y 
están presentes en un importante número de pacientes (entre un 50 y un 70%, según Slade y 
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Bentall, 1988; y Andreasen y Flaum, 1991). Aunque este fenómeno se da en un variado 
número de pacientes psiquiátricos y neurológicos, e incluso en sujetos sanos, las alucinaciones 
auditivas presentan unas características particulares en los pacientes psicóticos: suelen ser 
voces humanas que le hablan al paciente, con una intensa carga emocional e interpretadas por 
el sujeto como ajenas a él (alto grado de “insight”). Se caracterizan además por su naturaleza 
dimensional (Aleman y Larøi, 2008). El componente emocional es una de las dimensiones más 
interesantes, puesto que se sabe de su importancia en el propio fenómeno alucinatorio, así 
como en la respuesta del individuo a esas voces. Asimismo, se han hecho numerosos estudios 
de neuroimagen para dilucidar cuáles son las regiones cerebrales implicadas en este 
fenómeno. Los hallazgos más replicados son una reducción de la circunvolución temporal 
superior, así como una actividad anormal en aquellas áreas relacionadas con diferentes 
aspectos del lenguaje (Silbersweig et al., 1995; Woodruff, 2004; Aleman y Larøi, 2008).  
Asimismo, nuestro grupo ha desarrollado un paradigma de fMRI de tipo auditivo-emocional, 
mediante el cual se ha detectado la activación anormal de ciertas áreas como respuesta a 
palabras de contenido emocional (Sanjuán et al., 2007). A la luz de todos estos hallazgos, 
consideramos que las alucinaciones auditivas pueden ser un fenotipo alternativo útil en el 
campo de la genética psiquiátrica. La integridad de los circuitos responsables de la aparición de 
las alucinaciones auditivas podría pues estar modulada y controlada por factores genéticos. Sin 
embargo, hasta el momento, los estudios de genética molecular de las alucinaciones auditivas 
son más bien escasos y se han centrado principalmente en pacientes neurológicos (Aleman y 
Larøi, 2008).  Es por tanto necesario un conocimiento más profundo de las bases genéticas y 
biológicas de las alucinaciones auditivas, con una especial atención a su componente 
emocional. 
 
El deterioro cognitivo es también un síntoma de gran importancia en la esquizofrenia, por ser 
uno de los más severos y con un peor tratamiento, si se compara con los síntomas psicóticos. 
Además, es el causante de gran parte de la discapacidad psicosocial de estos pacientes (Breier 
et al., 1991; Lewis, 2004). En un meta-análisis (Heinrichs y Zakzanis, 1998), se estimó que el 
61%-78% de los pacientes esquizofrénicos presentaban problemas de tipo cognitivo. Además, 
se ha visto que la memoria de trabajo es uno de los elementos clave para entender el 
deterioro cognitivo en pacientes esquizofrénicos. La memoria de trabajo se define como un 
sistema de capacidad limitada que mantiene, almacena y procesa información relevante, a 
través de procesos complejos que implican al pensamiento y el lenguaje, entre otros 
(Baddeley, 2003). Muchos estudios han hallado un funcionamiento anormal de la memoria de 
trabajo en pacientes esquizofrénicos (Goldberg et al., 1987; Goldman-Rakic, 1994; Silver et al., 
2003). Esto suscitó el interés de muchos investigadores por conocer las bases biológicas de la 
memoria de trabajo y otros aspectos cognitivos de vital importancia en la patogénesis de la 
esquizofrenia. Las habilidades cognitivas pueden ser consideradas un endofenotipo válido por 
varias razones. En primer lugar, son altamente heredables en humanos. Además, las técnicas 
de neuroimagen funcional permiten correlacionar el rendimiento en un test cognitivo con 
alteraciones en ciertos sistemas cerebrales. De hecho, hay claras evidencias de la implicación 
del cortex prefrontal dorsolateral en la memoria de trabajo (revisado en Tan et al., 2007). 
Asimismo, la neuroimagen estructural permite detectar cambios en el tamaño de ciertas áreas 
cerebrales. Se sabe de la existencia de déficits volumétricos que están asociados con el riesgo 
genético de padecer esquizofrenia (Cannon et al., 1998; Goldman et al., 2008; Honea et al., 
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2008). Como se puede ver, hay importantes motivos para estudiar la genética de los procesos 
cognitivos en pacientes esquizofrénicos. Uno de los genes más estudiados ha sido el de la 
COMT, lo que ha permitido constatar la implicación del polimorfismo funcional Val158Met en 
la memoria de trabajo (revisado en Meyer-Linderberg et al., 2006; Roffman et al., 2006; y Tan 
et al., 2007).   
 
En este estudio, diferentes cuestiones se han tenido en cuenta para seleccionar diferentes 
genes candidatos. Principalmente, la selección se ha basado en tres aspectos de la 
esquizofrenia fuertemente interrelacionados: las alucinaciones auditivas, la disfunción 
cognitiva y la respuesta emocional. De esta manera se han seleccionado 9 genes candidatos. 
 
Genes del sistema serotoninérgico. La serotonina es un neurotransmisor de tipo monoamina 
con un importante papel en los sistemas nerviosos central y periférico. Como resultado de su 
amplia localización y la expresión ubicua de sus numerosos receptores, juega un papel clave en 
la regulación de diferentes comportamientos cognitivos, fisiológicos y emocionales (Jacobs y 
Azmitia, 1992; Baumgarten y Grozdanovic, 1997). El sistema serotoninérgico es la diana de 
muchos medicamentos para el tratamiento de enfermedades psiquiátricas y por esta y otras 
razones este sistema se ha relacionado con la patofisiología de numerosos trastornos 
psiquiátricos. Por estos motivos, en el presente estudio se han seleccionado 3 genes que 
codifican para tres elementos clave del sistema serotoninérgico: el transportador de 
serotonina, el receptor 5-HT2A y la triptófano hidroxilasa 2.  
El transportador de serotonina es un elemento de vital importancia para el sistema 
serotoninérgico, ya que esta proteína localizada en la membrana presináptica se encarga de la 
recaptación de la serotonina presente en el espacio sináptico, controlando así la duración de la 
señalización serotoninérgica. El gen humano del transportador de serotonina (SLC6A4, SERT o 
5-HTT) está localizado en el cromosoma 17 (17q11.2). Su actividad transcripcional está 
principalmente regulada por un elemento repetitivo localizado en una región reguladora aguas 
arriba del inicio de transcripción. Este polimorfismo recibe el nombre de 5-HTTLPR (5-HTT gene 
linked polimorphic region) y mayoritariamente da lugar a la aparición de dos alelos: el alelo l 
(largo) y el s (corto)(Heils et al., 1996). Se ha visto que el alelo s presenta unos niveles más 
bajos de expresión y función que el alelo l (revisado en Murphy et al., 2008). Además, otro 
polimorfismo (rs25531), un cambio A/G en la región del 5-HTTLPR, también afecta a los niveles 
de expresión del gen, dando lugar al alelo LA , de alta expresión, y a los alelos LG, SA y SG, de 
baja expresión. Se han llevado a cabo un número importante de estudios para evaluar la 
posible contribución del 5-HTTLPR en la susceptibilidad a diferentes trastornos mentales, como 
el trastorno bipolar (Cho et al., 2005), trastorno obsesivo-compulsivo (Bengel et al., 1999) o la 
depresión mayor (Kraft et al., 2005). El alelo s también se ha asociado con altos niveles de 
neuroticismo (Lesch et al., 1996), mayor depresión como respuesta a sucesos vitales 
estresantes (Caspi et al., 2003)  y una mayor activación de la amígdala como respuesta a 
estímulos amenazantes (Hariri et al., 2002). También se ha estudiado la relación del 5-HTTLPR 
y otros polimorfismos del gen con la esquizofrenia, aunque los resultados son más 
contradictorios (Fan y Sklar, 2005; Allen et al., 2008; Shi et al., 2008). Con respecto a las 
alucinaciones auditivas, hay un trabajo previo de Malhotra y colaboradores (1998) que asoció 
el alelo largo con una mayor intensidad de las alucinaciones auditivas. 
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El receptor de serotonina 5-HT2A está codificado por el gen HTR2A, localizado en 13q14-q21. 
Dos polimorfismos de este gen (T102C o rs6313, localizado en el primer intrón, y -1438A/G o 
rs6311, localizado en la región promotora) han sido ampliamente estudiados en relación con la 
susceptibilidad a padecer esquizofrenia, debido a la conocida afinidad de los antipsicóticos 
atípicos por los receptores 5-HT2A (Worrel et al., 2000). Además, también se sabe que algunos 
agonistas de este receptor, como el LSD y la mescalina, tienen potentes efectos alucinógenos 
(Glennon et al., 1984). Sin embargo, los resultados existentes hasta el momento son 
contradictorios y no permiten llegar a ninguna conclusión clara. Lo mismo ha ocurrido también 
al estudiar cómo influye la variación de este gen en los trastornos afectivos (Golimbet et al., 
2002; Anguelova et al., 2003) y en la respuesta a la medicación en pacientes esquizofrénicos 
(Arranz et al., 1995; Anttila et al., 2007). 
La enzima triptófano hidroxilasa (TPH) es el principal elemento regulador en la síntesis de 
serotonina. La isoforma específica de cerebro fue denominada TPH2 (Walther y Bader, 2003) y 
está codificada por el gen del mismo nombre. La búsqueda de variantes genéticas con un 
efecto sobre la actividad de la enzima se ha convertido en una aproximación interesante para 
estudiar la neurobiología de los desórdenes psiquiátricos, especialmente de aquellos que 
implican alteraciones afectivas y de tipo emocional. Siguiendo esta hipótesis, se han estudiado 
diferentes polimorfismos, aunque uno de los más estudiados es el SNP rs4570625, que tiene 
un impacto sobre la funcionalidad de la enzima. Hasta el momento, se han asociado diferentes 
variaciones en el gen TPH2 con a) diferentes desórdenes afectivos, como depresión y ansiedad 
(Zhang et al., 2005; Zhou et al., 2005) y trastorno bipolar (Harvey et al., 2004; Cichon et al., 
2008); b) enfermedades con alteraciones cognitivas o que afectan al control ejecutivo, como el 
trastorno por déficit de atención e hiperactividad y trastorno obsesivo-compulsivo (Baehne et 
al., 2008); y c) rasgos de la personalidad relacionados con la emocionalidad (Gutknecht et al., 
2007; Herrmann et al., 2007). Sin embargo, los resultados relacionados con esquizofrenia son 
hasta el momento negativos  (De Luca et al., 2005a; Higashi et al., 2007). A pesar de ello, 
consideramos que este gen podría tener un papel importante en el procesado emocional de 
las alucinaciones auditivas en pacientes esquizofrénicos. 
 
Gen de la óxido nítrico sintasa 1. El óxido nítrico (NO) es una molécula gaseosa que puede 
actuar como neurotransmisor en el sistema nervioso central, en estrecha relación con la 
transmisión glutamatérgica (Garthwaite, 2008). El  NO es sintetizado en el sistema nervioso 
por la NO sintasa 1 (NOS-I). Esta enzima está codificado por un gen extremadamente complejo 
localizado en el cromosoma 12 (Hall et al., 1994; Zhang et al., 2004), que presenta diferentes 
exones no codificantes. Entre estos exones, destaca el exón 1f, puesto que contiene una región 
de elementos repetitivos, concretamente nucleótidos CA (Reif et al., 2006). Este VNTR es de 
especial importancia, puesto que se ha visto que los alelos cortos reducen la eficiencia 
transcripcional del promotor. Éste y otros polimorfismos del gen NOS1 se han asociado con 
diferentes patologías psiquiátricas, entre ellas la esquizofrenia. Así, diferentes estudios de 
asociación apoyan el papel del gen NOS1 en la patogénesis de la esquizofrenia y otras 
enfermedades psiquiátricas (Detera-Wadleigh et al., 1999; Shinkai et al., 2002; Fallin et al., 
2005; Reif et al., 2006; Tang et al., 2008; O’Donovan et al., 2008), aunque también existen 
resultados negativos (Liou et al., 2003). 
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Stathmin. Stathmin pertenece a una familia de proteínas encargada de regular la dinámica de 
polimerización-despolimerización de los microtúbulos (Belmont y Mitchinson, 1996; Gavet et 
al., 1998). En humanos, esta proteína está codificada por un pequeño gen (STMN1) localizado 
en 1p36-1-p35. Entre las diferentes tareas en las que participa, destacan la regulación de la 
proliferación celular; transporte, motilidad celular y mantenimiento de la forma celular; 
migración celular; y por último, desarrollo, maduración y regulación funcional del sistema 
nervioso central (Curmi et al., 1999). Esta última función es de gran interés para el presente 
estudio. Se ha comprobado que stathmin se expresa enormemente durante el crecimiento de 
neuritas y la formación de sinapsis, lo que apoyaría su papel en la diferenciación neuronal (Di 
Paolo et al., 1997). Sin embargo, es intrigante el hecho de que la inactivación de este gen en 
ratón no parecía producir un fenotipo aparente (Schubart et al., 1996). Sin embargo, 
recientemente se ha comprobado que esto no es realmente así, puesto que el gen STMN1 es 
clave en el ratón para la inducción de la potenciación a largo plazo en aquellos tractos que 
proyectan hacia la amígdala, así como para regular el miedo innato y aprendido. Esto tiene 
consecuencias en comportamientos relacionados con estos sistemas, como el cuidado 
materno innato y las interacciones sociales (Shumyatsky et al., 2005; Martel et al., 2008). 
Stathmin podría por tanto tener un papel clave en aquellos trastornos psiquiátricos donde el 
procesado del miedo y las interacciones sociales están comprometidos. Los desórdenes 
afectivos y la esquizofrenia son un claro ejemplo de ello.  
 
Genes de selección positiva: ASPM. Desde un punto de vista evolutivo, se puede hipotetizar 
que el incremento de habilidades cognitivas sufrido por la especie humana pudo haber 
favorecido la aparición de ciertas patologías que cursan con alteraciones cognitivas, tales como 
la esquizofrenia (Crow, 1997; Horrobin, 1998). Esta idea genera una paradoja que podría 
explicar por qué la esquizofrenia mantiene una frecuencia más o menos invariable a lo largo 
del tiempo a pesar de su gravedad. Por ello, aquellos genes que hayan sufrido una evolución 
acelerada en el linaje humano y que tengan un papel clave en el funcionamiento del sistema 
nervioso central son excelentes genes candidatos a estar implicados en la vulnerabilidad a 
padecer esquizofrenia. En este estudio, hemos seleccionado para su estudio un gen de 
selección positiva: el gen ASPM (abnormal spindle-like microcephaly associated). Este gen tiene 
un papel muy importante en el desarrollo del cortex cerebral. Está localizado en 1q31 (Bond et 
al., 2002) y codifica una proteína con varios dominios, siendo el más grande e importante un 
dominio de repeticiones Isoleucina-Glutamina (IQ), que da lugar a una estructura de orden 
superior que podría tener un papel importante en las interacciones entre la proteína ASPM y 
proteínas poliméricas como la actina y la calmodulina (Kouprina et al., 2005). El gen ASPM  se 
expresa durante el desarrollo embrionario en un gran número de tejidos, incluido el cerebro. 
Sin embargo, no se expresa en el cerebro adulto (Bond et al., 2002; Kouprina et al., 2005). 
Diferentes estudios han permitido constatar que la proteína se localiza en los polos durante la 
mitosis celular y parece ser necesaria para asegurar la simetría proliferativa de los 
progenitores que darán lugar al cortex cerebral. (Fish et al., 2006). Sin embargo, el rasgo más 
llamativo del gen ASPM son las evidencias que apoyan una evolución acelerada de este gen, 
presumiblemente por selección positiva, en el linaje humano (Zhang, 2003; Evans et al., 2004; 
Kouprina et al., 2004). Asimismo, esta selección positiva parece que sigue actuando en la 
actualidad (Mekel-Bobrov et al., 2005). Este hecho sugiere que el gen ASPM podría haber 
tenido un papel clave en la expansión del cerebro observada a lo largo de la evolución de los 
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primates. Sin embargo, a pesar de los indicios de selección positiva, ninguna variación 
polimórfica de este gen ha podido ser asociada todavía con el tamaño cerebral global (Woods 
et al., 2006; Rushton et al., 2007; Timpson et al., 2007; Wang et al., 2008) o con parámetros 
relacionados con la inteligencia (Mekel-Bobrov et al., 2007; Rushton et al., 2007) en población 
sana. Son necesarios más estudios para conocer el verdadero papel de este gen en la cognición 
y la susceptibilidad a la esquizofrenia. 
 
Otros genes candidatos. Los tres últimos genes que se han incluido en este estudio se 
seleccionaron a partir de un trabajo dirigido por el Dr. Lesch cuyo principal objetivo era la 
búsqueda de variaciones en el número de copias en una muestra de pacientes con trastorno 
por déficit de atención e hiperactividad (TDAH). A partir de este estudio, se seleccionaron tres 
genes, PDE4D, PLEKHB1 y RAB6A.  
PDE4D. Este gen codifica una fosfodiesterasa (PDE), proteína encargada de degradar el AMP 
cíclico (cAMP), molécula de gran importancia como segundo mensajero en un importante 
número de procesos neurales (Dudai, 1986). Concretamente la familia de fosfodiesterasas 
PDE4 se caracteriza por su inhibición mediante rolipram, sustancia neuroactiva con efecto 
antidepresivo. El gen PDE4D es un gen de gran tamaño localizado en el cromosoma 5 que 
presenta procesado alternativo, lo que da lugar a un elevado número de isoformas diferentes 
(Wang et al., 2003b). De especial interés es la isoforma PDE4D6, isoforma de pequeño tamaño 
específica de cerebro, cuya localización celular es hasta el momento desconocida. El hecho de 
que la proteína PDE4D se vea inhibida por rolipram (Henkel-Tigges y Davis, 1990) sugiere que 
podría tener un papel clave en el comportamiento humano. Asimismo, se ha comprobado que 
PDE4D interacciona con DISC1 (Murdoch et al., 2007). Hay por tanto suficientes razones para 
sugerir que variaciones en el gen PDE4D podrían impactar sobre el riesgo de padecer 
esquizofrenia o desórdenes afectivos. De acuerdo con esta hipótesis, varios autores (Shifman 
et al., 2008b; Heck et al., 2008) han encontrado muy recientemente asociaciones entre 
polimorfismos de este gen y ciertos rasgos de la personalidad como el Neuroticismo o la 
Evitación de Daño, tanto en sujetos sanos como en pacientes depresivos.   
PLEKHB1 y RAB6A. Son dos genes adyacentes pero en orientaciones opuestas localizados en el 
cromosoma 11. PLEKHB1 (anteriormente llamado PHR1) es una proteína integral de 
membrana que contiene un dominio de homología con la pleckstrina. Se expresa en las células 
fotorreceptoras, en las células pilosas cocleares y vestibulares, así como en las neuronas 
receptoras olfatorias (Xu et al., 1999; Xu et al., 2004). Su función parece estar relacionada con 
la transducción de señales. La existencia de dos promotores diferentes y el procesado 
alternativo del exón 7 da lugar a 4 isoformas diferentes. Por otra parte, RAB6A es un gen que 
da lugar a dos isoformas diferentes, Rab6A y Rab6A’ (Echard et al., 2000), pertenecientes a la 
familia de pequeñas GTPasas, proteínas de vital importancia en el tráfico intracelular de 
membranas (Wanschers et al., 2008). Aunque ambos genes (PLEKHB1 y RAB6A) se expresan en 
el cerebro, su relación con la esquizofrenia no es tan clara a priori como en los casos 
anteriores. Sin embargo, el hecho de estar asociados con una enfermedad psiquiátrica como el 
TDAH los convierte en interesantes genes candidatos. 
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Objetivos 
Este estudio es parte de un proyecto de investigación multidisciplinario más amplio que buscar 
profundizar en las bases genéticas de la esquizofrenia y sus síntomas más característicos. De 
acuerdo con este marco general, la hipótesis general y los objetivos de este estudio son los 
siguientes: 
 
Hipótesis general: variaciones en los genes previamente descritos modulan la vulnerabilidad a 
padecer esquizofrenia o alguno de sus rasgos más importantes, particularmente las 
alucinaciones auditivas, el deterioro cognitivo, alteraciones neuroanatómicas y, finalmente, la 
disfunción emocional asociada a las condiciones patológicas descritas previamente. 
 
Objetivos generales:  
1. Análisis de varios polimorfismos localizados en los genes candidatos mediante estudios 
de asociación caso-control y basados en familias. Para este propósito, diferentes 
muestras de pacientes y sujetos sanos serán incluidas.  
2. Búsqueda de asociaciones entre alelos, genotipos o haplotipos y diferentes variables 
cuantitativas y rasgos patológicos, incluyendo a) puntuaciones en escalas generales y 
de alucinaciones, y b) rendimiento en diferentes tareas de naturaleza cognitiva. 
3. Evaluación del impacto de algunos polimorfismos de interés sobre ciertos fenotipos de 
neuroimagen que están afectados en pacientes esquizofrénicos. 
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Resultados y conclusiones 
 
En este estudio se ha trabajado con tres muestras de diferente origen: 
- Un grupo de 328 pacientes psicóticos (76% de ellos diagnosticados con esquizofrenia; 
además 246 sufrían alucinaciones auditivas) y 348 controles sanos no emparentados, todos 
ellos de Valencia (España). Los pacientes fueron evaluados mediante diferentes escalas 
clínicas psiquiátricas generales (BPRS, PANSS, KGV), así como con escalas específicas 
(subescalas PSYRATS de alucinaciones auditivas y delirios). 
- Una muestra de 336 pacientes (247 sufrían de esquizofrenia, 89 presentaban desorden 
bipolar) y 540 controles sanos, procedentes de la Baja Franconia (Alemania).  
- Una muestra procedente de los Estados Unidos de América, consistente en 466 familias con 
individuos afectados de esquizofrenia o trastorno esquizoafectivo, así como 483 individuos 
sanos no emparentados. Las familias incluidas se componían, en total, de 498 pacientes, 
612 padres y 427 hermanos no afectados. Tanto los pacientes como los controles sanos 
fueron sometidos a una batería de tests cognitivos. A partir de sus resultados, se 
elaboraron una serie de medidas numéricas derivadas de los tests cognitivos (Genderson et 
al., 2007): Memoria Verbal; Memoria de Trabajo-N Back; Memoria Visual; Cociente 
Intelectual (CI)-Velocidad de Procesamiento-Fluidez; Función Ejecutiva-Wisconsin Card 
Sorting Test (WCST); Atención; y Repetición de Números (Digit Span).  
 
A partir del ADN obtenido, bien de sangre o de saliva, se genotiparon una serie de 
polimorfismos en cada uno de los 9 genes candidatos elegidos en este estudio. A continuación 
se llevaron a cabo diferentes estudios de asociación dependiendo de la muestra de individuos 
(caso-control, basado en familias, asociación con variables cuantitativas). Asimismo, se analizó 
el impacto de ciertos polimorfismos sobre el volumen cerebral total o regional y sobre la 
activación de ciertas áreas mediante el uso de determinados paradigmas de resonancia 
magnética funcional (fMRI). 
 
Los resultados para cada gen y las conclusiones obtenidas se muestran a continuación.  
 
Gen SLC6A4 (Transportador de serotonina) 
 
Se seleccionaron 12 polimorfismos a lo largo del gen (incluyendo tagSNPs y otros 
polimorfismos adicionales seleccionados por su posible funcionalidad), que fueron 
genotipados en la muestra caso-control española. 
 
Los resultados procedentes del análisis de asociación caso-control revelaron la existencia de 
dos SNPs (rs140700 y rs2020936) asociados con el riesgo de psicosis (tabla C1) y psicosis con 
alucinaciones (datos no mostrados). Estos resultados se obtuvieron tanto en el análisis de 
asociación de las frecuencias alélicas como en el de las genotípicas (tabla C2). Además, los 
resultados significativos obtenidos con el SNP rs2020936, localizado en el intrón 1A del gen, 
resistieron la corrección para comparaciones múltiples. Sin embargo, el polimorfismo funcional 
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5-HTTLPR no pareció impactar sobre el riesgo de psicosis; de hecho, este dato es coherente 
con la literatura existente (Fan y Sklar, 2005; Levinson, 2005). Asimismo, se encontraron varios 
haplotipos protectores de 2, 3 y 4 marcadores, los cuales eran variaciones de los mismos alelos 
de los SNPs rs3813034, rs140700, rs2020942, rs2020939 y rs2020936 (datos no mostrados). 
Desafortunadamente, estos resultados dejaron de ser significativos tras 1000 permutaciones. 
 
 
Tabla C1. Comparación de las frecuencias alélicas de los polimorfismos del gen SLC6A4 en pacientes 
psicóticos y controles sanos de la muestra española. 
Polimorfismo Alelo 
Frecuencia 
pacientes 
Frecuencia 
controles 
OR (95% IC) χ
2
 P
a
 
rs3813034 
G 0.4715 0.4693 1 
0.006 0.938 (1) 
T 0.5285 0.5307 0.991 (0.796-1.235) 
rs1042173 
G 0.4815 0.4721 1 
0.113 0.737 (1) 
T 0.5185 0.5279 0.963 (0.773-1.2) 
rs140700 
A 0.04833 0.08254 1 
5.45 
0.0196 
(0.2152) G 0.9517 0.9175 1.772(1.09-2.879) 
rs2020942 
A 0.3658 0.3284 1 
1.959 0.162 (1) 
G 0.6342 0.6716 0.848 (0.673-1.068) 
STin2 
12 rep 0.6429 0.6776 1 
1.668 0.197 (1) 
10 rep 0.3571 0.3224 1.168 (0.923-1.478) 
rs2020939 
C 0.5406 0.558 1 
0.359 0.549 (1) 
T 0.4594 0.442 1.073 (0.852-1.35) 
rs2020936 
C 0.1644 0.2141 1 
5.075 
0.0243 
(0.2427) T 0.8356 0.7859 1.384 (1.042-1.838) 
rs2066713 
C 0.646 0.6711 1 
0.892 0.345 (1) 
T 0.354 0.3289 1.118 (0.887-1.409) 
rs4251417 
A 0.06506 0.07166 1 
0.198 0.657 (1) 
G 0.9349 0.9283 1.109 (0.702-1.753) 
5-HTTLPR 
(incluyendo 
rs25531) 
LA 0.4505 0.4797 1 
1.104 0.576 (1) 
LG 0.04785 0.05072 1.005 (0.599 - 1.686) 
SA 0.4901 0.4638 1.125 (0.899 - 1.409) 
SG 0.01155 0.005797 2.122 (0.615 - 7.324) 
rs12945042 
G 0.7286 0.719 1 
0.133 0.715 (1) 
A 0.2714 0.281 0.9532 (0.737-1.233) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, Intervalos de confianza; rep, repeticiones. 
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Tabla C2. Comparación de las distribuciones genotípicas de los polimorfismos del gen SLC6A4 en 
pacientes psicóticos y controles sanos de la muestra española. 
Polimorfismo Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
OR (95% IC) P 
b
 AIC Modelo 
rs3813034 
T/T-G/T 270 (79%) 230 (77.2%) 1.00 
0.59 (1) 887.9 Recesivo 
G/G 72 (21.1%) 68 (22.8%) 1.11 (0.76-1.61) 
rs1042173 
T/T-T/G 268 (78.6%) 228 (76.5%) 1.00 
0.53 (1) 886.5 Recesivo 
G/G 73 (21.4%) 70 (23.5%) 1.13 (0.78-1.64) 
rs140700 
G/G 265 (84.1%) 243 (90.3%) 
0.56(0.34-
0.91)
a
 
0.017 
(0.17) 
804.3 Aditivo A/G 48 (15.2%) 26 (9.7%) 
A/A 2 (0.6%) 0 (0%) 
rs2020942 
G/G 156 (45.8%) 119 (39.9%) 1.00 
0.14 (1) 884.7 Dominante 
A/G-A/A 185 (54.2%) 179 (60.1%) 1.27 (0.93-1.74) 
STin2 
12/12 156 (46.6%) 118 (41.1%) 1.00 
0.17 (1) 860.7 Dominante 
10/12-10/10 179 (53.4%) 169 (58.9%) 1.25 (0.91-1.72) 
rs2020939 
C/C-C/T 259 (81.2%) 214 (79%) 1.00 
0.5 (1) 817.5 Recesivo 
T/T 60 (18.8%) 57 (21%) 1.15(0.77-1.72) 
rs2020936 
T/T 204 (59.8%) 211 (70.8%) 1.00 
0.0045 
(0.0495) 
878.1 Codominante T/C 128 (37.5%) 76 (25.5%) 0.57 (0.41-0.81) 
C/C 9 (2.6%) 11 (3.7%) 1.18 (0.48-2.91) 
rs2066713 
C/C 156 (45.6%) 121 (40.6%) 1.00 
0.2 (1) 886.6 Dominante 
C/T-T/T 186 (54.4%) 177 (59.4%) 1.23 (0.90-1.68) 
rs4251417 
G/G 269 (85.7%) 234 (87%) 1.00 
0.64 (1) 808.5 N/A 
A/G 45 (14.3%) 35 (13%) 0.89 (0.56-1.44) 
5-HTTLPR 
(including 
rs25531) 
low/low 257 (75.4%) 239 (80.2%) 1.00 
0.14 (1) 884.8 Recesivo high/low-
high/high 
84 (24.6%) 59 (19.8%) 0.76 (0.52-1.10) 
rs12945042 
G/G-G/A 285 (90.5%) 253 (94%) 1.00 0.11 
(0.99) 
807.4 Recesivo 
A/A 30 (9.5%) 16 (6%) 0.60 (0.32-1.13) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado se corresponde con la diferencia que se le atribuye a cada alelo en el modelo aditivo.  
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, Intervalos de confianza; N/A, no aplicable. 
 
 
El polimorfismo rs2020936 no había sido asociado previamente con la susceptibilidad a 
padecer esquizofrenia aunque Kim et al. (2002) encontraron una transmisión preferencial del 
alelo T en una muestra de pacientes autistas. Sin embargo, nuestros resultados deberían ser 
interpretados con cuidado, puesto que este polimorfismo estaba ligeramente fuera del 
Equilibrio de Hardy-Weinberg (HWE por sus siglas en inglés) en la muestra de controles, lo que 
dificulta la interpretación y valoración de los resultados. Aunque tampoco podemos descartar 
que este SNP, u otro SNP en alto desequilibrio de ligamiento (LD) con él, pueda tener algún 
efecto sobre la funcionalidad del transportador de serotonina. 
 
Con respecto al análisis de asociación con variables cuantitativas, se encontraron un gran  
número de resultados significativos, aunque los resultados más interesantes son las 
asociaciones del 5-HTTLPR con parámetros relacionados con aspectos emocionales (tabla C3), 
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como los ítems Excitación  y Hostilidad de la escala PANSS, que forman parte del Componente 
Excitativo de esta escala (Kay y Sevy, 1990). Asimismo, este polimorfismo localizado en el 
promotor del gen se asoció con tres ítems emocionales de la escala PSYRATS de alucinaciones 
auditivas: Intensidad de la Ansiedad, Frecuencia de la Ansiedad y Repercusión.  
 
 
Tabla C3. Asociaciones significativas del polimorfismo 5-HTTLPR del transportador de serotonina con diferentes 
ítems clínicos relacionados con emocionalidad. 
Polimorfismo 
Distribución 
genotípica
a
 
Puntuación 
media (SE) 
Diferencia 
(95% IC) 
Modelo P
b
 BIC 
KGV - Ansiedad 
5-HTTLPR 
baja/baja : 78 1.72 (0.119) 0.00 
Dominante 
0.04 
(0.44) 
789 
alta/baja-alta/alta: 135 1.44 (0.08) -0.29 (-0.57 - -0.01) 
  PANSS P4 - Excitación 
5-HTTLPR 
baja/baja : 37 2.43 (0.18) 0.00 
Dominante 
0.0014 
(0.015) 
394.3 
alta/baja-alta/alta:92 1.77 (0.11) -0.67 (-1.07 - -0.27) 
PANSS P7 - Hostilidad 
5-HTTLPR 
baja/baja : 37 2.19 (0.2) 0.00 
Dominante 
0.0004 
(0.0044) 
364.9 
alta/baja - alta/alta : 92 1.53 (0.09) -0.67 (-1.03 - -0.32) 
PSYRATS AA – Frecuencia de la ansiedad 
5-HTTLPR 
baja/baja : 68 1.78 (0.21) 0.00 
Dominante 
0.011 
(0.121) 
799.5 
alta/baja-alta/alta:140 1.21 (0.13) -0.61 (-1.08 - -0.14) 
PSYRATS AA – Intensidad de la ansiedad 
5-HTTLPR 
baja/baja : 68 1.79 (0.2) 0.00 
Dominante 
0.0061 
(0.0671) 
790.1 
alta/baja-alta/alta:140 1.18 (0.13) -0.65 (-1.11 - -0.19) 
PSYRATS AA - Repercusión 
5-HTTLPR 
baja/baja : 68 1.84 (0.18) 0.00 
Dominante 
0.012 
(0.132) 
765.3 
alta/baja-alta/alta:140 1.28 (0.12) -0.56 (-0.99 - -0.13) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. La designación “baja” o “alta” hace referencia a los alelos de alta y baja expresión del polimorfismo 5-HTTLPR.  
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: SE, error estándar; IC, intervalo de confianza; AA, alucinaciones auditivas; N/A, no aplicable. 
 
 
Estos interesantes resultados nos animaron a profundizar en el efecto de este polimorfismo 
sobre aquellas regiones cerebrales asociadas con el procesado de las emociones. Por ello, se 
realizaron estudios de resonancia magnética funcional (fMRI) y estructural (sMRI) y los datos 
obtenidos se correlacionaron con los datos genéticos. Con respecto al estudio de neuroimagen 
funcional, se empleó un paradigma de tipo auditivo-emocional mediante el cual se detectó una 
mayor activación de la amígdala derecha frente a palabras emocionales en los pacientes S/S en 
comparación con los L/L (figura C1). Además, los estudios de neuroimagen estructural han 
permitido detectar que tanto los pacientes esquizofrénicos alucinadores como los controles 
sanos portadores de al menos un alelo S presentan una reducción en la densidad de materia 
gris en ciertas zonas del sistema límbico. Sin embargo, las áreas implicadas son diferentes 
(hipocampo y parahipocampo en controles, ver figura C2; córtex anterior cingulado en 
pacientes, ver figura C3).  
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Figura C1. Diferencias en la activación de la amígdala derecha ante palabras emocionales en 
pacientes esquizofrénicos dependiendo del genotipo para el polimorfismo 5-HTTLPR. 
Figura C2. Áreas con reducción en la densidad de material gris en sujetos control con al 
menos una copia del alelo corto del polimorfismo 5-HTTLPR y gráfico con los valores 
normalizados de materia gris en el hipocampo (bilateral) y la circunvolución 
parahipocámpica (izquierda). p < 0.05 FDR corregido k=34. 
Abreviaturas: MG, material gris; LSD, least significant difference; FDR, false discovery 
rate; I, izquierda; D, derecha. 
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A nuestro entender, éste es el primer estudio que ha intentado profundizar en las bases 
genéticas de las alucinaciones auditivas en la psicosis, teniendo en cuenta además un punto de 
vista dimensional. Nuestros resultados claramente sugieren la existencia de un efecto de la 
variación genética del transportador de serotonina en aquellos circuitos neurales implicados 
en el procesado emocional, tanto en sujetos sanos como psicóticos. La amígdala, así como 
otros elementos del sistema límbico (hipocampo, córtex anterior cingulado) juegan un papel 
clave en estos procesos tanto en situaciones normales como patológicas (Hariri et al., 2002; 
Furmark et al., 2004; Hariri et al., 2005; Canli et al., 2005b; Heinz et al., 2005; Canli et al., 2006; 
Domschke et al., 2006; Heinz et al., 2007; Rao et al., 2007). Nuestros resultados también 
sugieren que las alucinaciones auditivas son sucesos estresantes, y que la respuesta del 
individuo a ellas puede ser modulada por el acervo genético del individuo. En este sentido, 
también hay estudios que relacionan claramente este mismo polimorfismo con la 
vulnerabilidad a eventos estresantes y la tendencia a la depresión (Caspi et al., 2003; Eley et 
al., 2004; Kaufman et al., 2004; Grabe et al., 2005; Kendler et al., 2005; Cervilla et al., 2007). 
Los resultados del análisis estructural de neuroimagen también apoyan un efecto del 
polimorfismo del promotor del transportador de serotonina en áreas límbicas. La reducción de 
Media e IC 95% 
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Figura C3. Áreas con reducción en la densidad de material gris en pacientes 
esquizofrénicos con al menos una copia del alelo corto del polimorfismo 5-HTTLPR y 
gráfico de los valores normalizados de materia gris en la circunvolución anterior 
cingulada. p < 0.05 FDR corregido k=34.  
Abreviaturas: MG, material gris; LSD, least significant difference; FDR, false discovery 
rate; I, izquierda; D, derecha. 
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la densidad de materia gris en el córtex anterior cingulado (ACC) ventral y dorsal observada en 
pacientes del grupo S es especialmente relevante puesto que esta estructura desempeña un 
papel importante en la neurobiología de la esquizofrenia (Baiano et el al., 2007). Por otra 
parte, el ACC está implicado en la regulación del estado de ánimo y estos procesos están 
afectados en pacientes esquizofrénicos. Por lo tanto, podemos presumir que los pacientes que 
sufren de esquizofrenia y alucinaciones auditivas presentan una alteración del procesado 
emocional, que está modulada por el 5-HTTLPR y se traduce a su vez en una reducción de 
materia gris en el ACC. Esta reducción podría a su vez relacionarse con las diferencias 
observadas en la activación de la amígdala derecha. En coherencia con esta hipótesis, Pezawas 
y colaboradores (2005) encontraron un volumen reducido en el ACC y la amígdala de sujetos 
sanos portadores de al menos un alelo corto del 5-HTTLPR. Desafortunadamente, en nuestro 
estudio no se han detectado diferencias en el volumen de materia gris de la amígdala 
dependiendo del 5-HTTLPR. Varias razones, tales como un efecto del sexo o del tamaño 
muestral, podían explicar estas diferencias. Sin embargo, los resultados de nuestro análisis de 
sMRI en sujetos control han sido diferentes a los del grupo esquizofrénico, puesto que para 
este grupo hemos encontrado reducciones volumétricas en el hipocampo y el parahipocampo 
asociadas al alelo S. Una vez más, ciertos factores, como el sexo, los efectos de la medicación, 
el reducido tamaño muestral o el papel potencial del estrés sobre el eje hipotalámico-
hipofisario-suprarrenal podrían explicar las divergencias. Con relación al efecto del estrés 
sobre el eje hipotalámico-hipofisario-suprarrenal, que controla la liberación de cortisol, se ha 
encontrado una interacción entre el alelo S del 5-HTTLPR y niveles altos de cortisol, que se 
asocia a una reducción en el volumen del hipocampo (O’Hara et al., 2007). También hay 
estudios previos que relacionan situaciones de estrés severo en la infancia con un menor 
tamaño del hipocampo (Stein et al., 1997; Vythilingam et al., 2002).  
Desafortunadamente, no encontramos ninguna diferencia en el volumen hipocámpico 
dependiente del genotipo en nuestro grupo de pacientes. Esto sugiere la existencia de otros 
factores de riesgo adicionales (genéticos o ambientales) que contribuyen a la determinación 
del volumen de las estructuras temporales. Por otra parte, tampoco se puede olvidar que las 
condiciones ambientales que influencian un fenotipo esquizofrénico pueden diferir 
enormemente de las de un sujeto sano. 
En resumen, en este estudio se han encontrado dos SNPs (rs140700 and rs2020936), así como 
varios haplotipos protectores, asociados con la psicosis y la psicosis con alucinaciones 
auditivas. Asimismo, el polimorfismo funcional del promotor (5-HTTLPR) parece estar asociado 
con la dimensión emocional de las alucinaciones auditivas, lo que ha sido corroborado 
mediante diferentes aproximaciones. 
 
Otros genes del sistema serotoninérgico: HTR2A (receptor 5-HT2A) y TPH2 (triptófano 
hidroxilasa 2) 
 
Los interesantes resultados obtenidos con el gen del transportador de serotonina nos llevaron 
a hacer un análisis preliminar de otros dos genes del sistema serotoninérgico: HTR2A y TPH2. 
Para ello, seleccionamos una serie de polimorfismos de interés: del gen HTR2A, los SNPs 
rs6311 (también conocido como -1438A/G y localizado en la región promotora) y rs6313 
(conocido como T102C y situado en el exón 1); del gen TPH2, el polimorfismo rs4570625 
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(también llamado -703G/T y situado en el promotor del gen). Los 3 SNPs se genotiparon en la 
muestra caso-control española. 
 
Desafortunadamente, no se detectó ninguna asociación significativa en las comparaciones 
caso control (datos no mostrados). Por el contrario, los resultados más interesantes son las 
asociaciones entre los dos polimorfismos del gen HTR2A y diferentes variables cuantitativas 
relacionadas con la emocionalidad (tabla C4): ítem “Ansiedad” de la escala BPRS, ítems 
“Ansiedad” y “Depresión” de la escala KGV, ítems “Ansiedad” y “Preocupación” de la escala 
PANSS; y, finalmente, “Intensidad de la Ansiedad”, de la subescala PSYRATS de alucinaciones 
auditivas. En todos los casos, los individuos G/G (rs6311) y C/C (rs6313) puntuaron más alto. 
Esta asociación fue particularmente fuerte para los niveles de ansiedad medidos con las 
escalas PANSS y BPRS. Además, los resultados presentan una gran coherencia entre diferentes 
escalas.  
 
Tabla C4. Asociaciones significativas de los polimorfismos del gen HTR2A con diferentes ítems clínicos 
relacionados con emocionalidad. 
SNP 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia (95% IC) Modelo P 
b
 BIC 
KGV - Ansiedad 
rs6313 
C/C : 87 1.75 (0.11) 0.00 
Dominante 0.014 (0.014) 781.6 
T/C - T/T : 180 1.42 (0.08) -0.33 (-0.59 - -0.07) 
rs6311 
G/G : 72 1.82 (0.12) 0.00 
Dominante 0.0041 (0.0082) 779.4 
A/G - A/A : 195 1.42 (0.07) -0.40 (-0.68 - -0.13) 
KGV - Depresión 
rs6313 
C/C : 87 1.09 (0.11) 
-0.22 (-0.38 - -0.05)
a
 Aditivo 0.011 (0.022) 756.3 T/C : 130 0.93 (0.09) 
T/T : 50 0.64 (0.11) 
rs6311 
G/G - A/G : 216 1 (0.07) 0.00 
Recesivo 0.022 (0.022) 757.6 
A/A : 51 0.65 (0.11) -0.35 (-0.65 - -0.05) 
BPRS - Ansiedad 
rs6313 
C/C : 52 3.38 (0.21) 
-0.32 (-0.63 - -0.02)
a
 Aditivo 0.041  (0.06) 652 T/C : 93 2.96 (0.14) 
T/T : 34 2.76 (0.27) 
rs6311 
G/G : 53 3.4 (0.2) 
-0.34 (-0.64 - -0.04)
a
 Aditivo 0.03 (0.06) 651.5 A/G : 91 2.96 (0.14) 
A/A : 35 2.74 (0.26) 
PANSS G2 – Ansiedad 
rs6313 
C/C : 39 3.18 (0.22) 
-0.50 (-0.80 - -0.19)
a
 Aditivo 0.0021 (0.0038) 430.7 T/C : 67 2.6 (0.14) 
T/T : 23 2.22 (0.25) 
rs6311 
G/G : 39 3.18 (0.22) 
-0.50 (-0.80 - -0.19)
a
 Aditivo 0.0019 (0.0038) 430.4 A/G : 66 2.61 (0.14) 
A/A : 24 2.21 (0.24) 
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Tabla C4 (continuación). Asociaciones significativas de los polimorfismos del gen HTR2A con diferentes 
ítems clínicos relacionados con emocionalidad. 
SNP 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia (95% IC) Modelo P 
b
 BIC 
PANSS G15 - Preocupación 
rs6313 
C/C : 39 3.08 (0.23) 0.00 
Dominante 0.012 (0.024) 457.8 
T/C - T/T : 90 2.41 (0.14) -0.67 (-1.18 - -0.16) 
rs6311 
G/G : 39 3.08 (0.23) 0.00 
Dominante 0.012 (0.024) 457.8 
A/G - A/A : 90 2.41 (0.14) -0.67 (-1.18 - -0.16) 
PSYRATS AA – Intensidad de la ansiedad 
rs6311 
G/G : 53 1.74 (0.24) 
-0.33 (-0.64 - -0.01)
a
 Additive 0.042 (0.084) 788.2 A/G : 112 1.32 (0.14) 
A/A : 43 1.09 (0.23) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado se corresponde con la diferencia que se le atribuye a cada alelo en el modelo aditivo.  
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: SE, error estándar; IC, intervalo de confianza; AA, alucinaciones auditivas. 
 
 
Diferentes estudios previos han relacionado el gen HTR2A con enfermedades afectivas, como 
depresión (Choiy et al., 2004), algunos rasgos de personalidad relacionados con el desorden 
bipolar (Ni et al., 2006), trastorno afectivo estacional (Levitan et al., 2002) y desorden de 
pánico (Unschuld et al., 2007). Un estudio de Golimbet y colaboradores (2002) es 
particularmente interesante, puesto que asocia el polimorfismo rs6313 con algunos rasgos de 
personalidad, como Ansiedad y Neuroticismo, en pacientes psicóticos. Sin embargo, serías 
necesarias otras aproximaciones para entender mejor el papel de este gen en la emocionalidad 
y los trastornos afectivos. 
 
 
Con respecto al polimorfismo funcional del gen TPH2 (rs4570625), los resultados han sido 
principalmente negativos. Únicamente al considerar la submuestra de pacientes 
esquizofrénicos alucinadores, se ha encontrado una ligera asociación entre este SNP y varios 
parámetros de la escala PSYRATS de alucinaciones auditivas (tabla C5): Puntuación Total, 
Duración, Localización, Intensidad, Frecuencia de Contenido de Negativo y Frecuencia de la 
Ansiedad.  
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Tabla C5. Asociaciones significativas del polimorfismo del gen TPH2 con diferentes ítems de la subescala 
PSYRATS de alucinaciones auditivas. 
SNP 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia (95% IC) Modelo P  BIC 
PSYRATS AA - Total 
rs4570625 
G/G : 124 16.94 (1.38) 1.00 
Codominante 0.037 1446.5 G/T : 43 22.98 (2.41) 6.03 (0.69 - 11.38) 
T/T : 5 9 (5.51) -7.94 (-21.72 - 5.83) 
PSYRATS AA - Duración 
rs4570625 
G/G : 124 1.62 (0.15) 1.00 
Codominante 0.031 684.1 G/T : 43 2.35 (0.26) 0.73 (0.15 - 1.31) 
T/T : 5 1 (0.63) -0.62 (-2.12 - 0.88) 
PSYRATS AA - Localización 
rs4570625 
G/G : 124 1.47 (0.14) 1.00 
Codominante 0.042 668.2 G/T : 43 2.07 (0.26) 0.60 (0.05 - 1.16) 
T/T : 5 0.6 (0.4) -0.87 (-2.30 - 0.57) 
PSYRATS AA - Intensidad 
rs4570625 
G/G : 124 1.24 (0.11) 1.00 
Codominante 0.043 588.4 G/T : 43 1.67 (0.21) 0.43 (-0.01 - 0.87) 
T/T : 5 0.4 (0.24) -0.84 (-1.98 - 0.30) 
PSYRATS AA – Cantidad de contenido negativo 
rs4570625 
G/G : 124 1.49 (0.15) 1.00 
Codominante 0.037 675.5 G/T : 43 2.16 (0.26) 0.67 (0.10 - 1.24) 
T/T : 5 0.8 (0.49) -0.69 (-2.16 - 0.77) 
PSYRATS AA – Intensidad de la ansiedad 
rs4570625 
G/G : 124 1.33 (0.14) 1.00 
Codominante 0.02 665.8 G/T : 43 2 (0.25) 0.67 (0.12 - 1.22) 
T/T : 5 0.4 (0.4) -0.93 (-2.35 - 0.49) 
Los resultados corresponden a la submuestra de pacientes esquizofrénicos con alucinaciones auditivas.  
Los valores de P significativos (P < 0.05) se indican en negrita. 
Abreviaturas: SE, error estándar; IC, intervalo de confianza; AA, alucinaciones auditivas. 
 
 
El hecho de que el genotipo G/T se asocie con una mayor ansiedad frente a las alucinaciones 
auditivas es particularmente interesante, puesto que es coherente con trabajos previos 
(Gutknecht et al., 2007; Brown et al., 2005; Canli et al., 2005a). Sin embargo, los resultados 
obtenidos en este estudio habría que considerarlos con cautela, puesto que la significación es 
baja y no resistió la corrección para comparaciones múltiples. Además, hay que considerar que 
la frecuencia del alelo menor es relativamente baja (0.15 en pacientes), por lo que el número 
de individuos homozigotos para el alelo menor también es bajo. Sería por tanto necesaria una 
muestra de mayor tamaño, para poder afirmar si estos resultados están indicando una 
verdadera asociación o por el contrario son el resultado de una variación aleatoria de las 
distribuciones genotípicas que han dado como resultado un falso positivo. 
 
 
 
 
Resumen en castellano 283 
 
Gen NOS1 (Óxido Nítrico Sintasa 1) 
 
Se realizó un análisis preliminar y exploratorio para conocer si este gen podría tener alguna 
implicación en la vulnerabilidad a padecer esquizofrenia o en el desarrollo de alguno de sus 
síntomas. Por ello, un polimorfismo situado en el gen de la Óxido Nítrico Sintasa 1 (NOS1), 
concretamente la VNTR funcional localizada en el exón 1f, fue genotipada en la muestra de 
origen español.  
 
Desafortunadamente, no se obtuvo ningún resultado significativo en las comparaciones caso-
control. Con respecto al análisis de regresión con variables cuantitativas, se detectó una 
asociación entre este polimorfismo y diferentes ítems de la escala PANSS (tabla C6): tres ítems 
Generales del componente Depresivo (Kay y Sevy, 1990): Preocupación, Sentimientos de Culpa 
y Ansiedad; un ítem negativo (Fluidez de la Conversación); y dos ítems positivos 
(Suspicacia/Perjuicio y Hostilidad). En todos los casos, los pacientes homozigotos para alelos 
cortos (S/S) puntuaban más alto. A la luz de estos resultados, es muy probable que este 
polimorfismo funcional tenga un efecto en la severidad de los síntomas de la esquizofrenia. 
Nuestros resultados son además coherentes con otros trabajos previos, como el trabajo de 
Reif y colaboradores (2006), en el que encontraron que el genotipo S/S se asociaba con 
mayores puntuaciones en la subescala positiva de la PANSS y en la escala de depresión de 
Hamilton. Sin embargo, a pesar de que nuestros resultados son bastante sugerentes, deben 
ser considerados con cautela, debido al reducido tamaño muestral (N = 102) y al hecho de que 
no se encontró asociación con aquellas escalas donde el número de pacientes evaluados fue 
mayor, como la BPRS o la KGV. Sería además de gran interés estudiar otros polimorfismos 
adicionales localizados en este gen.  
 
Tabla C6. Asociaciones significativas del polimorfismo del gen NOS1 con diferentes ítems de la PANSS. 
Polimorfismo 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia 
 (95% IC) 
Modelo P BIC 
PANSS General  
NOS1 Ex1f-VNTR 
L/L - S/L : 78 30.14 (1.04) 0.00 
Recesivo 0.048 750.7 
S/S : 24 34.38 (1.74) 4.23 (0.09 - 8.38) 
PANSS G2 - Ansiedad 
NOS1 Ex1f-VNTR 
L/L - S/L : 78 2.55 (0.15) 0.00 
Recesivo 0.044 353.4 
S/S : 24 3.17 (0.26) 0.62 (0.02 - 1.21) 
PANSS G3 – Sentimientos de culpa 
NOS1 Ex1f-VNTR 
L/L - S/L : 78 1.54 (0.11) 0.00 
Recesivo 0.0012 325.9 
S/S : 24 2.42 (0.32) 0.88 (0.36 - 1.39) 
PANSS G15 - Preocupación 
NOS1 Ex1f-VNTR 
L/L : 35 2.2 (0.2) 
0.46 (0.11 - 0.82)
a
 Aditivo 0.012 365.5 S/L : 43 2.67 (0.23) 
S/S : 24 3.12 (0.28) 
PANSS N6 – Falta de espontaneidad y fluidez de la conversación 
NOS1 Ex1f-VNTR 
L/L : 35 2.09 (0.23) 0.00 
Dominante 0.032 309.8 
S/L - S/S : 67 1.61 (0.1) -0.47 (-0.90 - -0.05) 
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Tabla C6 (continuación). Asociaciones significativas del polimorfismo del gen NOS1 con diferentes ítems 
de la PANSS. 
Polimorfismo 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia 
 (95% IC) 
Modelo P BIC 
PANSS P6 – Suspicacia / Persecución 
NOS1 Ex1f-VNTR 
L/L - S/L : 78 2.08 (0.15) 0.00 
Recesivo 0.0018 378.4 
S/S : 24 3.17 (0.37) 1.09 (0.42 - 1.76) 
PANSS P7 - Hostilidad 
NOS1 Ex1f-VNTR 
L/L : 35 1.51 (0.16) 
0.30 (0.03 - 0.56)
a
 Aditivo 0.029 304.1 S/L : 43 1.7 (0.15) 
S/S : 24 2.12 (0.23) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado se corresponde con la diferencia que se le atribuye a cada alelo según un modelo aditivo. 
Abreviaturas: SE, error estándar; IC, intervalo de confianza. 
 
 
Gen STMN1 (Stathmin) 
 
Teniendo en cuenta los valores de desequilibrio de ligamiento de la región genómica donde se 
sitúa el gen STMN1, se seleccionaron dos tag SNPs (rs182455 y rs12037513), que fueron 
genotipados en la muestra española.  
 
El resultado más interesante del estudio de asociación caso-control es la asociación entre el 
SPN rs182455 (localizado en la supuesta región 5’ reguladora del gen) y el riesgo de 
esquizofrenia (tabla C7) y esquizofrenia con alucinaciones (datos no mostrados). De acuerdo a 
la información presentada, los individuos homozigotos T/T eran menos frecuentes en el grupo 
de pacientes diagnosticados con esquizofrenia (según los criterios del DSM-IV) que en el grupo 
control. Sin embargo, estas asociaciones no resistieron la corrección de Bonferroni secuencial 
(Rice, 1989). Estudios en otras muestras caso-control serían necesarios para confirmar 
nuestros resultados. 
 
 
Tabla C7. Comparación de las distribuciones genotípicas de los polimorfismos del gen STMN1 en 
pacientes esquizofrénicos y controles de la muestra española.  
SNP Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes SCZ 
OR (95% IC) P 
b
 AIC Modelo 
rs12037513 
T/T 149 (47.5%) 107 (52.2%) 
0.86 (0.65-1.13)
a
 
0.28 
(0.28) 
699.3 Aditivo T/C 136 (43.3%) 82 (40%) 
C/C 29 (9.2%) 16 (7.8%) 
rs182455 
C/C - T/C 285 (77.5%) 185 (84.9%) 1.00 0.027 
(0.54) 
772.7 Recesivo 
T/T 83 (22.6%) 33 (15.1%) 0.61 (0.39-0.95) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado se corresponde con la diferencia que se le atribuye a cada alelo según un modelo aditivo. 
b. El valor de P corregido se indica entre paréntesis. 
Abbreviations: SCZ, esquizofrenia; OR, Odds Ratio; IC, intervalo de confianza. 
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Asimismo, el SNP rs182455 se ha asociado con diferentes parámetros que evalúan los 
síntomas negativos de la esquizofrenia (tabla C8): Afecto Aplanado e Incoherencia del 
Lenguaje (escala KGV); Evitación Social Activa y Fluidez de la Conversación (PANSS); y 
finalmente, la puntuación negativa total de la PANSS. En todos los casos, el genotipo C/C se 
correlacionaba con mayores puntuaciones en los ítems enumerados. Asimismo, este mismo 
SNP se asoció con el ítem positivo de la PANSS Suspicacia/Persecución, resistiendo la 
corrección de Bonferroni Secuencial. Con respecto a la escala PSYRATS de alucinaciones 
auditivas, el SNP rs182455 se asoció ligeramente (sin resistir la corrección para comparaciones 
múltiples) con dos parámetros: Creencias sobre el Origen de las Voces e Intensidad de la 
Ansiedad.   
 
Con respecto al otro SNP, rs12037513, también se ha asociado con ciertos parámetros de la 
escala PANSS (tabla C8): Preocupación Somática (un ítem relacionado con la depresión) y 
Afecto Aplanado, de la subescala negativa.  
 
Todos nuestros hallazgos sugieren que pequeñas variaciones en el gen STMN1 pueden estar 
implicadas en la severidad de los síntomas negativos. Sin embargo, por el momento se 
desconoce si los dos polimorfismos analizados (u otros en alto desequilibrio de ligamiento con 
éstos) tienen alguna implicación funcional. Además, las asociaciones con parámetros 
emocionales también indican que este gen podría tener también un papel importante en la 
disfunción emocional que sufren los pacientes esquizofrénicos, así como en la respuesta 
emocional a las alucinaciones auditivas. 
 
Tabla C8. Resultados significativos del análisis de asociación entre los polimorfismos del gen STMN1 y 
diferentes escalas clínicas.  
SNP 
Distribución 
genotípica  
Puntuación 
media (SE) 
Diferencia (95% CI) Modelo P 
a
 BIC 
KGV -  Afecto aplanado 
rs182455 
C/C - T/C : 222 1.29 (0.07) 0.00 
Recesivo 
0.038 
(0.076) 
813.1 
T/T : 45 0.93 (0.15) -0.37 (-0.71 - -0.02) 
KGV – Incoherencia del lenguaje 
rs182455 
C/C : 85 0.87 (0.13) 0.00 
Dominante 
0.027 
(0.054) 
799.6 
T/C - T/T : 182 0.57 (0.07) -0.31 (-0.58 - -0.04) 
PANSS G1 – Preocupación somática 
rs12037513 
T/T : 63 1.49 (0.12) 0.00 
Dominante 
0.029 
(0.058) 
345.8 
T/C - C/C : 45 1.98 (0.19) 0.48 (0.06 - 0.91) 
PANSS G16 – Evitación social activa 
rs182455 
C/C - T/C : 106 1.96 (0.15) 0.00 
Recesivo 
0.027 
(0.054) 
471.4 
T/T : 23 1.26 (0.16) -0.73 (-1.36 - -0.09) 
PANSS Negativa 
rs182455 
C/C - T/C : 106 15.57 (0.61) 0.00 
Recesivo 0.05 (0.1) 840.7 
T/T : 23 12.96 (0.94) -2.70 (-5.36 - -0.03) 
PANSS N1 – Afecto aplanado 
rs12037513 
T/T : 63 2.43 (0.16) 0.00 
Dominante 
0.015 
(0.03) 
352 
T/C - C/C : 45 1.91 (0.15) -0.55 (-0.99 - -0.11) 
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Tabla C8 (continuación). Resultados significativos del análisis de asociación entre los polimorfismos del 
gen STMN1 y diferentes escalas clínicas.  
SNP 
Distribución 
genotípica  
Puntuación 
media (SE) 
Diferencia (95% CI) Modelo P 
a
 BIC 
PANSS N6 – Falta de espontaneidad y fluidez en la conversación 
rs182455 
C/C - T/C : 106 1.83 (0.11) 0.00 
Recesivo 
0.029 
(0.058) 
395.7 
T/T : 23 1.3 (0.12) -0.54 (-1.01 - -0.06) 
PANSS P3 – Comportamiento alucinatorio 
rs12037513 
T/T - T/C : 106 2.32 (0.2) 0.00 
Recesivo 
0.023 
(0.046) 
480.7 
C/C : 2 6 (0) 3.45 (0.52 - 6.38) 
PANSS P6 - Suspicacia / Persecución 
rs182455 
C/C : 38 1.76 (0.17) 0.00 
Codominante 
0.0013 
(0.0026) 
465.6 T/C : 68 2.68 (0.19) 0.91 (0.37 - 1.45) 
T/T : 23 1.83 (0.32) 0.03 (-0.68 - 0.73) 
PSYRATS AA – Creencias sobre el origen 
rs182455 
C/C : 70 1.43 (0.2) 0.00 
Dominante 
0.041 
(0.082) 
832 
T/C - T/T : 138 1.94 (0.15) 0.52 (0.02 - 1.01) 
PSYRATS AH – Intensidad de la ansiedad 
rs182455 
C/C : 70 1.07 (0.17) 0.00 
Dominante 
0.044 
(0.088) 
793.6 
T/C - T/T : 138 1.54 (0.14) 0.46 (0.02 - 0.91) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: SE, error stándar; IC, Intervalo de confianza; AA, alucinaciones auditivas. 
 
 
Se sabe que el gen STMN1 se expresa en la amígdala basolateral, así como en otras estructuras 
talámicas y corticales también asociadas con el procesado de estímulos condicionales e 
incondicionales (Shumyatsky et al., 2005).  Además, la inactivación de la expresión de este gen 
en el ratón altera patrones de comportamiento relacionados con el miedo y la evaluación de 
situaciones amenazadoras (Shumyatsky et al., 2005), lo que a su vez repercute en 
determinados comportamientos sociales, como el cuidado de las crías y las interacciones 
sociales (Martel et al., 2008). Puesto que la esquizofrenia es una enfermedad que afecta la 
emocionalidad y las interacciones sociales del individuo, podemos hipotetizar que este gen 
tienen un papel importante en la etiopatogénesis de la enfermedad. Sin embargo, serían 
necesarios estudios complementarios para corroborar esta hipótesis.  
 
 
Efecto de las interacciones gen x gen en el procesado emocional 
 
El término epistasia hace referencia a la interacción no aditiva entre diferentes loci que afecta 
a un determinado fenotipo. Como resultado de nuestros propios hallazgos, así como por 
estudios previos que relacionaban ciertos genes con desórdenes emocionales, se investigaron 
en este trabajo el efecto de las epistasias gen x gen en diferentes ítems emocionales. Para este 
fin, seleccionamos una serie de polimorfismos localizados en genes implicados en el procesado 
de emociones: 5-HTTLPR (gen SLC6A4), rs6313 (gen HTR2A), rs4570625 (gen TPH2), ex1f VNTR 
(gen NOS1) y rs182455 (gen STMN1). Posteriormente, se estudió el posible efecto de 
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interacciones entre estos polimorfismos sobre diferentes variables de tipo emocional. Como se 
esperaba, se encontraron algunas interacciones significativas (tabla C9): 
 Se encontró un efecto de la interacción SLC6A4xHTR2 sobre las variables Intensidad de la 
Ansiedad, Frecuencia de la Ansiedad y Repercusión (escala PSYRATS de alucinaciones 
auditivas), así como sobre los ítems “Ansiedad” de las escalas BPRS y KGV. 
 La interacción TPH2xHTR2A afectó a su vez a los siguientes parámetros: Repercusión y 
Frecuencia de la Ansiedad (subescala PSYRATS de delirios) y el ítem Depresión de la PANSS. 
 
Entre estos hallazgos, los más significativos son el efecto de la interacción SLC6A4 x HTR2A 
sobre la intensidad y la frecuencia de la ansiedad frente a las voces, ya que resistieron la 
corrección de Bonferroni secuencial. Sin embargo, no se encontró ninguna interacción 
significativa que implicara a los genes STMN1 y NOS1.   
 
De acuerdo con nuestros resultados, es probable que haya múltiples polimorfismos genéticos 
que estén actuando en la misma dirección o en direcciones opuestas, llevando a cabo el 
modelado de ciertos fenotipos asociados a comportamientos afectivos. Además, hay un 
importante número de evidencias previas que sugieren que esto es realmente así. Por 
ejemplo,  se han descrito interacciones entre los genes SLC6A4, COMT y DRD4 que influyen 
sobre el rasgo de personalidad Búsqueda de Novedad  (Benjamin et al., 2000; Strobel et al., 
2003), así como interacciones entre los genes SLC6A4 y TPH2 que modulan la respuesta a 
estímulos visuales emocionales (Herrmann et al., 2007). Asimismo, se ha descrito un efecto 
aditivo de los genes COMT y SLC6A4 sobre la activación de áreas límbicas en respuesta a 
estímulos negativos emocionales (Smolka et al., 2007). También hay resultados en modelos de 
ratón que apoyan la existencia de relaciones epistáticas entre diferentes genes del sistema 
serotoninérgico (Murphy et al., 2008). 
 
Tabla C9. Resultados significativos del análisis de interacción entre diferentes polimorfismos relacionados 
con el procesado emocional.  
Polimorfismo 1  Polimorfismo 2  Variable de estudio OR o β
a
 Stadístico P
b
 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) PSYRATS AA – Intensidad Ansiedad 0.6877 9.921 
0.001634 
(0.0098) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) PSYRATS AA –Frecuencia Ansiedad 0.6726 9.058 
0.002616 
(0.0156) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) PSYRATS AA - Repercusión 0.4607 4.94 
0.02625 
(0.1575) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) BPRS - Ansiedad 0.4756 4.184 
0.0408 
(0.2448) 
rs6313 (HTR2A) 5-HTTLPR (SLC6A4) KGV - Ansiedad 0.2709 4.127 
0.04221 
(0.2533) 
rs4570625 (TPH2) rs6313 (HTR2A) PSYRATS delirios - Repercusión 0.6679 5.62 
0.01775 
(0.1065) 
rs4570625 (TPH2) rs6313 (HTR2A) 
PSYRATS delirios – Frecuencia 
ansiedad 
0.6692 5.462 
0.01944 
(0.1166) 
rs4570625 (TPH2) rs6313 (HTR2A) PANSS G6 - Depresión 0.6451 3.86 
0.04945 
(0.2967) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. Este valor se refiere a los valores β que dan una idea sobre la magnitud de cada epistasia gen x gen sobre una 
determinada variable cuantitativa.  
b. El valor de P corregido se indica entre paréntesis. 
Abbreviatura: OR, Odds ratio. 
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El efecto de un gen de selección positiva, el ASPM, sobre la esquizofrenia y el deterioro 
cognitivo. 
 
Como una parte importante del presente estudio, se ha llevado a cabo el análisis del impacto 
de la variación en el gen ASPM sobre el riesgo de padecer esquizofrenia. Asimismo, también se 
abordó el estudio de la influencia de este gen sobre ciertos fenotipos relacionados con la 
cognición y la estructura cerebral, los cuales se sabe que están alterados en pacientes 
esquizofrénicos y sus hermanos sanos (Cannon et al., 1998; Kremen et al., 1994; Egan et al 
2001). Con este propósito, se estudiaron 8 SNPs en la muestra española y 6 SNPs en la muestra 
americana (5 de ellos comunes a ambas muestras: rs3762271, rs12138336, rs41310927, 
rs10922163 y rs6677082). Los resultados obtenidos son bastante coherentes. 
 
Con respecto a la muestra española, dos SNPs en alto desequilibrio de ligamiento entre ellos 
(rs6700180 y rs10922163) se asociaron con el riesgo de psicosis (tabla C10) y psicosis con 
alucinaciones auditivas (datos no mostrados). Los resultados permanecieron significativos tras 
aplicar la corrección de Bonferroni secuencial. Además, se detectaron varios haplotipos 
protectores que también incluían el SNP rs10922163 (datos no mostrados).  
 
Además, varios SNPs se asociaron con diferentes variables, como la edad de inicio de la 
enfermedad, y diferentes parámetros de las escalas BPRS, PANSS y PSYRATS. Además, como se 
observa en la tabla C11, el gran número de asociaciones con síntomas negativos sugiere que el 
gen ASPM podría estar implicado en la patofisiología de la dimensión negativa de la 
esquizofrenia. Sin embargo, tampoco se puede olvidar el hecho de que los polimorfismos 
rs6700189 y 10922163 están fuera del equilibrio de Hardy-Weinberg en la muestra de sujetos 
control. Aunque esta desviación es sutil, podría indicar un error de genotipado (poco probable 
en este caso) o bien podría ser consecuencia de factores que escapan de nuestro control, 
como la existencia de procesos de selección. En este sentido, hay evidencias que sugieren que  
el gen ASPM está en la actualidad bajo un proceso de selección positiva (Mekel-Bobrov et al., 
2005).   
 
Tabla C10. Comparación de las frecuencias genotípicas de los polimorfismos del gen ASPM entre 
pacientes psicóticos y controles sanos de la muestra española.  
Marcador Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
OR (95% IC) P 
b
 AIC Modelo 
rs6700180 
C/C 102 (32%) 62 (22.9%) 1.00 
0.0091 
(0.0637) 
810.6 Codominante T/C 139 (43.6%) 151 (55.7%) 1.79 (1.21-2.64) 
T/T 78 (24.4%) 58 (21.4%) 1.22 (0.77-1.95) 
rs3762271 
C/C - A/C 275 (80.7%) 253 (84.9%) 1.00 0.16 
(0.84) 
884.9 Recesivo 
A/A 66 (19.4%) 45 (15.1%) 0.74 (0.49-1.12) 
rs12138336 
G/G 298 (87.4%) 248 (83.2%) 1.00 0.14 
(0.84) 
884.7 Dominante 
C/G - C/C 43 (12.6%) 50 (16.8%) 1.40 (0.90-2.17) 
rs41310927 
A/A - A/G 302 (81.8%) 253 (84.9%) 1.00 
0.29 (1) 920 Recesivo 
G/G 67 (18.2%) 45 (15.1%) 0.80 (0.53-1.21) 
rs10922163 
A/A 104 (33%) 61 (22.7%) 1.00 
0.005 
(0.04) 
801.4 Codominante G/A 137 (43.5%) 151 (56.1%) 1.88 (1.27-2.78) 
G/G 74 (23.5%) 57 (21.2%) 1.31 (0.82-2.10) 
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Tabla C10 (continuación). Comparación de las frecuencias genotípicas de los polimorfismos del gen 
ASPM entre pacientes psicóticos y controles sanos de la muestra española.  
Marcador Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
OR (95% IC) P 
b
 AIC Modelo 
rs4915337 
A/A 277 (81.2%) 235 (78.9%) 
1.15 (0.79-1.67)
a
 0.46 (1) 886.4 Aditivo A/T 62 (18.2%) 61 (20.5%) 
T/T 2 (0.6%) 2 (0.7%) 
A/A 277 (81.2%) 235 (78.9%) 1.00 
0.45 (1) 886.4 Dominante 
A/T - T/T 64 (18.8%) 63 (21.1%) 1.16 (0.79-1.71) 
rs6677082 
T/T 248 (78.7%) 214 (79.5%) 
0.96 (0.65-1.41)
a
 0.82 (1) 809.9 Aditivo T/C 66 (20.9%) 54 (20.1%) 
C/C 1 (0.3%) 1 (0.4%) 
T/T 248 (78.7%) 214 (79.5%) 1.00 
0.81 (1) 809.9 Dominante 
T/C - C/C 67 (21.3%) 55 (20.5%) 0.95 (0.64-1.42) 
rs9726778 
G/G 269 (78.9%) 229 (76.8%) 
1.14 (0.80-1.62)
a
 0.48 (1) 886.4 Aditivo C/G 70 (20.5%) 66 (22.1%) 
C/C 2 (0.6%) 3 (1%) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado se corresponde con la diferencia que se le atribuye a cada alelo según un modelo aditivo. 
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, intervalo de confianza. 
 
Tabla C11. Resultados significativos del estudio de asociación entre los SNPs del gen ASPM y diferentes 
parámetros clínicos que evalúan los síntomas negativos.  
Polimorfismo 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia (95% IC) Modelo P 
a
 BIC 
KGV – Afecto aplanado 
rs6700180 
C/C - T/C : 
189 
1.38 (0.08) 0.00 
Recessive 
0.031 
(0.248) 
739.2 
T/T : 51 1.04 (0.14) -0.38 (-0.71 - -0.04) 
rs10922163 
A/A - G/A : 
189 
1.36 (0.08) 0.00 
Recessive 
0.049 
(0.343) 
721.3 
G/G : 50 1.04 (0.14) -0.34 (-0.68 - -0.00) 
PANSS Negativa 
rs3762271 
C/C : 49 13.84 (0.73) 
1.63 (0.16 - 3.09)
a
 Additive 
0.031 
(0.217) 
839.9 A/C : 60 15.58 (0.81) 
A/A : 20 16.75 (1.59) 
rs41310927 
A/A : 49 13.69 (0.74) 
1.77 (0.31 - 3.22)
a
 Additive 
0.019 
(0.152) 
839 A/G : 60 15.58 (0.81) 
G/G : 20 17.1 (1.54) 
PANSS N1 – Afecto aplanado 
rs6700180 
C/C - T/C: 87 2.36 (0.13) 0.00 
Recessive 
0.0053 
(0.0424) 
354.6 
T/T : 23 1.7 (0.16) -0.76 (-1.28 - -0.24) 
rs41310927 
A/A : 49 1.88 (0.14) 
0.32 (0.04 - 0.59)
a
 Additive 
0.026 
(0.156) 
410.1 A/G : 60 2.28 (0.15) 
G/G : 20 2.45 (0.31) 
rs10922163 
A/A - G/A:84 2.37 (0.14) 0.00 
Recessive 
0.007 
(0.049) 
350.6 
G/G : 24 1.67 (0.16) -0.73 (-1.24 - -0.21) 
Los  valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado se corresponde con la diferencia que se le atribuye a cada alelo según un modelo aditivo. 
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, intervalo de confianza. 
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Con respecto a la muestra Americana, el alelo T del SNP rs677082 se asoció con la 
esquizofrenia tanto en el estudio caso-control (tabla C12) como en el basado en familias (tabla 
C13). Además, los portadores del alelo G del SNP rs10922163 eran más frecuentes en la 
muestra de afectados que en la de controles (tabla C12), y también se observó una tendencia a 
un exceso de transmisión de ese mismo alelo de los padres a los hijos afectados (tabla C13). 
También se encontraron dos haplotipos de riesgo que incluían los polimorfismos rs6677082 y 
rs10922163 (datos no mostrados). Por último, el SNP rs12116571 se asoció también con la 
esquizofrenia mediante la aproximación caso-control (tabla C12), aunque este dato hay que 
considerarlo con cautela, puesto que este SNP no estaba en equilibrio de Hardy-Weinberg en 
la muestra de afectados. Este dato podría estar sugiriendo que la falta de equilibrio es una 
manifestación de la asociación de este SNP con la enfermedad. 
 
Tabla C12. Análisis de asociación caso-control de los SNPs del gen ASPM en la muestra Americana.  
SNP Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
P test exacto 
de Fisher
a,b
 
OR (95% IC) 
P Regresión 
logística
b
 
rs3762271 
C/C 149 (34.57%) 151 (37.94%) 
0.580 (1) 
0.927  
(0.672-1.279)
c
 
0.646 (1)
c
 
C/A 209 (48.49%) 185 (46.48%) 
0.831  
(0.541 - 1.279)
d
 
0.401 (0.813)
d
 
A/A 73 (16.94%) 62 (15.58%) 
rs12138336 
G/G 371 (86.08%) 324 (83.08%) 
0.417 (1) 
1.263  
(0.838 - 1.901)
c
 
0.264 (1)
c
 
C/G 58 (13.46%) 65 (16.67%) 
0.659  
(0.0386-11.254)
d
 
0.774 (0.813)
d
 
C/C 2 (0.46%) 1 (0.26%) 
rs41310927 
A/A 143 (33.18%) 148 (37.47%) 
0.397 (1) 
0.910  
(0.659 - 1.257)
c
 
0.568 (1)
c
 
A/G 211 (48.96%) 185 (46.84%) 
0.786 
 (0.512 - 1.206)
d
 
0.271 (0.813)
d
 
G/G 77 (17.87%) 62 (15.70%) 
rs10922163 
A/A 119 (27.74%) 89 (21.92%) 
0.135 (0.54) 
1.441  
(1.012 - 2.049)
c
 
0.042 (0.21)
c
 
A/G 218 (50.82%) 217 (53.45%) 
1.481  
(0.975 - 2.248)
d
 
0.065 (0.325)
d
 
G/G 92 (21.45%) 100 (24.63) 
rs12116571 
G/G 321 (75.65%) 320 (81.42%) 
0.001 (0.006) 
0.604  
(0.416 - 0.877)
c
 
0.008 (0.048)
c
 
G/A 105 (24.42%) 61 (15.52%) 
2.508  
(0.769 - 8.179)
d
 
0.127 (0.508)
d
 
A/A 4 (0.93%) 12 (3.05%) 
rs6677082 
T/T 353 (80.78%) 329 (83.29%) 
0.03 (0.15) 
0.829  
(0.536 - 1.22)
c
 
0.344 (1)
c
 T/C 77 (17.62%) 66 (16.71%) 
C/C 7 (1.60%) 0 (0.00%) 
Los  valores de P significativos (P < 0.05) se indican en negrita. 
a. Este test compara las frecuencias genotípicas de pacientes y controles asumiendo un modelo codominante.  
b. El valor de P corregido se indica entre paréntesis. 
c. Resultado obtenido cuando los homozigotos para el alelo más frecuente se comparan con los heterozigotos.  
d. Resultado obtenido cuando los homozigotos para el alelo más frecuente se comparan con los homozigotos para el 
alelo menor.  
Abreviaturas: OR, Odds Ratio. 
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Tabla C13. Resultados del gen ASPM para el test de desequilibrio de transmisión basado en familias.  
Polimorfismo 
Alelo 
transmitido en 
exceso 
Nº de 
familias
a
 
Estadístico
b
 
Estadístico 
esperado
c
 
Z  P
d
 
rs3762271 C 144 179.000 170.281 1.206 0.21 (0.8) 
rs12138336 C 64 37.000 34.000 0.688 0.53 (1) 
rs41310927 A 150 187.000 176.348 1.444 0.20 (0.8) 
rs10922163 C 157 173.000 157.898 2.017 0.071 (0.355) 
rs12116571 G 76 108.000 106.550 0.280 0.75 (1) 
rs6677082 A 71 118.000 108.667 2.132 0.038 (0.228) 
Los  valores de P significativos (P < 0.05) se indican en negrita. 
a. Número de familias informativas.  
b. Estadístico del test proporcionado por el programa FBAT para el número observado de alelos transmitidos. 
c. Valor esperado del estadístico si se cumple la hipótesis nula de no asociación. 
d. El valor de P corregido se indica entre paréntesis. 
 
 
Hay algunas coincidencias especialmente alentadoras entre la muestra española y la 
americana, ya que en ambos casos el SNP rs10922163 se ha asociado con la enfermedad; 
además, en ambos casos es el alelo G el más frecuente en el grupo afectado. Esta asociación 
también se detectó al realizar un análisis de asociación caso-control usando una muestra en la 
que se combinaron los sujetos españoles y americanos (datos no mostrados). Sin embargo 
también hay datos no coincidentes. Como se ha comentado anteriormente, la falta de 
replicación estricta es algo habitual en los estudios de asociación, en contraposición a otras 
enfermedades como la diabetes tipo 2 (Florez et al., 2005) o la degeneración macular asociada 
a la edad (Edwards et al., 2005; Haines et al., 2005; Hageman et al., 2005). Este hecho podría 
tener diversas explicaciones, como la posibilidad de falsos positivos, o diferencias en la 
estructura genética de diferentes poblaciones o subpoblaciones que podrían a su vez 
influenciar cuáles son los alelos y haplotipos de riesgo en cada una de estas poblaciones.  
 
Sin embargo, ya ha sido anteriormente comentado que la asociación con fenotipos de tipo 
clínico puede ser poco potente para identificar los genes causantes de enfermedades 
complejas como la esquizofrenia, debido al pequeño efecto que se le presupone a cada gen 
(Risch, 1990; Riley y Mc Guffin, 2000; Weiss y Terwilliger, 2000). Por este motivo, 
consideramos interesante estudiar el efecto de la variación en el gen ASPM sobre otros 
fenotipos intermediarios relacionados con la cognición, usando para ello la información 
disponible en la muestra americana de la Clinical Brain Disorders Branch. Con este enfoque, 
encontramos que 3 SNPs (rs3762271, rs12138336 y rs41310927) influenciaban las 
puntuaciones de diferentes medidas cognitivas directamente relacionadas con la memoria de 
trabajo (tabla C14): Wisconsin Card Sorting Test (WCST) y N Back en controles, y Repetición de 
Números (Digit Span) en pacientes. Los tres SNPs asociados con parámetros cognitivos están 
situados en el exón 18, que codifica para gran parte del dominio IQ, una de las regiones más 
importantes de la proteína y que además ha sufrido la mayor tasa de evolución (Kouprina et 
al., 2004), por lo que se ha especulado sobre su posible papel durante la división celular en el 
desarrollo del Sistema Nervioso Central (Kouprina et al., 2005). Además, rs3762271 y 
rs41310927 (ambos en casi completo desequilibrio de ligamiento) han estado sujetos a un 
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reciente proceso de selección positiva (Mekel-Bobrov et al., 2005), lo que sugiere que estos 
dos cambios podrían tener implicaciones funcionales que explicarían nuestros resultados. 
 
 
Tabla C14. Efecto de tres SNPs del gen ASPM en diferentes medidas cognitivas.  
Polimorfismo Contraste Coef. regresión  P
a
 Submuestra 
N Back 
rs12138336 C/C vs C/A -1.748 0.011 (0.066) Controles 
WCST 
rs3762271 C/C vs C/A -1.609 0.017 (0.085) Controles 
rs41310927 A/A vs A/G -1.834 0.008 (0.048) Controles 
Repetición de números (Digit Span) 
rs12138336 G/G vs G/A -1.616 0.023 (0.138) Pacientes 
Los  valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: WCST, Wisconsin Card Sorting Test; Coef, coeficiente del análisis de regresión lineal; vs, versus. 
 
Asimismo, se evaluó el efecto de diferentes polimorfismos del gen ASPM sobre el volumen 
cerebral y sobre la activación de ciertas áreas cerebrales durante la realización de la tarea N 
Back.  En este caso, pudimos asociar 3 SNPs con cambios en el volumen de los ganglios basales, 
el córtex prefrontal y el córtex cingulado subgenual en controles, mientras que los pacientes 
presentaban diferencias según el genotipo en el córtex prefrontal y el cerebelo (en las figuras 
C4 y C5 se muestran los resultados para el SNP rs3762261). Además el estudio de resonancia 
magnética funcional permitió detectar que el SNP rs10922163 tenía un efecto sobre la 
activación del córtex anterior cingulado en controles, durante la realización de la tarea N Back 
(figura C6).  
 
 
 
 
 
 
 
 
 
 
Figura C4. Correlación entre los datos estructurales de morfometría basada en vóxels (VBM) y el 
SNP rs3762271 en sujetos sanos. Los portadores del alelo A mostraban (a) un volumen reducido en 
el córtex prefrontal (área de Brodmann 9) comparados con los homozigotos C/C, así como (b)  un 
incremento de volumen en el córtex cingulado subgenual (área de Brodmann 25). 
Umbral del mapa: P < 0.001 no corregido.  
C/C > C/A + A/A  
 
C/C < C/A + A/A  
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Estos resultados son muy interesantes. Se sabe que el córtex prefrontal, y especialmente el 
área dorsolateral, está conectado con diferentes áreas corticales y subcorticales, incluyendo el 
estriado (caudado y putamen) (Alexander et al., 1986). Esta red es crucial para el buen 
funcionamiento de la función cognitiva, especialmente de la memoria de trabajo (Alexander et 
al., 1986; Dunnett et al., 2005). Además se ha visto también que el córtex cingulado, que está 
profusamente conectado con el córtex prefrontal, también juega un papel clave en numerosas 
funciones cerebrales, entre ellas la memoria de trabajo (Callicott et al., 1999; Paus, 2001). Por 
último, no se debe olvidar que se ha postulado que un elemento clave en la fisiopatogenia de 
la esquizofrenia es la disfunción del córtex prefrontal dorsolateral (Weinberger et al., 2001). 
Figura C5. Correlación entre los datos estructurales de morfometría basada en vóxels (VBM) y el 
SNP rs3762271 en pacientes esquizofrénicos. Los portadores del alelo A mostraban (a) un volumen 
reducido en el córtex prefrontal (área de Brodmann 9) comparados con los homozigotos C/C, así 
como (b)  un incremento de volumen en el cerebelo. 
Umbral del mapa: P < 0.001 no corregido.  
C/C > C/A + A/A  
 
C/C < C/A + A/A  
 
Figura C6. Efectos del SNP 
rs10922163 del gen ASPM 
sobre las respuestas 
fisiológicas cerebrales en 
sujetos sanos. 
Se observa una mayor 
activación en el córtex 
anterior cingulado izquierdo 
(medido mediante 
resonancia magnética 
funcional – BOLD) en los 
sujetos homozigotos A/A 
durante la realización de la 
tarea N Back, que evalúa la 
memoria de trabajo. 
 
 
A/A > A/G > G/G 
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Nuestros resultados apoyan la correlación entre variaciones sutiles del gen ASPM y 
alteraciones morfológicas y funcionales en aquellas áreas directamente relacionadas con la 
memoria de trabajo, tanto en sujetos sanos como en pacientes esquizofrénicos. Además, el 
efecto de este gen sobre el volumen del cerebelo de los pacientes esquizofrénicos sería 
coherente con las hipótesis de algunos autores, los cuales han postulado el papel importante 
del cerebelo en el fenotipo observado en los pacientes esquizofrénicos (Andreasen et al., 
1998). En resumen, nuestros resultados sugieren un efecto del gen ASPM sobre la 
vulnerabilidad a padecer esquizofrenia. Además los datos de neuroimagen podrían indicar que 
este gen tiene un papel en el desarrollo de estructuras corticales, subcorticales y cerebelares. 
Asimismo, las diferencias observadas entre pacientes y controles sugieren la existencia de 
otros factores de susceptibilidad genéticos o ambientales que estarían modulando la 
manifestación del fenotipo patológico en los pacientes. 
Gen PDE4D  
El gen PDE4D se presenta como un interesante candidato en genética psiquiátrica. En primer 
lugar, se sabe que interacciona con DISC1, otra proteína fuertemente relacionada con la 
fisiopatología de la esquizofrenia (Murdoch et al., 2007). Además, todas las proteínas de la 
familia PDE4 pueden ser inhibidas por rolipram, una sustancia con propiedades antidepresivas. 
Finalmente, la isoforma más pequeña codificada por el gen PDE4D (PDE4D6, de acuerdo a la 
nomenclatura de Wang et al., 2003) ha sido asociada con una condición psiquiátrica, el 
Trastorno por Déficit de Atención e Hiperactividad (TDAH) en un estudio de búsqueda de 
variaciones en el número de copias dirigido por el profesor K.P. Lesch en la Universidad de 
Würzburg (Alemania).  Todos estos hallazgos nos llevaron a estudiar el efecto de la variación 
del gen PDE4D sobre el riesgo de esquizofrenia. Para ello, nos centramos en la región del gen 
que codifica para la isoforma PDE4D6. Se usaron dos muestras caso-control, la muestra de 
Valencia (España) y la muestra de Alemania. Asimismo, se analizaron 9 SNPs en la muestra 
española y diez marcadores en los individuos de origen alemán (los 10 SNPs de la muestra 
española más un décimo SNP, rs10056492).  
Los resultados procedentes de los estudios de asociación caso-control son principalmente 
negativos. Con respecto a la muestra española, únicamente el SNP rs12656462 se asoció con la 
esquizofrenia diagnosticada según criterios DSM-IV (tablas C15 y C16), aunque al incluir en el 
análisis todos los pacientes psicóticos, el resultado dejaba de ser significativo (datos no 
mostrados).  
 
 
Tabla C15. Resultados significativos del análisis de asociación caso-control para comparar las frecuencias 
alélicas de los SNPs del gen PDE4D en pacientes esquizofrénicos y controles de la muestra española.  
Polimorfismo Alelo 
Frecuencia 
esquizofrénicos 
Frecuencia 
controles 
OR (95% IC) χ
2
 P
a
 
rs12656462 
T 0.918 0.9531 1 
4.477 
0.03285 
(0.309) A 0.08197 0.04687 1.815 (1.043 – 3.161) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, intervalos de confianza. 
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Tabla C16. Resultados significativos del análisis de asociación caso-control para comparar las frecuencias 
genotípicas de los SNPs del gen PDE4D en pacientes esquizofrénicos y controles de la muestra española.  
Polimorfismo Genotipo 
Frecuencia 
controles 
Frecuencia 
esquizofrénicos 
OR (95% IC) P 
a AIC Modelo 
rs12656462 
T/T 232 (90.6%) 153 (83.6%) 1.00 0.028 
(0.252) 
595.6 N/A 
A/T 24 (9.4%) 30 (16.4%) 1.90 (1.07-3.37) 
a. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, intervalos de confianza; N/A, no aplicable. 
 
 
Además, se detectaron tanto un haplotipo protector como un haplotipo de riesgo, ambos de 
dos marcadores, que diferían únicamente en el SNP rs12656462 (datos no mostrados). Sin 
embargo, todos los resultados significativos asociados con el SNP rs12656462 deben ser 
considerados con cautela puesto que la frecuencia de su alelo menor es bastante baja (0.047), 
por lo que el número de individuos homozigotos para ese alelo es especialmente bajo. Con 
respecto a los resultados obtenidos con la muestra de Alemania, los únicos resultados 
significativos fueron la asociación de 3 SNPs (rs10056492, rs4700316 y rs7714708) con el 
trastorno bipolar (tabla C17). Aunque la significación fue alta y resistió la corrección de 
Bonferroni secuencial, el número de individuos aquejados de este trastorno es demasiado 
bajo, por lo que sería conveniente realizar análisis adicionales en muestras de mayor tamaño. 
Además, puesto que el uso de muestras grandes es útil, se llevó a cabo un análisis de 
asociación con una muestra caso-control que combinaba a los controles y pacientes 
esquizofrénicos procedentes de Alemania y España. Sin embargo, los resultados fueron 
negativos (datos no mostrados), aunque este hecho podría estar relacionado con las 
diferencias en la estructura genética de las poblaciones española y alemana (Seldin et al., 
2006; Heath et al., 2008). El uso de muestras más grandes, homogéneas y no estratificadas 
sería útil para ayudar a entender el papel de PDE4D en la vulnerabilidad a las enfermedades 
psiquiátricas.  
 
Tabla C17. Comparación de las distribuciones genotípicas de los SNPs del gen PDE4D en pacientes con 
trastorno bipolar y sujetos control de la muestra alemana. 
SNP Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
bipolares 
OR (95% IC) P 
b
 AIC Modelo 
rs17291089 
A/A 466 (87.8%) 70 (82.3%) 1.00 
0.18 (1) 496.6 Dominante 
C/A-C/C 65 (12.2%) 15 (17.6%) 0.65 (0.35-1.20) 
rs829259 
T/T 184 (34.5%) 33 (37.9%) 1.00 
0.53 (1) 506.8 Dominante 
A/T - A/A 350 (65.5%) 54 (62.1%) 1.16 (0.73-1.86) 
rs17719378 
A/A 220 (41.2%) 37 (42%)  
0.79 (1) 511 Aditivo A/G 253 (47.4%) 42 (47.7%) 1.05 (0.74-1.48)
a
 
G/G 61 (11.4%) 9 (10.2%)  
rs10055954 
G/G 365 (68.3%) 64 (72.7%)  
0.32 (1) 510.1 Aditivo C/G 155 (29%) 23 (26.1%) 1.26 (0.79-1.99)
a
 
C/C 14 (2.6%) 1 (1.1%)  
 
 
296 Resumen en castellano 
 
 
Tabla C17 (continuación). Comparación de las distribuciones genotípicas de los SNPs del gen PDE4D en 
pacientes con trastorno bipolar y sujetos control de la muestra alemana. 
SNP Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
bipolares 
OR (95% IC) P 
b
 AIC Modelo 
rs10461656 
G/G 232 (43.5%) 46 (52.3%)  
0.12 
(0.840) 
508.6 Aditivo A/G 244 (45.7%) 35 (39.8%) 1.32 (0.93-1.89)
a
 
A/A 58 (10.9%) 7 (8%)  
rs7713345 
C/C 373 (69.8%) 63 (73.3%)  
0.38 (1) 502.5 Aditivo G/C 145 (27.1%) 22 (25.6%) 1.22 (0.77-1.94) 
G/C 16 (3%) 1 (1.2%)  
rs12656462 
T/T 442 (83.1%) 68 (77.3%) 1.00 
0.2 (1) 508.8 Dominante 
A/T - A/A 90 (16.9%) 20 (22.7%) 0.69 (0.40-1.20) 
rs10056492 
C/C 268 (75.3%) 80 (90.9%)  
0.0004 
(0.004) 
433.7 Aditivo C/T 83 (23.3%) 8 (9.1%) 3.23 (1.52-6.83)
a
 
T/T 5 (1.4%) 0 (0%)  
rs4700316 
C/C - C/G 339 (63.6%) 67 (76.1%) 1.00 0.019 
(0.152) 
505.3 Dominante 
G/G 194 (36.4%) 21 (23.9%) 1.83 (1.08-3.07) 
rs7714708 
C/C 211 (39.6%) 49 (55.7%) 1.00 0.0049 
(0.041) 
502.9 Dominante 
T/C - T/T 322 (60.4%) 39 (44.3%) 1.92 (1.22-3.02) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado corresponde a la diferencia que se le atribuye a cada alelo en el modelo aditivo.  
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, intervalos de confianza. 
  
Asimismo, además de estudiar el efecto de este gen sobre la vulnerabilidad a padecer algún 
tipo de psicosis, se analizó cómo este gen influía sobre diferentes variables clínicas. Como 
resultado de este estudio, se encontró que dos polimorfismos del gen PDE4D (rs17291089 y 
rs7713345) presentaban una distribución genotípica significativamente diferente dependiendo 
de la edad de inicio de la psicosis (datos no mostrados). Sin embargo, en este caso se debe 
volver a tener en cuenta que se contaba con una muestra de pacientes de inicio temprano muy 
reducida, por lo que el resultado, aunque sugerente, podría ser un falso positivo. Por otra 
parte, también es de especial interés el SNP rs17719378, ya que se ha relacionado con un 
número importante de variables clínicas (tabla C18).  
Un dato interesante es el hecho de que este SNP se ha asociado principalmente con síntomas 
positivos, sugiriendo un posible papel en la severidad de estos síntomas, especialmente 
delirios. Además, la asociación de este SNP con el ítem de Ansiedad de la escala BPRS es 
también alentador, debido a la existencia de evidencias previas que han asociado el gen PDE4D 
con depresión y neuroticismo (Henkel-Tigges y Davis, 1990; Shifman et al., 2008; Heck et al., 
2008). 
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Tabla C18. Resultados significativos del análisis de asociación entre el SNP rs17719378 (gen PDE4D) y 
algunos ítems de ciertas escalas clínicas.  
SNP 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia  
(95% IC) 
Modelo P
b
 BIC 
KGV – Incoherencia del lenguaje 
rs17719378 
A/A : 80 0.55 (0.1) 
0.30 (0.08 - 0.52)
a
 Aditivo 
0.0089 
(0.0712) 
589.2 A/G : 93 0.77 (0.12) 
G/G : 25 1.2 (0.26) 
BPRS - Ansiedad 
rs17719378 
A/A - A/G : 109 3.09 (0.14) 0.00 
Recesivo 
0.025 
(0.2) 
435.2 
G/G : 12 4.08 (0.36) 0.99 (0.13 - 1.85) 
PANSS total  
rs17719378 
A/A : 37 59.32 (2.9) 0.00 
Dominante 
0.034 
(0.272) 
676.8 
A/G - G/G : 42 67.26 (2.33) 7.94 (0.71 - 15.16) 
PANSS G11 – Atención pobre 
rs17719378 
A/A -A/G : 74 2.03 (0.13) 0.00 
Recesivo 
0.002 
(0.016) 
245.1 
G/G : 5 3.6 (0.24) 1.57 (0.61 - 2.54) 
PANSS Positiva 
rs17719378 
A/A : 37 13.49 (0.87) 0.00 
Codominante 
0.0057 
(0.0456) 
516.4 A/G : 37 17.38 (1.07) 3.89 (1.25 - 6.54) 
G/G : 5 11 (1.05) -2.49 (-7.90 - 2.93) 
PANSS P1 - Delirios 
rs17719378 
A/A : 37 2.03 (0.27) 0.00 
Codominante 
0.0046 
(0.0368) 
336.2 A/G : 37 3.3 (0.35) 1.27 (0.42 - 2.12) 
G/G : 5 1.2 (0.2) -0.83 (-2.56 - 0.91) 
PANSS P3 – Comportamiento alucinatorio 
rs17719378 
A/A : 37 2.16 (0.33) 0.00 
Codominante 
0.024 
(0.192) 
360.2 A/G : 37 3.27 (0.39) 1.11 (0.12 - 2.09) 
G/G : 5 1 (0) -1.16 (-3.18 - 0.85) 
PANSS P5 - Grandiosidad 
rs17719378 
A/A : 37 1.54 (0.2) 0.00 
Dominante 
0.026 
(0.208) 
304.3 
A/G - G/G : 42 2.33 (0.28) 0.79 (0.11 - 1.48) 
PSYRATS AA – Grado de control 
rs17719378 
A/A - A/G : 154 2.09 (0.14) 0.00 
Recesivo 
0.046 
(0.414) 
717.1 
G/G : 22 1.27 (0.37) -0.82 (-1.62 - -0.02) 
PSYRATS Delirios - Total 
rs17719378 
A/A : 44 4.14 (1.01) 0.00 
Dominante 
0.03 
(0.24) 
695.8 
A/G - G/G : 54 7.69 (1.2) 3.55 (0.39 - 6.71) 
PSYRATS Delirios – Convicción sobre el origen de los delirios 
rs17719378 
A/A : 44 0.84 (0.21) 0.00 
Dominante 
0.035 
(0.28) 
376.9 
A/G - G/G : 54 1.52 (0.23) 0.68 (0.06 - 1.30) 
PSYRATS Delirios – Duración de la preocupación 
rs17719378 
A/A : 44 0.77 (0.19) 0.00 
Dominante 
0.048 
(0.384) 
364.8 
A/G - G/G : 54 1.37 (0.22) 0.60 (0.01 - 1.18) 
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Tabla C18 (continuación). Resultados significativos del análisis de asociación entre el SNP rs17719378 
(gen PDE4D) y algunos ítems de ciertas escalas clínicas.  
SNP 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia  
(95% IC) 
Modelo P
b
 BIC 
PSYRATS Delirios - Repercusión 
rs17719378 
A/A : 44 0.59 (0.15) 0.00 
Dominante 
0.013 
(0.104) 
330.9 
A/G - G/G : 54 1.22 (0.19) 0.63 (0.14 - 1.12) 
PSYRATS Delirios – Intensidad de la ansiedad 
rs17719378 
A/A : 44 0.57 (0.15) 0.00 
Dominante 
0.018 
(0.144) 
329.8 
A/G - G/G : 54 1.17 (0.19) 0.60 (0.11 - 1.09) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: SE, error estándar; IC, intervalos de confianza.; AA, alucinaciones auditivas. 
 
Genes PLEKHB1 y RAB6A  
Al igual que el gen PDE4D, estos dos genes adyacentes localizados en el cromosoma 11 fueron 
seleccionados por su posible relación con otro trastorno psiquiátrico (el trastorno por déficit 
de atención e hiperactividad o TDAH) en un estudio de búsqueda de variaciones en el número 
de copias realizado en la Universidad de Würzburg (Alemania). Se seleccionaron diferentes 
SNPs que capturaban toda la variabilidad de la región y, una vez eliminados aquellos que 
resultaron ser monomórficos o bien que se desviaban enormemente del equilibrio de Hardy-
Weinberg, se analizaron 6 SNPs en la muestra española y 11 SNPs en la alemana. 
Con respecto al análisis de asociación caso-control, un SNP localizado en el gen PLEKHB1, 
rs663303, se asoció con psicosis y psicosis con alucinaciones auditivas en la muestra española: 
(ver tabla C19 para los datos de las distribuciones genotípicas). Además, se detectaron un 
haplotipo de riesgo y uno protector que implicaban a los marcadores rs663303, rs940828 y 
rs3741147, en coherencia con los estudios de SNPs individuales (datos no mostrados). 
Desafortunadamente, casi ninguno de estos hallazgos (con la excepción del haplotipo 
protector), resistieron la corrección estadística para comparaciones múltiples. Con respecto a 
la muestra alemana, algunos SNPs se asociaron con esquizofrenia (tabla C20) o desorden 
bipolar (tabla C21), aunque los polimorfismos diferían de los de la muestra española. 
Concretamente, un SNP del gen PLEKHB1 (rs940828) se asoció con esquizofrenia y desorden 
bipolar. Curiosamente, este marcador está localizado en la misma región que el SNP rs663303, 
uno de los SNPs asociados con psicosis en la muestra española, aunque el desequilibrio de 
ligamiento entre ambos polimorfismos es moderado (D’ = 1; r2 = 0.436). Además, se encontró 
que otros dos SNPs del gen PLEKHB1 (rs4944850 y rs6592527) estaban asociados con riesgo de 
padecer desorden bipolar, mientras que el polimorfismo rs7127066 del gen RAB6A se asoció 
con esquizofrenia y desorden bipolar. Finalmente, los resultados fueron completamente 
negativos cuando se usó una muestra combinada de individuos españoles y alemanes (datos 
no mostrados). 
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Tabla C19. Comparación de las distribuciones genotípicas de los SNPs de los genes PLEKHB1 y RAB6A en 
pacientes psicóticos y sujetos sanos de la muestra española.  
SNP Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
OR (95% IC) P 
b
 AIC Modelo 
rs663303 
C/C 223 (82.3%) 171 (74.3%) 
1.57 (1.05-2.34)
a
 
0.025 
(0.15) 
690.2 Aditivo T/C 46 (17%) 55 (23.9%) 
T/T 2 (0.7%) 4 (1.7%) 
rs940828 
T/T 161 (61.9%) 138 (60.3%) 
1.07 (0.78-1.47)
a
 0.68 (1) 679.8 Aditivo G/T 91 (35%) 83 (36.2%) 
G/G 8 (3.1%) 8 (3.5%) 
rs3741147 
T/T 187 (65.8%) 163 (71.5%) 
0.75 (0.55-1.04)
a
 
0.085 
(0.425) 
704.7 Aditivo G/T 83 (29.2%) 60 (26.3%) 
G/G 14 (4.9%) 5 (2.2%) 
rs12274970 
T/T - T/C 254 (87.6%) 205 (89.1%) 1.00 
0.59 (1) 717.6 Recesivo 
C/C 36 (12.4%) 25 (10.9%) 0.86 (0.50-1.48) 
rs11235876 
G/G - G/A 209 (73.3%) 177 (77%) 1.00 
0.34 (1) 711.2 Recesivo 
A/A 76 (26.7%) 53 (23%) 0.82 (0.55-1.23) 
rs7127066 
G/G 167 (60.3%) 133 (57.8%) 
1.10 (0.82-1.47)
a
 0.51 (1) 702.1 Aditivo C/G 96 (34.7%) 83 (36.1%) 
C/C 14 (5%) 14 (6.1%) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado corresponde a la diferencia que se le atribuye a cada alelo en el modelo aditivo.  
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, intervalos de confianza. 
 
 
Tabla C20. Comparación de las distribuciones genotípicas de los SNPs de los genes PLEKHB1 y RAB6A en 
pacientes esquizofrénicos y sujetos sanos de la muestra alemana.  
SNP Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
OR (95% IC) P 
b
 AIC Modelo 
rs663303 
C/C 408 (76.4%) 191 (78.6%) 1.00 
0.5 (1) 969 Dominante 
T/C - T/T 126 (23.6%) 52 (21.4%) 0.88 (0.61-1.27) 
rs4944850 
A/A 255 (72%) 188 (78%) 1.00 0.099 
(0.891) 
804.5 Dominante 
C/A - C/C 99 (28%) 53 (22%) 0.73 (0.50-1.07) 
rs591804 
A/A 162 (45.6%) 119 (49%) 
0.87 (0.68-1.12)
a
 0.28 (1) 810.8 Aditivo A/G 155 (43.7%) 104 (42.8%) 
G/G 38 (10.7%) 20 (8.2%) 
rs6592527 
G/G - C/G 341 (96.1%) 226 (93%) 1.00 0.1 
(0.891) 
809.2 Recesivo 
C/C 14 (3.9%) 17 (7%) 1.83 (0.89-3.79) 
rs940828 
T/T - G/T 510 (96%) 223 (92.5%) 1.00 0.045 
(0.495) 
958.6 Recesivo 
G/G 21 (4%) 18 (7.5%) 1.96 (1.02-3.75) 
rs3741147 
T/T 422 (79%) 196 (80.7%)  
0.56 (1) 969.1 Aditivo G/T 106 (19.9%) 45 (18.5%) 0.90 (0.63-1.28)
a
 
G/G 6 (1.1%) 2 (0.8%)  
rs12274970 
T/T 315 (59%) 153 (63%) 1.00 
0.29 (1) 968.4 Dominante 
T/C - C/C 219 (41%) 90 (37%) 0.85 (0.62-1.16) 
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Tabla C20 (continuación). Comparación de las distribuciones genotípicas de los SNPs de los genes 
PLEKHB1 y RAB6A en pacientes esquizofrénicos y sujetos sanos de la muestra alemana.  
SNP Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
OR (95% IC) P 
b
 AIC Modelo 
rs10736793 
C/C - C/A 346 (97.5%) 240 (98.4%) 1.00 
0.45 (1) 813.1 Recesivo 
A/A 9 (2.5%) 4 (1.6%) 0.64 (0.20-2.10) 
rs11235876 
G/G - G/A 447 (83.7%) 199 (81.9%) 1.00 
0.53 (1) 969.1 Recesivo 
A/A 87 (16.3%) 44 (18.1%) 1.14 (0.76-1.69) 
rs11235880 
C/C - C/A 343 (96.3%) 229 (93.8%) 1.00 
0.16 (1) 812.8 Recesivo 
A/A 13 (3.6%) 15 (6.2%) 1.73 (0.81-3.70) 
rs7127066 
G/G - C/G 506 (94.8%) 221 (91%) 1.00 0.051 
(0.51) 
965.6 Recesivo 
C/C 28 (5.2%) 22 (9.1%) 1.80 (1.01-3.21) 
Los valores de P significativos (P < 0.05) se indican en negrita.  
a. El valor indicado corresponde a la diferencia que se le atribuye a cada alelo en el modelo aditivo.  
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, intervalos de confianza. 
 
Tabla C21. Comparación de las distribuciones genotípicas de los SNPs de los genes PLEKHB1 y RAB6A en 
pacientes con desorden bipolar y sujetos sanos de la muestra alemana.  
SNP Genotipo 
Frecuencia 
controles 
Frecuencia 
pacientes 
OR (95% IC) P 
b
 AIC Modelo 
rs663303 
C/C - T/C 525 (98.3%) 85 (96.6%) 1.00 
0.32 (1) 510.1 Recesivo 
T/T 9 (1.7%) 3 (3.4%) 0.49 (0.13-1.83) 
rs4944850 
A/A - C/A 344 (97.2%) 81 (92%) 1.00 0.04 
(0.36) 
441 Recesivo 
C/C 10 (2.8%) 7 (8%) 0.34 (0.12-0.91) 
rs591804 
A/A - A/G 317 (89.3%) 73 (83.9%) 1.00 0.18 
(0.9) 
440.6 Recesivo 
G/G 38 (10.7%) 14 (16.1%) 0.63 (0.32-1.21) 
rs6592527 
G/G - C/G 341 (96.1%) 78 (89.7%) 1.00 0.027 
(0.27) 
437.5 Recesivo 
C/C 14 (3.9%) 9 (10.3%) 0.36 (0.15-0.85) 
rs940828 
T/T 325 (61.2%) 57 (64.8%) 1.00 
0.024 
(0.264) 
504.8 Codominante G/T 185 (34.8%) 22 (25%) 1.47 (0.87-2.49) 
G/G 21 (4%) 9 (10.2%) 0.41 (0.18-0.94) 
rs3741147 
T/T 422 (79%) 62 (71.3%) 1.00 0.11 
(0.77) 
504.7 Dominante 
G/T - G/G 112 (21%) 25 (28.7%) 0.66 (0.40-1.09) 
rs12274970 
T/T 315 (59%) 51 (58%) 1.00 
0.86 (1) 511.1 Dominante 
T/C - C/C 219 (41%) 37 (42%) 0.96 (0.61-1.51) 
rs10736793 
C/C 243 (68.5%) 58 (65.9%) 1.00 
0.65 (1) 445.5 Dominante 
C/A - A/A 112 (31.6%) 30 (34.1%) 0.89 (0.54-1.46) 
rs11235876 
G/G - G/A 447 (83.7%) 68 (77.3%) 1.00 0.15 
(0.9) 
509 Recesivo 
A/A 87 (16.3%) 20 (22.7%) 0.66 (0.38-1.15) 
rs11235880 
C/C - C/A 343 (96.3%) 82 (94.2%) 1.00 
0.4 (1) 442.2 Recesivo 
A/A 13 (3.6%) 5 (5.8%) 0.62 (0.22-1.79) 
rs7127066 
G/G - C/G 506 (94.8%) 79 (89.8%) 1.00 0.089 
(0.712) 
508.2 Recesivo 
C/C 28 (5.2%) 9 (10.2%) 0.49 (0.22-1.07) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado corresponde a la diferencia que se le atribuye a cada alelo en el modelo aditivo.  
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: OR, Odds Ratio; IC, intervalo de confianza. 
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Es importante remarcar que, durante la realización de los análisis de asociación caso-control, 
se encontraron diferentes asociaciones que implicaban principalmente al gen PLEKHB1. Sin 
embargo, solamente se puede referir como una replicación parcial, ya que los SNP asociados 
con psicosis varían en cada muestra. Sin embargo, es arriesgado establecer una relación causal 
entre este gen y los desórdenes mentales. En primer lugar, la significación no ha sido muy alta. 
Además, el papel de este gen en el comportamiento o en la fisiopatología de los desórdenes 
mentales no ha sido explorado todavía. Por lo que sabemos, éste es el primer estudio que ha 
intentado relacionar este gen con una patología psiquiátrica. Se sabe poco sobre la función de 
este gen, aunque sí se ha sugerido que la proteína PLEKHB1 podría tener un papel en la 
modificación de los procesos de transducción de señales que tienen lugar en las células 
fotorreceptoras (Xu et al., 2004). De acuerdo con esto, se puede hipotetizar que las 
alteraciones en el gen PLEKHB1 podrían tener un papel en el desarrollo de alucinaciones 
auditivas asociadas a la psicosis. Además, la expresión de este gen es particularmente alta en 
áreas cerebrales que parecen tener un papel importante en la fisiopatología de la 
esquizofrenia, como el lóbulo temporal, el córtex prefrontal, el tálamo y el hipotálamo, entre 
otros. Estas evidencias, junto con los resultados obtenidos en nuestro análisis de asociación 
caso-control, nos llevaron a estudiar más en profundidad la relación de esta región del 
cromosoma 11 y la psicosis. 
Se estudió el impacto que la variación genética de los genes PLEKHB1 y RAB6A tenía sobre 
diferentes rasgos de la enfermedad, evaluados en la muestra de pacientes españoles. Como 
resultado de este análisis, se encontraron un número bastante elevado de asociaciones, que 
implicaban a los 6 SNPs genotipados. Sin embargo, muchos de estos hallazgos son 
posiblemente falsos positivos, debido a la reducida frecuencia del alelo menor y al bajo 
número de sujetos homozigotos para ese alelo. A pesar de esto, algunos resultados son 
especialmente interesantes, ya que resistieron la corrección de Bonferroni secuencial (tabla 
C22). Son: 
 
- La asociación del SNP rs12274970 (localizado en la región intergénica entre PLEKHB1 y 
RAB6A) y el ítem de la PANSS Trastorno de la Volición. 
-  La asociación del SNP rs11235976 (localizado en el gen RAB6A) y los siguientes ítems 
de la PANSS: Trastorno de la Volición, Retraimiento Social y Hostilidad. 
 
Los rasgos que parecen estar influidos por la variación genética son de naturaleza diversa. Por 
lo tanto, es difícil elaborar una hipótesis sobre el verdadero significado de estas asociaciones. 
Además, ninguno de los polimorfismos implicados parece ser funcional, de acuerdo a los 
resultados obtenidos mediante el análisis con PupaSuite (Conde et al., 2006). Es también 
posible que estos SNPs estén en fuerte desequilibrio de ligamiento con otras variantes 
funcionales. Por último, a pesar de que se hipotetizó que el gen PLEKHB1 podría estar 
implicado en la vulnerabilidad a padecer alucinaciones, no se ha encontrado ninguna 
asociación entre el gen PLEKHB1 y las dimensiones de las alucinaciones auditivas. 
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Tabla C22. Resultados más significativos (resistieron la corrección para comparaciones múltiples) del 
análisis de asociación entre los SNPs de los genes PLEKHB1 y RAB6A y diferentes escalas clínicas. 
Marcador 
Distribución 
genotípica 
Puntuación 
media (SE) 
Diferencia (95% IC) Modelo P
b
 BIC 
PANSS P7 - Hostilidad 
rs11235876 
G/G - G/A : 60 1.33 (0.18) 0.00 
Dominante 
0.0094 
(0.047) 
242.7 
A/A :19 2.08 (0.14) 0.75 (0.20 - 1.30) 
PANSS N4 – Pasividad / Retraimiento social 
rs11235876 
G/G : 18 2.06 (0.33) 
0.68 (0.18 - 1.18)
a
 Aditivo 
0.0093 
(0.0465) 
304.2 G/A : 42 3.02 (0.25) 
A/A :19 3.42 (0.34) 
PANSS G13 – Trastorno de la volición 
rs12274970 
T/T : 67 1.83 (0.19) 0.00 
Dominante 
0.0065 
(0.0325) 
275.9 
C/C : 12 2.65 (0.21) 0.82 (0.25 - 1.39) 
rs11235876 
G/G : 18 1.67 (0.21) 
0.67 (0.26 - 1.08)
a
 Aditivo 
0.0021 
(0.0126) 
273.8 G/A : 42 2.21 (0.21) 
A/A :19 3 (0.31) 
Los valores de P significativos (P < 0.05) se indican en negrita. 
a. El valor indicado corresponde a la diferencia que se le atribuye a cada alelo en el modelo aditivo.  
b. El valor de P corregido se indica entre paréntesis. 
Abreviaturas: SE, error estándar; IC, intervalo de confianza. 
 
En resumen, las evidencias a favor de la implicación de los genes PLEKHB1 y RAB6A en 
diferentes aspectos de las psicosis son débiles, por lo que necesitarían ser confirmadas en 
otras muestras adicionales. 
 
Limitaciones del estudio  
A pesar de los interesantes resultados, se han de tener en cuenta una serie de consideraciones 
y limitaciones. En primer lugar, se ha usado un importante número de variables clínicas 
(correspondientes a diferentes escalas) con el propósito de evaluar la existencia de 
correlaciones con las variaciones genéticas. Sin embargo, en algunos casos los pacientes 
evaluados han sido pocos. Asimismo, se ha especulado sobre la poca validez biológica de estas 
medidas. A pesar de ello, pensamos que pueden ayudar a detectar si determinado gen o 
polimorfismo influye en un determinado tipo de síntomas. En segundo lugar, somos también 
conscientes de que el tamaño de muestra puede ser considerado pequeño, especialmente en 
el caso de algunos grupos, como el de pacientes alucinadores. Asimismo, aunque los pacientes 
y controles fueron elegidos para evitar estratificaciones, no podemos descartar que no exista 
estratificación de la muestra. 
Otro aspecto importante es que el elevado número de SNPs analizados y de variables 
estudiadas puede aumentar peligrosamente la aparición de falsos positivos (error de tipo I). 
Por este motivo, se aplicó la corrección de Bonferroni secuencial (Rice, 1989), que es menos 
restrictiva que la corrección de Bonferroni, Actualmente, no hay consenso sobre si es 
necesario aplicar correcciones en los estudios de asociación, o sobre qué corrección es más 
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apropiada. En nuestro caso, se consideró que el ajuste de Bonferroni secuencial era el más 
idóneo.  
Por último, cabe reseñar la importancia de tener un adecuado tamaño muestral en los 
estudios de neuroimagen. Aunque en el caso del análisis realizado sobre la muestra española, 
el tamaño ha sido reducido, se espera aumentar el número de individuos para próximos 
estudios. Otras variables, como la edad, el sexo o la lateralidad se tuvieron también en cuenta 
para estos análisis. 
Hacia un modelo general de vulnerabilidad 
Cuando se estudia una enfermedad común y compleja, como la esquizofrenia, que se 
caracteriza por un patrón de herencia no mendeliano y una alta prevalencia, una de las 
hipótesis más plausibles es la Hipótesis “Enfermedad Común – Variante Común” (CDCV por sus 
siglas en inglés). Esta hipótesis plantea que el espectro de variantes alélicas que confieren 
susceptibilidad a cierta enfermedad compleja se compone de variantes comunes con un efecto 
moderado sobre el riesgo de padecer la enfermedad y compartidas por diferentes 
subpoblaciones. Esta hipótesis es de hecho nuestro marco de trabajo y, por esta razón, este 
trabajo se ha centrado en el estudio de diferentes polimorfismos genéticos localizados en 
varios genes candidatos. Al inicio de este estudio se esperaba que la contribución de cada uno 
de estos genes candidatos fuera pequeña y los resultados obtenidos apoyan esta idea y 
permiten la elaboración de un posible modelo integrativo de vulnerabilidad (figura C7). 
 
 
 
 
 
 
 
 
 
 
 
En primer lugar, existe una vulnerabilidad general a los trastornos psicóticos, que estaría 
influenciada por un cierto número de factores de origen genético y no genético. Entre estos 
factores, los genes SLC6A4 y ASPM pueden tener un papel importante. De acuerdo con este 
Figura C7. Modelo general de vulnerabilidad a la esquizofrenia que integra los hallazgos 
obtenidos en el presente estudio.  
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escenario, las proteínas codificadas por estos genes podrían influir sobre aquellos sistemas 
neurales que están implicados en la aparición de los síntomas psicóticos y esquizofrénicos. 
Asimismo, otros genes, como STMN1 y PLEKHB1, podrían tener también un papel sobre la 
susceptibilidad a la esquizofrenia, aunque en este caso las evidencias son menores. 
En segundo lugar, los resultados de este estudio sugieren que hay variantes polimórficas con 
un efecto sobre la severidad de los síntomas (figura C7). Un claro ejemplo es el efecto de la 
variación del gen STMN1 sobre la severidad de los síntomas negativos. Además, ligeras 
evidencias sugieren un posible papel de otros genes como NOS1 y PDE4D sobre los síntomas 
positivos. Estos resultados no son sorprendentes, sobre todo si consideramos el modelo 
presentado por Fanous y Kendler (2005). Según este modelo, algunos genes incrementarían la 
susceptibilidad a padecer esquizofrenia sin alterar sus características clínicas asociadas (genes 
de susceptibilidad), mientras que otros genes afectarían a esas características clínicas sin 
modificar la susceptibilidad a padecer la enfermedad. 
El presente estudio también contribuye al estudio de la vulnerabilidad a las psicosis desde una 
nueva óptica, llamada “deconstrucción del síntoma”, que permite el estudio de los sistemas 
neurobiológicos implicados en los síntomas más representativos de la esquizofrenia, como las 
alucinaciones auditivas, el deterioro cognitivo y el deterioro emocional. Con respecto a los 
aspectos cognitivos, se ha encontrado un efecto de la variación del gen ASPM sobre diferentes 
habilidades cognitivas y variables neuroanatómicas (figura C7), lo que sugiere que este gen 
puede tener un importante papel durante el desarrollo de aquellas áreas cerebrales implicadas 
en la patogénesis de la esquizofrenia, tales como el córtex prefrontal, el córtex anterior 
cingulado o los ganglios basales. Se puede también argumentar que el gen ASPM tiene un 
papel clave en la cognición normal y puede ser también considerado un interesante candidato 
para entender la evolución del cerebro humano. En conclusión, el papel activo de la proteína 
ASPM en la evolución del cerebro humano puede haber desencadenado la aparición de los 
déficits cognitivos y alteraciones mentales asociadas a la esquizofrenia. 
Además, la relación entre la variación genética del sistema serotoninérgico y las alteraciones 
emocionales son de especial interés. Nuestros resultados sugieren que la alteración en el 
funcionamiento de ciertos elementos clave de este sistema, como el transportador de 
serotonina o el receptor 5-HT2A y, en menor medida, la triptófano hidroxilasa 2, lleva a un 
estado emocional alterado en los pacientes aquejados de esquizofrenia. Además, la proteína 
stathmin, codificada por el gen STMN1, podría estar también implicada en la patogénesis de 
las alteraciones afectivas asociadas a la esquizofrenia, a través de su implicación en los 
síntomas negativos. Sin embargo, en este último caso las evidencias son menores. 
Finalmente, este estudio apoya la implicación de diferentes variantes polimórficas en la 
patogénesis de las alucinaciones auditivas. En realidad, este estudio forma parte de un 
proyecto más ambicioso cuyo principal objetivo es desentrañar, desde un punto de vista 
dimensional, los mecanismos moleculares que son responsables de la vulnerabilidad a las 
alucinaciones auditivas. Como consecuencia de nuestros resultados en este campo, tanto los 
presentados en este estudio como en otros estudios, hemos desarrollado un modelo que 
integra los diferentes hallazgos (figura C8), permitiendo dar una explicación sobre la 
etiopatogénesis de las alucinaciones auditivas. De acuerdo con este modelo, se puede 
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considerar que hay dos mecanismos principales implicados en la vulnerabilidad genética a las 
alucinaciones auditivas en pacientes psicóticos. El primer mecanismo está relacionado con la 
vulnerabilidad a trastornos del lenguaje, que implicaría al gen FOXP2, entre otros. En segundo 
lugar, hay una importante dimensión en la neurobiología de las alucinaciones auditivas: la 
vulnerabilidad a respuestas emocionales anormales. Tenemos razones para apoyar el 
importante papel del procesado emocional en la patofisiología de las alucinaciones auditivas, 
ya que, de igual manera que hemos detectado un efecto de la variación genética sobre el 
estado emocional del paciente, se ha detectado también un importante efecto de los genes 
serotoninérgicos sobre la respuesta emocional a las alucinaciones auditivas (Sanjuán et al., 
2006b), las cuales pueden ser entendidas como un elemento estresante para el paciente. Por 
último, los factores ambientales tampoco pueden ser olvidados en este modelo. 
Particularmente, los aspectos culturales pueden tener un efecto sobre el contenido y el ajuste 
social de las voces (Sanjuán et al., 2005; Sanjuán, 2006; Aleman y Larøi, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
Sin embargo, a pesar de que éste y otros estudios han conseguido desenmascarar algunos 
elementos clave en la patogénesis de la esquizofrenia, muchos otros elementos no han sido 
descubiertos todavía: existe todavía mucha incertidumbre y un importante número de factores 
genéticos, epigenéticos y ambientales esperan a ser descubiertos y entendidos. Sin embargo, a 
la luz de los más recientes descubrimientos, los estudios de asociación (tanto clásicos como de 
genoma amplio) parecen ser una herramienta limitada, al menos para los tamaños muestrales 
y las herramientas estadísticas actuales. Nuevas aproximaciones, como el uso de modelos 
animales, estudios epigenéticos y estudios de interacción gen x ambiente, son necesarias para 
desentrañar los mecanismos neurofisiológicos y etiopatogénicos responsables de una de las 
más graves enfermedades mentales. 
Figura C8. Modelo etiopatogénico general de vulnerabilidad a las alucinaciones auditivas  
(Adaptada de Sanjuán y Aguilar, 2007). 
306 Resumen en castellano 
 
En resumen, los datos de este estudio permiten obtener las siguientes conclusiones: 
 
1. El análisis caso-control ha permitido detectar asociación entre el SNP rs2020936 del 
gen del transportador de serotonina y la psicosis. También se han encontrado varios 
haplotipos protectores que eran más frecuentes en el grupo control que en el grupo 
de pacientes esquizofrénicos. 
 
2. Los datos del presente estudio apoyan la relación entre la variación en el polimorfismo 
5-HTTLPR y la respuesta emocional del paciente esquizofrénico. Concretamente, el 
alelo s se ha asociado con una mayor puntuación en los ítems emocionales de la escala 
PSYRATS, una mayor activación de la amígdala ante palabras de contenido emocional y 
una menor densidad de materia gris en determinadas áreas del sistema límbico (córtex 
anterior cingulado en pacientes esquizofrénicos; hipocampo y parahipocampo en 
sujetos sanos). 
 
3. Los estudios de asociación han puesto de manifiesto el efecto del gen HTR2A sobre la 
emocionalidad de los pacientes psicóticos, evaluada mediante diferentes ítems de 
escalas psicopatológicas: PANSS, BPRS y PSYRATS. El gen TPH2 también se ha asociado 
con diversos ítems de la escala PSYRATS de alucinaciones auditivas, si bien en este 
caso la significación es menor. 
 
4. La realización de análisis de interacción ha permitido la detección de efectos 
epistáticos que implican a los genes SLC6A4,  HTR2A y TPH2. Estas epistasias parecen 
modular diferentes parámetros relacionados con el procesado emocional y, 
especialmente, la respuesta emocional a las alucinaciones auditivas. 
 
5. Se ha detectado un efecto del VNTR del gen NOS1 sobre la puntuación en ciertos 
parámetros de la PANSS, tres del componente depresivo y dos ítems positivos. 
 
6. El gen STMN1 se ha asociado débilmente con el riesgo de esquizofrenia, así como con 
diferentes ítems de escalas psicopatológicas relacionados principalmente con la 
sintomatología negativa/afectiva de la esquizofrenia. 
 
7. A través de estudios caso-control y basados en familias realizados en dos muestras 
independientes, el gen ASPM se ha asociado con el riesgo de psicosis, así como con 
diferentes parámetros de tipo cognitivo relacionados principalmente con la memoria 
de trabajo. Concretamente, un SNP, rs10922163 se ha asociado con el riesgo de 
psicosis en ambas muestras estudiadas. Asimismo, se ha observado un efecto de la 
variación en el gen ASPM sobre la activación del cortex anterior cingulado durante la 
realización de un ejercicio de memoria de trabajo. Finalmente, el gen ASPM también 
influye en la densidad de materia gris de determinadas áreas cerebrales relacionadas 
con la patogénesis de la esquizofrenia, como son el cerebelo, el córtex prefrontal, el 
cortex anterior cingulado subgenual y los ganglios basales. 
 
8. Un SNP del gen PDE4D se ha asociado débilmente con el riesgo de esquizofrenia en la 
muestra española, mientras que en el caso de la muestra alemana se ha encontrado 
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una asociación de diferentes SNPs con el trastorno bipolar. Este gen también se ha 
asociado con la severidad de diversos síntomas, principalmente de tipo positivo. 
 
9. Se ha encontrado asociación débil entre diferentes SNPs del gen PLEKHB1 y el riesgo 
de esquizofrenia y/o desorden bipolar. 
 
10. Todos estos resultados permiten proponer un modelo de vulnerabilidad, mediante el 
cual ciertos genes tendrían un mayor efecto sobre la vulnerabilidad a sufrir 
esquizofrenia, mientras que otros genes tendrían un efecto sobre la severidad de 
ciertos síntomas. En cuanto a las alucinaciones auditivas, los resultados del presente 
estudio apoyan la existencia de una vulnerabilidad genética a respuestas emocionales 
aberrantes, que podría estar modulada por la variación en diferentes genes, por 
ejemplo el transportador de serotonina. 
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ABBREVIATIONS AND GENE SYMBOLS 
5-HIAA, 5-HydroxyIndole Acetic Acid  
5-HT, 5-HydroxyTryptamine or serotonin 
5-HTT, 5-HydroxyTryptamine or serotonin 
transporter 
5-HTTLPR, 5-HTT Linked Polymorphic Region 
ACC, Anterior Cingulate Cortex 
ADHD, Attention-Deficit Hyperactivity Disorder 
AH, Auditory Hallucinations 
AIC, Akaike’s Information Criterion 
ApoE4, Apolipoprotein ε4 allele 
ASPM, Abnormal Spindle-like Microcephaly-
associated 
BDNF, Brain-Derived Neurotrophic Factor 
BIC, Bayesian Information Criterion 
BLA, Basolateral Amygdala 
BOLD, Blood Oxygenation Level Dependent 
bp, base pairs 
BPD, Bipolar Disorder 
BPRS, Brief Psychiatric Rating Scale 
BSA, Bovine Serum Albumin 
cAMP, cyclic Adenosine Monophosphate  
CBDB, Clinical Brain Disorders Branch  
CDCV, Common Disease - Common Variant 
CEPH, Centre d'Etude du Polymorphisme 
Humain. (In the HapMap Project, it refers to 
DNA samples of Utah residents with ancestry 
from northern and western Europe). 
cGMP, cyclic guanosine monophosphate  
CH domain, Calponin-homology domain 
CNS, Central Nervous System 
CNV, Copy Number Variation 
COMT, Cathecol-O-methyl Transferase 
CPT, Continuous Performance Task  
DA, Dopamine 
DAAO, D-amino Acid Oxidase 
DAT, Discordant Allele Test 
DAT, Dopamine Transporter 
DISC1, Disrupted-in-schizophrenia 1  
DLPFC, Dorsolateral Prefrontal Cortex 
DMSO, Dimethyl Sulfoxide 
DNA, Deoxyribonucleic Acid 
DSM-IV, Diagnostic and Statistical Manual of 
Mental Disorders, 4
th
 edition. 
DZ, Dizygotic 
EEG, Electroencephalogram  
EF, Electrophoresis 
EM, Expectation-Maximization algorithm 
EMBL-EBI: European Molecular Biology 
Laboratory-European Bioinformatics Institute 
ER, Endoplasmic Reticulum 
ERP, Event-related Potential  
FBAT, Family Based Association Test 
FDR, False Discovery Rate 
fMRI, functional Magnetic Resonance Imaging 
GM, Gray Matter 
GWA, Genome-Wide Association 
HOR, high order repeat  
HPA, hypothalamic-pituitary-adrenal  
HTR2A, Serotonin Receptor 2A 
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HWE, Hardy-Weinberg Equilibrium 
indel, insertion-deletion 
IP, Inositol Phosphate 
IQ, Intelligence Quotient 
IQ domain, Isoleucine-glutamine domain 
IUBMB, International Union of Biochemistry 
and Molecular Biology 
IUPAC, International Union of Pure and Applied 
Chemistry 
Ka, rate of non-synonymous substitutions 
Ks, rate of synonymous substitutions 
kb, kilobase 
KGV, Krawiecka, Goldberg & Vaughan 
(psychiatric assessment scale) 
LA, Lateral nucleus of the amygdala 
LD, Linkage Disequilibrium 
LOD, Logarithm of Likelihood 
LSD, Lysergic Acid Diethylamide 
LTP, Long-Term Potentiation 
MAF, Minor Allele Frequency 
MALDI-TOF, Matrix-Assisted Laser 
Desorption/Ionization - Time-Of-Flight 
MAO, Monoamine Oxidase 
MCPH,  Microcephaly, Primary Autosomal 
Recessive 
MGB, Minor Groove Binder 
MNI, Montreal Neurological Institute 
MR, Magnetic Resonance 
MRI, Magnetic Resonance Imaging 
mRNA, Messenger Ribonucleic Acid 
MRS, Magnetic Resonance Spectroscopy 
MS, Mass Spectrometry 
MT, Microtubules 
MTL, Medial Temporal Lobe 
MZ, Monozygotic 
NAA, N-Acetyl Aspartate 
NET, Norepinephrine Transporter 
NFQ, Non-Fluorescent Quencher 
NIMH, National Institute of Mental Health 
NO, Nitric Oxide 
NOS, Nitric oxide synthase  
NRG1, Neuregulin 1  
OCD, Obsessive-Compulsive Disorder 
OR, Odds Ratio 
PANSS, Positive and Negative Syndrome Scale 
PCP, Phenylcyclidine  
PCR, Polymerase Chain Reaction 
PDE4D, phosphodiesterase 4D 
PET, Positron Emission Tomography 
PFC, Prefrontal Cortex 
PH, Pleckstrin homology  
PI3K, PhosphatidylInositide 3-Kinase  
PSYRATS, Psychotic Symptom Rating Scales 
RELN, Reelin  
REM, Rapid Eye Movement 
RFLP, Restriction Fragment Length 
Polymorphism 
RGS4, Regulator of G protein signaling 4 
ROI, Region of Interest 
rt, room temperature 
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SAP, Shrimp Alkaline Phosphatase  
SBE, Single Base Extension  
SD, Standard Deviation 
SE, Standard Error 
SERT, Serotonin Transporter 
SLC6A4, solute carrier family 6 
(neurotransmitter transporter, serotonin) – 
serotonin transporter 
sMRI, Structural Magnetic Resonance Imaging 
SNP, Single Nucleotide Polymorphism 
SPECT, Single-Photon Emission Computed 
Tomography  
SSCP, Single Strand Conformation 
Polymorphism 
SSRI, Selective Serotonin Reuptake Inhibitor 
S-TDT, Sib Transmission/Disequilibrium Test 
STG Superior Temporal Gyrus 
STin2, Serotonin Transporter intron 2 VNTR 
SVZ, Subventricular Zone 
TDT, Transmission/Disequilibrium Test 
Tm, Melting Temperature 
TM, Transmembrane 
TPH, Tryptophan Hydroxylase  
TPH2, Tryptophan hydroxylase 2 
UCR2, Ultra Conserved Region 2 
UCSC, University of California Santa Cruz 
UTR, Untranslated Region 
VBM, Voxel-Based Morphometry 
VCFS, Velocardiofacial Syndrome  
VNTR, Variable Number of Tandem Repeats 
WCST, Wisconsin Card Sorting test 
WHO, World Health Organization 
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